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Donor procurement makes the logistics of obtaining human bone marrow (BM) as a source of 
mesenchymal stem/ stromal cells (MSCs) complicated. Although BM MSCs from adult donors 
still have satisfactory abilities to be used for regenerative medicine purposes, from the 
manufacturing perspective, the best donors are in the pediatric age range. In addition, the 
procedure requires planning and it is painful; the derivation and identification of the MSCs 
according to ISCT are still controversial among scientists, and the isolation and quality of cells 
also varies among donors. Therefore, the MSCs therapy field is constantly looking for 
alternative sources.  
We hypothesized that human MSC derived from induced pluripotent stem cells (iPSCs) have 
biological qualities of native MSC and could be scaled up and used for therapeutic purposes. 
To test the hypothesis, we isolated native MSC (nMSC) from umbilical cord’s Wharton’s Jelly 
(WJ) of two donors (#012 and #013) in xeno-free conditions. Next, we reprogrammed them 
into iPSC (iPSC012 and iPSC013) and subsequently differentiated them back into MSC using 
two different protocols ARG and TEX (iMSC012ARG, iMSC012TEX, iMSC013ARG, and 
iMSC013TEX). Using the same protocols, we also differentiated the clinical grade human 
embryonic stem cell line (ESC) KCL034 into MSC (eMSC034ARG and eMSC034TEX).  
To assess which of the two differentiation protocols worked better, we compared differentiation 
capability, transcriptomics and immunomodulatory potential of the iMSCs (iMSC012ARG, 
iMSC012TEX, iMSC013ARG and iMSC013TEX) and eMSCs (eMSC034ARG and 
eMSC034TEX) with nMSCs (nMSC012, nMSC013 and BM MSC). Based on the expression 
of all expressed genes, the data demonstrated that both iMSCs and eMSCs differentiated 
following TEX protocol are closer to nMSC with higher differentiation potentials but lower 
immunomodulatory properties than ARG.  
Our data suggest that, following a careful selection and screening of donors, nMSCs from 
umbilical’s cord WJ can be reprogrammed into iPSCs providing an extensive source of material 
for differentiation into iMSCs of similar therapeutic potential as nMSC. iMSCs could be scaled 
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1.1 Stem Cells 
Stem cells (SCs) are defined as unspecialized cells characterized by both the ability to self-
renew and the ability to differentiate into functional adult cell types. Stem cells are responsible 
for the constant renewal of our skin and blood and are also responsible for wound healing. Stem 
cells enable us to exist and function. Furthermore, ‘dormant’ reserves of stem cells in our bodies 
await the opportunity either to replicate and produce more stem cells or to differentiate into 
more-specialized cells. Typically, when a stem cell divides, either both daughter cells remain 
stem cells, or one daughter cell remains a stem cell while the other daughter cell undergoes 
differentiation into a more-specialized cell type. This characteristic is restricted to stem cells, 
although some fully adult stem cells such as liver cells can divide to give rise to more cells like 
themselves only. Stem cells are not exclusively human cells; they can be found in all 
multicellular organisms, from plants to animals, including humans (Thomson et al., 1998; 
Weissman, 2000; Reubinoff, 2007).  
Stem cells are classified according to their capacity for differentiation or plasticity. 
Totipotent cells can form all lineages of an organism and extra-embryonic layers; only zygotes 
and first-cleavage blastomeres are totipotent. After a certain number of cell divisions, the cells 
of the zygote lose totipotency and become pluripotent. Embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSCs) are examples of pluripotent stem cells, with the ability 
to self-renew infinitely and the capability of generating all cell types belonging to the three 
embryonic germ layers (endoderm, ectoderm and mesoderm) in vivo and in vitro. Multipotent 
stem cells (also called somatic or adult stem cells) are derived from pluripotent cells through 
cell division and differentiation. Mesenchymal stem/stromal cells (MSCs) and haematopoietic 
stem cells (HSCs) are classified as multipotent stem cells, and they can only give rise to cells 
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of a particular lineage. They have been recognized in different tissues, such as bone, central 
nervous system, muscles and intestines. The most important function of these cells is to 
preserve the tissue through cell proliferation when needed. Unipotent stem cells are able to 
generate only one cell type, for example, spermatogonial stem cells, which give rise to sperm, 
and skin stem cells, which are one of the most abundant types of unipotent stem cell (Jaenisch 
and Young, 2008). 
From the time when Gurdon transplanted intestinal epithelium-cell nuclei from Xenopus 
tadpoles into enucleated frog eggs and managed to produce 10 normal tadpoles: Molly and her 
fellow clones (Gurdon, 1962), and Dolly the sheep was generated (Wilmut et al., 1997), the use 
of somatic cell nuclear transfer (SCNT) or nuclear cloning demonstrated that the epigenetic 
state of somatic cells, including the totally differentiated ones, is not irreversibly fixed but can 
be reprogrammed to an embryonic state that is able of developing a new organism. Nuclear 
transfer (NT), cell fusion and genetic manipulation can induce reprogramming.  
Thomson et al. (1998) were the first scientists to generate ESCs in vitro. To isolate and 
culture those cells, the inner cell mass (ICM), a cluster of pluripotent stem cells within an 
embryo in the blastocyst stage, is extracted following appropriate culture techniques. Because 
human ESCs arise from human embryos, there are significant ethical concerns surrounding this 
technology. Therefore, since then, biomedical research has focused on overcoming the ethical 
and immune rejection issues associated with human ESCs. In 2006, Takahashi and Yamanaka 
discovered that somatic or adult cells could be reprogrammed into a pluripotent state. Those 
cells, called iPSCs, were first generated by reprogramming adult cells via ectopic expression of 
transcription factors normally expressed in embryos. iPSCs exhibit the same characteristics as 
ESCs and have opened a new and exciting area in regenerative medicine. 
Regardless of their potency, stem cells can also be divided into four groups based on 
their origin: ESCs and foetal, perinatal and somatic (resident or tissue-specific) stem cells 
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(O'Donoghue and Fisk, 2004; Toma et al., 2001; Jaenisch and Young, 2008). Perinatal stem 
cells are harvested from extra-embryonic tissues, such as the placenta, foetal membranes and 
umbilical cord, and even though the cells isolated from these tissues are considered multipotent 
stem cells, some have proven to be more potent than was first thought. The focus of my thesis 
is the isolation of stem cells from umbilical cord tissue, iPSCs and, most importantly, MSCs 
derived from iPSCs.  
 
1.2  Mesenchymal stem/stromal cells 
MSCs were first isolated from animal bone marrow (BM) by Friedenstein et al. (1970), and 
they represent a rare population of nucleated cells (0.0001 – 0.01%) within adult BM. MSCs 
can also be found in muscles, periosteum, adipose tissue and other connective tissues (Castro-
Malaspina et al., 1980; Pittenger et al., 1999).  
Human MSCs are broadly characterized as a population of non-haematopoietic 
multipotent stem cells. Similarly to other stem cells, MSCs hold the potential for self-renewal 
and differentiation into further specialized cells of a particular lineage (Pittenger et al., 1999). 
MSCs were first described as plastic, adherent, clonogenic, colony-forming, fibroblast-like 
cells (Friedenstein et al., 1987). The lineage potential of these multipotent cells includes almost 
all derivatives of the mesoderm, such as the skeletal tissues bone, cartilage, fat and tendon and 
the non-skeletal tissues smooth muscle, skeletal muscle and possibly myocardium and 
endothelial cells. MSCs are found in BM, liver, synovium, adipose tissue, heart and other 
postnatal connective tissues, such as umbilical cord (UC) (Bianco et al., 2008).  
MSCs from neonatal tissues, including the placenta, amniotic membranes and UC, can 
provide a source of stem cells that is ethically non-controversial and easily accessible, since 
perinatal tissues are normally discarded after birth (Wolbank et al., 2010). They are ideal 
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candidates for regenerative medicine because they can be effortlessly isolated and expanded 
from adult and foetal tissues, they possess multilineage capacities, they hold 
immunomodulatory properties, they release growth factors, and they are capable of migration 
to damaged sites (Frausin et al., 2015). MSCs may exert a beneficial trophic effect on injured 
tissues, even without replacing dying cells (Crigler et al., 2006; Shen et al., 2013), establishing 
these cells as a good choice for cell therapies.  
Although criteria defining MSCs are still not available (Wagner and Ho, 2007; Wagner 
et al., 2006), MSCs can be identified by a combination of different markers and by phenotypic 
and functional characteristics. The ISCT (International Society of cell Therapy) proposes a set 
of criteria to identify MSCs intended for research and pre-clinical studies (Table 1.1). However, 
according to Dominici et al. (2006), future research will conduct to a revision of the criteria as 
new findings emerge.  In addition, they have low levels of HLA class I and II and do not express 
CD14, CD34 or CD45 (haematopoietic surface markers) or CD31 (endothelial marker) and 
show no expression of costimulatory molecules (CD80, CD86). MSCs should demonstrate 
multipotency by in vitro differentiation into the three mesenchymal lineages: adipocytes, 
chondrocytes and osteocytes (Bobis et al., 2006; Conget and Minguell, 1999; Djouad et al., 
2005; Fibbe and Noort, 2003; Gronthos et al., 2003; Pittenger et al., 1999). Additionally, MSC 
antigen-1 (MSCA-1) was present in cells that showed a >100-fold increased yield of colony-
forming units. Therefore, MSCA-1, which has been associated with cells of the osteoblast 
lineage, might also be a marker of BM MSCs (Gronthos et al, 2007; Battula et al., 2009; 






Table 1.1 Summary of ISCT criteria to identify MSCs (Dominici et al., 2006) 
1. Adherence to plastic culture vessel 






3. In vitro differentiation: osteoblasts, chondroblasts, adipocytes  
(demonstrating by staining) 
 
MSCs exhibit low immunogenicity and do not stimulate T-cell proliferation in vitro and 
can also suppress lymphocyte proliferation induced by phytohaemagglutinin (PHA). In 
addition, they do not express major histocompatibility complex class II (MHC-II) and only 
express low levels of MHC-I (Le Blanc et al., 2003), which are both proteins responsible for 
presenting peptides on the cell surface for recognition by T-cells, a feature that is essential for 
adaptive immunity (Wieczorek et al., 2017). However, the mechanisms of the 
immunomodulatory effects are still controversial among scientists. Some believe that contact 
between cells activates the immune regulatory activity, while others believe that it is linked to 
other factors, such as hepatocyte growth factor, interleukin (IL)-10, Interferon-g (IFNg) and 
transforming growth factor (TGF)-b1 (Nasef et al., 2007).  
Human MSCs hold great potential in today’s biomedical research and new approaches 
in the treatment of human diseases. The plasticity and in vitro proliferation of these cells make 
them an important instrument for cell transplantation (Mark et al., 2013). MSCs have been  
successfully used in treatments for various diseases, such as osteogenesis imperfecta (OI) and 
to reduce graft-versus-host disease (GvHD) via immunosuppression (Horwitz et al., 2002). In 
addition, MSCs have contributed to the regeneration process after myocardial infarction in mice 
(Kawada et al., 2004) and are also able to increase the results of allogeneic transplantation 
because those cells have immunomodulatory effects (Nesselmann et al., 2011). 
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1.3 Wharton’s Jelly mesenchymal stem/stromal cells 
The umbilical cord (UC) is an elastic structure that connects the placenta to the foetus during 
pregnancy. The UC consists of two umbilical arteries and one umbilical vein, both surrounded 
by a mucous proteoglycan-rich matrix known as Wharton’s Jelly (WJ), which is covered by 
amniotic epithelium (Figure 1) (Kim et al., 2013). The UC provides bidirectional flow, 
providing oxygen and nutrients that contribute to the adequate development of the foetus and 
eliminating waste and carbon dioxide (Taghizadeh et al., 2011). 
The UC is derived on day 26 of gestation from extra-embryonic mesoderm and/or 
embryonic mesoderm. At birth, the UC weighs approximately 40 g, is approximately 30–65 cm 
long, and has a diameter of 1.5 cm. WJ is composed of water (90%), sulphated 
glycosaminoglycans (GAGs) and a collagen-rich 3D extracellular matrix (ECM). The most 
abundant GAG is hyaluronic acid (~70%), and collagens of types I and III are more prevalent 
than IV, VI and VII (Sobolewski et al., 1997). The composition of the 3D matrix can be divided 
into three distinct zones—the sub-amnion, WJ per se, and peri-vascular zone—and even though 
different types of stromal cells are dispersed in different zones, the term WJ MSCs is often 
extended to all UC stromal cells (Corrao et al., 2013). They share common features with MSCs 
from adult tissues, for example from the bone marrow (BM), such as being positive for CD44, 
CD73, CD90, CD105, a-smooth muscle actin and vimentin (Huang et al., 2012; De Kock et al. 
2012). 
Thomas Wharton was the first to describe WJ (1656) as a gelatinous substance 
composed of various isoforms of collagen and proteoglycans. The main function of the WJ is 
to protect the arteries and veins from the compression and torsion that they can be exposed to 
during gestation. It has been demonstrated that human WJ MSCs present an elevated capacity 





Figure 1.1 Diagram of a cross section of human umbilical cord illustrating the anatomical 
compartments, including Wharton’s jelly (Figure adapted from Kim et al., 2013). 
 
There are a few hypotheses on how stem cells arrive in the WJ and their possible 
function during gestation. First, the cells within the WJ are primitive mesenchymal stromal 
cells (myofibroblasts) originating from the mesenchyme within the UC matrix or WJ. The 
function of these cells might be to secrete various glycoproteins, mucopolysaccharides, 
glycosaminoglycans (GAGs) and extracellular matrix (ECM) proteins to compose a gelatinous 
material whose main purpose is to prevent strangulation of the UC vessels during gestation. WJ 
stem/stromal cells release a secretion containing bioactive molecules such as interferons, 
growth factors, interleukins, GAGs and cell adhesion molecules, which are involved in 
immunomodulatory mechanisms and tissue repair and thus can be used for the repair of bone, 
cartilage and bone defects (Angelucci et al., 2010; Fong et al., 2012; Gauthaman et al., 2012). 
Second, there may be two waves of migration of foetal MSCs in early human expansion. The 
first wave consists of MSCs migrating from the yolk sac and aorta-gonadal mesonephros 
(AGM) to the placenta. In the second wave, the migration of MSCs is reversed, i.e., from the 
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placenta via the UC to the foetal liver and bone marrow. During these waves, MSCs are trapped 
in the gelatinous WJ. The stemness of these cells appears to be modified in their new 
environment, and they can differ from bone marrow MSCs (Wang et al., 2008; Taghizadeh et 
al., 2011).  
The hypothesis is that MSCs of foetal origin show potential between those of embryonic 
and adult stem cells. Stem cells harvested directly from the WJ have been shown to have low 
immunogenic properties (Weiss and Troyer, 2006). Weiss et al. (2008) demonstrated that WJ 
MSCs did not stimulate T-cell proliferation in a mixed lymphocyte reaction (MLR) assay but 
inhibit the proliferation of stimulated T-cells in a two-way MLR assay. They further showed 
that WJ MSCs do not express the co-stimulatory surface antigens CD40, CD80 and CD86. 
These researchers concluded that there is no evidence of immune rejection of undifferentiated 
WJ MSCs, and this cell type might be a good candidate for allogeneic transplantations. 
The definition and characterization of WJ MSCs remains unclear, and the general 
definition is not entirely accepted. However, the most significant in vitro characteristics of 
MSCs are the abilities of self-renewal and of differentiation into cells of adipogenic, osteogenic 
and chondrogenic lineages, proving their multipotent potential. Furthermore, there are a large 
number of stemness markers used to characterize these cells, including embryonic stem cell 
markers, such as OCT3/4, SSEA4, nucleostemin, SOX2, and NANOG (Ma et al., 2005; Tong et 
al., 2011; Prasanna et al., 2010; Khadan and Bhonde, 2010; Struys et al., 2011). In addition, 
WJ MSCs can express specific cell surface markers, including CD90, CD105, CD44, CD29, 
and CD73, and are negative for the haematopoietic markers CD34 and CD45 (Friedman et al., 




1.4 Potential therapeutic use of MSCs  
Among all stem cells currently available for clinical applications (Table 1.1), MSCs have been 
reported to be the most appealing source in regenerative medicine due to their therapeutic 
potential in various diseases, including heart attack, asthma, osteoarthritis, cartilage repair, 
critical limb ischaemia and stroke, to mention a few, resulting from their immunomodulatory, 
secretory and neoangiogenic properties. Currently, several clinical trials are investigating 
autologous and allogeneic hMSC therapy and show great promise (Cuomo et al., 2018).  
For a long time, MSCs have been the focus of cell-based therapies to promote cartilage 
repair, not only in humans but also in working animals such as horses (Branly et al., 2017). 
MSCs derived from adult tissues have fewer safety concerns and ethical issues regarding their 
applications, and they are the dominant source of MSCs for cell therapy for osteoarthritis (OA). 
Numerous studies have attempted to overcome the poor healing ability of articular cartilage. 
However, despite progressive advancements in MSC in vitro culture and the introduction of 
bioactive scaffolds, the feasibility and efficacy of these treatments are still uncertain. MSCs 
derived from adult tissues are the dominant source of MSCs for clinical trials involving 
osteoarthritis (OA) (Lee et al., 2017).   
BM MSC isolation involves uncertain safety and painful aspiration of BM, making it a 
challenge to recruit donors. However, clinicaltrials.gov showed 46 registered clinical trials 
displaying clinical status as: active, completed and/or recruiting, using BM MSCs, as of April 
2018, indicating the popularity and benefits of those cells in the regenerative medicine field. 
Out of the 46 studies, 12 are being performed in the Middle East, ranging from treating knee 
osteoarthritis and liver failure to emphysema. In Europe, there are 11 studies in total, of which 
4 are occurring in Italy, 4 in Spain, 3 in France and 3 in Germany. The studies vary between 
bone fractures, liver transplantation rejection, chronic renal failure, and osteonecrosis of the 
jaw to critical limb ischaemia. There are no such studies underway in the U.K. 
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UC MSCs are straightforwardly isolated and expanded in vitro, and they hold anti-
inflammatory and immunomodulatory activity and are also able to migrate to the injury site, 
making them an attractive tool for cellular therapy. At present (as of April 2018), 43 registered 
clinical trials displaying clinical status as active, or completed and/or recruiting using UC MSCs 
can be found on clinicaltrials.gov, indicating the popularity of those cells in the field of 
regenerative medicine, similar to BM MSCs. The majority of clinical studies are happening in 
China (28 studies found) and only 1 in Europe, specifically in Italy, which is recruiting 47 
patients to treat severe cases of GvHD using UC MSCs. In Chile, one study is using UC MSCs 
to treat knee osteoarthritis, the only such study in South America. More than 195 conditions are 
being treated and/or will be treated by those cells in those studies, including heart failure (in 
China), Alzheimer’s disease (Neurostemâ in Seoul, South Korea), GVHD (Kansas Medical 
Center, U.S.A.) and erectile dysfunction (Cell Therapy Center, Jordan).  
Can et al. (2017) performed a systematic analysis of 93 peer-reviewed published results, 
limitations and obstacles of clinical trials using UC MSCs. The first problems that they noted 
were the name and origin of those cells. MSCs can be isolated from different sources, and UC-
derived “multipotent stromal cells” have several stem cell-like properties; thus, they should be 
classified differently than MSCs isolated from the amnion, placenta and cord blood. However, 
several published reports are not clear about the origin of the cells used in the studies they 
describe. The subsequent concerns were the route of application, followed by the 
biodistribution of UC MSCs in a living human body, which is one of the most controversial 
topics in the cell therapy field. The majority of in vivo data are on rodents, and UC MSCs can 
be detectable at low frequencies in tissues after transplantation; moreover, when they are 
injected intravenously, signals were found in the lungs, as well as in the liver and spleen 
(Leibacher and Henschler, 2016). Moreover, the dose of cells administered (i.e., the number of 
cells per transplantation, the number of cell deliveries, and the intervals between deliveries) 
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varied immensely between the studies. The maximum number of cell deliveries was reported 
as seven by Zheng et al. (2015) in patients with acute GvHD (article in Chinese) and by Patel 
and Riordan (2015) in one patient with Duchenne muscular dystrophy (DMD), who, after each 
treatment, had an improved quality of life lasting 5-6 months and no side effects. However, 
repeated local or systemic delivery of UC MSCs may generate reactive antibodies that would 
block the beneficial effect, even though those cells lack HLA class II antigens and T-cell 
costimulatory molecules (Cho et al., 2008).  
Cells intended for cell therapy should be produced under internationally recognized 
current GMP conditions and acquire clinical-grade status. In spite of this, only 26 (28%) of the 
93 trials reviewed by Can et al. (2017) described GMP when isolating and preparing their 
clinical-grade UC MSCs for cell therapy. In addition, only 18 of those trials reported cell 
viability assessment and characterization of those cells. Furthermore, there are cells going into 
clinical applications outside clinical trials.gov, for instance by Hospital Exemption for 
Advanced Therapy for Medicinal Products, which only local hospital’s R&D have access to the 
data. Unfortunately, in the stem cell field, positive findings are more likely to be published, and 
there are a variety of biases in some of the publications, with all the reviewed trials reporting 









Table 1.2 Comparison of advantages and limitations of different types of SCs for clinical applications (adapted 
from Sun et al., 2014) 
Stem Cell Type Advantages Limitations 
Embryonic 
Stem Cells 
Pluripotent; differentiate into any type 
of cells from the three germ layers 
(endo-, ecto- and mesoderm) 
Ethical issues; possible high 






Pluripotent; differentiate into any type 
of cells from the three germ layers 
(endo-, ecto- and mesoderm); possible 
autologous treatment; low 
immunogenicity; avoids ethical 
concerns; few clinical trials in progress 
High costs; genetic 
instability; ethical issues 
(genetic material); more 
research is needed  
Adult Stem 
Cells 
Avoids ethical concerns; lower risk of 
immune rejection; available for some 
clinical treatments 
Acquisition and isolation 





Allow for allogeneic grafting without 
the use of immunosuppressive agents; 
can self-renew, proliferate and 
differentiate into specific lineages 
(multipotent); promote growth of 
adjacent cells; less susceptible to 
mutations; easy to collect and isolate 
More research needed; do not 
have specific characterization; 
signalling pathways still not 
fully characterized  
Haematopoietic 
Stem Cells  
Capable of myogenesis and 
angiogenesis; proliferate and migrate to 
injury site in response of physiological/ 
pathological stimuli 
High maintenance; unknown 
signalling pathways; low 
frequencies 
 
MSCs are known to have the ability to differentiate into different types of cell 
progenitors, including bone, cartilage, skeletal muscle and neural precursors. For that reason, 
the regenerative field, at first, studied those cells to regenerate defective cartilage and bone. 
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Because MSCs can be effortlessly isolated from different sources, such as BM, synovium and 
adipose tissue, autologous MSCs could represent an alternative source for cell therapy, avoiding 
the immunological adverse effects of allogeneic treatment. MSCs from UC are known to have 
lower immunogenicity and increased self-renewal, proliferation and expansion capacities, as 
well as trilineage differentiation capacities. The selection of the most suitable MSC population 
for cartilage and bone repair depends on their availability and ease of isolation and on their 
potential for chondrogenic and osteogenic differentiation (Orth et al., 2014; Pittenger et al., 
1999; Sudo et al., 2007; Campagnoli et al., 2001; Yang et al., 2008; Hu et al., 2003; Romanov 
et al., 2003; Heng et al., 2004).  
The therapeutic effects of MSCs in different cardiovascular and neurodegenerative 
disorders have also been investigated in clinical trials. In addition to their multilineage 
differentiation potential, MSCs might have regenerative properties via the secretion and 
stimulation of different paracrine factors, such as IL-6, vascular endothelial growth (VEGF), 
hepatocyte growth factor (HGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT3), thrombospondin, glial-derived neurotrophic factor (GDNF) and fibroblast growth factor 
(FGF) (Kalladka and Muir, 2014; Mastri et al., 2014; Hsuan et al., 2016).  Furthermore, 
secretory product of MSCs, such as exosomes, can have a similar regenerative effect as the 
parental MSCs. It is believed that MSCs-exosomes release biologically active molecules that 
affect migration, proliferation and survival of neighbouring cells without the risks associated 






1.5 Immunomodulatory effects of MSCs  
The major advantages of MSCs are their anti-inflammatory and immunosuppressive effects, 
which make them suitable and desirable cells for clinical applications. They secrete an array of 
biological mediators, such as cytokines, chemokines and growth factors, that are involved in 
tissue regeneration and other functions, including anti-fibrotic, mitogenic, anti-apoptotic, 
wound-healing and angiogenic functions (Koelling and Miosge, 2009; Caplan, 2007; Goldberg, 
2012; Gupta et al., 2012). 
The immunosuppressive function of MSCs is activated by pro-inflammatory cytokines. 
It has been reported that, in vitro, IFN-g can interact with TNF-a, IL-1a, and IL-1b to induce 
the ability of MSCs to inhibit T-cell proliferation (Zhang et al., 2008). Cytokines are small 
glycoproteins that regulate immunity, inflammation and haematopoiesis and are produced by a 
number of cells, such as leukocytes. They regulate physiological and pathological immune and 
inflammatory functions, and their secretion is a self-limited event (Khan, 2008). 
T helper type 1 (Th1) cells are a lineage of CD4 T-cells responsible for cell-mediated 
immune responses and are activated during host defence against intracellular viral and bacterial 
pathogens. Th1 cells secrete IFNg, IL-2, IL-10, and TNFa/b. As an effector cytokine of Th1 
immunity, IFNg is a regulator, and its production by natural killer (NK) cells, CD4 T-cells and 
CD8 T-cells targets antigen recognition in antigen-presenting cells (APCs), such as 
macrophages and dendritic cells. IFNg activates macrophages stimulating them to express high 
levels of pro-inflammatory cytokines, such as TNFa, IL-12, IL-23 and IL-1b, and also by 
promoting Th1 T-cell responses and robust inflammation. APCs express major 
histocompatibility complex (MHC) I and II proteins, providing signals to stimulate proliferation 
and differentiation of lymphocytes by cross-presentation of antigenic pathways. 
Concomitantly, IFNg signalling releases other cytokines and factors that sustain inflammation 
for longer maintenance of Th1 responses and to inhibit differentiation of regulatory T (Treg) 
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cells (Sica and Mantovani 2012, Shachar and Karin, 2013). Treg cells suppress the activation, 
proliferation and cytokine production of CD4 T-cells and CD8 T-cells, suppressing the immune 
response, and they may also suppress B-cells and dendritic cells by producing soluble 
messengers such as TGFb, IL-10 and adenosine. Tregs are formed by the differentiation of 
naïve T-cells outside the thymus (Moncrieffe, 2018). Therefore, IFNg expression is an 
important parameter for which exposure levels, target organ and cellular environment define 
the outcome of the immune response and impact the balance between physiological protection 
and pathological autoimmune responses. Thus, independent of the signalling pathway, IFNg 
will directly or indirectly define the intensity of the inflammatory response (Green et al., 2017).  
MSCs from certain tissues have a unique tumour-homing capacity that enables them to 
serve as vehicles for gene therapy of advanced cancers. The tumour tropism of these MSCs is 
mediated by multiple chemokine receptors such as CXCR4 and CXCR6, CD44, and VEGFR1 
and by integrins such as ITGA6 and ITGB1 (Zhao et al., 2015).  
Chemokines are dependent on IFN-g and can be secreted by endothelial cells, 
fibroblasts, keratinocytes, MSCs, thyrocytes and more. High levels of CXC chemokines in 
peripheral fluids are therefore a marker of the host immune response (Antonelli et al., 2014; 
Khan 2008). Chemokines are a large family of small heparin-binding chemotactic cytokines 
released by many cells and consist of four groups based on cysteine number and amino acids: 
CXC, CC, C and CX3C. Neutrophils and lymphocytes are the targets of CXC chemokines, 
including CXCL1 to CXCL17. CXC chemokines contribute to the pathogenesis of many 
autoimmune diseases from type 1 diabetes to rheumatoid arthritis and systemic lupus 
erythaematosus (SLE).  
BM MSCs constantly supply new stem cells to support natural cell turnover and repair 
in various tissues, including the kidneys (Cornacchia et al., 2001; Poulsom et al., 2001). Of the 
two major marrow-derived stem cell lineages, haematopoietic and mesenchymal, MSCs 
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possess unique promises for renal repair because nephrons are largely of mesenchymal origin. 
In a model of cisplatin-induced acute kidney injury (AKI), MSCs were more efficacious than 
haematopoietic stem cells in repairing damage (Morigi et al., 2004). Li et al. (2006) 
successfully infused BM MSCs to prevent death by renal failure in a rodent model.  
 
1.6 Issues with using MSCs in cellular therapy  
The production of MSCs faces limitations, including the variability among donors, scarcity of 
MSCs in adult tissues, dependence upon donors (younger donors have advantages over older 
ones), and a low proliferative rate compared to other pluripotent stem cells (Siegel et al, 2013).  
BM MSCs are the most common and generally used MSCs for human stem cell research and 
clinical applications. In the BM, MSCs contribute to the formation of the haematopoietic stem 
cell niche, making them the first choice of treatment for haematological malignancy (Uccelli et 
al., 2008). However, the procedure to obtain BM is painful and carries the risk of infection, and 
it is difficult to recruit donors. For this reason, the cell therapy field is continually searching for 
new, non-invasive sources of MSCs. Among the various options are peripheral blood, placental 
tissue, amniotic tissue, dental pulp, nasal mucosa and adipose tissue-derived (AD) MSCs 
isolated from extra fat tissue obtained from cosmetic surgery. AD MSCs have proven suitable 
for clinical applications, although there are hypotheses that these cells bear abnormal metabolic 
features related to excessive body weight (Devito et al, 2014; Pikula et al., 2013).  
BM MSCs appear to be clearly different and have disadvantages over UC MSCs in 
regard to in vitro culture and clinical applications (Huang et al., 2012). UC MSCs have higher 
proliferation rates and show increased colony-forming units (CFUs) and stemness 
characteristics that last longer after serial cell passaging (Fong et al., 2010). Additionally, UC 
MSCs express some of the ESC markers at different levels, such as OCT4, embryonic surface 
marker antigens (SSEA-4, TRA-1-60 and TRA-1-80), alkaline phosphatase (ALP), DNMT3B and 
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GABRB3 and genomic markers (SOX2, NANOG, REX2) (Conconi et al., 2011; Carlin et al., 
2006; Hoynowski et al., 2007). 
MSCs from different sources have proven to suppress immunological responses in 
different diseases in animal models and in vitro, but the mixed results in clinical trials for the 
treatment of autoimmune and inflammatory diseases make them an unpredictable source. The 
major challenge is to develop a consistent and effective MSC-based immunosuppressive 
therapy using MSCs from different tissues of origin, different manufacturing processes and 
different donors (Griffin et al, 2013; Sharma et al., 2014; English, 2013; Klinker and Wei, 
2015; Ho et al., 2008; Phinney et al., 2012).  
Based on their capacity to migrate to injuries sites, MSCs promise an improved 
treatment for cancer patients. They are able to repair tissues damaged by cancer and/or by 
radical therapies, and they are also capable of delivering different anticancer agents. 
Donnenberg et al. (2010) reported promising regeneration capacities of MSCs after radical 
cancer treatment in animal models and after soft tissue reconstruction after damaging surgery 
of the neck, breasts or head. Moreover, the osteogenic differentiation properties of MSCs 
combined with their injury-homing capacities make them the best candidate for tumour-induced 
osteolysis (Fritz et al., 2008; Li et al., 2011). However, tissue-derived MSCs, including those 
from the UC, BM and AD, have also shown a predisposition to promote cancer rather than 
inhibit it, and endogenous MSCs can promote cancer growth (Droujinine et al., 2013; 
Zimmerlin et al., 2013; Chaturvedi et al., 2013; Quante et al., 2011; Song et al., 2011; Jung et 
al., 2013). 
As mentioned before, UC MSCs hold great advantages over adult MSCs, first because 
they can be isolated in a non-invasive, low-cost and pain-free manner; second, because of their 
high proliferation rate and their low immunogenicity because of their naive cell character; and 
last, because of their potential allogeneic and autologous application in congenital disorders 
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and, when cryopreserved, in adulthood (Erices et al., 2000; Joerger-Messerli et al., 2016). 
However, these progenitor cells isolated from post-natal or adult tissues are susceptible to 
differences between lines, i.e., between donors, and to senescence during in vitro expansion. 
Human PSC MSCs, including those derived from ESC MSCs and those derived from iPSC 
MSCs, could avoid this issue and represent a cell source with consistent qualities and an 
expanded source of MSCs but without the tumorigenicity issues associated with the pluripotent 
cells (Yen et al., 2009). PSC-derived MSCs are able to differentiate into mesodermal lineages 
and show immunomodulatory effects similar to those of adult BM MSCs (Peng et al., 2016).  
 
1.7 Reprogramming and Induced Pluripotent Stem Cells  
Resetting the epigenome of a somatic cell to a pluripotent state, i.e., reprogramming, is a 
technology developed from various advances in the field of developmental biology. First, 
somatic cell nuclear transfer (SCNT), or nuclear cloning, the procedure used to generate Dolly 
the cloned sheep, demonstrated that a somatic cell nucleus could change its epigenetic state and 
reset to an early developmental state, inducing reprogramming (Wilmut et al., 1997). Second, 
ESC isolation and culture conditions were developed and improved, allowing the successful in 
vitro culture of pluripotent stem cells (Martin, 1981; Evans & Kaufman, 1981; Thomson et al., 
1998). Last, various studies of early embryonic development identified a set of transcription 
factors able to contribute to the maintenance of the ESC phenotype and proliferation in culture, 
including OCT3/4 (Nichols et al., 1998; Niwas et al., 2000), SOX2 (Avilion et al., 2003), and 
NANOG (Chambers et al., 2003; Mitsui et al., 2003), which could be used alongside 
transcription factors associated with genes that are upregulated in tumours, such as c-MYC and 
KLF4 (Cartwright et al., 2005; Li et al., 2005).  
Weintraub et al. (1989) were the pioneers in cellular reprogramming, reporting 
successful reprogramming of human fibroblasts into muscle cells via overexpression of the 
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transcription factor MYOD1, the first report showing that cell development could be modified 
and that transcription factors are crucial for determining cell fate (Ronquista et al., 2017). 
In 2006, Takahashi and Yamanaka investigated the properties of 24 transcription factors 
involved in the conventional biology of ESCs. Using retroviruses as vectors to introduce and 
overexpress all 24 of those transcription factors, four factors in particular were able to convert 
mouse somatic cells (fibroblasts) into cells showing characteristics similar to those of ESCs. 
The four factors were SRY-related HMG-box 2 (SOX2), Octamer binding protein 4 (OCT4), 
also known as POU5F1, Kruppel-like factor 4 (KLF4) and MYC.  
In 2007, James Thomson (Yiu et al., 2007) and colleagues derived iPSCs using a 
different combination of reprogramming factors that included NANOG and LIN28 instead of 
MYC and KLF4. More than 10 years later, the same transcription factors (OCT4, SOX2, KLF4, 
MYC, NANOG and LIN28) remain the foundation of the iPSC field (Li and Belmonte, 2016).  
Transcription factors (TFs) are proteins that bind specific sites or elements in regulatory 
regions of DNA sequences (silencers and enhancers). Those factors may increase or decrease 
gene transcription and protein synthesis and consequently change cellular behaviour. Their 
activation is complex and consists of multiple intracellular signalling pathways, which are 
stimulated by cell-surface receptors and by ligands such as glucocorticoids and vitamins A and 
D. Transcription factor activation can be temporary and can produce effects ranging from 
transient changes at the cell surface to long-term changes in gene transcription. Therefore, 
transcription factors can be activated within the nucleus, binding directly to the DNA, or within 
the cytoplasm, sending specific nuclear signals to target the nucleus, acting as a “nuclear 
messenger”. Many transcription factors have been identified, and a large amount of the human 
genome appears to code for these proteins (Adcock and Gaetano, 2009).  
Reprogramming somatic cells comprises various steps that result in the expression of 
markers associated with pluripotency such as NANOG. Although morphological changes can 
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be identified in the early stages of the reprogramming process, the gene expression of those 
markers occurs during the late stage and indicates complete reprogramming. The main 
reprogramming factors used for reprogramming are OCT4, SOX2 and KLF4 (O, S and K - 
OSK), but additional factors, such as c-MYC, which was used to convert mouse fibroblast into 
iPSCs in the original reprogramming experiment by Takahashi and Yamanaka (2006) but later 
shown to be dispensable, are used to enhance the efficiency of iPSC generation (Okita et al., 
2007; Maherali et al., 2007; Nakagawa et al., 2008; Wernig et al., 2008; Wernig et al., 2007). 
Furthermore, two- or three-factor reprogramming using exogenous OCT4 with either SOX2 or 
KLF4 were able to establish transient states of pluripotency of mouse embryonic fibroblasts 
(MEF) (Nemajerova et al., 2012). In another study by Kim et al. (2008), OCT4 together with 
either KLF4 or c-MYC were sufficient to generate iPS cells from adult mouse neural stem cells, 
showing the possibility of reprogramming cells with less transcription factors.  
In humans, there is limited natural regeneration of cells and tissues, and it can be 
produced through activation of somatic stem cells located in a niche (for example, blood cells) 
or by inducing differentiated cells to proliferate (for example, the liver). Transdifferentiation, a 
natural mechanism in which manipulation of chromatin dynamics occurs to the point at which 
cells can switch lineages, and reprogramming studies have documented that reprogramming 
somatic cells directly to a cell of another somatic fate involved dedifferentiation and passage 
through a less differentiated progenitor state. Dedifferentiation is another mechanism that 
occurs before the transdifferentiation associated with natural regeneration of cells and tissues, 
and it involves the reversion of a fully differentiated somatic cell back to a less differentiated 
state. This stage allows the cell to proliferate again before re-differentiating, allowing the 
regeneration of cells that have been lost (Xie et al., 2004; Jopling et al., 2011).  
The reprogramming efficiency at which somatic cells transform into iPSCs is typically 
below 1%, suggesting not only that are the reprogramming factors essential in initiating the 
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changes but also that the subsequent events are required to maintain the reprogramming 
process. Changes in epigenetic status, such as DNA methylation and histone modification, are 
critical events for reprogramming, but their mechanisms and driving force are still unclear 
(Takahashi, 2014). It is known that TFs are responsible for restructuring the chromatin 
landscape in the regions where they bind, either by allowing the binding of other TFs or by 
inducing locus-specific DNA demethylation. However, the success of the reprogramming 
process requires complete erasure of the existing somatic epigenetic memory followed by the 
formation of a new epigenetic signature. Therefore, although ectopic expression of TFs such as 
OSK can change cell fate, chromatin modifications are still a well-described barrier to the 
reprogramming process (Mikkelsen et al., 2008; Pasque et al., 2012; Chen et al., 2013; Gaspar-
Maia et al., 2013; Sridharan et al., 2013).  
The low reprogramming efficiency of some cell types, including melanocytes, neural 
stem cells, adipose stem cells, meningiocytes, keratinocytes and fibroblasts (Aasen et al., 2008; 
Kin et al., 2008; Sun et al., 2009; Utikal et al., 2009; Qin et al., 2008), has prompted scientists 
to look for not only better reprogramming methods but also highly reprogrammable and better 
accessible tissues. The advantages and disadvantages of reprogramming different human cell 
types are still uncertain, but a specific cell type might result in a better reprogramming 
efficiency. The umbilical cord and vessels of the placenta originate from the hypoblast, while 
the amniotic membrane of the placenta and the foetus originate from the epiblast. The amniotic 
membrane contains a layer of epithelial cells surrounding the amniotic cavity, and the internal 
layer is formed of mesenchymal-like cells. The trophectoderm, the outer layer of the blastocyst 
(embryo), is responsible for implantation of the embryo in the mother’s uterus and also gives 
rise to extra-embryonic tissues, and its cells may retain an immature phenotype while the 
embryo itself develops. Thus, the placenta and umbilical cord, normally discarded after birth, 
contain a valuable source of cells with stem-cell-like properties (Red-Horse et al., 2004; Can 
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& Karahuseyinoglu, 2007; Yen et al., 2005; Fukuchi et al., 2004; Miki & Strom, 2006), and 
they may represent a better choice of cells for reprogramming and a useful tool for cross-
comparisons with iPSCs generated from other tissues. Moreover, it is interesting to think that 
extra-embryonic tissues are less differentiated and carry fewer mutations than adult somatic 
cells; thus, iPSCs from these sources can be more faithfully reprogrammed. Likewise, neonatal 
tissues, such as umbilical cord, are commercially stored, and they could perhaps be used for 
future personalized stem cell-based therapies (Cai et al., 2010).  
Another important factor in the successful generation of iPSCs is the reprogramming 
method used (Table 1.1). The method should be chosen according to the goals of the research 
project and whether the presence of integrated sequences will hold back the applications of the 
iPSC line. If the iPSC line is generated for research purposes, with no translational aim, a viral 
infection with the STEMCCA (stem cell cassette expressing OSKM) will be adequate, as this 
method works well for multiple cell types. On the other hand, if the research goal has 
translational purposes, the reprogramming method chosen should cause no genome-sequence 
modifications (Malik and Rao, 2013). A variety of methods for delivering transcription factors 
to somatic cells have been reported. Some are classified as integrating methods, which involve 
the integration of genetic material; others are classified as non-integrating and involve no 
genetic modifications of the target cells. The original method of reprogramming murine 
fibroblasts by Takahashi and Yamanaka used a retrovirus as a vector, an integrating method, to 
transduce the four transcription factors OSKM into mouse fibroblasts (MEFs). Other 
integrating methods of reprogramming are excisable lentiviral and adenovirus vectors. Non-
integrating methods include direct protein transduction (Kim et al., 2009), episomal vectors 
(Yu et al., 2009), RNA-based Sendai virus (Fusaki et al., 2009), micro-RNA transfection 
(Anokye-Danso et al., 2011; Miyoshi et al., 2011) and mRNA-based methods (Warren et al., 
2010). 
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Table 1.3 Summary of reprogramming methods for derivation of iPSCs 
 
Delivery Method Advantages Disadvantages 
MMLV-derived 
retrovirus 
Very efficient Genome integration; infects dividing cells; 
random viral integration with risk of 
mutagenesis 
Adenovirus Infects dividing and non-dividing 
cells; transgene-free and vector-free; 
no genomic integration 
Slow and inefficient 
 
Lentivirus Infects dividing and non-dividing 
cells; very efficient 
Genome integration with risk of mutagenesis  
Protein Non-integrating Low efficiency; slower reprogramming 
kinetics; short protein half-life; requires 
multiple transfections 
Sendai virus Non-integrating RNA virus; high 
efficiency 
Multiple passages are required to eliminate 
viral transgenes; virus biosafety concerns 
mRNA Non-integrating; non-virus; high 
efficiency; fast kinetics 
Requires multiple transfections; requires use 
of B18R to suppress interferon response 
miRNA Non-integrating; non-virus; no 
overexpression of transcription 
factors 
Low efficiency; requires multiple 
transfections 
Minicircle vectors Non-integrating; non-virus Works for a few cells; super-low efficiency 
PiggyBac transposon Non-virus; non-integrating; good 
efficiency 
Works for a few cells; low efficiency  
Episomal plasmid Non-integrating; non-virus Super-low efficiency; requires transfections 
daily for long period of time 
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The rapid advances in iPSC technology in regenerative medicine have motivated many 
exciting research advances, and the major two applications of iPSCs are as follows: (1) to 
develop human disease models that can be used to better understand the disease and also to 
provide more accurate toxicity assessment of new drugs, leading to new treatments, and (2) to 
treat diseases or injuries, i.e., cell-based therapy; however, the iPSCs must be fully 
differentiated into a tissue-specific cell type before use in cell therapy. In 2014, in a Japanese 
clinical trial, the first patient received a transplant of iPSC-derived retinal pigmented epithelial 
cells for age-related macular degeneration, which was the first of its kind using iPSC-based 
















1.8 Differentiation of iPSCs into MSCs  
To address the limitations of the in vitro expandability and uniformity of MSCs, Zhao et al. 
(2015) and Luzzani et al. (2015) derived MSCs from iPSCs that can be expanded consistently 
and provide cell banks from a single cell clone. We have chosen these two protocols because 
the modifications from previous reports of ESCs and iPSCs differentiated MSCs (de Peppo et 
al., 2013; Sanchez et al., 2011) lead to better results.   
Zhao et al. (2015) reported a protocol capable of producing highly enriched MSC-like 
cells with high efficiency, without the invasion and stemness of cancer cells as is seen with BM 
MSCs. Moreover, their iPSC MSCs expressed lower levels of pro-tumour factors, including IL-
6, prostaglandin E2 (PGE2) and hyaluronan, than BM MSCs, revealing an alternative and 
valuable source of MSCs. They adapted the protocol from Sanchez et al. (2011), who reported 
that inhibition of SMAD-2/3 signalling promoted derivation of MSCs from ESCs. They used a 
chemically defined medium supplemented with SMAD-2/3 inhibitor. SMAD is a transcription 
factor involved in TGFb signalling, and it plays an important role in directing fate decisions for 
MSCs. TGFb is considered a potent inhibitor of haematopoiesis, a mesodermal tissue and 
Sanchez et al. (2011) hypothesized that inhibition of SMAD-2/3 would have an effect similar 
to that in the hematopoietic system, generating MSCs from PSCs.  However, their protocol was 
not xeno-free, and their medium and coating matrix, for cellular attachment and growth, 
contained animal-derived products. Because the aim of our experiment was to derive MSCs for 
clinical purposes, we adapted their protocol to xeno-free conditions.  
Luzzani et al. (2015) developed a simple protocol of derivation of pluripotent-derived 
(PD) MSCs using only human platelets and B27 (Thermo Fisher) as supplements, a xeno-free 
derivation. Human platelets (HPLs) are known to produce significant levels of growth factors 
(Rauch et al., 2011; Iudicone et al., 2014). B27 is a supplement made with 21 ingredients, 
including hormones such as corticosterone, fatty acids such as linoleic acid and L-carnitine, as 
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well as insulin and glutathione, and it supports neuronal cultures (Chen et al., 2008). This 
protocol generated significant numbers of cells in a consistent and robust way in only 3 – 4 
weeks at low cost. The group also performed parallel tests using the same protocol but with 
foetal bovine serum (FBS) as a supplement; however, the growth rate of those cells was much 
lower than with HPL. Because MSC autologous therapies often require large and repeated 
doses, a limitless source of MSCs generated from an individual could offer an economical and 
valid alternative. We used this second protocol to differentiate iPSCs into MSCs and 
subsequently compared them to iPSC MSCs derived using the protocol adapted from Zhao et 
al. (2015).  
Currently, Australian company Cynata is testing their technology of producing 
mesenchymoangioblasts (MCAs) from a single-donor iPSC at a commercial scale. The clinical 
trials for GvHD using these cells are already underway, with promising results, in the U.K., 















Aims and objectives 
The overall goal of the project is to investigate the potential of WJ MSCs in cellular therapy. 
We hypothesized that WJ MSCs  
• Have the potential to replace BM MSCs for clinical applications and 
• Can be reprogrammed into iPS cells suitable for clinical applications.  
The first aim of the project is to critically assess WJ MSCs as a potential replacement for BM 
MSCs in cellular therapy. 
Objectives: 
1) To develop chemically defined, animal-product-free culture conditions for derivation 
and expansion of WJ MSCs.  
2) To compare the expression profile of putative MSC “markers” in clinical-grade BM 
MSCs with that of WJ MSCs grown under animal-product-free conditions. 
3) To determine the proliferative potential of WJ MSCs cultured under chemically 
defined, animal-product-free culture conditions. 
4) To test the adipogenic, osteogenic and chondrogenic differentiation potential of WJ 
MSCs grown under chemically defined, animal-product-free culture conditions. 
5) To assess the immunomodulatory potential of WJ MSCs grown under chemically 




The second aim of the project is to critically assess WJ MSCs as a potential tissue source for 
clinical-grade iPSCs.  
Objectives: 
1)  To develop a reprogramming protocol in chemically defined, animal-product-free 
culture conditions using a genome non-integrating delivery system. 
2) To determine the reprogramming efficiency of various WJ MSC fractions. 
3) To compare the transcriptome profile and differentiation potential of WJ MSC-





















2. EXPERIMENTAL PROCEDURES 
2.1 HUMAN TISSUE PROCESSING AND CELL CULTURE 
2.1.1 Umbilical cord (UC) collection 
The National Health Service Research Ethics Committee protocol 12/NE/0371 was used for 
isolation and derivation of WJ MSC and 14/SW/0042 was GMP compliance of the protocol. 
The protocols include reprogramming and characterization of iPSCs. Informed consent was 
obtained in the morning before the scheduled Caesarean sections (C-section) of Caucasian 
healthy women at gestational age ≥ 37 weeks. We collected the UCs from C-sections only to 
minimize bacterial contamination.  
After C-section delivery, whole placenta with the attached UC was inspected by the 
nurse in charge for any possible anomalies. After inspection, she consented to proceed with 
collection. Subsequently, a 10 -20-cm piece of the UC was cut and placed immediately inside 
a sterile 500-ml bottle containing PBS (ThermoFisher, cat. no. 10010023). The cord was then 
rinsed twice, in the same bottle, with PBS to eliminate any remaining blood. The bottle 
containing the UC in PBS supplemented with gentamicin/amphotericin solution 
(ThermoFisher, cat. no. R01510) was transported inside a Bio Carrier Bag at room temperature 
(RT) to the laboratory.  
 
2.1.2 Material and Medium preparation for MSC derivation 
We cultured UC explants under three different conditions. 
1) Chemically defined, xeno-free conditions (dXF): We used the xeno-free (XF) defined 
culture medium StemGro (Corning, cat. no. 40-410-KIT) and CTS CELLstart substrate 
(ThermoFisher, cat. no. A1014201)-coated 100-mm tissue culture dishes (Corning, cat. no. 
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430167). The CELLstart was diluted according to manufacturer’s instruction. Briefly, 133.4 µl 
of CELLstart was diluted in 10 ml of Dulbecco’s Phosphate Buffered Saline with calcium and 
magnesium (DPBS +Ca +Mg) (Thermo Fisher, cat. no. 14040133). Subsequently, the plate was 
incubated for a minimum of 1 h 45 min and a maximum of 2 h at 37°C with 5% O2.  
2) Non-defined, XF conditions (nXF): we used Alpha Minimum Essential Medium 
Eagle (α MEM) (ThermoFisher, cat. no. 32561029) supplemented with 5% GMP graded 
Human Platelet Lysate (hPL) (Stemulate; Cook Regentec, cat. no. G35220).  
3) Standard (STD) conditions: we used Dulbecco’s Modified Eagle Medium (DMEM) 
(ThermoFisher, cat. no. 41965039) supplemented with 10% foetal bovine serum (FBS) 
(HyClone; GE Healthcare, cat. no. SH3007).  
 
2.1.3 Plating UC explants 
The bottle containing the UC was placed inside a biosafety cabinet, and the UC was transferred 
into a 140-mm dish (Nunc, cat. no. Z717231). We cut the cord into three equal pieces and 
washed each piece thoroughly with PBS until any remains of blood were eliminated. Each piece 
of the cord was cut open longitudinally with a sterile scalpel to expose the Wharton’s jelly (WJ) 
and then sliced into 0.5 - 1 cm3 pieces. Ten to fifteen pieces (explants) were transferred into a 
pre-labelled 100-mm dish that had been previously coated with CTS CELLstart for dXF 
conditions and/or into a pre-labelled 100-mm tissue culture dish without any coating for nXF 
and/ or STD conditions. To facilitate the attachment of the UC to the plastic surface, the plated 
explants were exposed to air inside the biosafety cabinet for 5 - 10 min before slowly adding 
15 - 25 ml of cell culture medium (Reinisch and Strunk, 2009).  
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Three conditions, dXF, nXF and STD, as described before, were tested. After covering 
the plated explants with the appropriate medium, the plates were transferred to an incubator 
(Heraus) and cultured at 37 ˚C with 5% or 20% O2.  
 
2.1.4 WJ MSC derivation, passaging, counting of cells, cryopreservation and thawing 
We replaced the explant medium freshly every 3 days until cell outgrowth was observed under 
a phase contrast microscope. The WJ MSCs were expanded for 7 - 14 days before the first 
passaging. 
For cell passaging, we first washed the cell monolayer with pre-warmed DMEM and 
then incubated it in Tryple Select (ThermoFisher, cat. no. 12604-021) for 3 min at 37°C. The 
Tryple Select was then diluted in an equal amount of pre-warmed DMEM. Cells were collected, 
counted and centrifuged at 160 g for 5 min. The cell pellet was resuspended according to the 
number of cells in complete medium and seeded into a new cell culture flask or resuspended in 
freezing solution for cryopreservation. For freezing, we froze 0.8 - 1 x 106 cells/ vial. For 
passaging, 1:3 ratios were used, i.e., one confluent T75-cm2 flask (between 1 - 3 x 106 cells) 
(Corning, cat. no. 3276) was seeded into three T75-cm2 flasks (between 0.33 - 1.0 x 106 cells/ 
flask).  
For cell counting, the cells were resuspended in growth medium and counted using a 
haemocytometer (Hausser). Population doublings (PDs) were calculated according to the 
formula: PD = [log (A/B)] / 0.301, where A is the number of cells harvested and B is the number 
of cells seeded into the plate.  
The cells grown under STD conditions were frozen in 10% DMSO (Merck, cat. no. 
D4540) in FBS, whereas the cells grown under nXF or dXF conditions were frozen in Cryostor 
CS10 (Merck, cat. no. C2874) and stored in liquid nitrogen (LN2). For freezing, we resuspended 
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1 x 106 cells/ ml in freezing solution and aliquoted them into Nalgene freezing vials 
(ThermoFisher, cat. no. 5000-1012). Subsequently, the vials were stored in a freezing container, 
Mr. Frosty™ (ThermoFisher), for the first hour at -20°C and then transferred to -80°C freezer 
for at least 4 h, prior to being transferred into LN2 for extended storage at -196°C.  
For thawing, the cryovial was thawed inside the incubator at 37°C for 5 min. 
Subsequently, the thawed contents of the vial were transferred to a 15-ml conical tube (Thermo 
Scientific) containing 5 ml of pre-warmed DMEM and centrifuged at 160 g for 5 min. The cell 
pellet was resuspended in complete medium and seeded into a new cell culture flask or plate.  
 
2.1.5 Maintenance of WJ MSCs 
Cells were ready for passaging when they reached 60 - 80% confluence levels, and the 
subculture was performed based on the general methods described above. Before plating, the 
cells were counted, and the concentration was readjusted to 0.5 - 1.0 x 106 cells/ ml. Next, 
typically 1 ml of resuspended cells was seeded in a new flask, and the remaining cells were 
frozen. WJ MSCs used for the reprogramming protocol in this study were no older than passage 
number 6 (PD = 16).  
 
2.1.6 Culture of Bone Marrow MSCs 
The human bone marrow (BM) MSCs used in this study were derived and donated by the 
Department of Haematology, Imperial College London. The BM MSCs were used as part of a 
collaboration agreement with Prof. Dr. Francesco Dazzi and Dr. Antonio Galleu. 
Human BM MSCs were cultured in DMEM supplemented with 10% hPL. The medium 
was exchanged every 4 - 5 days, and the cells were ready for subculture when the monolayer 
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reached 60 - 80% confluence. To passage BM MSCs, the same procedure for WJ MSC as 
described above (section 2.1.4) was followed.  
 
2.1.7 Culture of the Kasumi Cell line 
During this study, we also used the commercially available cell line Kasumi (ATCC-CRL-
2724), which was generated from the peripheral blood of an acute myeloid leukaemia patient. 
Cells were maintained in RPMI-1640 medium (ThermoFisher, cat. no. 11875093) 
supplemented with 20% FBS. Fresh medium was added every 2 days, and the cells were 
passaged after 5 to 7 days in culture. These cells were used as a positive control for CD34 and 
CD45 markers to establish the correct populations of cells by flow cytometry. 
 
2.1.8 Culture of Dermal Fibroblasts 
During this study, we used commercially available fibroblast primary cells: the BJ cell line 
(ATCC, cat. no. CRL-2522). Cells were recovered for culture by transferring the purchased 
cryovials from liquid nitrogen to the incubator at 37°C until most of the cells were thawed. The 
cells were then transferred into a 15-ml conical tube containing 5 ml of pre-warmed fibroblast 
medium and then centrifuged at 160 g for 5 min to wash away the DMSO, followed by 
aspiration of the supernatant and cell pellet resuspension in 10 ml of fibroblast medium. The 
resuspended cells were then transferred to a T75-cm2 flask for further expansion. The medium 
was changed every other day.  
The fibroblasts were ready for subculture when the monolayer reached 80 to 90% 
confluence based on the above-described WJ MSC protocol. The passage number used for 
generation of iPSC lines was no more than passage number 6.  
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To passage dermal fibroblasts, the same procedure for WJ MSCs as described above 
(section 2.1.4) was followed. 
 
2.1.9 Human Embryonic Stem Cells (hESCs) 
The human embryonic stem cell line (hESC) used in this study was KCL034, a hESC line 
derived in the Stem Cell Laboratory at King’s College London with Guy’s Hospital ethical 
approval (06/Q0702/90) under Human Fertilisation and Embryology Authority (HFEA) 
research license R0133 (Devito et al., 2014; 2016).  
The KCL034 cell line was grown on Vitronectin XF™ (STEMCELL Technologies, cat. 
no. #07180 kit), a defined XF cell culture coating matrix For Vitronectin XF coating, the matrix 
was diluted in CellAdhere buffer provided with the kit to a final concentration of 10 µg/ ml 
(i.e., 40 µl of matrix in 1 ml of buffer). We coated each well of a non-tissue culture-treated 6-
well plate with 1 ml and incubated the plate at RT for at least 1 h at 37˚C, 5% O2. The excess 
coating was then removed from each well, and the well was gently washed once with 1 ml of 
CellAdhere buffer before plating the cells. The culture medium used for expansion and 
maintenance of hESCs was TeSR2™ (STEMCELL Technologies, cat. no. #05860). To 
improve the recovery of cryopreserved hESCs, we added the ROCK inhibitor Y-27632 
dihydrochloride (Santa Cruz, cat. no. CAS129830-38-2) to a final concentration of 10 µM in 
the culture medium in the first 24 h of culture.  
When the hESC colonies were large and beginning to merge, normally at 4 to 6 days 
after initial seeding, we performed enzymatic passaging using dispase (STEMCELL 
Technologies, cat. no. #07923) at a concentration of 1 U/ml. The culture medium was aspirated, 
and the cell monolayer was rinsed twice with pre-warmed DMEM. Dispase was added to the 
well (1 ml per well in a 6-well plate), followed by incubation at RT for 1 min. Subsequently, 
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the dispase was aspirated, and the cell monolayer was rinsed twice with pre-warmed DMEM to 
wash away any residue. In the last step, TESR2 was added to the well, and the cells were 
removed with the assistance of a cell lifter (Corning, cat. no. 3008). The colonies were detached 
and disaggregated into a smaller cluster of cells by gently pipetting up and down. Finally, we 
plated the cells and distributed them evenly into a new Vitronectin XF-coated 6-well plate. 
Between 1 – 1.5 x 105 cells were plated into each new well of a 6-well plate. The colonies were 
expanded for further procedures such as immunocytochemistry and cell differentiation. 
 
2.2 CHARACTERIZATION OF NATIVE WJ MSCs (nMSCs) 
2.2.1 Flow Cytometry 
Using flow cytometry, we analysed cell surface epitope profiles to compare nMSCs isolated 
under different conditions.  
To determine the correct antibody concentration and avoid wasting antibodies, we 
titrated each antibody used in this experiment. The concentration of all antibodies was not 
given, and the manufacturers’ recommended dilution was 1:11 for up to 1 x 107 cells/100 µl. 
Using the recommended dilution as the starting point, three more concentrations were tested 
(1:25; 1:50 and 1:100). The dilution of 1:25 (4 µl of the antibody into 100 µl of PBS) was found 
to be the best dilution for all antibodies.  
Using a FACS CANTO II and FACSDIVA software (BD Biosciences), the expression 
of cell surface molecules was evaluated on WJ MSCs (STD, nXF and dXF conditions) in 
different passages, and BM MSCs and dermal fibroblasts were used for comparison. For this 
purpose, 1 x 106 cells were resuspended in 100 µl of ice-cold PBS supplemented with 10% FBS 
and then mixed with the appropriate primary antibody (Table 2.2.1). Subsequently, they were 
incubated in the dark for 15 min at RT. After washing with PBS, the cells were resuspended in 
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500 µl of ice-cold PBS with 10% FBS. All antibodies used in the flow cytometry experiment 
were purchased from Miltenyi Biotech. 
The data were analysed using FACSDIVA software. Briefly, using the most common 
parameters to estimate cell size, forward scatter (FSC) and side scatter (SSC), we selected only 
viable, single cells events and eliminated dead cells and cell debris from the analyses. 
Moreover, gating controls were established with positive and negative controls to determine 
the correct signal.  
Four different fluorophores were used for this experiment: allophycocyanin (APC); 
fluorescein isothiocyanate (FITC), phycoerythrin (PE or R-PE) and Violet or Pacific Blue (e-




Figure 2.2.1 Map of the multicolour spectral overlap of the fluorophores. Map showing absorption/ 
emission (wavelengths) spectra of the fluorophores used for flow cytometry (Parenteau, 2011). APC, 




Table 2.1 Antibodies used for Flow cytometry. The antibodies were diluted in PBS with 10% FBS. 
All antibodies used in the flow cytometry experiments were purchased from Miltenyi Biotech. APC, 
allophycocyanin; FITC, fluorescein isothiocyanate, PE, phycoerythrin 
Antigen 





















Table 2.2 Markers for characterization of MSCs (adapted from Feng-Juan et al., 2014) 
Marker What? Where? Comment 
CD90 Cell surface glycoprotein Subset of fetal liver cells 
and fetal thymocytes, 
fibroblasts, MSCs, 
activated endothelial 
cells, and some leukemia 
cell lines. CD34+CD90+ 
cells are primitive 
hematopoietic stem cells 
 
Promotes T cell 
activation and is 
involved in cellular 
adhesion, neurite 
outgrowth, migration, 
cell death, and tumor 
growth. 
 
CD105 Cell membrane glycoprotein (also 
known as endoglin) 
 
Endothelial cells, some 
bone marrow cells, 
MSCs and activated 
macrophages 
A receptor for 
transforming growth 
factor (TGF) beta  
CD73 Membrane-bound enzyme 
 
Present on subsets of T 
and B lymphozytes, 
follicular dendritic cells, 
endothelial cells and 
MSCs 
 
The encoded protein is 
used as a determinant of 
lymphocyte 
differentiation. 
CD44 Cell-surface glycoprotein involved in 
cell–cell interactions, cell adhesion and 
migration  
 
Found in stem cells 
(including MSCs); 
normal adult and fetal 
tissue; cancer cells  
A receptor for 
hyaluronic acid (HA)  
CD29 Integrin beta-1 is a protein that in 
humans is encoded by the ITGB1 gene 
Involved in cell adhesion 
and recognition in a 
variety of processes 
including 
embryogenesis, 
hemostasis, tissue repair, 
immune response and 
metastatic diffusion of 
tumor cells 
 
ITGB1: Integrins are 
ubiquitously expressed 
adhesion molecules 
CD56 Neural cell-adhesion molecule 
(NCAM) 
 
Marker for natural killer, 
muscle cells and neural 




were able to differentiate 
into adipocytes. MSCA-
1+CD56+ MSC may be 
used as the starting 
population of choice for 
the treatment of several 








Mesenchymal stroma cell antigen 1 MSCs and ESCs MSCA-1 is identical to 
tissue non-specific 
alkaline phosphatase 
(TNAP), an ectoenzyme 
known to be expressed at 
high levels in liver, bone, 





2.2.2 Mitogen-induced proliferation assay 
To evaluate the nMSC immunosuppressive potential in vitro, human peripheral blood 
mononuclear cells (PBMCs) were isolated from leukocyte cones purchased from the National 
Blood Service, UK. Leukocyte cones were diluted 1:1 with PBS and layered on Histopaque 
(Merck, cat. no. 10831) for density gradient separation.  
We performed the PBMC proliferation assays in 0.2 ml of medium (RPMI supplemented 
with 10% HPL) per well of a 96-well flat-bottom plates (Corning Costar, cat. no. CLS3596). 
The vial of PBMCs was thawed at 37°C, and the cells were washed in PBS and then 
resuspended at a concentration of 1 x 106 cells/ ml. Native MSCs from four donors derived 
under dXF conditions and three clinical grade BM MSCs were serially diluted and plated 
overnight. A total of 5 x 105 PBMCs per well were added to nMSCs to obtain co-cultures with 
increasing PBMC/nMSC ratios from 10:1 to 80:1. PBMCs were then stimulated with 5 µg/ml 
phytohaemagglutinin (PHA; Sigma, cat. n. L8754), and after 72 h, proliferation was measured 
by the incorporation of radiolabelled [3H]-thymidine (TdR; Amersham Bioscience, no cat. no.) 
during the final 18 h of incubation. Briefly, cell cultures were pulsed with 0.5 μCi/well of [3H]-
TdR for 18 h before the cultures were harvested onto a glass fibre Wallac filter mat A (Perkin-
Elmer, cat. no. 1450-421) using a Skatron 96-well plate automated cell washer (Molecular 
Devices). Scintillation fluid was added, and [3H]-TdR incorporation was measured by liquid 
scintillation spectroscopy on a counter (Wallac Quantulus). The results are expressed as the 
percentage of control proliferation for triplicate cultures. Cultures of stimulated PBMCs 
without nMSCs were used as a positive control. 
The relative proliferation of each PBMC/nMSC ratio was calculated using the following 
formula: A/B x 100, where A is the proliferation at one specific PBMS/nMSC ratio and B is 
the proliferation of the positive control. The percentage of inhibition was then calculated by 
subtracting the percentage of proliferation from 100 (maximum of inhibition).   
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2.3 GENERATION OF INDUCED PLURIPOTENT STEM CELL (iPSC) LINES 
2.3.1 Preparation of NuFF as a feeder-layer and for medium conditioning 
Mitotically inactivated new-born foreskin fibroblast (NuFF) vials with 4 - 5 x 106 cells (Global 
Stem, cat. no. GSC-3001G) were recovered per the manufacturer’s instructions. Briefly, the 
vial was thawed inside the incubator at 37°C for 5 to 6 min. Subsequently, we transferred the 
thawed contents of the vial to a 15-ml conical tube containing pre-warmed DMEM, followed 
by centrifugation at 160 g for 5 min. We aspirated the supernatant, and the cells were 
resuspended at a concentration of 1 x 106 cells/ ml (4 – 5 ml) in DMEM supplemented with 
10% FBS.  
NuFFs were used either to condition the Pluriton™ Reprogramming Medium 
(Stemgent, cat. no. 00-00070), a chemically defined serum-free medium, and/or used as feeder-
layer to support newly transduced WJ MSCs on day 7 of Sendai virus reprogramming.  
For medium conditioning, 4.0 - 4.5 x 106 of NuFF were plated in a T75 flask in 12 ml 
of DMEM supplemented with 10% FBS, and they were incubated for 24 h at 37°C with 5% 
CO2. Next, the attached NuFFs were rinsed twice with PBS to remove any residual FBS before 
supplementation with 30 ml of Pluriton with 4 ng/ml of recombinant human fibroblast growth 
factor basic protein (rhFGF) (Bio-techne, cat. no. 233-FB-025). After every 24 h of incubation, 
we collected the medium, and fresh Pluriton medium with rhFGF was added. After 7 to 10 days, 
we pooled all the daily aliquots, which were then filtered by a bottle-top vacuum 0.22 μm filter 






2.3.2 Reprogramming by Sendai Virus (SeV) 
SeV carrying four transcription factors, OCT3/4, SOX2, KLF-4 and c-MYC, was used to 
promote the reprogramming of primary donor nMSCs. The entire system is commercially 
available as a kit CytoTune™ - iPS Reprogramming Kit (ThermoFisher, cat. no. A16517) that 
contains all the synthesized transcription factors listed above.  
The protocol was followed per the manufacturer’s instruction with a few modifications. 
Briefly, the reprogramming timeline (Table 2.3 and Figure 2.3.1) describes the steps required 
to produce iPSCs using the reprogramming kit. 
The CytoTune kit recommends the use of iPSC medium from day 7 after transduction 
onwards. However, according to our own experience with previous reprogramming protocols, 
we decided to switch to Pluriton Reprogramming medium (Stemgent), which is normally used 
in the mRNA reprogramming Factors Set™ (Stemgent). Pluriton supports the emerging 
colonies very well (day 8 to 21) and is conditioned in NuFF as described previously.   
 The protocol recommends ‘Fibroblast’ medium (see Appendix) for the first 7 days after 
transduction. However, this medium contains FBS and could not be used for our XF conditions. 
Therefore, FBS was replaced with the CTS KnockOut™ SR XF (ThermoFisher, cat. no. 
12618013), a supplement that maintains the pluripotency, normal morphology, and karyotype 
of human pluripotent stem cells. 
Inactivated human foreskin fibroblast (HFF) feeder layers (described further on 2.3.3) 
were used to allow the expansion and propagation of iPSC lines. The primary iPSC colonies 
showing defined colony edges, uniform and compact cells were manually picked using a 
hypodermic needle and re-plated onto 4-well plates containing the HFF feeder layer. We used 
hESC defined medium or KOSR medium (see Appendix) for the culture and expansion of the 
cells in this step.  
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Table 2.3 Reprogramming timeline of modified CytoTune - iPSC Reprogramming kit 
Description Day Activity 
Prepare cells 
for transduction  
- 2 
 
Plate 2 or 3 wells (6-well plates) of target cells at different 
densities (1.5 to 2 x 105 cells/ well) in XF Fibroblast medium. 
The cell number on the day of transduction should be less 





Choose the best well among the 2 or 3 (70% confluence).  
The additional wells can be collected, counted and snap 
frozen for use as a negative control in RT-PCR. 
Add the indicated volumes (according to the manufacturer’s 
manual, the titre of each vector is lot-dependant) of each of 





Replace the medium (XF Fibroblast media) with fresh 





Plate NuFF feeders in P60 culture dishes at a density of 3 x 







The transduced cells (one well) are plated onto two P60 
NuFF feeder dishes 
Transduced cells from the additional wells can be collected 
and snap frozen for use as a positive control in RT-PCR 
Pluriton NuFF conditioned medium is used from now on 




8 - 28 
iPSC colonies were allowed to grow and expand in culture 





22 to 28 
Primary iPSC colonies with the best morphology (uniform 
and compact cells) were manually picked and passaged onto 





Figure 2.3.2 Reprogramming timeline of the production of iPSCs. Figure adapted from Life 
technologies website CytoTune™ - iPS Reprogramming Kit (thermofisher.com, 2017).  
  
2.5 to 4 weeks 
Plate 
cells
Day:   -2            0      1                       5          6          7       8                       12   15       
Xeno Free Fibroblast Medium (XF)                  Pluriton Conditioned Medium (PC) 
Transduction
Day
                                     Replace Medium 
                                   daily
Plate transduced cells 
in NuFF feeders
50% XF + 50% PC
Emerging 
colonies
iPSC colonies ready 
to transfer  
into HFF Feeders
  Prepare 






2.3.3 Preparation of HFF as a feeder layer 
Mitotically inactivated human Foreskin fibroblasts (HFFs) were used as feeder layer to support 
the expansion and growth of iPSC colonies after their generation. Those cells were expanded 
and frozen in the Stem Cell Laboratory at King’s College London.   
The frozen vial containing 1 x 106 HFF cells with PD 7.3 was thawed in the incubator 
at 37 ˚C for 5 min. Subsequently, we transferred the cells from the vial into a 15-ml conical 
tube containing 5 ml of pre-warmed DMEM. A 20-μl aliquot was acquired for subsequent cell 
counting. After centrifugation at 160 g for 5 min, the supernatant was aspirated, and the cells 
were resuspended in sufficient HFF medium (DMEM with 10% FBS) to achieve a 
concentration of 1 x 105 cells/ml.  
For plating, we coated 4-well plates with CELLstart as described in section 2.1.2. The 
cells were seeded in a number of 2 x 105 cells per well (200 μl of resuspended cells/ well) and 
then transferred to the incubator (Heraus) for culture at 37 ˚C with 5% O2. The feeder layer was 
ready to use after 48 h. The HFF feeder medium was replaced every 3 days, and the feeder-
layer plates were used within a maximum of 2 weeks from generation.  
 
2.3.4 iPSC expansion, maintenance and cryopreservation 
Before picking the iPSC colonies, the HFF feeder-layer plates were rinsed twice with pre-
warmed DMEM to eliminate any trace of FBS in the culture, and Pluriton and KOSR complete 
media were added at a 50:50 ratio. The plate was equilibrated for a minimum of 1 h at 37 ˚C 
with 5% O2 before the procedure.  
Using a hypodermic needle or a pipette tip, we manually picked the iPSC colonies and 
replated them onto the 4-well plates of the HFF feeder layer. They were then cultured for the 
first 2 days in a mixture of Pluriton and KOSR complete media at a 50:50 ratio for gradual 
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adaptation in the new medium. Following the first 2 days, the iPSCs were cultured in pure 
KOSR medium.  
The iPSC colonies were ready for passaging onto new feeders or to be adapted feeder-
free either when there were an excessive number of colonies per well or when the colonies in 
each well reached an average size of 300-400 cells per colony as estimated visually, showing 
delimited borders, a dense centre with bright phase compared with their edges. 
For feeder-free adaptation, we manually picked up the colonies and subcultured them 
in Vitronectin XF-coated dishes. For the first 2 days after plating, the cells were cultured in 
KOSR complete medium and TESR2 at a 50:50 ratio before replacing it with pure TESR2. Any 
differentiation parts were scraped mechanically using a pipette tip and discarded.  
When iPSCs in feeder-free conditions reached higher densities, which normally 
occurred at 4 to 6 days after initial seeding, they were passaged and/or frozen. The same 
procedure of enzymatic passaging for hESCs with dispase as described in section 2.1.9 was 
used for iPSCs.  
For cryopreservation, cells were frozen in Cryostor CS10 (Merck, cat. no. C2874) and 
stored in LN2. A total of 1 x 106 cells was resuspended in 1 ml of freezing solution and 
transferred into Nunc 1-ml freezing vials (Thermo Fisher, cat. no. 374081). Next, the vials were 
stored in a freezing container, Mr. Frosty™ (Thermo Fisher, cat. no. 5100-0001), for the first 
hour at -20°C and then transferred to a -80°C freezer for at least 4 h before being transferred 






2.4 VITRIFICATION OF FEEDER-DEPENDANT iPSC COLONIES 
The iPSC colonies (on the HFF feeder layer) were vitrified at passage 2 and/or 3 to preserve 
earlier passages of the line and to avoid loss of the line due any possible drawback. We vitrified 
at least 10 - 15 straws for each iPSC line.  
The colonies to be vitrified were cut into smaller pieces using a pipette tip or a 
hypodermic needle and placed inside a well (4-well plate) containing ES-HEPES solution (see 
Appendix).  
Before starting the process of vitrification, we prepared two lines of 30 μl microdrops 
each, one with 10% and another with 20% vitrification solution (see Appendix) using a 4-well 
plate lid. Subsequently, a timer was set to start for 1 min and 25 sec. Immediately, 4 to 8 iPSC 
colony pieces were transferred to the first microdrop containing 10% vitrification solution for 
1 min. When the timer reached the last 25 sec, all iPSC pieces were then transferred to the 
adjacent microdrop with 20% vitrification solution. When the timer ended, the pieces were 
aspirated into a labelled vitrification straw using capillary action, followed by plunging into 
LN2 (using a portable Dewar or a Styrofoam box). Once all the colonies were vitrified, the 
straws were then placed inside labelled 4,5-ml Nunc Cryogenic tubes (Thermo Scientific, cat. 









2.5 ANALYSIS OF SeV GENE EXPRESSION IN iPSC LINES 
To confirm that the generated iPSC lines were vector-free, we investigated the expression of 
SeV by initially isolating RNA from all iPSC lines followed by reverse transcription 
polymerase chain reaction (RT-PCR) using the Precision nanoScript2 Reverse Transcription 
kit (Primerdesign, no cat. no.) and GoTaq Green Master Mix (Promega, cat. no. M712). 
 
2.5.1 Isolation of Total Cellular RNA 
Prior to starting the RNA extraction, the bench and all equipment (i.e., pipettes) were wiped 
with RNA-Zap (Thermo Fisher, cat. no. AM9780) to remove any RNase enzymes present on 
the workstation. All samples containing RNA were stored at -80°C, and the number of times 
the samples were freeze-thawed was maintained at a minimum. Total RNA was isolated from 
cells using the QIAgen RNeasy Mini kit (Qiagen, cat. no. 74104) according to the 
manufacturer’s instructions. This protocol uses a silica-based membrane and a series of high 
salt buffers that enable binding of up to 100 μg of RNA (over 200 bases in length). Briefly, 1 
ml of lysis buffer (RLT) containing 10 μl/ml β-mercaptoethanol was added to the cell pellet. 
The cell lysate was then homogenized by pipetting the lysate through a QIAshredder spin 
column (QIAgen) and centrifugation at RT for 2 min at high speed. One volume of 70% ethanol 
was added to the homogenized lysate and the sample were transferred to an RNeasy spin 
column, which was centrifuged for 15 sec at 8,000 g. The flow-through was discarded, and the 
column was washed with 700 μl of RW1 buffer by spinning for 15 sec at 8,000 g. Subsequently, 
500 μl of RPE buffer was added to the column, and the tube was centrifuged one more time for 
2 min at 8,000 g to wash the membrane. The spin column containing RNA bound to the silica-
based membrane was then placed in a new 1.5-ml microfuge tube, and the RNA was eluted 
using 40 μl nuclease-free water (Thermo Fisher, cat. no. AM9937), which was added to the 
membrane of the spin column. The samples were then centrifuged for the last time for 1 min at 
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8,000 g. The resultant total RNA was either used immediately for cDNA preparation or stored 
at -80°C. 
 
2.5.2 RNA quantification and quality control 
Using a NanoDrop ND-100 Spectrophotometer (Labtech International), we assessed the 
concentration of total RNA and the optical density at 260 and 280 nm. The ratio of the light 
absorbance indicated the purity of the RNA. The ideal ratio ranges were between 1.8 and 2.1, 
and RNA of sufficient purity was used for RT-PCR.  
 
2.5.3 cDNA synthesis 
The Precision nanoScript2 Reverse Transcription kit (Primer Design, no cat. no.) was used 
according to manufacturer’s instruction to convert RNA into cDNA. Briefly, we chose to 
convert 150 ng of RNA, and the RNA was diluted in nuclease-free water (Thermo Fisher, cat. 
no. AM9937) to a total volume of 10 μl and incubated with 1 μl of oligo-dT primers (0.5 μg/ml 
final concentration) for 5 min at 65°C and then cooled to 4°C. For the master mix, in a total of 
10 μl for RT reaction, 1 μl dNTPs (10 mM final concentration), 1 μl nanoScript enzyme, 5 μl 
NanoScript buffer, and 3 μl RNase-free water were added to each sample and incubated at 42°C 
for 20 min, followed by heating to 75°C for 10 min. cDNA samples were either used 







2.5.4 RT-Polymerase chain reaction (PCR) 
SeV expression was assessed by RT-PCR using GoTaq Green Master Mix (Promega, cat. no. 
M712) according to manufacturer’s protocol. Briefly, the reaction contained 12.5 μl GoTaq 
Green Master Mix, nuclease-free water, the respective template (2 μl) and primers (10 μM) (see 
Appendix) in a total volume of 25 µl.  
We placed the reaction tube in a thermal cycler G-star (Thermo Fisher) and performed 
35 cycles of PCR amplification (3 steps) as follows: 
Denaturation: 95°C for 30 sec 
Annealing: 55°C for 30 sec 
Elongation: 72°C for 30 sec 
 
The PCR products were analysed by agarose gel electrophoresis (see Appendix). The 
products were visualized using a PhotoDoc-IT UVP Imaging system transilluminator (Cole-
Parmer, cat. no. 97-0274-05).  
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2.6 CHARACTERIZATION OF iPSC LINES 
2.6.1 Embryoid Body Formation 
iPSC lines were evaluated for spontaneous differentiation in vitro. The lines were cultured until 
they formed a round cluster of cells resembling an embryo: the embryoid body (EB). 
After enzymatic passaging of 70-80% confluent iPSCs as described before (section 
2.1.9), the cells were gently harvested into small clumps and then transferred into a new 6-well 
plate with an ultra-low attachment surface (Corning, cat. no. CLS3471) for spontaneous 
formation of 3-dimensional aggregates. EB formation was completed following culture in 
DMEM with 20% FBS for 7 days at 370C with 5% O2, exchanging the 50% of the medium 
every 3 days.  
 
2.6.2 Immunocytochemistry   
To examine the expression of markers associated with pluripotency in undifferentiated iPSCs 
and germ layer markers for spontaneous differentiated iPSCs, all lines were fixed and processed 
for immunocytochemistry.  
The iPSC lines were cultured on top of a Vitronectin XF-coated coverslip previously 
placed inside a 4-well plate (Thermo Scientific, cat. no. 144444).  
For undifferentiated iPSCs, the cells were processed after 24 – 48 h of plating. For 
spontaneous differentiation, cells were cultured for an extra 7 days in DMEM supplemented 
with 20% FBS before processing.  
When cells were ready for immunocytochemistry, the medium was aspirated, and the 
cell monolayer was washed twice with DPBS+Ca +Mg (Thermo Fisher, cat. no. 14040133). 
Fixation was carried out with 3.7% paraformaldehyde (PFA) (Merck, cat. no. 252549) at RT 
for 20 min. After removing the fixative, the cells were rinsed two to three times with DPBS+Ca 
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+Mg. Permeabilization was performed by adding 0.5% Triton X100 (Thermo Fisher, cat. no. 
85111) / DPBS+Ca +Mg to the cells for 5 min at RT. After permeabilization, the cells were rinsed 
at least three times with DPBS +Ca +Mg to eliminate any residual Triton X100.  
Subsequently, we incubated the cells overnight with the primary antibody at 4°C. After 
the incubation period, the cell monolayer was thoroughly rinsed with DPBS+Ca +Mg, and the cells 
were incubated for 30 min at RT with the conjugated secondary antibody. The primary 
antibodies are described in Table 2.6.1 (undifferentiated iPSCs) and Table 2.6.2 (spontaneously 
differentiated iPSCs), whereas the secondary antibodies are shown in Table 2.6.3.  
After secondary antibody incubation, the cells were washed with DPBS+Ca +Mg, and all 
remaining liquid was removed. Subsequently, without allowing the samples to dry, a drop of 
Vectashield mounting medium (Vector Lab, cat. no. H-1200) was added on top of the cells, and 
the cover slip, with the cells attached, was flipped over on a microscope slide. The mounted 
cells were ready to be processed for data analysis on a Nikon Eclipse 50i epifluorescence 
microscope (Nikon). Images were captured and analysed using Infinity Capture software 
(Lumenera) and processed using Adobe Photoshop CC (Adobe system).  
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2.6.3 Teratoma Assay 
iPSC lines were evaluated for their ability to differentiate into the three germ layers (endoderm, 
mesoderm and ectoderm) in vivo.  
iPSCs were expanded in 6-well plates until the cells reached a total of 6 x 106, usually 
when all 6 wells reached approximately 80 - 90% confluency. When the number of cells was 
achieved, we performed cell detachment using Accutase (STEMCELL technologies, cat. no. 
#07920), a non-enzymatic cell detachment solution containing EDTA, at a concentration of 1 
U/ml to obtain a single cell suspension. The culture medium was aspirated, and Accutase was 
added to the wells (1 ml/ well) followed by incubation at RT for 1 to 2 min. Subsequently, 1 ml 
of DMEM was added to the well, and the single cell suspension was collected into a 15-ml 
conical tube containing an extra 5 ml of pre-warmed DMEM. The cells were then washed by 
centrifugation at 160 g for 5 min. After washing, the supernatant was discarded, and the cell 
pellet was resuspended into 300 μl of BD-Matrigel: DMEM F-12 at a 1:2 ratio.  
In the final step, the cells were transferred into a 1-ml syringe (Terumo, cat. no. 
PMC0593) fitted with a 30-gauge intradermic needle (BD Microlance, cat. no. 305771) and 
then transported to the animal facility inside a cooler box.  
The animal experiment was performed at James Black Centre Biological Sciences Unit 
at King’s College London by Dr Yanhua Hu. All procedures were performed according to 
protocols approved by the Institutional Committee for Use and Care of Laboratory Animals.  
After inspection of the mice (for any signs of distress and/or injuries), the cells were 
injected subcutaneously into the right or left flank of female immunodeficient mice 
(NOD.CB17-Prkdc<scid>/NcrCrl) (Charles River, cat. no. NDSSIFE35D). A total of 2 mice 
were used per iPSC line (4 in total).  
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Characteristically, the tumour can be palpated between 6 to 12 weeks post-injection, 
and the mice were inspected for tumour growth on a weekly basis. When the tumour was 
palpated and its diameter reached 1 cm or more, the mice were sacrificed in accordance with 
Schedule 1 of Animal (Scientific Procedures) Act 1986 of the Home Office license guidelines.   
The dead mouse was secured with tape around its paws on top of a clean stainless steel 
working table, exposing its belly with easy access to the tumour. The tumour was removed 
using surgical scissors and tweezers. After removal, the tumour was placed inside a 50-ml 
conical tube containing PBS and transported to the laboratory.  
In the laboratory, the tumour was washed, sliced into ~0.3-mm3 pieces and placed in 4% 
PFA for 48 h in 4°C for fixation of the tissue.  
The histological staining, immunohistochemistry staining and sample analysis of all 
teratomas were performed at the Wolfson CARD Histology laboratory at King's College 
London by Carl Hobbs. 
Each teratoma was processed in paraffin wax (VWR) using a Leica 2010 processing 
machine. Following processing, the teratoma was embedded into heated moulds containing 
molten wax. The moulds were then cooled at 4°C until the wax had solidified. Subsequently, 
the wax-embedded teratoma was sectioned into 6-mm serial slices using a rotary microtome 
and allowed to float on the surface of water heated to 45°C to soften the wax and allow the 
tissues to flatten out. Sections were then mounted onto Superfrost Plus microscope slide (Fisher 
Scientific). These slides are specially pre-treated to allow the tissue sections to electrostatically 
adhere to the glass. Sections mounted o slides were then placed in a 60°C oven for 1 h to ensure 




The samples were dewaxed to allow staining of the samples. Briefly, the samples were 
washed twice in xylene (SLS) under agitation for 10 min per wash at RT to soften the wax, 
followed by rehydration in four quick baths using absolute alcohol and a final plunge in water. 
Next, the samples were stained using Mayer’s haematoxylin for nuclei (VWR, cat. no. 
1.09249.0500) and eosin for cytoplasm and extracellular structures (Merck, cat. no. 230251). 
Immunohistochemistry was performed using germ layer-specific markers (see Table 2.6.4). 
 
Table 2.6.4 Primary antibodies or dyes used for visualization of germ layers in teratoma 
histological sections. AFP, α-fetoprotein; DES, desmin; GATA4, GATA binding protein 4; GFAP, glial 
fibrillary acidic protein; MTCO2, mitochondrially encoded cytochrome c oxidase II; TUBB3, tubulin β 
3 class III. 
Tissue/antibody or dye Supplier, Cat. no. Concentration 
Human / Anti-MTCO2 Abcam, AB110258 4 μg/ml 
Endoderm / Anti-AFP  Sigma-Aldrich, A8452 1:400 
Endoderm / Anti-GATA4 R&D, AF2606 1.3 µg/ml 
Mesoderm / Anti-DES Sigma-Aldrich, D1033 1:1500* 
Mesoderm / Alcian Blue Sigma-Aldrich, B8438 1% Alcian blue in 3% Alcian blue pH 2.5 
Ectoderm / Anti-TUBB3 Abcam, ab7751 2 μg/mL 
Ectoderm / Anti-GFAP Abcam, ab7260 1:2500** 
*Anti-desmin is an ascites fluid, and the final antibody concentration was estimated.  
**Anti-GFAP is a whole anti-serum, and the final antibody concentration was estimated.  
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2.7 DERIVATION OF MSC-LIKE CELLS FROM iPSCs and hESCs 
The iPSC lines derived in this study were differentiated into iMSCs (iMSC, iPSC-derived 
MSC). As a control, we used the hESC line KCL034. hESC-derived MSCs were termed 
eMSCs. Two protocols were used to achieve differentiation (Luzzani et al., 2015; Zhao et al., 
2015).  
The first protocol used was called TEXAS (TEX) and was based on the experiment by 
Zhao et al. (2015), who used SMAD 2/3 inhibitor to promote differentiation. On the first day 
of differentiation, when iPSCs reached 60 – 80% confluency, the cells were harvested using 
dispase (as described in section 2.1.9), seeded at a concentration of 2 x 105 cells/ well in new 
Vitronectin XF-coated wells (6-well plates) and cultured with TESR2 supplemented with 10 
μM SB-431542 (SMAD 2/3 inhibitor) (Sigma) in an atmosphere of 5% CO2. The cells were 
further expanded for 25 days with continuous passaging (every 3 to 4 days) under the same 
culture conditions.  
According to the protocol, after 25 days, most of the cells change their morphology and 
become spindle-shaped cells. At this point, cells were passaged using Tryple Express (Thermo 
Fisher, cat. no. 12604021) as a dissociation reagent. Briefly, we washed the cell monolayer with 
pre-warmed DMEM and then incubated it in Tryple Express for 3 min at 37°C. Tryple was then 
diluted with an equal amount of pre-warmed DMEM. Cells were then collected, counted and 
centrifuged at 800 g for 5 min. Subsequently, the cell pellet was resuspended to a concentration 
of 1.5 x 105 cells/ ml in ESC-MSC medium (see Appendix) supplemented with 10 μM SB-
431542 and transferred into a standard tissue culture well without any coating. The cells were 
incubated under the same conditions for an additional 20 days, with continuous passaging of 
the cells, at 80 – 90% confluency (Zhao et al., 2015; Sanchez et al., 2011). After 20 days, the 
cells were treated as fully differentiated MSCs in a standard tissue vessel with αMEM (Thermo 
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Fisher, cat. no. 32561029) supplemented only with 10% hPL (Stemulate, Cook Regentec, cat. 
no. G35220).   
The second differentiation protocol used was called ARGENTINA (ARG) based on 
the protocol described by Luzzani et al. (2015), which consists of several cell passages using 
αMEM supplemented with hPL at 37°C with 5% O2. On the first day of differentiation, when 
iPSCs reached 70 - 80% confluency, the cells were passaged using the dissociation reagent 
Accutase, as described in section 2.6.3, to obtain a single cell suspension and seeded at a 
concentration of 2 x 105 cells/ well in Vitronectin XF-coated wells (6-well plates). αMEM 
supplemented with 10% hPL and 2% B27 Supplement (Thermo Fisher, cat. no. A1486701), a 
supplement used to support induction of human neural stem cells (thermofisher.com, December 
2017), was used for the first 14 days of culture and differentiation. In addition, 10 μM of Rock 
inhibitor Y27632 was added every time the cells were harvested and seeded until day 14 of 
differentiation. The cells were then passaged using Tryple Express without coating. 
Subsequently, the cells were continually expanded in αMEM supplemented only with 10% hPL. 
Characterization experiments were performed after 30 days of differentiation (Luzzani et al., 
2015). 
The iMSCs and eMSCs transitioning morphologically towards MSC’s morphology, 
from both TEX and ARG protocols, were further expanded followed by cell sorting. When the 
cells reached 70 - 80% confluency, they were collected as described previously using Tryple 
Express, and the cell pellet was resuspended to 1 x 10 6 cells/ ml in MSC medium (αMEM 
supplemented only with 10% hPL) supplemented with the antibiotics penicillin-streptomycin 
(Gibco). Using a FACSAria II cell sorter (BD) and FACSDIVA software (BD) for acquisition 
and analysis, only cells that were triple positive for the MSC markers CD73, CD90 and CD105 
were sorted. The instrument was operated at the BRC Flow Cytometry Core at King’s College 
London. After sorting, the cells were washed with 5 ml of pre-warmed DMEM by 
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centrifugation at 160 g for 5 min. Subsequently, the cells were plated in a standard tissue vessel 
with MSC medium supplemented with penicillin/ streptomycin for further expansion. 
Subsequently, the iMSC and eMSC lines were subjected to immunomodulatory assays 
and further differentiation into osteogenic, adipogenic and chondrogenic lineages.  
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2.8 CHARACTERIZATION OF iMSCs AND eMSCs 




To assess the adipogenic potential of nMSCs and iMSCs, cells were seeded at a density of 1 x 
104 cells/cm2 on a coverslip placed inside a 4-well plate and cultured for 14 days using the 
StemPro Adipogenesis Differentiation kit (Thermo Fisher, cat. no. A1007001). Thermo Fisher 
does not supply the compound information, but the most common reagents used for adipogenic 
induction include insulin, dexamethasone and Isobutylmethylxanthine (IBMX) (Scott et al., 
2011).  
The medium was exchanged every 3 – 4 days for 14 days in total. After two weeks, the 
cells were fixed with 3.7% PFA for 20 min. After removing the fixative, we rinsed the cells 
two times with DPBS+Ca +Mg. Next, we incubated the cells for 20 min at RT with (1:100) Lipid- 
TOX™ Green Neutral Lipid Stain (Thermo Fisher, cat. no. H34475) to evaluate the deposition 
of lipids on the cell membrane. Subsequently, the cells were rinsed two more times with 
DPBS+Ca +Mg, and a drop of Vectashield was added to the cells followed by flipping the coverslip 
on top of a microscope slide. The cells were examined under a Nikon Eclipse 50i 
epifluorescence microscope. Images were captured and analysed using Infinity Capture 
software and processed using Adobe Photoshop CS5. 
 
B) CHONDROGENIC 
To assess the chondrogenic potential of nMSCs and iMSCs, cells were seeded at a density of 2 
× 104 cells/cm2 and cultured for 21 days in αMEM supplemented with 2 mM L-glutamine 
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(Merck, cat. no. G3126), 347 μM L-proline (Merck, cat. no. P0380), 100 nM dexamethasone 
(Merck, cat. no. 265005), 1% insulin–transferrin–selenium solution (ITG-S, Thermo Fisher cat. 
no. 41400045), 137 μM ascorbate-2-phosphate (Merck, cat. no. A8960) and 0.38 μM (10 ng/ml) 
recombinant human TGF-β1/3 (PeproTech, cat. no. 100-21) (Solchaga et al., 2011).  
The medium was refreshed every 3 – 4 days. After 21 days, the cells were fixed in 3.7% 
PFA for 30 min, washed twice with DPBS+Ca +Mg, stained with 1% Alcian Blue 8GX (Merck, 
A5268) for 30 min at RT, washed again twice with DPBS +Ca +Mg and examined with an 
Olympus CK40 inverted phase contrast microscope to detect the formation of 
glycosaminoglycans. Images were captured and analysed using Infinity Capture software and 
processed in Adobe Photoshop CS5. 
 
C) OSTEOGENIC 
To assess the osteogenic potential of nMSCs and iMSCs, the cells were seeded at a density of 
2 × 104 cells/cm2 and cultured for 21 days in αMEM supplemented with 2 mM L-glutamine 
(Merck, cat. no. G3126), 100 nM dexamethasone (Merck, cat. no. 265005), 50 μM ascorbate-
2-phosphate (Merck, cat. no. A8960) and 2.5 mM β-glycerophosphate (Merck, cat. no. G9422) 
(Wang et al., 2009).  
The medium was changed every 3 – 4 days. After 21 days, the cells were washed twice 
with DPBS+Ca +Mg, fixed with ice-cold 70% ethanol for 1 h, rinsed again with DBPS+Ca +Mg, and 
stained with 20 mg/ml of Alizarin Red S (Merck, cat. no. A5533) for 30 min at RT. They were 
then washed again with DBPS+Ca +Mg. The calcium deposits were visualized under an Olympus 
CK40 inverted phase contrast microscope. Images were captured and analysed using Infinity 
Capture software and processed in Adobe Photoshop CS5.  
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2.8.2 Immunomodulatory assay 
To test the immunosuppressive potential of the iMSCs and eMSCs, both TEX and ARG, in 
vitro, the CellTrace™ Violet kit (Thermo Scientific) was used according to the manufacturer’s 
instructions. This method monitors distinct generations of proliferating cells by dye dilution. 
We performed PBMC proliferation assays in 200 µl of medium (RPMI 1640, Thermo Fisher, 
cat. no. 11875093, supplemented with 10% HPL) per well of 96-well flat-bottom plates (Costar, 
cat. no. CLS3595). In summary, at Day 1, cells were collected, and the concentration of each 
cell line was adjusted to 1 x 106 cells/ml. Subsequently, 96-well flat-bottom plates were 
prepared by adding 100 µl of fresh medium in 18 wells (Figure 2.8.1). The assay was performed 
in triplicate. The first 3 wells in the same row, the control wells, contained only an extra 100 µl 
of medium. The second to fifth rows had 1/5 to 1/80 dilutions of cells. Briefly, 200 µl (2 x 105 
cells) was added to each of the 1/5 dilution wells, and using a multichannel pipette, 100 µl was 
then collected from each 1/5 well and transferred into the 1/10 wells below. The contents were 
mixed well, avoiding bubble formation, and without emptying the pipette, another 100 µl was 
collected from each 1/10 well then transferred to the 1/20 wells below. The same procedure 
was used in rows with 1/20, 1/40 and 1/80 until all dilutions were completed. The plate was 
incubated overnight at 370C with 5% CO2. 
At Day 2, PBMCs (described in section 2.3.1) were thawed, washed with PBS by 
centrifugation at 800 g for 5 min, counted and resuspended in PBS to a concentration of 1 x 106 
cells/ ml. Subsequently, Violet tracer was added to a concentration of 1 µM in 2 ml of 
resuspended cells and incubated at 37°C for 10 min. The cells were then washed twice by 
centrifugation, first with PBS and then with RPMI 1640 supplemented with 10% HPL. They 
were then counted and resuspended to a concentration of 1 x 106 cells/ ml. Next, 50 µl of the 
resuspended cells (5 x 105 cells) was added to each well containing the different dilutions (1/5 
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to 1/80), followed by the addition of phytohaemagglutinin (PHA, Merck, cat. no. L1668) at a 
concentration of 5 µM. For controls, PBMCs without PHA were added to 3 additional wells 
(with 50 µl of fresh medium), and another 3 wells contained PBMCs without Violet (non-
stained PBMCs). The cells were then incubated at 37°C with 5% CO2 for 72 h and subjected to 
flow cytometry.  
 
Figure 2.8.1 Preparation scheme of 96-well flat bottom plates for Immunoassay by Violet tracer 
staining. PBMCs, peripheral blood mononuclear cells; PHA, phytohaemagglutinin. 
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2.8.3 GENE EXPRESSION ARRAY RT-qPCR  
We investigated the gene expression of osteogenic (RUNX2), chondrogenic (COL11A1), 
adipogenic (FABP4) and markers associated with pluripotent cells (NANOG and ZFP42) from 
all iMSC lines by real-time quantitative PCR (RT-qPCR) using the iScript cDNA Synthesis Kit 
(Bio-Rad, cat. no. 1708891SP) and SYBR Green Mastermix (Roche, cat. no. 04707516001).  
 
2.8.3.1 Isolation and quantification of Total Cellular RNA 
The procedure described previously in section 2.5.1 was used for RNA extraction. 
Using the Qubit RNA BR assay kit (ThermoFisher, cat. no. Q10210), we determined 
the RNA concentrations of the samples. The kit was used per the manufacturer’s instructions. 
Briefly, the master mix volume was calculated by the total number of samples to be quantified, 
which were individually prepared by diluting the provided kit reagent in kit’ buffer to 1:200. 
Two Standard tubes were individually prepared by mixing 190 μl of the master mix with 10 μl 
of Standard 1 solution in tube 1 and 10 μl of Standard 2 solution in tube 2. Next, sample tubes 
were prepared by combining 199 μl of the master mix with 1 μl of sample. The tubes containing 
the diluted RNA samples were then vortexed for 2-3 sec and incubated at room temperature for 
2 min. Using the Qubit 2.0 Fluorometer (Thermo Fisher), the standard curve for the assay was 
determined by obtaining a reading first from Standard 1 and then from Standard 2; 
subsequently, the RNA was quantified for each sample. 
 
2.8.3.2 RNA quality control  
Using the Agilent RNA 6000 Nano Kit (Agilent, no cat. no. 5067-1511), we assessed the RNA 
quality, integrity and sample quantification using the 2100 Bioanalyser.  
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The kit contains chips and reagents designed for analysis of RNA fragments. Each RNA 
chip contains an interconnected set of micro-channels, which is used for the separation of 
nucleic acid sections based on their size as they are pushed through it electrophoretically.  
The kit was used according to the manufacturer’s instructions. Briefly, the bench and 
all equipment, including pipettes, were wiped with RNA-Zap to remove any residual of RNase 
enzymes, and the Bioanalyser was cleaned using an electrotrode cleaning cartridge with 
nuclease-free water. Before starting, the RNA samples and RNA ladder were thawed on ice, 
heat-denatured for 2 min at 70°C and placed back on ice. The other reagents were thawed for 
30 min at RT. Before loading the samples in the chip, the gel-dye mix was prepared by adding 
1 µl of dye to 65 µl of filtered gel. After setting up the chip priming station by adjusting the 
base plate to position C and changing the syringe clip to the lowest position, a new RNA chip 
was loaded with 9 µl of the gel-dye mix in the first well marked with a ‘G’. The syringe was 
then plunged, and after waiting 30 sec, released back to the start position. The other two wells 
marked with ‘G’ were each then loaded with 9 µl of gel-dye mix, followed by the addition of 5 
µl of RNA 6000 Nano marker and 1 µl of RNA ladder to the ladder well. Finally, 1 µl of each 
sample was added to each of the 12 wells of the chip. Subsequently, the chip was vortexed for 
60 sec and assessed in the 2100 Bioanalyser instrument within 5 min after preparation.  
The 2100 Bioanalyser software uses the RNA integrity number (RIN) tool, allowing us 
to predict the integrity of the RNA. The RIN is independent of the concentration, instrument 
and analyst and therefore provides reliable data for RNA integrity. The Bioanalyser provides 
gel and electrophoretogram traces, and high-quality samples are identified by one marker peak, 




2.8.3.3 cDNA synthesis 
Using the iScript cDNA Synthesis Kit, we synthesized cDNA from the RNA isolated 
previously. This kit provides a sensitive and reliable solution for two-step RT-qPCR. The kit 
was used according to manufacturer’s instruction. In brief, the Master mix was calculated 
according to the total number of samples for each experiment by adding 4 µl of 5x iScript 
Reaction mix to 1 µl of iScript Reverse transcriptase. Subsequently, 90 ng of RNA was 
converted, and therefore the RNA was diluted in RNase-free water to a total volume of 15 µl 
according to the RNA quantity of each sample. In a total volume of 20 µl, the complete reaction 
mixture was incubated in a thermal cycler using the following protocol:  
Priming: 5 min at 25°C 
Reverse transcription: 20 min at 46°C 
RT inactivation: 1 min 95°C 
Hold for 4°C 
cDNA sample storage at 4°C. 
 
2.8.3.4 RT-qPCR  
To assess the gene expression of target genes, RT-qPCR was performed with the LightCycler 
480 RT PCR Instrument using SYBR Green Mastermix according to the manufacturer’s 
protocol. Briefly, the reaction contained 5 μl SYBR Green Master Mix (2X), nuclease-free 
water (2 µl), the respective template (2 μl) and 10 μM primers (0.5 µl/ each) in a total volume 
of 10 µl.  
We placed the reaction tube in a LightCycler 480 II Instrument (Roche) and performed 
45 cycles of PCR amplification as follows: 
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Pre-incubation : 95°C for 5 min 
Amplification (45 cycles): 95°C for 10 sec 
                                  60°C for 10 sec 
                                  72°C for 10 sec 
Melting curve: 95°C for 5 sec 
                65°C for 1 min 
                65-97°C for 0.11°C/sec  
 
          Primer pairs for target genes are listed in the Appendix. Data were collected and analysed 
using the comparative threshold cycle method with TBP and GUSB as reference genes. The 
mean ± SD was calculated, and statistical analysis was performed using the Prism curve-fitting 












2.9 ARRAY BASED GENE EXPRESSION ANALYSES  
The Illumina HumanHT-12 v4 Expression BeadChip (Illumina, cat no. BD-103-0204) supplies 
genome-wide transcriptional coverage of well-known genes, delivering high-throughput 
processing of 12 samples per chip. Each array targets more than 47,000 probes derived from 
the National Center for Biotechnology Information Reference Sequence (NCBI) and other 
sources (illumina.com, January 2018). We used the array to compare gene expression in 
nMSCs, iMSC TX and ARG with and without 18 h of IFNg treatment. 
iMSC TX, iMSC ARG and nMSCs were cultured in HPL media (aMEM supplemented 
with 5% Stemulate) and expanded until they reached 70 - 80% confluency. Subsequently, 
recombinant human IFNg (Peprotech, cat no. 300-02) was added to the media at 10 ng/ml and 
cells were cultured for 18 h prior to collection for RNA extraction.  
 
2.9.1 Isolation and quantification of total cellular RNA 
The procedure described previously in section 2.8.3.1 was used to extract and quantify RNA. 
 
2.9.2 RNA quality control 
The RNA quality control using the Agilent RNA 6000 Nano Kit, described previously in section 




2.9.3 cDNA synthesis and labelling kit  
RNA samples were converted to cDNA and labelled using the TargetAmp Nano Labelling Kit 
for the Illumina Expression BeadChip (Epicentre, cat no. TAN07924). 
For first-strand cDNA synthesis, SuperScript III Reverse Transcriptase (RTr) 
(ThermoFisher, cat no. 18080-093) was used to convert RNA into cDNA. Briefly, we chose to 
convert 500 ng of RNA; therefore, the RNA samples were topped up with Nuclease-free water 
(Thermo Fisher, cat no. AM9937) to a total volume of 2 μl and incubated with 1 μl of oligo-dT 
primers (50 µM) for 5 min at 65°C, then cooled on ice for 1 min. For the master mix, in a total 
of 2 μl for the RTr reaction, 1.5 μl First-strand buffer, 0.25 μl of 0.1 M DTT, and 0.25 µl of 
SuperScript III were added to each sample prior to incubation at 50°C for 30 min.  
For second-strand cDNA synthesis, the TargetAmp Nano Labeling kit 2nd strand cDNA 
regents were used. For the master mix, in a total of 5 µl per reaction, 4.5 µl of the 2nd-strand 
cDNA PreMix with 0.5 µl of the 2nd-strand DNA polymerase was added to each 5 µl of the 1st 
strand cDNA made previously. The 10 µl reaction was then incubated at 65°C for 10 min, 
followed by a further incubation at 80°C for 3 min, then cooled on ice and stored at -20°C or 
used immediately.  
The next step was the in vitro transcription of Biotin cRNA. The reaction produces 
Biotin cRNA by incorporating Biotin-UTP into RNA transcripts. For each reaction, the reagents 
were combined in a total of 20 µl per reaction, as follows: 2 µl of T7 transcription buffer, 3 µl 
of Biotin-UTP, 10 µl of NTP premix, 3 µl of DTT, and 2 µl of T7 RNA polymerase. The 
reaction was then added to the cDNA made previously (total of 30 µl/ sample) and incubated 
at 42°C for 4 h. Then, 2 µl of RNAse-free DNase I was added to each reaction, and the samples 
were incubated at 37°C for 15 min.  
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The last step was the Biotin cRNA purification. This step uses a silica-based membrane 
and a series of high salt buffers that enable the binding of cRNA to the membrane. Briefly, 350 
µl of lysis buffer (RLT) containing 3.5 μl of β-mercaptoethanol, 250 µl of 100% Ethanol and 
48 µl of RNase free-water was added to each sample. The cell lysate was homogenized and 
then transferred to a spin column and centrifuged at > 8,000 g for 15 sec. The flow through was 
discarded and the column was washed with 650 µl of RPE buffer by spinning for 15 sec at 
8,000 g. Subsequently, the flow through was discarded again and 650 µl of 80% Ethanol was 
added to the column and the tube was centrifuged once more for 15 sec at 8,000 g. The spin 
column was then transferred to a new collection tube and centrifuged at full speed for 5 min. In 
the last step, cRNA was eluted by placing the spin column inside a 1.5 ml collection tube and 
adding 20 µl of RNase free-water directly to the centre of the silica membrane and centrifuging 
at high speed for 1 min. The procedure was repeated using the same silica membrane and 1.5 
ml collection tube; 20 µl of RNase free-water was added to the centre of the membrane and 
centrifuged at high speed for 1 min. The total of 40 µl cRNA was stored at -80°C.  
 
2.9.4 Illumina HumanHT-12 v4 Expression BeadChip 
The Expression BeadChip step was executed by a Senior Technician at the BRC Genomic 
Facility at Guy’s Hospital. 
The BeadChip was used according to the manufacturer’s instructions. The process 
comprises of a series of steps to allow the labelled RNA strand to hybridize to the bead on the 
BeadChip containing the complementary gene-specific sequence (Assay Guide, illumina.com, 
January 2018).  
 87 
Briefly, the steps were as follows: (1) cRNA was prepared for hybridization by 
preheating cRNA at 65°C for 5 min; (2) the Hyb Chamber was assembled; (3) the BeadChips 
were placed one by one inside the Hyb chamber; care was taken to ensure that the bar code in 
the BeadChips is aligned with the symbol in the chamber; (4) the samples were loaded using a 
single-channel high precision pipette; (5) the BeadChips were hybridized by closing and 
locking the Hyb Chamber lid and then placing the chamber in the Illumina Hybridization Oven 
and incubating for 14 - 20 h at 58°C; and (6) the BeadChip was washed in four distinctive steps. 
The first wash was a high-temperature wash, followed by two RT washes, one with E1BC1 
buffer and another with 100% ethanol. The last step, the blocking step, was performed by 
washing the BeadChip in block E1 buffer. The next steps in the process were as follows: (8) 
The signal was detected. Cy3-SA was introduced to bind to the probes that have been 
hybridized to the BeadChip, facilitating the detection of the signal. The BeadChip was bathed 
in block E1 Buffer containing Streptavidin-Cy3 in a rocker mixer for 10 min at RT. (9) The 
BeadChip was washed with E1BC buffer 5 times and then bathed in the buffer for 5 min at RT. 
(10) After the chip was dyed by centrifuging at 8,000 g for 4 min, the BeadChip was ready to 
be scanned using the iScan Reader. The scanner uses a laser to excite the fluorophores of the 
single-base extension products on the beads of the BeadChip sections. They are then recorded 
in high-resolution images (Assay Guide, illumina.com, January 2018). 
 
2.9.5 Bioinformatics 




2.9.6 RT-qPCR  
Using the same RNA isolated from cells with and without 18 h IFNg treatment that were used 
in the Illumina Expression BeadChip, we assessed the gene expression of the target genes 
IDO1, GPB2 and CXCL11.  
RT-qPCR was performed using the StepOne System Instrument (ThermoFisher, cat no. 
4376357) using a TaqMan® RNA-to-CT™ 1-Step Kit (ThermoFisher, cat no. 4392938), 
according to the manufacturer’s instructions.  
Briefly, for the master mix, the reaction contained 10 µl of TaqMan RT-PCR Master 
Mix (2X), 0.5 µl of TaqMan probe, 0.5 µl of TaqMan RT Enzyme Mix, 20 ng of the appropriate 
RNA template, 1 µl of each primer (900 nM), and up to 20 µl of nuclease-free water.  
We placed the reaction tube in a StepOne System and performed 40 cycles as follows: 
Holding: 48°C for 15 min 
Holding: 95°C for 10 min  
Cycling (40 cycles): 95°C for 15 sec 
                                 60°C for 1 min 
          Primers pairs for target genes are listed in the Appendix. Data were collected and 







3.1 WJ MSC ISOLATION AND CULTURE UNDER STANDARD AND XENO-FREE 
CONDITIONS 
The standard medium commonly used by research groups around the world for the isolation 
and expansion of MSCs is DMEM supplemented with 10% FBS. To avoid high lot-to-lot 
variability of FBS and risk of contamination with xenopathogens, chemically defined medium 
would be an ideal replacement in terms of compliance with good manufacturing practice 
(GMP). However, such chemically defined media are lacking a number of factors that are 
present in FBS and are required for optimal MSC proliferation.  
 To validate the performance of the chemically defined medium Stemgro, which has 
components that are either chemically synthesized or recombinantly produced and purified, we 
cultured explants from the same UCs (n=7) under STD (DMEM supplemented with 10% FBS) 
and dXF (Stemgro) conditions. Commonly, chemically defined media do not contain 
extracellular matrix proteins; therefore, we used CELLstart to coat the surface of the culture 
dishes. CELLstart is a defined substrate containing only components of human origin, the main 
one being fibronectin (Hughes et al., 2011).  
WJ MSC initial outgrowth from the attached UC explants was typically observed within 
8 to 11 days. The mean (± standard deviation, SD) time to the first observation of outgrowth 
was 9.13 (± 0.3; n=7) under STD and 12.1 (± 0.5; n=8) under dXF conditions (Figure 3.1.1). 
Based on the Wilcoxon signed-rank test, the difference in observation of the first outgrowth 
between donor matched STD and dXF conditions was statistically significant (p=0.021).  
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Figure 3.1.1 First outgrowth from UC explants was earlier under STD (medium containing FBS) 
than under chemically defined (dXF conditions). The first outgrowth was observed sooner under STD 
(9.29 ± 0.3 days post plating, n=7) than under dXF conditions (12.13 ± 0.5 days post plating, n=8). The 
difference was statistically significant (p<0.05). The difference between the groups was tested by 
Wilcoxon signed-rank test. The value of test statistics V = 28, and p = 0.021. Based on this test, we 
concluded that STD and dXF groups are non-identical populations. The pseudomedian of the differences 
between samples from these two groups was 2.5, with 90% confidence interval (1.5, 4.0). The 
nonparametric confidence interval is calculated here as a continuity-corrected normal approximation. 
 
Apparently, FBS-containing medium supports WJ MSC proliferation better than the 
xeno-free chemically-defined medium Stemgro. In an attempt to mimic the effects of FBS and 
retain xeno-free conditions, we then tested hPL, one of the most commonly used FBS 
alternatives that relies on human blood-derived components (Bieback, 2015).  
Non-defined, xeno-free culture (nXF) had a similar effect on appearance of the first 
outgrowth as STD conditions, with both of them performing significantly better (*p≤0.05) than 
chemically defined xeno-free culture (dXF) conditions (Figure 3.1.2). 
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Figure 3.1.2 Both FBS (STD conditions) and HPL (nXF conditions) support better MSC 
proliferation measured by time of the first outgrowth from UC explants than chemically defined 
(dXF) conditions. The first outgrowth was observed sooner under STD (9.29 ± 0.3 days post plating, 
n=7) and XF (8.70 ± 0.8 days post plating, n=3) than under dXF conditions (12.13 ± 0.5 days post 
plating, n=8). The difference between dXF and the other two conditions is statistically significant 
(*p<0.05), whereas the difference between STD and nXF conditions was not significant by the 
Wilcoxon rank-sum test. For the significant difference dXF/ nXF test statistic is W=23.5, and p=0.022. 
The shift in location of the difference between samples from these two groups was 3.0, with 95% 
confidence interval (1.0, 6.0). For non-significant difference STD/ nXF test statistics is W=14.5, and 
p=0.403. The shift in location between samples from these two groups was 1.0, with 95% confidence 
interval (-1.0, 3.0). The nonparametric confidence intervals are calculated here again as continuity-
corrected normal approximations. 
 
Appearance of the first outgrowth might be a consequence of higher proliferation rate, 
faster cellular migration or both. To determine what is causing this effect, we calculated 
population doublings (PD) between the two first passages (P1 and P2) to establish the 
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proliferation rate under the conditions used (Figure 3.1.3). The median (range) PD for STD 
conditions was 105.40 h (85.92 - 115.20) for nXF conditions and 119.00 h (88.08 - 146.90) and 
for dXF conditions 121.90 h (77.52 – 162.70). Analysis using the Kruskal-Wallis Rank Sum 
Test showed no significant difference between all groups (p=0.228), and there was also no 
significant difference between pairs of groups using the Wilcoxon rank-sum and Wilcoxon 
signed-rank tests. 
The Wilcoxon rank-sum test was used to compare nXF to other two groups, whereas 
the Wilcoxon signed-rank test to compare dXF and STD. The results were: 
• nXF/ dXF: W=10; p=1; difference in location = -0.12, 95% CI= (-1.82, 1.73) 
• nXF/ STD: W=15; p=0.3605; difference in location = 0.57, 95% CI= (-1.13, 1.95) 
• dXF/ STD: V=1; p=0.0625; pseudomedian = -0.795; 95% CI= (-2.61, 0.22). 
Taken together, these data suggest that the earlier observation of the initial outgrowth 
from UCs explants under STD and nXF conditions is due to an increase in cellular migration 
rather than to faster cell migration. A plausible explanation is that both FBS under STD and 
hPL under nXF conditions are richer in growth factors and different molecules such as 
chemokynes and cytokines from the platelet rich plasma that facilitate cellular migration than 




Figure 3.1.3 The Kaplan-Meier curve using an overall median of 114 h indicates that there was 
no significant difference in the median time to doubling (p=0.086). dXF, chemically defined, xeno-
free condition; nXF, non-defined, xeno-free condition (medium containing hPL); STD, standard 
condition (medium containing FBS). Two-sided 95% confidence intervals were calculated as log(-
log(hazard)). For Kruskal-Wallis Rank Sum Test that compared all groups, statistics were as follows: 
Kruskal-Wallis chi-squared=2.9567, df=2, p=0.228.  
  
In general, cells under all three conditions exhibited a similar spindle shape with a flat 




Figure 3.1.4 WJ MSCs in culture. The cells in initial outgrowth from attached UC explants grown 
under STD and nXF conditions looked more like typical fibroblasts, whereas the cells grown under dXF 
conditions were less elongated and never as tightly packed as the cells in standard culture. After 4 
passages, WJ MSCs under dXF still looked more elongated than the cells under STD and dXF conditions 




3.2 WJ MSC PROFILING SURFACE MARKERS WITH FLOW CYTOMETRY 
3.2.1 WJ MSCs express all markers seen in BM MSC 
We assessed the effect of STD (n=3; donors ID: 8, 12 and 13), nXF (n=3; donors ID: 3, 4, and 
5) and dXF (n=10; donors ID: 8, 9, 10, 11, 12, 13, 14, GMP 03, GMP 04 and GMP 05) on the 
isolation and propagation of WJ MSCs by determining the profile of nine surface markers: 
CD29, CD34, CD44, CD45, CD56, CD73, CD90, CD105 and MSCA-1. Clinical grade BM 
MSCs (from 3 different donors) cultured under nXF conditions were used for comparison of 
the expression of cell surface markers with WJ MSCs derived and expanded under STD, nXF 
and dXF conditions (Figure 3.2.1).  
BM MSCs and WJ MSCs cultured under all conditions were negative for CD34 and 
CD45 hematopoietic markers (Appendix: Figure 5). As positive control for the hematopoietic 




Figure 3.2.1 Surface marker expression of BM MSCs, clinical grade, and WJ MSCs cultured 
under three conditions: STD, nXF and dXF. Groups were compared with the Kruskal-Wallis test, 
and in cases in which the differences were statistically significant, pairs of mediums were checked by 
Wilcoxon (Man Whitney) test. The overall differences between groups were significant for markers 
CD73, CD56, CD90, CD105 and MSCA-1. Confidence interval (CI) is 90%. 
 
For CD29 (ITGB1 (integrin β1)), clinical grade BM MSCs and all WJ MSCs from all 
donors, regardless of culture conditions, expressed the marker at higher levels.  
CD44, the receptor for hyaluronic acid, was also expressed in almost the entire 
population of cells isolated from all donors regardless of culture condition, as well as BM 
MSCs.  
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The expression of CD56, the neural cell adhesion molecule 1 (NCAM1), varied from 
donor to donor, with the dXF group having the lowest levels (8 ± 1.7%), followed by BM MSCs 
(9.2 ± 4.3%), whereas the nXF and STD groups had higher levels (34.6 ±17.3% and 56 ± 
18.1%) (*P<0.05).  
 CD73, ecto-5ʼ-nucleotidase, was expressed in almost the entire population of BM MSCs 
(87.4 ± 8.1%) and WJ MSCs cultured under dXF (98 ± 0.9%) and nXF (98.3 ± 0.9%), whereas 
WJ MSCs cultured under STD were approximately 30% less positive for CD73 (65.4 ± 2.7%). 
Significant differences were observed between BM MSCs and dXF (*p<0.05) and between 
STD and dXF (***p<0.0001).  
The expression of CD90, also known as thymocyte differentiation antigen (Thy-1) was 
generally lower in the WJ MSC dXF (33.4 ± 5.9%) and STD (35.2 ± 7.7%) groups than in the 
BM MSCs (70.8 ± 11.1%) and nXF (97.5 ± 2%) groups, varying among donors under dXF 
conditions (8.4% in donor 13 to 70.8% in donor 05). A significant difference was observed 
between BM MSCs and dXF (*p<0.05). 
Endoglin (CD105) is expressed on endothelial cells and MSCs, particularly 
proliferating cells (Saad et al., 2004). More BM MSCs (79.7 ± 9%) and STD (74.4 ± 7%) than 
WJ MSC dXF and nXF were positive for CD105. Although the population of CD105+ cells 
varied from donor to donor, in general, the results were similar between the WJ MSCs cultured 
under dXF conditions (54 ± 4.8%) and those cultured under nXF conditions (55.9 ± 21). WJ 
MSC nXF had an enormous variation among all 3 donors (89.1%, 63.7% and 15.1%). A 
significant difference was observed between BM MSCs and dXF (*p<0.05). 
MSCA-1, however, displayed a curious pattern. Whereas it was barely detectable in 
nXF (0.03 ± 0.03%) and STD conditions (0.13 ± 0.1%) and was lowly expressed in BM MSCs 
 98 
(3.5 ± 2%), in WJ MSCs cultured under dXF conditions, 13.5 – 86.1% of cells were positive. 
Donor 9 and 05 were an exception, with 4.4% and 7.3% MSCA-1+ cells under dXF.  
The profiling of cell surface markers from a total of 10 independent donors cultured 
under all conditions confirmed that WJ MSCs isolated in this study expressed all MSC markers 
seen in BM MSCs, although at a variety of levels. Interestingly, it seems that the dXF group 
favours expression of the MSCA-1 marker, which was barely detectable in STD and nXF or in 
clinical grade BM MSCs. 
 
3.2.2 Different levels of O2 did not affect expression of the MSC surface markers examined 
Increasing evidence has demonstrated that oxygen (O2) levels play an important role in cell 
proliferation and plasticity (Ma et al., 2009). An atmospheric oxygen tension of 20% is a non-
physiological condition, representing a hyperoxic environment. Culturing the cells at 5%, 
which is closer to their physiological microenvironment in vivo, increased their proliferation 
and, in the case of MSC, also affected their differentiation potential (Ma et al., 2009; Ivanovic 
et al., 2000; Katahira and Mizoguchi, 1987; Bradley et al., 1978). It has been shown that WJ 
MSCs also proliferate faster at lower O2 tensions without affecting the profile of their surface 
markers (Widowati et al., 2014). Therefore, we opted to work at 5% O2.  
 To determine whether different levels of O2 affect the expression of WJ MSC cell 
surface markers in XF media in our system, we ran a comparison between 20% and 5% O2 on 
WJ MSC (n=3) isolation and expansion using nXF and dXF media. We assessed the differences 
between groups by determining the profile of nine surface markers: CD29, CD34, CD44, CD45, 
CD56, CD73, CD90, CD105 and MSCA-1. 
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The WJ MSC isolation and culture conditions were grouped as follows: nXF and dXF 
in 5% O2 (5nXF and 5dXF) and in 20% O2 (20nXF and 20dXF).  
WJ MSC lines cultured under all conditions were negative for CD34 and CD45 
hematopoietic markers (Appendix: Figure 6.3.1 and 6.3.2).  
In general, the expression levels of all surface markers were not significantly different 
between 5 and 20% O2 (Figure 3.2.2). However, the levels were different depending on the 
culture media used (nXF or dXF). Comparison between media in 20% found that the difference 
is marginally significant for all markers but CD90, and in 5% the difference is seen as 
marginally significant for markers CD29, CD90, and MSCA1. Bt the Wicoxon (Mann- 
Whitney) test, CD44 and MSCA1 were the only surface markers with significant differences in 





Figure 3.2.2 Expression levels of MSC surface markers were dependent on the culture media used 
(nXF or dXF), not on the level of O2. Confidence interval (CI) is 90%. 
 
All 4 groups were positive for CD29 (20nXF: 99.6%; 5nXF: 99.5%; 20dXF: 91.7%; 
5dXF: 98.6%) and CD73 (20nXF: 97.8%; 5nXF: 98.3; 20dXF: 92.2%; 5dXF: 96.8%) without 
significant differences between all groups. 
CD44 was lower in the 20dXF group (73.7%) than 5dXF, 20nXF and 5nXF (95.3%, 
99.5% and 99.2%, respectively). 
CD90 was lower in the 20dXF (68.2%) and 5dXF (50.4%) groups than the 20nXF 
(95.4%) and 5nXF (97.5%) groups. 
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CD105 showed higher expression levels in the 5nXF groups independent of the O2 
levels, with 59.2% under 20nXF and 56% under 5nXF conditions versus 16.2% under 20dXF 
and 42.6% under 5dXF conditions. 
MSCA1 was only expressed in the dXF groups, with 8.5% under 20dXF and 20.8% 
under 5dXF conditions.  
 Taken together, our data were in agreement with the findings of Widowati et al. (2014), 
who showed that O2 level does not affect the expression level of surface MSC markers.  
 
3.2.3 MSCA-1 expression is induced by exposing WJ MSCs to dXF conditions. 
In spite of large variations in the size of the MSCA-1+ subpopulation amongst donors (4.4% - 
86.1%), MSCA-1+ subpopulations were detected in MSCs from all donors (Table 3.2.1). 
However, only under dXF conditions, regardless of the O2 level.  
Table 3.2.1 Population size of MSCA+ cells in the MSC of each of 7 donors when cells were 
cultured under dXF conditions at 5% O2.  
Donor # 8 9 10 11 12 13 14 
MSCA-1+ cells [%] 15.8 4.4 23.5 13.5 38.8 86.1 29.5 
 
To confirm that the chemically defined XF culture conditions described here selectively 
privileged the expansion of MSCA-1+ cells, we transferred WJ MSC derived and expanded 
under STD conditions (n = 2 donors; donor 12 and donor 14) into dXF medium for 14 days and 
assessed the proportion of MSCA-1+ cells. For both donors, the numbers of MSCA-1+ cells 
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increased, from 0.1% to 0.9% in donor 12 and from undetectable (0%) to 9.9% in donor 14 
(Figure 3.2.3). Since the population doubling time of WJ MSCs derived under dXF conditions 
is slightly over two days (55.2 ± 2.6 h) and the cells were cultured for only 14 days, this increase 
is likely due to the stimulation of MSCA-1 expression, not increased cell proliferation of 
already present MSCA-1+ cells. 
 
Figure 3.2.3 MSCA-1 expression is induced by exposing WJ MSCs to XF conditions. WJ MSCs 
derived and expanded under STD condition (n = 2 donors) were exposed to XF conditions for 14 days 
(STD->XF). That was sufficient to significantly induce an increase in the MSCA-1+ subpopulation from 





3.3 DIFFERENTIATION POTENTIAL 
Next, we wanted to determine whether the isolated WJ MSCs (PD 5) have a differentiation 
potential into the three mesenchymal lineages by testing their response to adipogenic, 
chondrogenic and osteogenic induction media. To do that, we used the cells isolated from three 
randomly chosen donors for each of media conditions tested. After 14 days of culture, in 
adipogenic medium, we could detect fat droplets (Figure 3.3.1). It took 21 days to induce Alcian 
Blue-positive glycosaminoglycan depositions (cartilage; Figure 3.3.2) or mineralized nodules 
(bone), as shown by Alizarin Red staining (Figure 3.3.3).  
 




Figure 3.3.2 WJ MSCs derived under one of three conditions (STD, nXF or dXF) displayed 
chondrogenic potential. 
 
Figure 3.3.3 WJ MSCs derived under one of three conditions (STD, nXF or dXF) displayed 
osteogenic potential. 
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We assessed the differentiation potential into three lineages qualitatively. To address 
whether any of the three media render the cells more prone to adipo-, chondro- or osteogenic 
lineages, we would need to carry out quantitative analyses with either a much larger number of 
samples or using the cells from the same donor derived under the three given conditions. 
Regardless, the qualitative analyses suggested that none of the three different conditions 
impaired markedly the differentiation potential of WJ MSCs or depleted stem cell 
subpopulations from the isolated cells. 
 
3.4 IMMUNOMODULATORY ACTIVITY OF WJ MSC 
MSCs are known for their ability to exert potent immunosuppressive and immuneregulatory 
effects on a variety of cell types mediating both adaptive and innate immunities (Marigo and 
Dazzi, 2011). Next, we compared the immunomodulatory effect of clinical grade BM MSCs 
(n=3) and WJ MSCs isolated and grown under dXF (n=4). 
WJ MSCs inhibited PHA-stimulated PBMC proliferation in a dose-dependent manner 
in a similar fashion as BM MSCs, although there was a significantly higher antiproliferative 
activity at the 1/20 ratio (Figure 3.4.1). These data suggest that WJ MSCs retain similar 
immunosuppressive activities to the ones originally described in BM MSCs.  
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Figure 3.4.1 Immunomodulatory activity of MSCs under XF conditions. The magnitude of the 
immune response of WJ MSC in dXF and clinical grade BM MSC in nXF were similar between the 
ratios (PBMCs/MSCs), with the exception of the ratio 20/1, where WJ MSC dXF appears to be slightly 











3.5 REPROGRAMMING OF WJ MSCs INTO iPSCs 
The experiments described in chapters 3.1 – 3.4 demonstrated that WJ MSCs could be isolated 
successfully from the umbilical cord under dXF conditions. The cells derived in such a way 
retain all the characteristics of MSCs: the expression of typical MSC surface “markers”, 
differentiation potential into adipocytes, chondrocytes and osteocytes, and immunomodulatory 
activity. Therefore, to test our hypothesis that clinical grade iPSC-derived WJ MSCs can be 
derived from the beginning to the end under xeno-free conditions, we chose WJ MSCs derived 
and propagated under dXF conditions from three of seven donors for reprogramming into iPSC 
lines. The criterion for the selection of the donors was the size of the MSCA-1+ subpopulation 
(Table 3.2.1). MSCA-1+ cells are mesenchymal precursor cells and its expression is linked with 
an increased capacity of colony forming units >100-fold in comparison with the MSCA-1- 
subpopulation (Sobiesiak et al., 2010; Bühring et al., 2009; Gronthos et al., 2007). WJ MSCs 
derived under dXF that had the highest number of MSCA-1+ cells were from donor 13 (86.1%), 
12 (38.8%) and 14 (29.5%). To distinguish them from iPSC-derived MSC lines, we dubbed the 
primary native WJ MSCs as native MSCs (nMSCs). Therefore, from donor 12, we have 
nMSC12; from donor 13, we have nMSC13; and from donor 14, we have nMSC14. 
We reprogrammed WJ MSCs into iPSCs using a commercially available SeV 
reprogramming kit (CytoTune-iPS Sendai Reprogramming Kit, Life Technologies) following 
the manufacturer’s protocol, with a few modifications (Figure 3.5.1). This method uses 
incompetent SeV to safely deliver the four transcription factors (OCT4, SOX2, c-Myc and 
KLF4) responsible for reprogramming somatic cells into iPSCs (Takahashi and Yamanaka, 
2006). The kit is simple to use with a few steps involved, and generates iPSCs with an efficiency 
of 1%, a 100-fold improvement in efficiency compared with other methods such as lentivirus 
and episomal (efficiency between 0.0001% to 0.01%). In parallel with the three WJ MSC lines 
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(nMSC12, nMSC13 and nMSC14) no older than passage number 6 (PD 16), we used for 
reprogramming: primary dermal fibroblast BJ as a control.  
 
 
Figure 3.5.1 Reprogramming timeline of production of iPSC. Figure adapted from Life technologies 
website CytoTune kit (lifetechnologies.com, 2017).  
 
Mitotically inactivated gamma-irradiated newborn human foreskin fibroblasts (NuFFs) 
were used as the feeder layer for the newly reprogrammed cells. They are commonly used as a 
foundation for the cells and are capable of secreting growth factors that positively influence the 
health of the culture, the success of reprogramming and the maintenance of primary iPSC 
colonies. This particular batch of NuFFs has been previously used in our laboratory to sustain 
fibroblasts undergoing mRNA reprogramming (Petrova et al., 2014). 
To increase cell viability following SeV transduction and provide optimal cell culture 
conditions, we used NuFF-conditioned Pluriton medium from day 7 after reprogramming until 
the primary iPSC colonies were re-plated onto NuFF feeder plates (normally at Day 22).  
2.5 to 4 weeks 
Plate 
cells
Day:   -2            0      1                       5          6          7       8                       12   15       
Xeno Free Fibroblast Medium (XF)                  Pluriton Conditioned Medium (PC) 
Transduction
Day
                                     Replace Medium 
                                   daily
Plate transduced cells 
in NuFF feeders
50% XF + 50% PC
Emerging 
colonies
iPSC colonies ready 
to transfer  
into HFF Feeders
  Prepare 






After transduction with SeV, the cells were monitored daily for morphological changes. 
Cell death could be observed in the first 24 h post-transduction. The changes in morphology 
that occurred during reprogramming were similar among all three lines (nMSC12, nMSC13 
and nMSC14) and are illustrated in Figures 3.5.2 – 3.5.4. From day 5, cells started showing 
visible signs of transition from mesenchymal to epithelial morphology. From day 10, we could 
identify cell compaction and colony formation. Primary iPSC colonies could be observed from 
day 14 after SeV transduction.  
Compact colonies of cells with distinct borders were easily distinguishable 
approximately three weeks from the start of reprogramming. A large number of such colonies 
were present in all 3 lines (Figure 3.5.5 and Table 3.5.1). Ten colonies chosen by their similar 
morphology as ESC colonies with distinct borders and compact cells were manually picked and 
transferred onto the HFF feeder layer on day 22 - 25 for each of the three cell lines. 
Reprogrammed nMSC12 we called iMSC12 (abbreviated from iPSC-MSC12). Reprogrammed 




Figure 3.5.2 Changes in morphology of nMSC12 during SeV-mediated reprogramming. D1, donor 
12 nMSCs first day of transduction with SeV. D7, cell death could barely be observed and the cells 
showed the first signs of transition. D14, cells already plated onto NuFF feeders showing signs of cell 
compaction and colony formation. Plated onto HFF, primary iMSC colony plated and attached onto 
the HFF feeder layer (day 23 after transduction with SeV and day 4 after plating onto HFF) for further 




Figure 3.5.3 Changes in morphology of nMSC13 during SeV-mediated reprogramming timeline 
in pictures. D1, donor 13 nMSCs first day of transduction with SeV. D7, cell death could be observed. 
D14, cells were plated onto NuFF feeders and the attachment occurred successfully. Plated onto HFF, 
primary iMSC colony plated and attached onto HFF feeder layer (day 25 after transduction with SeV 




Figure 3.5.4 Changes in morphology of nMSC14 during SeV-mediated reprogramming. D1, donor 
14 nMSCs first day of transduction with SeV. D7, cell death could be observed and also signs of changes 
in cell morphology. D14, cells were plated onto NuFF feeders and signs of cell compaction and colony 
formation were identified. Plated onto HFF, primary iMSC14 colonies plated and attached onto the 
HFF feeder layer (day 25 after transduction with SeV and day 3 after plating onto HFF) for further 





Figure 3.5.5 Trypan blue staining of colonies in one P60 culture dish (60-mm diameter) at Day 21 
post SeV transduction.  
 
Table 3.5.1 Colony counting using ImageJ Software.  
Donor Colony count 
nMSC12 – iMSC12 1413 
nMSC13 – iMSC13 2586 
nMSC14 – iMSC14 1789 




We continued expanding only four colonies out of the ten chosen previously from each 
of the three iMSC lines. The four colonies were chosen by their morphology (as similar as 
possible with ESC colonies, with distinct border and compact cells showing no signs of cell 
differentiation). After three passages onto HFF feeders, we vitrified the majority of the colonies. 
However, iMSC14 colonies in general grew slower and were more difficult to maintain than 
iMSC12 and iMSC13 colonies. Therefore, for further work, we focussed on iMSC12 and 
iMSC13 only. One colony from each background was expanded further and adapted to feeder-
free conditions (Stephenson et al., 2012) (Figure 3.5.6). 
 
 
Figure 3.5.6 iMSC12 and iMSC13 adapted to feeder-free conditions showed typical morphology 






3.6 ANALYSIS OF SeV GENE EXPRESSION IN iPSC LINES 
SeV is a non-integrating RNA virus that remains in the cytoplasm of cells and therefore 
can be diluted out of the cells after 10 or more passages. Following feeder-free adaptation and 
60 days in culture with constant passages, the SeV gene was undetectable in the genome of 
iMSC12 and iMSC13 (Figure 3.6.7). This means that no exogenously expressed genes were 
present and the lines from this point were fully reprogrammed. Further characterization and 
differentiation followed to prove the lines were indeed iPSCs.  
 
 
Figure 3.6.7 SeV DNA was undetectable in iMSC12 and iMSC13 two months after transduction. 
Original non-transduced native MSC lines (nMSC12 and nMSC13) were used as negative controls; 7 
days post-SeV transduction cells were used as positive controls (Day 7). Two points were analysed, Day 
60 and Day 90 in culture, and both points were negative for SeV expression. Β-Actin (ACTB) PCR 





3.7 CHARACTERIZATION OF iPSC LINES 
Characterization was performed following our standard procedures with hESC lines 
(Stephenson et al., 2012) and included detection of markers associated with pluripotency, 
spontaneous differentiation into three germ layers in vitro and in vivo, DNA fingerprinting and 
array CGH.  
 
3.7.1 Expression of markers associated with pluripotency 
Pluripotency was confirmed by immunostaining for four markers associated with pluripotency: 
transcription factors NANOG and POU5F1 (OCT4) and surface antigens TRA-1-60 and TRA-




Figure 3.7.1 iMSC12 and iMSC13 showing markers associated with pluripotency by 
immunostaining (OCT4, NANOG, TRA-1-60, TRA-1-81). hESC line KCL034 was used as a positive 





3.7.2 Spontaneous differentiation into three germ layers in vitro 
Differentiation of three germ layers in vitro is confirmed by the detection of the following 
markers: smooth muscle actin (red) for mesoderm, β-III tubulin (red) for ectoderm and α-
fetoprotein (red) for endoderm. 
 
Figure 3.7.2 Both iMSC12 and iMSC13 can differentiate into all three germ layers in vitro. 
Spontaneous differentiation is confirmed by the detection of germ-layer markers: β-tubulin for 
ectoderm, α-fetoprotein for endoderm and smooth muscle actin for mesoderm. hESC line KCL034 was 
used as a positive control. Scale bar: 20 µm. 
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3.7.3 Spontaneous differentiation into three germ layers in vivo 
The standard in vivo assay for demonstrating the pluripotency of hESCs and iPSCs is their 
ability to form teratomas, non-malignant tumours, when implanted into a host animal, 
commonly an immunocompromised mouse (Prokhorova et al., 2009; Przyborski, 2005). Solid 
parts of teratomas generated from iMSC12 and iMSC13 contained tissue derived from all three 
germ layers, confirming their pluripotent nature (Figure 3.7.3).  
 
Figure 3.7.3 Both iMSC12 and iMSC13 can differentiate into all three germ layers in vivo. 
Spontaneous differentiation is confirmed by the detection of germ-layer markers: β tubulin (TUBB3) 
and glial fibrillary acidic protein (GFAP) for ectoderm, α-fetoprotein (AFP) and GATA binding protein 
4 (GATA4) for endoderm and desmin (DES) and Alcian blue – Periodic Acid Schiff (PAS) for 




3.7.4 Genotyping – DNA fingerprint 
To identify cell lines to the individual level in case of possible cross contamination in the future, 
we performed DNA fingerprinting on parental nMSC12 and nMSC13 lines (Figure 3.7.4). 
Although this method is highly specific to the level of an individual and can better discriminate 
any cross-contamination with cell lines of human origin, it is not designed to detect inter-species 
contamination. Since the whole laboratory is working under xeno-free conditions and we do 
not carry any animal cell lines, inter-species contamination was not of concern. 
 
Figure 3.7.4 DNA fingerprinting. Microsatellite markers specific for chromosomes 13, 18, 21, X and 
Y were amplified. The sex chromosome markers were consistent with a female complement in both 
lines. The allele sizes in base pairs for markers on chromosomes 13, 18 and 21 are listed. 
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3.8 DIFFERENTIATION OF iPSCs AND hESCs INTO MSC-LIKE CELLS 
To determine how close MSCs differentiated from pluripotent stem cells are to nMSC, we 
followed two different protocols: ARGENTINA (ARG; Luzzani et al. 2015) and TEXAS 
(TEX; Zhao et al., 2015). The pluripotent lines were iPSC12, iPSC13 and the hESC line 
KCL034, which was used as a control (Figure 3.8.1).  
 
Figure 3.8.1 Schematic diagram of the experimental strategy. 
 
A difference between the two protocols was obvious in cell morphology after 4 days 
(Figure 3.8.2 and 3.8.3) and it persisted among CD73+CD90+CD105+ sorted cells cultured in 




Figure 3.8.2 Change in cell morphology during differentiation of iPSCs into iMSC ARG. Top row 
(Day 4): Tight cell-cell contacts, typical for densely packed pluripotent stem cell colonies, are 
completely lost. Middle row (Day 12): Appearance of large flattened cells indicated cellular senescence 






Figure 3.8.3 Change in cell morphology during differentiation of iPSCs into iMSC TEX. Top row 
(Day 4): The fibroblast-like cells undergoing differentiation are mixed with seemingly intact pluripotent 
stem cell colonies (yellow arrowheads). Middle row (Day 12): All differentiating iPSC12 and iPSC13 
have uniform fibroblast-like morphology, whereas some of the differentiating hESC KCL034 still form 
colonies resembling pluripotent stem cells (yellow arrowheads). Bottom row: iMSCs and eMSCs 




Senescent cells were observed in both iPSC12 and 13 and hESC KCL034 lines 
undergoing the ARG differentiation protocol as early as Day 12. They were never observed in 
any of three lines undergoing the TEX differentiation protocol. This suggested that the iMSC12 
TEX, iMSC13 TEX and eMSC34 TEX might maintain some of their stem cell-like 
characteristics and represent a type of MSC progenitor, whereas iMSC12 ARG, iMSC13 ARG 
and eMSC34 ARG might be closer to primary MSC, which are a mixture of progenitors and 




3.9 CHARACTERIZATION OF iMSCs AND eMSCs 
3.9.1 iMSCs and eMSC originating from the TEX protocol have significantly higher 
differentiation potential to adipo- and chondrogenic than those originating from the ARG 
protocol 
 
Figure 3.9.1 Differentiation potential. (A) nMSCs that were exposed to adipogenic differentiation 
medium showed accumulation lipid droplets as detected with LipidTOX stain and had a significantly 
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higher (**p≤0.01) expression of fatty acid binding protein 4 (FABP4). No significant difference in 
FABP4 levels was detected between nMSC12 and nMSC13. (B) nMSCs that were exposed to 
chondrogenic differentiation medium were positive for cartilage glycosaminoglycans as detected by 
Alcian Blue staining and had a significantly higher (**p≤0.01) expression of collagen 11 (COL11A1). 
No significant difference in COL11A1 levels was detected between nMSC12 and nMSC13. (C) nMSCs 
that were exposed to osteogenic differentiation medium were full of mineral accumulations as detected 
by Alizarin Red staining and had a significantly higher (*p≤0.05) expression of runt related transcription 
factor 2 (RUNX2). No significant difference in RUNX2 levels was detected between nMSC12 and 
nMSC13. (D) Following adipogenic differentiation, all i/eMSC lines showed accumulation of lipid 
droplets and significantly higher (***p≤0.001, **p≤0.01, *p≤0.05) expression of FABP4. All lines 
generated using the TEX protocol (iMSC12 TEX, iMSC13 TEX and eMSC34 TEX) had a significantly 
higher (####p≤0.0001, ##p≤0.01) expression of FAPB4 than the lines generated using the ARG protocol 
(iMSC12 ARG, iMSC13 ARG and eMSC34 ARG). (E) Following chondrogenic differentiation, all 
i/eMSC lines were positive for cartilage glycosaminoglycans as detected by Alcian Blue staining and 
had a significantly higher (****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05) expression of COL11A1. 
All lines generated using the TEX protocol (iMSC12 TEX, iMSC13 TEX and eMSC34 TEX) had a 
significantly higher (##p≤0.01, #p≤0.05) expression of COL11A1 than the lines generated using the ARG 
protocol (iMSC12 ARG, iMSC13 ARG and eMSC34 ARG). (F) Following osteogenic differentiation, 
all i/eMSC lines were full of mineral accumulation and had a significantly higher (***p≤0.001, 
**p≤0.01, *p≤0.05) expression of RUNX2. There were no significant differences in RUNX2 expression 
between the lines generated using the TEX protocol (iMSC12 TEX, iMSC13 TEX and eMSC34 TEX) 
and the lines generated using the ARG protocol (iMSC12 ARG, iMSC13 ARG and eMSC34 ARG) after 
culture under osteogenic conditions. 
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To determine whether iMSCs and eMSCs possess MSC differentiation ability, we 
cultured them in adipo-, chondro- and osteogenic differentiation medium. All MSC, regardless 
of their origin, were positive for markers of adipose tissue, cartilage or bone (Figure 3.9.1). 
However, when we compared the lines generated from pluripotent stem cells, all that were 
generated using the TEX protocol had significantly higher expression of adipogenic and 
chondrogenic markers than those of ARG origin (Figure 3.9.1 D, E). Such a difference was not 
found after osteogenic differentiation (Figure 3.9.1 F). These data are in agreement with the 
previous observation of cellular morphology, which suggested that lines of TEX origin are 
closer to the progenitor level. 
 
3.9.2 iMSCs and eMSC originating from the TEX protocol have significantly lower 
immunomodulatory potential than those originating from the ARG protocol 
Since MSCs can exert potent immunosuppressive and immunoregulatory effects (Wang et al., 
2014; Ma et al., 2014; Marigo and Dazzi, 2011), we assessed the immunomodulatory properties 
of triple positive (CD73+CD90+CD105+) iMSCs and eMSCs (Figure 3.9.2). The cells were 
compared for their ability to inhibit phytohemagglutinin A (PHA)-induced proliferation of 
peripheral blood mononuclear cells (PBMC). nMSCs had similar immunomodulatory 
properties with the clinical grade BM MSCs used as a reference. nMSCs performed slightly 
better, whereas at an MSC:PBMC ratio of 1:80, no immunomodulatory effect was observed 
with BM MSCs, but nMSCs were still able to inhibit the proliferation of PBMCs. The weakest 
immunosuppressive effect was observed in the presence of e/iPSCs originating through the 
TEX protocol (undetectable at 1:20), whereas e/iPSCs originating with the ARG protocol were 




Figure 3.9.2 Immunomodulatory properties are less effective in MSCs derived from pluripotent 
stem cells. nMSCs inhibited phytohemagglutinin-stimulated human PBMC proliferation in a dose-
dependent manner in a similar fashion as BM MSCs (MSC:PSC ratio 1:80), whereas an 
immunosuppressive effect could not be detected at an MSC:PBMC ratio of 1:20 in e/iMSCs of the TEX 









3.10 TRANSCRIPTOME ANALYSES 
To determine which of two differentiation protocols, ARG or TEX, yields MSCs 
phenotypically and functionally closer to parental nMSCs, we ran multiple comparative 
analyses of a whole transcriptome array of unstimulated and interferon gamma (IFNg) 
stimulated MSC lines of different origin using the Illumina HumanHT-12 v4 Expression 
BeadChip. To normalise the data, the housekeeping genes used were GAPDH, ACTB and 
HPRT1 (see Appendix). 
3.10.1 Comparison of iMSC12 ARG and iMSC12 TEX with nMSC12 
To determine the differentially expressed genes and their associated pathways between iMSC12 
TEX and nMSC12 and between iMSC12 ARG and nMSC12, we used the R/Bioconductor 
software package limma that provides an integrated solution for differential expression analyses 
of data from gene expression experiments. 
 We found that iMSC12 from both protocols (TEX and ARG) have a high number of 
differentially expressed genes (Table 3.10.1). The number of differentially expressed genes is 
higher using TEX than ARG (2401 vs. 2029). However, there were no significant differences 
between protocols in terms of fold-change median values (2.85 in iMSC12 ARG vs. nMSC12 
and 2.78 in iMSC12 TEX and nMSC12).  






FC Significant pathways 
iMSC12 ARG vs. nMSC12 2029 (975/1054) 
2.85 • Cell adhesion 
• Immune system 
iMSC12 TEX vs. nMSC12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             2401 (1124/1277) 
2.78 
• Cell cycle 
• Cell adhesion 
• Immune system 
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Approximately half of the genes with different regulation in iMSC12 ARG (1054 out 
of 2029 genes or 51.9%) are also differently regulated in iMSC12 TEX (1054 out of 2401 genes 
or 43.9%). Most of the common genes have the same up/down regulation (Figure 3.10.1).  
 
 
Figure 3.10.1 Overlap between two comparisons (iMSC12 ARG vs. nMSC12 and iMSC12 TEX 
vs. nMSC12) shown as Venn diagrams. 
 
To determine whether iMSC12 ARG or iMSC12 TEX is closer to paternal nMSC12, 
we used the R/Bioconductor software packages limma and hclust for Euclidean distance. Even 
if there were more regulated genes with TEX than ARG (2401 vs. 2029), based on the 
expression of all expressed genes, samples from the TEX protocol (iMSC12 TEX) were clearly 
closer to nMSC12 than samples from the ARG protocol (iMSC12 ARG) (Figure 3.10.2). 
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Figure 3.10.2 Unsupervised clustering (Euclidian distance) of samples from donor 12 (nMSC12, 
iMSC12 ARG and iMSC12 TEX). 
  
To explain this difference, we checked the variance distribution between iMSC12 
ARG/nMSC12 and iMSC12 TEX/nMSC12 (Figure 3.10.3). The variances were higher between 
gene expression from the iMSC12 ARG/nMSC12 groups than between gene expression from 
the iMSC12 TEX/nMSC12 groups.  
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Figure 3.10.3 Distribution variance and mean values.  
Taking these data together, even though the number of differentially expressed genes is 
slightly higher using the TEX protocol, unsupervised clustering and variance analysis show that 
iMSC12 TEX cells are closer to nMSC12 than iMSC12 ARG. 
 
3.10.2 Comparison of iMSC13 ARG and iMSC13 TEX with nMSC13 
Using the same approach, we then determined the differentially expressed genes and their 
associated pathways between iMSC13 TEX and nMSC13 and between iMSC13 ARG and 
nMSC13 on the other side. 
 We found that iMSC13 from both protocols (TEX and ARG) have a high number of 
differentially expressed genes (Table 3.10.2). However, in this case, the number of 
differentially expressed genes was higher using ARG than TEX (3065 vs. 2724). Similarly, 
there were no significant differences between protocols in terms of fold-change median values 
(2.83 in iMSC13 ARG vs. nMSC13 and 2.87 in iMSC13 TEX and nMSC13). 
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FC Significant pathways 
iMSC13 ARG vs. nMSC13 3065 (1612/1453) 
2.83 
• Cell cycle 
• DNA repair 
• Cell adhesion 
• Immune system 
iMSC13 TEX vs. nMSC13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2401 (1371/1353) 
2.87 
• Cell cycle 
• DNA repair 
• Cell adhesion 
• Immune system 
 
The majority of genes with different regulation in iMSC13 TEX (2312 out of 2724 
genes or 84.9%) are also differently regulated in iMSC13 ARG (2312 out of 3065 genes or 
75.4%). Most of the common genes have the same up/down regulation (Figure 3.10.4). 
 
Figure 3.10.4 Overlap between two comparisons (iMSC13 ARG vs. nMSC13 and iMSC13 TEX 
vs. nMSC13) shown as Venn diagrams. 
Based on the expression of all expressed genes, samples from the TEX protocol 
(iMSC13 TEX) were clearly closer to nMSC13 than samples from the ARG protocol (iMSC13 
ARG) (Figure 3.10 5). 
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Figure 3.10.5 Unsupervised clustering (Euclidian distance) of samples from donor 13 (nMSC13, 
iMSC13 ARG and iMSC13 TEX). 
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Variance distribution between iMSC13 ARG/nMSC13 and iMSC13 TEX/nMSC13 
(Figure 3.10.6). The variances were higher between gene expression from the iMSC13 
ARG/nMSC13 groups than between gene expression from the iMSC13 TEX/nMSC13 groups. 
 
Figure 3.10.6 Distribution variance and mean values. 
 
 Unsupervised clustering and variance analysis together show that iMSC13 TEX cells 




3.10.3 Comparison of iMSCs and eMSCs obtained with ARG and TEX protocols 
iPSC clones might carry epigenetic memory of their parental cell origin and such epigenetic 
footprints could affect their differentiation propensity (Kim et al., 2011; Ohi et al., 2011, Lister 
et al., 2011; Polo et al., 2011). Therefore, we compared iMSC ARG and iMSC TEX with MSCs 
differentiated from the hESC line KCL034 (eMSC34 ARG and eMSC34 TEX), which has a 
naïve/intact epigenome. 
 We found that eMSC from the TEX protocol have a high number of differentially 
expressed genes compared to the corresponding iMSCs from the ARG protocol (Table 3.10.3). 
Compared to the corresponding iMSCs, eMSC from the ARG protocol have a high number of 
differentially expressed genes for donor 13 and are close to iMSCs for donor 12 (2214 vs 136), 
whereas eMSC from the TEX protocol have a higher number of differentially expressed genes 
compared to the corresponding iMSCs for donor 12 than for donor 13 (5489 vs 4761). There 
were no significant differences between protocols in terms of fold-change median values (2.34 
– 2.88). 






FC Significant pathways 
iMSC12 ARG vs. eMSC34 ARG 136 (54/82) 
2.34 • Cell adhesion 
iMSC13 ARG vs. eMSC34 ARG 2214 (1214/1000) 
2.80 
• Cell cycle 
• DNA repair 
• Cell adhesion 
• Immune system 
iMSC12 TEX vs. eMSC34 TEX 5489 (2771/2718) 
2.87 




In the ARG protocol, nearly one half of the genes regulated in cells originating from 
donor 12 (iMSC12 ARG) are also regulated in cells originating from donor 13 (iMSC13 ARG) 
when compared with eMSC34 ARG (71 out 136 or 52.2%) from which only 19 (26.8%) have 
the same up/down regulation (Figure 3.10.7). 
 
 
Figure 3.10.7 Overlap between two comparisons (iMSC12 ARG and nMSC12 vs. eMSC13 ARG 
and iMSC13 ARG and nMSC13 vs. eMSC13 ARG) shown as Venn diagrams. 
 
In the TEX protocol, most of the genes regulated using one of the protocols are also 
regulated using the other protocol (4065 out of 4761 or 85.4% in cells originating from donor 
13 and 4065 out of 5489 or 74.1% in cells originating from donor 12). Almost all the common 




Figure 3.10.8 Overlap between two comparisons (iMSC12 TEX and nMSC12 vs. eMSC13 TEX 
and iMSC13 TEX and nMSC13 vs. eMSC13 TEX) shown as Venn diagrams. 
 
 Unsupervised clustering showed that iMSC12 TEX and iMSC13 TEX are closer to each 
other than to eMSC34 TEX, whereas iMSC12 ARG are closer to iMSC34 ARG than to iMSC13 
ARG (Figure 3.10.9). 
 Taking these data together, the answer to the question whether hESC-derived MSCs 
(eMSCs) are similar to iPSC-derived MSCs (iMSCs) is quite disappointing, as it might depend 
on the donor as well as the protocol. The differential analysis and the unsupervised clustering 
show that when using the ARG protocol, eMSC (eMSC34 ARG) are close to iMSCs from donor 
12 (iMSC12 ARG). When using the TEX protocol, eMSC (eMSC34 TEX) are very different 
from eMSC34 ARG and all iMSCs regardless of the protocol.  
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Figure 3.10.9 Unsupervised clustering (Euclidian distance) of nMSC, iMSC and eMSC samples 
from two donors (donor 12 and 13). 
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3.10.4 Comparison of native nMSCs with iMSCs and eMSCs obtained with the ARG and 
TEX protocols 
In the final step of transcriptome analysis, to answer the question as to which differentiation 
protocol is better, ARG or TEX, we compared all MSCs derived from pluripotent lines with the 
ARG protocol (iMSC12 ARG, iMSC13 ARG, and eMSC34 ARG) with primary native MSCs 
(nMSC12 and nMSC13) and all MSCs derived from pluripotent lines with the TEX protocol 
(iMSC12 TEX, iMSC13 TEX, and eMSC34 TEX) with primary native MSCs (nMSC12 and 
nMSC13). 
Table 3.10.4 Differentially expressed genes between nMSCs and MSCs obtained from pluripotent 






FC Significant pathways 
iMSC12 ARG & iMSC13 ARG 
& eMSC34 ARG  
vs. nMSC12 & nMSC13 
1539 
(687/852) 
2.84 • Cell adhesion 
• Immune system 
iMSC12 TEX & iMSC13 TEX & 
eMSC34 TEX  




• Cell cycle 
• Cell adhesion 
• Immune system 
 
We found that MSCs from both protocols, TEX and ARG, have a high number of 
differentially expressed genes (Table 3.10.4). The number of differentially expressed genes is 
higher using TEX than ARG (2833 vs. 1539). However, there are no significant differences 
between protocols in terms of fold-change median values (2.84 in the ARG protocol vs. 2.77 in 
the TEX protocol). 
The majority of differently regulated genes in the ARG protocol (1130 out of 1539 or 
73.4% genes) are also differently regulated in the TEX protocol (1130 out of 2833 genes or 
39.9%). Most of the common genes have the same up/down regulation (Figure 3.10.10). 
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Figure 3.10.10 Overlap between two comparisons (nMSCs vs. all MSCs derived from pluripotent 
stem cells following the ARG protocol and nMSCs vs. all MSCs derived from pluripotent stem 
cells following the TEX protocol) shown as Venn diagrams. 
 
 Based on expression levels of all expressed genes, iMSCs from the TEX protocol 
(iMSC12 TEX and iMSC13 TEX) and iMSCs and eMSC from the ARG protocol (iMSC12 
ARG, iMSC 13 ARG, eMSC34 ARG) are closer to each other than to native samples (nMSC12 




Figure 3.10.11 Unsupervised clustering (Euclidian distance) of nMSCs (nMSC12 and nMSC13) 
and all MSCs differentiated from pluripotent stem cells (hESCs and iPSCs) following either ARG 
(iMSC12 ARG, iMSC 13 ARG, eMSC34 ARG) or TEX (iMSC12 TEX, iMSC 13 TEX, eMSC34 
TEX) protocols.  
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 The mean variance between primary nMSCs (nMSC12 and nMSC13) and all MSCs 
differentiated from pluripotent stem cells (hESCs and iPSCs) following the ARG (iMSC12 
ARG, iMSC 13 ARG, eMSC34 ARG) protocol is slightly lower than between primary nMSCs 
(nMSC12 and nMSC13) and all MSCs differentiated from pluripotent stem cells (hESCs and 
iPSCs) following the TEX (iMSC12 TEX, iMSC 13 TEX, eMSC34 TEX) protocol (Figure 
3.10.12). 
 
Figure 3.10.12 Distribution variance and mean values. 
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 Taking all data together, we can conclude the following: 
• MSCs differentiated from pluripotent stem cells (hESCs and iPSCs) with either the 
ARG or TEX protocol have a high number of differentially expressed genes compared 
to the parental primary nMSC line.  
• The number of differentially expressed genes is lower using the ARG protocol. 
• Unsupervised clustering shows that the MSCs differentiated from pluripotent stem cells 
with either the TEX or ARG protocols are closer to each other than to primary nMSC. 
• Based on differentially expressed genes, in general, the ARG protocol is better than 
TEX. However, if the parental source of the iPSCs is MSCs, then the TEX protocol is 
better. 
 
3.10.5 Analysis of signalling pathways related to the immune system 
To exercise their immunoregulatory role, which is the basis of their clinical application, MSCs 
secrete soluble mediators that regulate the proliferation and function of multiple types of 
immune cells, including induction of regulatory T cells (Treg) either directly or indirectly 
(Sharma et al., 2014; Le Blanc et al., 2004, 2008).  
 To determine whether the MSCs differentiated from pluripotent stem cells with either 
the TEX or ARG protocols react in a similar way as the primary nMSCs, we analysed their 
response to IFNg treatment. IFNg stimulates the production of indoleamine 2,3-dioxygenase 
activity 1 (IDO1), which is the main modulator of the MSC immunosuppressive role (Krampera 
et al., 2006). 
 To verify that IFNg treatment induced the expected signalling response in all lines 
treated, we compared mRNA levels of IDO1, guanylate binding protein 4 (GBP4) and CXC 
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motif chemokine ligand 11 (CXCL11) between untreated and treated cells (Figure 3.10.13-15). 
These three genes have been used extensively as markers of IFNg responsiveness (Krampera et 
al., 2006; Vestal et al., 2005; Tensen et al., 1999).  
 
 
Figure 3.10.13 IFNg treatment induced IDO1 mRNA levels across all MSC samples regardless of 




Figure 3.10.14 IFNg treatment induced GBP4 mRNA levels across all MSC samples regardless of 
their origin (probe ILMN_1771385). ***,p≤0.001. 
 
 
Figure 3.10.15 IFNg treatment induced CXCL11 mRNA levels across all MSC samples regardless 
of their origin (probe ILMN_2067890). ***,p≤0.001, *,p≤0.05  
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 We confirmed the transcriptome array data with IDO1-, GBP4- and CXCL11-specific 
qPCR (Figure 3.10.16-18). 
 
 
Figure 3.10.16 qPCR analysis confirmed that IFNg treatment induces expression of CXCL11, 
GBP4 and IDO1 in all our eight MSC lines (n=3 for each non-treated and IFNg-treated sample). 
Red lines represent values in non-treated cells. Only two treated individual lines significantly differed 







Figure 3.10.17 Upon IFNg treatment, nMSC (n=6) and the MSC differentiated from pluripotent 
stem cells with either TEX (n=9) or ARG (n=9) protocols display a similar increase in expression 
of CXCL11 and IDO1, whereas significant differences were found in expression of GBP4. Red lines 
represent values in non-treated cells. p values were determined with t-test and adjusted using Bonferroni 




Figure 3.10.18 IFNg treatment induced significantly higher expression of all three genes (CXCL11, 
GBP4, IDO1) assessed by qPCR in nMSC (n=18) and the MSC differentiated from pluripotent 
stem cells with ARG (n=27) protocols than in those differentiated with TEX (n=27) protocol. Red 
lines represent values in non-treated cells. p values were determined with a non-parametric one-way 
ANOVA on ranks or Kruskal-Wallis H test as well as Tukey’s honest significant difference (HSD) post-
hoc analysis.  **, p≤0.01; *, p≤0.05 
 
Having confirmed that the all MSC lines responded in a predictable way to IFNg 
treatment, we could analyse their whole transcriptome with confidence. 
Treated MSCs differentiated from pluripotent stem cells with either the TEX or the 
ARG protocol have fewer differentially expressed genes than nMSCs differentiated from 
untreated cells (Table 3.10.5). Interestingly, whereas a similar number of genes were 
upregulated (830 out of 1685 genes or 49.3%) and downregulated (855 out of 1685 genes or 
50.7%) in nMSCs, MSCs differentiated from pluripotent stem cells with either the ARG or 
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TEX protocols had many more upregulated genes than downregulated genes. After IFNg 
treatment, e/iMSCs differentiated following the ARG protocol had upregulated 642 out 954 
differentially expressed genes (67.3%), whereas e/iMSCs differentiated following the TEX 
protocol had upregulated 716 out of 909 differentially expressed genes (78.8%). There were no 
significant differences in terms of fold-change median values (2.59 – 2.61). 






FC Significant pathways 
nMSC12 & nMSC13 




• Cell cycle 
• Immune system 
• DNA replication 
iMSC12 ARG & iMSC13 ARG 
& eMSC34 ARG vs. iMSC12 





• Cell cycle 
• Immune system 
• DNA replication 
iMSC12 TEX & iMSC13 TEX & 
eMSC34 TEX vs. iMSC12 
TEX(T) & iMSC13 TEX(T) & 
eMSC34 TEX(T)  
909 
(716/193) 
2.60 • Immune system  
 
 Whereas most of the downregulated genes were specific to each comparison and only 
12 were common for all cell types, almost half of the upregulated genes were common to at 
least 2 comparisons and 329 upregulated genes were common for  





Figure 3.10.19 Overlap between comparisons shown as Venn diagrams. 
 
 
Figure 3.10.20 Unsupervised clustering (Euclidian distance) of IFNg-treated and untreated cells. 
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 Further analyses have shown that treated cells cluster with their corresponding untreated 
counterparts (Figure 3.10.20). There were higher differences between each group (e/iMSCs 
differentiated from pluripotent stem cells with either TEX or ARG protocols and nMSC) than 
between treated and untreated cells. 
 This IFNg experiment demonstrated that: 
• All MSC lines, regardless of their background, responded to pro-inflammatory cytokine 
IFNg treatment. 
• IFNg treatment had less impact on iMSCs and eMSCs than on nMSCs.  
• iMSCs and eMSC differentiated using the ARG protocol have more common regulated 
genes with nMSCs than iMSCs and eMSC differentiated using the TEX protocol.  
Finally, we compared the significantly upregulated pathways in each of the three 
groups: nMSCs, e/iMSCs differentiated from pluripotent stem cells using the ARG protocol 
and e/iMSCs differentiated from pluripotent stem cells using the TEX protocol. We used the 
following three different databases for comparison: 
• Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(www.genome.jp/kegg/) 
• REACTOME database (www.reactome.org)  
• Gene Ontology (GO) analysis (www.geneontology.org) 
According to the KEGG, IFNg treatment activated 29 pathways in nMSCs (Table 
3.10.6), 26 in e/iMSCs differentiated from pluripotent stem cells using the ARG protocol (Table 
3.10.7), and 20 in e/iMSCs differentiated from pluripotent stem cells using the TEX protocol 
(Table 3.10.8). Interestingly, 19 out of 20 pathways activated in e/iMSCs from the TEX 
protocol are shared with nMSCs and e/iMSCs from the ARG protocol (highlighted yellow in 
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Tables 3.10.6 - 3.10.8). nMSCs and e/iMSCs from the ARG protocol share an additional two 
pathways (highlighted blue in Tables 3.10.6 and 3.10.7). 
Table 3.10.6 KEGG pathway analysis of regulated genes highlighted 29 pathways in untreated vs. 
IFNg-treated nMSCs. Pathways shared with e/iMSCs from both the ARG and TEX protocols are 





Table 3.10.7 KEGG pathway analysis of regulated genes highlighted 26 pathways in untreated vs. 
IFNg-treated e/iMSCs differentiated using the ARG protocol. Pathways shared with nMSCs and 





Table 3.10.8 KEGG pathway analysis of regulated genes highlighted 20 pathways in untreated vs. 
IFNg-treated e/iMSCs differentiated using the TEX protocol. Pathways shared with nMSCs and 
e/iMSCs from ARG protocols are highlighted yellow. 
 
 The REACTOME database (www.reactome.org) suggested involvement of 8 
significant pathways in nMSCs (Table 3.10.9), 5 in MSCs differentiated from pluripotent stem 
cells using the ARG protocol (Table 3.10.10) and 4 in MSCs differentiated from pluripotent 
stem cells using the TEX protocol (Table 3.10.11). Only one pathway, Signalling in Immune 
System, was shared among all three groups of cells (highlighted yellow in Tables 3.10.9 – 
3.10.11). Among the pathways involved, Signalling in Immune System was at the first place 
with 33 genes upregulated in MSCs originated through the TEX protocol, at the second place 
with 25 genes upregulated in MSCs originated through the ARG protocol and at sixth place 
with 24 genes upregulated and 6 downregulated in nMSCs. 
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Table 3.10.9 REACTOME pathway analysis of regulated genes highlighted 8 pathways in 
untreated vs. IFNg-treated nMSCs. The pathway shared with e/iMSCs from ARG and TEX protocols 
is highlighted yellow. 
 
Table 3.10.10 KEGG pathway analysis of regulated genes highlighted 5 pathways in untreated vs. 
IFNg-treated e/iMSCs differentiated using the ARG protocol. The pathways shared with nMSCs 
and e/iMSCs from TEX protocols are highlighted yellow. 
 
Table 3.10.11 KEGG pathway analysis of regulated genes highlighted 20 pathways in untreated 
vs. IFNg--treated e/iMSCs differentiated using the TEX protocol. The pathway shared with nMSCs 




Gene Ontology (GO) analysis (www.geneontology.org) found that Immune Response 
and Immune System Process were the top two biological processes in all three groups analysed 
(Table 3.10.12). 
Table 3.10.12 Top two biological processes highlighted by GO analysis of regulated genes. 
 
 
 Taken together, signalling pathway data analyses using three databases demonstrated 
that MSCs differentiated from iPSCs or hESCs using either the ARG or TEX differentiation 









4.1 WJ MSCs isolation  
 
The isolation of MSCs from WJ has a widely varied procedure, and this variation generates 
unreliable results between studies (Jeschke et al., 2011). The enzymatic treatment with 
collagenase is widely used; however, this treatment fluctuates in the literature. Trypsin and 
other proteases, such as hyaluronidase, are frequently added in different concentrations, and the 
incubation time also changes from 4 to 24 h at room temperature or at 37°C (Tsagias et al., 
2011; Pereira et al., 2008; Kadam et al., 2009; Weiss et al., 2008). We opted to use the explant 
technique because, aside from being less harsh on cells and less cumbersome for researchers, it 
was much cheaper, and the results could be standardized.  
We successfully isolated fibroblast-like cells from full-term gestational UCs and 
demonstrated some of their characteristics by analysing their morphology and 
immunophenotype profile using flow cytometry. The UC explant isolation method used in this 
study appeared to be efficient, simple and consistent. In all conditions, dXF, nXF and STD 
yielded good population numbers of stem/ stromal cells (median of 5 x 10 3 cells/ explant).  
The UC explant method of WJ MSC isolation possesses advantages over the enzymatic 
method since cell damage by enzymes is avoided and WJ contains growth factors that support 
the proliferation of MSCs. However, primary cultures obtained by UC explants appear to be 
heterogeneous (Conconi et al., 2011). Mark et al. (2013) also isolated and expanded a 
population of fibroblast-like cells with a different cell shape and size. In our experimental 
setting, MSCs isolated in each condition were morphologically similar but different between 
conditions (Figure 3.1.4).  
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The use of animal-derived supplements in clinical grade cells, such as FBS, should be 
eliminated to avoid the risks in transmitting animal pathogens and the risks of immunogenic 
reactions after clinical transplantation. The optimization of an XF culture represents a positive 
step for the future production of these cells in a clinical grade scale. In addition, the content and 
concentration of cytokines, growth and other soluble factors greatly varies from batch to batch 
of FBS and even for the purpose of basic research, the trend is to culture cells in a serum-free 
medium (Amit et al., 2004; Javazon et al., 2004; Li et al., 2005; Shahdadfar et al., 2005; Berger 
et al., 2006; Moore, 2006; Thirumala et al., 2009). Different research groups have established 
a range of protocols for the isolation and characterization of stromal cells from Wharton’s Jelly 
(Batsali et al., 2013; Kim et al., 2013; Trivanović et al., 2013; Devito et al., 2014; Hendijani et 
al., 2014; Swamynathan et al., 2014; Frausin et la., 2015; Watson et al., 2015; Joerger-Messerli 
et al., 2016; Batsali et al., 2017). However, the effects of the XF culture upon the isolation and 
expansion of MSCs, on the gene, protein and functional profiles of WJ MSCs have not been 
completely explored. Defined (XF) culture systems allow for better multipotent differentiation 
and expansion rates of adipose tissue and BM MSCs, which serve as a preferred alternative to 
FBS containing media for the production of large scale, functionally competent, clinical grade 
MSCs (Gottipamula et al., 2013; Patrikoski et al., 2013; Chase et al., 2012). Human platelet 
lysate (HPL) possesses a variety of growth factors (GFs), which are secreted by alpha granules 
from platelets (50-80 per platelet). Proteomic studies exposed the complexity of the platelet 
secretome and found that not only GFs but also different molecules are involved, including 
cytokines, chemokines, adhesive proteins, enzymes, fibrinolytic and antifibrinolytic proteins 
(Avanzini et al., 2009). Reinisch et al. (2007) showed a successful isolation of MSCs from a 
full-term UC using HPL, generating cell numbers suitable for clinical applications.  
Although our dXF condition showed slower initial outgrowth and population doublings, 
the end results exhibited a robust and reliable way to isolate MSCs in a clinical grade condition, 
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completely xeno free. Adding 5% HPL to our cell culture medium improved the efficiency of 
isolation, expansion and maintenance of the MSC culture, stimulating the proliferation rate of 
the cells. According to Rubio-Azpeotia and Andia (2014), who performed a meticulous review 
on platelet rich plasma (PRP), or HPL, and its effects on human MSC proliferation, migration, 
differentiation and immune response, out of 32 articles using BM MSCs, all articles found a 
positive correlation between PRP and proliferation and migration, accelerating the time 
necessary for the population to duplicate (PD). Jenhani et al. (2011) also found that HPL 
enhances the proliferation of UC MSCs. Those findings explain why in our study, the nXF and 
STD groups had faster population doubling and first outgrowth observations compared to the 
dXF group. 
 
4.2 Profiling surface markers and trilineage differentiation  
The International Society for Cellular Therapy (ISCT) encourages investigators to use as many 
markers to characterize MSCs as seem relevant to their research, although their established 
minimal criteria are the expression of CD105, CD73 and CD90 and the lack of expression of 
CD34, CD45, CD11a, CD19 and HLA-DR (Horwitz et al., 2005; Dominici et al., 2006). 
However, CD105, CD73 and CD90 are not specific markers for MSCs, as some of them are 
also expressed by smooth muscle (Kisselbach et al., 2009), vascular populations (Jurisic et al., 
2010), and fibroblasts (Halfon et al., 2011; Ishii et al., 2005).  
Until now, there is no unique cell marker able to characterize MSCs and there is not yet 
an absolute agreement on the markers that could characterize MSCs from either fresh BM or 
other tissues (Samsonraj et al., 2017). 
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The expanded MSCs in this experiment, from BM and WJ, similar to other experiments 
in the literature, expressed the marker CD105, CD73, CD29, CD44, MSCA-1, CD56 and CD90, 
and they lack the expression of CD45 and CD34 (Bianco et al., 2001; Caplan, 1991; Huss, 
2000; Jones et al., 2002). We also investigated the expression of the same markers in primary 
dermal fibroblasts from three different donors (data in Appendix) and found that majority of 
the cells were positive for all markers and negative for CD34, CD45 and MSCA-1. MSCs have 
to fulfil consensus criteria regarding their phenotype and biological behaviour (Horwitz et al., 
2005), but the criteria are highly debatable and therefore our findings support the previous idea 
that MSCs lack specific cell markers.  
Lim et al. (2016) successfully isolated WJ MSCs from three separated segments of an 
UC. They found differences in the cell viability and expression of pluripotent embryonic 
markers of WJ MSCs from different segments collected from the same donor. They also found 
differences between the groups in CD44 and CD73 markers, both markers related to cell 
migration and proliferation. They concluded that maternal and foetal segments are better than 
the middle segment of the UC. In contrast, Dinesh et al. (2017) did not find any differences 
between WJ MSCs isolated from different segments of the same UC. Even though we did not 
compare WJ MSCs from different segments of the UC, we isolated WJ MSCs from the whole 
UC, and we found differences in CD44 and CD73 expression levels and differences in 
population doublings between donors. 
The WJ MSCs isolated in this study expressed higher levels of CD44 with no 
differences between conditions. However, CD44 expression was lower in the dXF group 
isolated and expanded at 20% O2 than in the other conditions (dXF at 5% O2 and nXF at both 
20 and 5% O2) (Figure 3.2.2). The difference in expression under one particular condition is 
unlikely to be of any functional significance for WJ MSCs. CD44, also known as CDW44, 
CSPG8, ECMR-III, HCELL, HUTCH-I, IN, LHR, MC56, MDU2, MDU3, MIC4, and Pgp1 
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(https://www.ncbi.nlm.nih.gov/gene/960), is a cell surface glycoprotein and receptor for 
hyaluronic acid. It can also interact with collagens, osteopontin and matrix metalloproteinases. 
There are multiple functionally distinct isoforms due to the complex alternative splicing of the 
transcripts. CD44 is expressed by different cell types, including MSCs and differentiated 
osteogenic lineages, and is often used in conjunction with other markers to identify MSCs 
(Bianco et al., 2001; Liu et al., 2008). In addition, CD44 is related to migration and cell 
adhesion (Lesley et al., 2000; Zhu et al., 2005), but it has also been identified as a marker for 
some types of cancer stem cells and is connected to metastatic spread. The reduction of CD44 
in cancerous stem cells can cause them to differentiate into non-cancerous stem cells (Puré and 
Cuff, 2001; Sapaeth et al., 2013).  
Significant differences in the time to the observation of the first outgrowth among the 
conditions tested suggested condition-dependent rates of cellular migration and/or proliferation 
(Figure 3.1.1). Since the population doubling of WJ MSC was relatively similar, it was likely 
that the difference observed is due to cellular migration. However, there were no differences in 
the levels of ITGB1 (integrin b1) or CD29, also known as FNRB, GPIIA, MDF2, MSK12, 
VLA-BETA, and VLAB (https://www.ncbi.nlm.nih.gov/gene/3688), which is involved in 
MSC migration in vivo and in vivo (Ip et al., 2007). 
The other MSC marker implicated in the cellular migration of MSCs is NT5E or CD73, 
also known as CALJA, E5NT, NT, NT5, NTE, eN, and eNT 
(https://www.ncbi.nlm.nih.gov/gene/4907;Ode et al., 2011). CD73 is encoded by the 5'-
nucleotidase ecto NT5E gene, which is a classic hypoxia-inducible factor (HIF) target gene and 
its expression and function is stimulated by hypoxic conditions (Antonioli et al., 2016). 
Moreover, overexpression of CD73 is also involved in the proliferation and migration of 
cervical cancer cells (Gao et al., 2017). However, there were no marked differences in CD73 
expression levels regardless of oxygen tension, indicating further that the expression levels of 
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MSC surface markers were dependent on the culture media used (nXF or dXF), not on the level 
of O2 (Figure 3.2.1 and 3.2.2).  
THY1 (Thy-1 cell surface antigen) or CD90 was surprisingly lower in cells grown under 
the dXF and STD groups, and higher in the BM MSCs and nXF groups (Figure 3.2.1). CD90 
is a glycoprotein and considered to be one of the T lymphocyte markers, although it is also 
expressed in different cell types, such as neural cells, fibroblasts, endothelial cells, cancer stem 
cells, haematopoietic cells and MSCs (Maleki et al., 2014). Campione et al. (2009) 
demonstrated that BM MSCs derived from hMSCs from haematological malignancies showed 
down-regulation of CD90, suggesting that this molecule might be considered a predictive 
marker for the inhibitory ability of MSCs, decreasing its inhibitory immunological function. 
However, our results showed that the dXF group immunogenicity was as high as in the BM 
MSC group. Moraes et al. (2016) showed that a reduction in CD90 expression enhances the 
osteogenic and adipogenic differentiation in dental pulp, adipose tissue and amniotic fluid 
MSCs in vitro. We did not see any obvious qualitative differences in the adipogenic (Figure 
3.3.1) and osteogenic (Figure 3.3.3) potential of our MSCs cultured under different conditions 
regardless of the CD90 expression level (Figure 3.2.1). 
Expression of ENG or CD105, also known as endoglin, END, HHT1, and ORW1 
(https://www.ncbi.nlm.nih.gov/gene/2022), had large variations within each of the culture 
conditions tested (Figure 3.2.1). The smallest variations, though the lowest expression levels, 
were detected in the dXF medium with 5% O2 (Figure 3.2.2). CD105 has been shown to be 
expressed on endothelial cells and is classified as a receptor for transforming growth factor beta 
(TGF-b). It is also known as a marker for tumour-related angiogenesis and neovascularization, 
playing an important part in the prognosis, diagnosis and even treatment of neoplasm. The 
endothelial cells of neoplasms proliferate at a higher rate than the endothelial cells of healthy 
tissues and, as a result, they expressed higher rates of CD105 (Wong et al., 2000; Miller et al., 
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1999; Wikstrom et al., 2002). Another study sorted CD105+ WJ MSCs through enzymatic 
digestion and cultured those cells in suspension. This CD105+ population were positive for 
CD73 and CD90 and were able to differentiate into adipocytes, chondrocytes and osteocytes 
lineages, confirming their MSC status. Interestingly, they also expressed markers associated 
with pluripotency OCT3/4, NANOG and SOX2 suggesting that WJ MSCs are more than 
multipotent cells (Amiri et al., 2015). In contrast, WJ contains heterogeneous populations of 
cells which might have different sub-populations of more naive cells. WJ-MSCs do not express 
markers associated with pluripotency, but they may express them at a very low level and 
momentarily for a short period in their existence (Mitchell et al., 2003; Sarugaser et al., 2005). 
All of our isolated WJ MSCs and BM MSCs expressed CD105, although a larger variation was 
found between the donors in the nXF group than in the other groups, confirming the 
heterogenicity of cells isolated from WJ.  
WJ MSC had relatively low expression of NCAM1 or CD56 across all conditions, 
especially with dXF (Figure 3.2.1). Bühring et al. (2007) have shown that CD56, a marker for 
natural killer, neural and muscle cells, is expressed in a small population within BM MSC 
CD271+ cells. In addition, MSCA1 (W8B2 antigen) is also expressed on the same CD271+ 
sub-population, and they hypothesized that the MSCA1 antibody reacts with CFU-F (colony 
forming units-fibroblast), as these clonogenic cells are known to be present in the CD271+ 
population. CD271, a nerve growth factor receptor (LNGR), has been described as one of the 
most specific markers for human BM MSCs (Bühring et al., 2007; Quirici et al., 2002). 
However, CD271 was not detected in any of the cells grown in our laboratory including BM  
MSCs (data in Appendix). Data published by Alvarez-Viejo et al. (2013) and Margossian et al. 
(2012) show that CD271 is an undetectable marker for WJ MSCs. In contrast, CD56 expression 
was lower in the WJ MSCs dXF group but also in the BM MSCs, whereas it was higher in the 
WJ MSCs STD and nXF groups. Battula et al. (2009) introduced MSCA-1 as a marker for 
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MSCs, showing that only cells MSCA-1+ and CD56- were able to differentiate into adipocytes, 
whereas MSCA-1+ and CD56+ were phenotypically heterogenous clones able to differentiate 
into chondrocytes. He claimed that this particular sub-population should be isolated and chosen 
for the treatment of several diseases, such as rheumatoid arthritis, trauma, acute osteochondral 
fractures and even spinal disk injuries. Although the differentiation potential tested in this 
experiment was only qualitative, all of our groups were able to differentiate into adipocytes, 
chondrocytes and even osteocytes independently of CD56 and MSCA-1 expression.  
An exceptionally large population of WJ MSC grown with dXF conditions expressed 
MSCA-1. MSCA-1, also known as a tissue non-specific alkaline phosphatase (TNSALP) 
ectoenzyme, was expressed at high levels in the liver, bone and kidney, as well as in ESCs 
(Jones et al., 2006). MSCA-1/ TNAP is a repressor of NFκB-inducing kinase (nuclear factor 
kinase, NIK) activity and regulates both classical and alternative NIK-mediated signalling (Hu 
et al., 2004; Pike et al., 2013). According to an extended review by Li and Verma (2002), the 
activation of NFκB signalling pathways is crucial for the function of different immune cell 
interactions leading to an immune response. Overall, alkaline phosphatases dephosphorylate 
several substrates engaged specifically in the stimulation of inflammation and in such a way 
possess potent anti-inflammatory effects (Pike et al., 2013). Whether the presence of large 
MSCA-1/TNAP+ subpopulations in WJ MSCs might provide an additional benefit in MSC-
based cellular therapy of inflammatory diseases such as graft-vs-host disease, or for the 
development of novel cellular therapies for regeneration medicine, remains to be explored 
(Capelli et al., 2011; Fonta et al., 2005; Tisato et al., 2007). In our experiment, the dXF group 
expressed a higher immunogenic response at a 1:20 ratio (WJ MSC: PBMC) than the BM MSC 
group, although there were no significant differences, and a broader number of donors should 
be considered because MSCA-1 positive cells seem to have higher immunogenic properties.  
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Other criteria for established human MSCs is their capacity for trilineage mesenchymal 
differentiation. Accordingly, cells must be capable of differentiating into osteoblasts, 
adipocytes and chondroblasts using traditional in vitro culture conditions (Dominici et al., 
2006). All of our isolated WJ MSCs were capable of trilineage differentiation.  
 
4.3 Immunomodulatory activity  
Perinatal tissues have numerous advantages, including easy accessibility, painless collection 
from donors, and they can be a possible source for autologous and allogeneic cell therapy. In 
cord blood, the amount of MSCs isolated is relatively limited and usually the MSCs have low 
proliferative activity (Musina et al., 2007). WJ can be a better source of MSCs for allogeneic 
cell therapy since these cells have a low immunogenicity capacity and a higher proliferative 
rate.  
Recent publications demonstrated that WJ MSCs are potential transplantable cells for 
the treatment of different diseases, such as GvHD cancer and diabetes. They exhibit excellent 
qualities to be considered for cell therapy, such as a low doubling time, a high proliferate rate, 
and the capacity to function with non-immune-supressed laboratory animals (Usha et al., 2010; 
Nagamura-Inoue and He, 2014). Our dXF WJ MSCs and BM MSCs have shown similar 
immunomodulatory responses; however, at a 1:20 ratio, the dXF group had a stronger immune 
response than the BM MSCs, agreeing with results from Chang et al. (2006), who reported a 
stronger immunosuppression from placenta-derived MSCs than from BM MSCs.  
MSCs are able to pass almost undetected through the immune system, because of the 
low expression of HLA molecules making them suitable for allogenic cell therapy, and, 
depending on the cell delivery route and the preparation of these cells, they can survive in 
recipients and exert their action for weeks (Kurtz, 2008).  
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Jin et al. (2013) compared human MSCs isolated from BM, adipose tissue (AT), and 
UC for surface antigen expression, differentiation ability, proliferation capacity, tolerance for 
ageing, clonality, and paracrine activity. All MSCs isolated from different tissues had similar 
surface antigen expression, immunosuppressive features, and related differentiation capacities. 
However, UC MSCs had the highest rate of cell proliferation and clonality, and lower 
expression of p53, p21 and p16, well known markers for senescence. The anti-inflammatory 
capacity of UC MSCs showed a reduced expression of inflammatory cytokines, including 
interleukin-1α (IL-1α), IL-6, and IL-8 via angiopoietin-1 (Ang-1). Thus, UC MSCs have 
biological advantages in comparison to adult sources, making the UC a useful source of cells 
for clinical applications. 
Phenotypically, adult MSCs are very similar to WJ MSCs; however, the WJ MSC gene 
expression profile is different. Gene ontology analysis showed that WJ MSCs have a higher 
expression of genes associated with proliferation, cell adhesion and the immune system. 
Moreover, WJ MSCs overexpress genes associated with neurotrophic support, and their 
secretome stimulates neuronal maturation to a greater extent than BM MSCs. In vivo 
experiments with WJ MSCs confirmed their immunomodulatory effect on T cells. WJ MSC is 
an attractive candidate for neurodegenerative and immune-mediated disorders, such as 








4.4 Reprogramming of WJ MSCs and differentiation into MSCs 
MSCs have a great potential for cell-based therapies, and lately, have been the focus of several 
research groups and clinical trials. On the other hand, these cells require constant isolation from 
donors to avoid senescence and genomic instability. One way of minimizing the inconsistent 
manufacturing of clinical-grade cellular products is to derive adult stem cells from PSCs such 
as iPSCs (Temple and Studer, 2017). Therefore, we first generated iPSCs from WJ MSCs and 
later differentiated them into MSCs. 
Different somatic cells demonstrate a variable vulnerability to reprogramming methods. 
We assumed that WJ MSCs, which were isolated from ‘young’ tissue, might have a better 
reprogramming rate than fully adult cells, such as dermal fibroblasts. Although no significant 
differences were calculated, donor #13, which had a higher percentage of the MSCA-1 marker, 
showed a higher colony counting than the other lines (Table 3.5.1). However, the dermal 
fibroblast line that was used as control showed similar colony counting rates.  
One of the most promising applications for iPSC technology is the prospect of 
investigating key molecules involved in diseases and providing an excellent tool for toxicologic 
studies (Unternaehrer and Daley, 2011). The reprogramming method chosen is fundamental in 
the translational use of these cells. We have successfully established a completely xeno-free 
methodology using a non-integrating method, Sendai virus, for derivation of iPSCs from WJ 
MSCs.  
To use iPSCs in cell-based therapies, differentiation into a more specialized cell type is 
necessary to avoid the risk of tumourigenicity when cells are transferred in vivo. However, 
differentiation is a complex process and the efficiency is variable. In theory, PSCs (ESC and 
iPSC), can differentiate into all cell types in the human body; but, in practice, differentiation 
processes are mostly inconsistent among published scientific papers. In this experiment, we 
tested two published iPSC MSC differentiation protocols: one based on HPL (ARG protocol; 
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Luzzani et al. 2015) and the other based on the SMAD 2/3 inhibitor to promote differentiation 
(Zhao et al., 2015). Both differentiation protocols used in this experiment demonstrated that all 
6 lines (iMSC #12 TEX, iMSC #13 TEX and eMSC 034; iMSC #12 ARG, iMSC #13 ARG 
and eMSC 034 ARG) fulfilled the minimal criteria established by ISCT (Dominici et al., 2006) 
for characterization of MSCs.  
Zhao et al. (2015) achieved a highly efficient rate of iPSC MSCs positive for CD73 and 
CD105 (>99.6%) and eliminated the need for flow cytometric sorting. Additionally, their iPSC 
MSCs expanded faster than BM MSCs. Using the same protocol, our TEX protocol and the 
ARG protocol, we were unable to get such an efficient positive rate and we chose to sort cells 
that were triple positive for CD73, CD105 and CD90.  
Human ESCs have been differentiated into mesenchymal precursor cells by different 
research groups, using murine OP9 stromal cells as the feeder layer and an alpha MEM medium 
containing 20% FBS and supplemented with 2 mM L-glutamine. After 40 days of coculture, 
CD73 positive cells were sorted, and only approximately 5% of them were positive. 
Subsequently, the cells were expanded for 7 to 14 days until they were fully characterized for 
MSCs (Barberi et al., 2005; Peng et al., 2016; Olivier et al., 2006). Although we were capable 
of differentiating PSCs into MSCs in xeno-free conditions using both protocols (ARG and 
TEX), we also sorted the cells for MSCs markers (data not shown), indicating that it is very 
difficult to obtain a high differentiation efficiency.  
Prockop and Keating (2012) reported that the early introduction of tissue culture plastic 
dishes was responsible for the selection of MSC progenitors, probably because pre-treated 
tissue culture dishes increase oxygenated derivatives on their surface, thereby making them 
more hydrophilic and increasing the adherence of cells. Moreover, the selection by adherence 
in tissue culture vessels are one of the minimal criteria for human MSCs as defined by the 
International Society of Cellular Therapy (Dominici et al., 2006). In both differentiation 
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methods used in this experiment, the capacity of plastic adherence was used as MSC selection. 
Coating was no longer used from day 25 in TEX differentiation, and from day 14 in the ARG 
protocol, where cells continued to grow and expand.  
Barberi et al. (2006) differentiated different lines of hESCs into multipotent 
mesenchymal precursors and found no obvious differences in the marker and gene-expression 
profile or in adipo-, chondro- and osteogenic differentiation. However, some of the lines (ECS 
MSCs) showed a tendency of osteogenic differentiation after prolonged expansion. On the other 
hand, in our experiments, all of our TEX lines showed enhanced trilineage differentiation: 
adipogenic, osteogenic, and chondrogenic lineages. TEX lines showed a higher expression rate 
of genes related to each lineage than the ARG counterparts, possibly because TEX groups 
exhibited a higher resemblance to PSCs, keeping their stemness instead of fully differentiating 
into mesenchymal progenitors. Those findings were confirmed by transcriptome array, where 
the TEX group (iMSC and eMSC) exhibited more differentiated genes than the ARG group 
when comparing to native groups.  
Three recent studies have compared the genomic features of iPSCs from hundreds of 
individuals (between 100 – 300 individuals), and the iPSC lines have shown to be 
heterogeneous, raising questions about the suitability of these lines for genetic studies. These 
studies were able to show that the genetic background of each individual has a superior 
influence on variation in the iPSC lines compared to other non-genetic factors, including copy 
number status, culture conditions (cell recovery and processing), passage, and gender. 
Therefore, even though cell recovery and processing can result in variation among the lines, it 
seems that the majority of iPSC heterogeneity is driven by inherent genetic variation between 
individuals, rather than by any variation in culture conditions and duration, or in the 
reprogramming method used. All three reports showed that a great amount of genomic 
variations between the iPSC lines affected the genes involved in stem cell maintenance and the 
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differentiation efficiency of the iPSCs (Lund et al., 2012; Carcamo-Orive et al., 2017; Kilpnen 
et al., 2017; DeBoever et al., 2017). Our iPSC MSC lines from both groups, TEX and ARG, 
showed individual differences in gene expression that could be attributed to the genetic 
background to each parental cell. Comparing both differentiation protocols of eMSCs and 
iMSCs, we believe that TEX is a better protocol if the parental cells are MSCs; otherwise, if 
parental cells are from other adult origins, ARG is a better protocol choice to differentiate iPSCs 
into MSCs based on the comparison of differentiated genes between these cells and native WJ 
MSCs.  
 
4.5 Analysis of signalling pathways related to the immune system 
One of the most important feature of MSCs is their role in the immune system, which makes 
them the best choice for cell therapy when immunomodulatory activity is desirable.  
Wang et al. (2018) reported an experiment similar to ours generating and differentiating 
four lines of human iPSCs into MSCs using different protocols (Yen et al., 2009; Yen et al., 
2011), and using transcriptome analyses and immunomodulatory activities, compared them to 
ESC MSCs and BM MSCs. They found iPSC MSC lines significantly supressed in vitro-
activated human peripheral blood mononuclear cell (PBMC) proliferation to a similar degree 
as ESC MSCS and BM MSCs, and also modulated the CD4 T-lymphocyte fate and IL-17A-
expressing (Th7) cell fate to a regulatory T cell (Treg) phenotype. Additionally, iPSC MSCs 
significantly supressed cytotoxic CD8 T proliferation and activation. The iPSC MSC 
immunomodulatory activity results in an overall shift of secreted cytokines from a pro-
inflammatory climate to a more immunotolerant environment, which was validated by an in 
vivo mouse model of inflammation. Therefore, their findings support the idea that iPSC MSCs 
hold low oncogenicity and strong immunomodulatory capacities regardless of cell of origin or 
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the reprogramming method. However, in our experiment, all lines of iPSC MSCs showed a 
much lower immunomodulatory activity in supressing PBMC than nMSCs and BM MSCs.  
MSCs are surrounded by surface receptors for a large number of factors such as 
interleukins, inflammatory factors, prostaglandins and a number of vitamins. Treatment of 
MSCs by such factors, for example, the inflammatory factor interferon gamma (IFNγ), or the 
cytokine tumour necrosis factor alpha (TNFα) and/or interleukin 17 (IL-17), induces MSCs to 
react and adapt a more immunomodulatory phenotype modifying their immunogenicity 
(Prasanna et al., 2010; Sivanatham et al., 2015; de Witte et al., 2015). TEX lines demonstrated 
a lower ability to inhibit phytohemagglutinin A (PHA)-induced PBMC proliferation than ARG 
lines, with both groups exhibiting a lower immune response compared to WJ MSCs and BM 
MSCs. However, both groups, TEX and ARG, responded positively to IFNg treatment, 
increasing gene expression of IDO1, GBP4 and CXCL11, which are all markers of IFNg 
responsiveness (Krampera et al., 2006; Vestal et al., 2005; Tensen et al., 1999).  
The therapeutic benefit of MSCs is unpredictable, and despite being 
immunosuppressive, they are undetectable following in vivo injection. Thus, understanding 
their fate could predict clinical responses. Using a murine model of Graft-versus-Host Disease 
(GvHD), Galleu et al. (2017) demonstrated that MSCs are actively induced to undergo 
extensive apoptosis after infusion in the presence of cytotoxic granules contained in the 
recipient cytotoxic cells, which also mediate GvHD. This process is essential to initiate MSC 
immunosuppressive activity. They found that only cells with high cytotoxic activity responded 
to MSC infusion, whereas cells with low activity did not. Therefore, the cytotoxic activity 
against MSCs can be detected in the PBMC of GvHD patients, predicting the therapy response, 
and it might be used as a potential biomarker to scan patients undergoing MSC treatment. Their 
study highlights that although MSCs remain the starting point for immunomodulatory activity, 
patient-derived cells play an important role in delivering immunosuppression, and the next 
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generation of clinical trials should take this matter into consideration and not only choose the 
best MSCs but choose patients most likely to respond to the treatment.  
Wang et al. (2017) investigated the interaction of cells from autoimmune disease 
systemic lupus erythaematosus (SLE) patients on UC MSCs. Using a co-culture system with 
PBMCs from SLE patients, they noticed changes in MSCs, mainly a higher proliferation and a 
greater production of modulatory factors, such as vascular endothelial growth factor (VEGF) 
and CXCL-12. Moreover, baseline levels of IFNg predict the clinical efficacy of allogeneic 
MSC transplantation in SLE patients; i.e., high serum levels of IFNg indicated a better response 
to the transplantation when followed-up for 1 year. Of all the cytokines, IFNg is still the most 
essential, because it is responsible for inducing high levels of IDO1 and IDO2, indicating that 
IFNg mediates the induction expression of IDO family genes (Wang et al., 2014; de Witte et 
al., 2015).  
The CXC family of chemokines are chemoattractants for mononuclear leukocytes and 
are angiostatic. CXCL4, CXCL9, CXCL10, and CXCL11 chemokine production by these cells 
can be stimulated by multiple factors, including viruses, bacterial products, TNF, IL-1, C5, 
LTB4, IL-17, and IFN. CXCL9, CXCL10, and CXCL11 are all ligands for the receptor 
CXCR3, which is preferentially expressed on Th1 cells (Good et al., 2017).  
Immunomodulatory findings for iPSC-MSCs are inconsistent among the published 
research. Some reports described better immune regulatory effects with in vivo disease model 
studies, which demonstrate that MSCs modulate CD4 T-cells towards a Treg phenotype; 
however, effects on IFNγ, a cytokine representing effector Th1, were inconsistent and 
dependent on the disease model used (Cheng et al., 2015; Ng et al., 2016; Frobel et al., 2014; 
Fu et al., 2012). IFNγ modulates cell mediated immunity and immune rejection, which can be 
reduced by MSCs. Although these cells do not directly secrete IFNγ, they can reduce its 
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secretion by human peripheral blood and decreasing the risks of immune rejection (Zhou et al., 
2011).  
Chung et al. (2006) reported that pre-treatment of placenta-derived MSCs with the 
cytokine IFNg enhanced the immunosuppressive effects of these cells by increasing the 
secretion of TGFb and upregulating the inhibitory cell surface PD-L1. PD-L1 is a novel class 
of inhibitors that works as a tumour suppressing factor via the modulation of the immune cell-
tumour cell interaction. When activated, PD-L1 leads to the inhibition of T-cell receptor-
mediated lymphocyte proliferation and cytokine secretion. These findings agree with our 
results, where all groups (ARG and TEX, iMSCs and eMSCs) treated with IFNg showed a 
positive response in genes related to immunosuppressive effects. Increased levels of IFNg are 
found in acute GvHD patients and the infusion with MSCs may lower the incidence of this 
disease (Alsaab et al., 2017).  
Klinker et al. (2017) confirmed previous reports that IFNg pretreatment of MSCs 
significantly enhanced their immunosuppressive capacity (Krampera et al., 2006; Meisel et al., 
2004). Moreover, they also reported the importance of measuring other immunosuppressive 
factors to prove the capacity of MSCs, such as cytokine secretion and growth factor 
upregulation, and not only the measurement of T-cell proliferation. The magnitude of the 
suppression differs between activation measurements, and a combination of assays should be 
used to indicate the immunosuppressive features of MSC lines.  
Luk et al. (2017) pretreated adipose tissue-derived MSCs (aMSCs) for 18 h with IFNg 
to simulate inflammatory conditions. Subsequently, to analyse immunogenic function, they co-
cultured the aMSCs with B cells from spleens and found a significant reduction of B cell 
proliferation in the IFNg-treated group, while the control group (non-stimulated) did not inhibit 
B cell proliferation. In addition, IDO1 was highly induced in the MSC IFNg group. The next 
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step in our experiments would be to determine the immunomodulatory ability in supressing 
PBMC for the IFNg-treated, TEX and ARG groups. 
In 2009, Yen et al. reported the derivation of mesenchymal progenitors from human 
ESCs, called hESC-derived mesenchymal progenitors (EMPs). EMPs expressed a number of 
BM MSCs markers, such as CD73 and CD105, and expressed the ESC marker SSEA-4. They 
did not express HLA-DR or the costimulatory molecules CD80 and CD86. In contrast, EMPs 
express HLA-G, a non-classic MHC I protein involved in maternal-foetal immunological 
tolerance, and its expression was increased by IFNg stimulation. EMPs might be suitable for 
cell therapy. 
Oh et al. (2018) monitored the migration of MSCs to burn injury sites in vivo using 
MSCs expressing the firefly luciferase (Fluc) gene and green fluorescent protein (GFP) in a 
mouse model. Cutaneous burn injury was induced in the dorsal skin of the mice and MSC/ Fluc 
was introduced intravenously. The monitoring of MSC/ Fluc was performed using a 
bioluminescence imaging (BLI) system at specific timepoints. MSC/ Fluc signals appeared in 
the injury site after 4 days of injections and decreased consistently afterwards. Furthermore, 
they carried out an immunoblotting protein analysis to determine the expression of 
neovascularization genes in the burn injuries. TGF-β1 and VEGF showed higher levels in the 
MSC/ Fluc-treated group compared to the control group. MSCs might aid burn wound healing 
and MSCs expressing Fluc are a useful tool to track their migration to injury sites.  
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4.6 Clinical perspective of MSC therapy 
 
Tissue-derived MSCs have shown to be efficient for a variety of therapeutic applications such 
as through specific migration to injury site, immunomodulatory and paracrine activity, and also 
for releasing exosomes. Currently, there are 562 studies with the status of recruiting, active, not 
recruiting, completed, enrolling by invitation and unknown status published at clinicaltrials.gov 
(accessed April 2018) and happening all over the world, using autologous and allogeneic MSCs.  
Lately, the benefits of MSC conditioned medium (CM) in cell-based therapy have been 
investigated. It is common knowledge that CM enhances cell growth and stimulates the 
differentiation of in vitro cultured cells through the secretion of different cytokines, chemokines 
and growth factors. MSCs secrete pro-regenerative mediators that might promote repair. 
Currently, MSC CM has been investigated for its therapeutic promise, including the 
regeneration of neurons by secreting neuroprotective factors. Moreover, MSCs are able to 
secrete immunomodulatory proteins that affect innate and adaptive cells. Recent reports showed 
that MSC CM from multiple sclerosis (MS) patients reduced the secretion of inflammatory 
cytokines in a microglia and oligodendrocyte model cell line, and the intravenous injection of 
MSC CM in an animal model of MS showed significant improvements. In another in vivo 
experiment, MSC CM reduced neural degeneration in a spinocerebellar ataxia mice model 
(Ballerini et al., 2017; Bai et al., 2012; Suto et al., 2016; Ivanova-Todorova et al., 2012; Zappi 
et al., 2005; Ucceli et al., 2011; Kyurkchiev et al., 2014).  
Furthermore, other mechanisms have been investigated regarding the therapeutic 
potential of MSCs such as their release of exosomes. Exosomes are a class of extracellular 
vesicles (EV) belonging to a family of nanoparticles that are produced by multivesicular 
endosomes and secreted by different cell types, including T cells, B cells, dendritic cells, 
platelets, mast cells, epithelial cells, endothelial cells, neuronal cells, cancerous cells, 
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oligodendrocytes, embryonic cells, and MSCs. They are released in extracellular fluids, such 
as urine, blood, ascites, saliva, breast milk, and seminal, amniotic and cerebrospinal fluid. Their 
content depends on the cellular origin but, for example, B lymphocytes exosomes can stimulate 
T cell proliferation (Spees et al., 2016; Tkach and Thery, 2016; Raposo and Stoorvogel, 2013). 
MSCs EV, especially exosomes, have raised the interest of scientists regarding their use in 
regenerative therapy. They can be isolated from MSCs of different origin and could be as 
effective as the parental MSCs in supressing inflammatory response. In addition, MSCs EV are 
safer and cheaper, and it might become a cell-free alternative treatment. However, their 
isolation characterization, administration and functional mechanism is not fully understood and 
still needs further investigation (Keshtkar et al., 2018; Liu et al., 2018).  
Loftnia et al. (2016) were the first to provide experimental evidence of the potential of 
human ESC MSC-derived molecules. Differentiating ESCs into MSCs, they reported that these 
cells showed a similar morphology and cell surface markers compared with BM MSCs. In 
addition, ESC MSCs had a higher growth rate during early in vitro culture, along with 
osteogenic and adipogenic potential. However, the interesting finding was that treatment of 
acute liver failure (ALF) with CM ESC MSC improved primary hepatocyte viability and 
increased immunomodulatory interleukin-10 secretion. Further, using a secretome array, they 
found a link between higher amounts of secretory proteins, such as VEGF, and cell 
proliferation, cell migration, immune system processes, and apoptosis. ESC MSC-derived 
molecules provide trophic support to hepatocytes, which might offer a new treatment for ALF.  
Kunter et al. (2007) investigated the long-term effects of infused MSCs for renal failure 
and observed maldifferentiation of glomerular MSCs into adipocytes causing a fibrotic reaction 
encircling them, although the renal function was better in infused rats than in control ones. 
Another unwanted reaction of infused MSCs includes trapped cells in the lungs of an animal 
model that caused the deposition of collagen ‘cysts’ resulting in severe lung damage (Anjos-
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Afonso et al., 2004). Moreover, MSC transplantation into infarcted hearts in rodents caused 
bone formation in the myocardium (Breitbach et al., 2007), exposing the unwanted reactions 
of MSC treatment. For this reason, CM seems to be a better and valid option for therapy.  
Dahbour et al. (2018) reported positive results of a prospective phase I/IIa clinical study 
to treat MS using autologous BM MSCs in combination with CM MSC. They concluded that 
the combination was safe and efficient in stabilizing the disease and reversed the symptoms. 
Larger clinical trials are planned after such positive outcomes with both the combination 
therapy, BM MSC with CM MSC, and with CM MSC therapy by itself.  
Zhang et al. (2018) reported that hUC MSC injection was effective for the treatment of 
Crohn’s Disease with only mild side effects in a randomized, controlled clinical trial. However, 
the number of hUC-MSCs to reach the target tissue is limited and could not repair the damaged 
tissue. It is generally accepted that stem cells may repair damaged tissues by alternative or 
paracrine mechanisms, and CM is the most common treatment strategy (Liu et al., 2016). Fong 
et al. (2014) reported that CM UC MSC promoted haematopoietic stem cell proliferation and 
improved diabetic wound recovery. Duan et al. (2018) explored the therapeutics effects of CM 
from UC MSCs on nasal mucosa radiation damage in vivo and in vitro and concluded that UC 
MSC secreted a variety of soluble factors responsible for increasing cell proliferation and the 
migration of nasal epithelial cells. Furthermore, intranasal administration of CM UC MSC 
repaired nasal mucosa radiation damage, showing the benefits of CM MSC in cell regeneration 
and injury healing.  
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5. SUMMARY AND FUTURE WORK  
Donor procurement makes the logistics of obtaining human BM as a source of MSCs 
complicated. Although BM MSCs from adult donors still have satisfactory abilities to be used 
for regenerative medicine purposes, from a manufacturing perspective, the best donors are in 
the paediatric age range. In addition, the procedure requires planning, is painful and the quality 
of cells varies among donors. Therefore, the MSC therapy field is constantly looking for 
alternative sources.  
We hypothesized that human MSCs derived from iPSCs would have the biological 
qualities of native MSCs and could be scaled up and used for therapeutic purposes. To test this 
hypothesis, we isolated native MSCs (nMSC) from UC WJ of two donors (#012 and #013) in 
xeno-free conditions. Next, we reprogrammed them into iPSCs (iPSC012 and iPSC013) and 
subsequently differentiated them back into MSCs using two different protocols, ARG and TEX 
(iMSC012ARG, iMSC012TEX, iMSC013ARG, and iMSC013TEX). Using the same 
protocols, we also differentiated the clinical grade human embryonic stem cell line (ESC), 
KCL034, into MSCs (eMSC034ARG and eMSC034TEX).  
To assess which of the two differentiation protocols worked better, we compared the 
differentiation capability, transcriptomics, metabolomics and immunomodulatory potential of 
the iMSCs (iMSC012ARG, iMSC012TEX, iMSC013ARG and iMSC013TEX) and eMSCs 
(eMSC034ARG and eMSC034TEX) with the nMSCs (nMSC012, nMSC013 and BM MSC). 
Based on the expression of all expressed genes, the data demonstrated that both iMSCs and 
eMSCs differentiated following the TEX protocol are closer to nMSC with higher 
differentiation potentials but lower immunomodulatory properties than when using the ARG 
protocol.  
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Our data suggest that, following a careful selection and screening of donors, nMSCs 
from umbilical cord WJ can be reprogrammed into iPSCs, providing a suitable source of 
material for the differentiation into iMSCs resulting in a more consistent cell culture and 
scalability, and with similar therapeutic potential as nMSCs. iMSCs could be scaled up under 
GMP conditions and serve as an alternative of BM and MSCs from other sources for therapeutic 
purposes.  
In our experiments, as described above, we were able to successfully derive iPSCs from 
WJ MSCs and differentiate them into MSCs. The next step would be to demonstrate that iPSC-
derived MSCs might possess in vivo clinical benefits in animal models of specific diseases, 
such as liver disease models. Furthermore, a larger number of donors should be considered to 
further investigate donor variability and other individual characteristics should be taken to 
account depending on the therapeutic target. The use of an iPSC haplobank should be taken to 
consideration since donors could be selected on the basis of transplant antigen systems to match 
recipients diminishing the risks if immunological rejection and the degree of immune 
suppression required (Barry et al., 2015). 
Recently, there are ongoing human clinical trials using patented iPSC-derived MSCs 
for GvHD in the U.K. with successful results thus far. According to the company, its technology 
addresses the limitations that are inherent to the current adult stem cell technologies, such as 
donor dependence and variability, inconsistency in cell culture and limited scalability, which 
are the same limitations driving our experiments. Even though they are using a different 
protocol to generate and differentiate iPSC-derived MSCs, the outcome MSCs are quite similar 
to those from our experiments.  
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Reagent Catalog number Company 
DMEM 10566-016 Thermo Fisher 
CTS Knockout Serum Replacement A1099201 Thermo Fisher 
Non-essential Amino Acids Solution 11140035 Thermo Fisher 
 
 
Defined media for hESC (KOSR media) 
 
Reagent Catalog number Company 
Knockout DMEM F12 12660012 Thermo Fisher 
CTS Knockout Serum Replacement A1099201 Thermo Fisher 
Non-essential Amino Acids Solution 11140035 Thermo Fisher 
L-Glutamine 200 mM 25030081 Thermo Fisher 
2β-Mercaptoethanol 21985023 Thermo Fisher 





Reagent Catalog number Company 
Knockout DMEM 10829018 Thermo Fisher 
CTS Knockout Serum Replacement A1099201 Thermo Fisher 
Non-essential Amino Acids Solution 11140035 Thermo Fisher 
L-Glutamine 200 mM 25030081 Thermo Fisher 
2β-Mercaptoethanol 21985023 Thermo Fisher 










Cryopreservation Solution:  Vitrification media 
 
Base Supplements 
(List all supplements with  
appropriate concentrations) 




1. ES-HEPES solution (for 20mL): 
    DMEM/F12 
    KSR XF 
    1M HEPES 
 
2. 1M Sucrose solution: 
     Sucrose 
     ES-HEPES Solution  
 
3. 10% Vitrification Solution 
    ES-HEPES Solution  
    Ethylene Glycol 
    DMSO 
 
4. 20% Vitrification Solution 
    ES-HEPES Solution 
    1M Sucrose Solution 
    Ethylene Glycol 



































































Agarose gel electrophoresis 1% 
40 ml 1x TAE (Tris acetate EDTA) 
0.4 g Agarose  












6.2 PRIMERS USED IN THIS STUDY 







Forward: 5’- GGATCACTAGGTGATATCGAGC-3’ 






Forward: 5’-CAA CCG CGA GAA GAT GAC-3’ 





































































































































6.3 SUPLEMENTARY DATA 
 
FIRST OUTGROWTH AND POPULATION DOUBLINGS OF WJ MSC 
 
Table 6.3.1 WJ MSCs First outgrowth table. First outgrowth observed in the edges of the 
attached umbilical cord (UC) explants and population doublings of each condition (STG, HPL, 
STD). STG condition showed a higher proliferative capacity over a period of 7 to 10 days in 
culture. ND, non-determined.  
Donor 
ID 




























7 D14 ND ND ND D9 0.8 
8 D14 2.2 ND ND ND ND 
9 D11 2.3 ND ND D10 1.3 
10 D14 2.4 ND ND D11 1.6 
11 D11 1.8 ND ND D9 1.5 
12 D11 2.7 ND ND D8 2.2 
13 D10 2.7 ND ND D9 2.3 
14 D12 2.2 ND ND D9 1.9 
GMP_03 ND ND D8 1.6 ND ND 
GMP_04 ND ND D8 1.4 ND ND 









Table 6.3.2 Calculation of Population doublings of Native WJ MSCs from Initial 
outgrowth 
nMSC STD  
DONOR ID 
SEEDED  
(X 106) (B) 
HARVESTED   
(X 106) (A) P1 FROM T75 FLASK 
PD  
[log (A/B)] / 0.301 
7 0.1 2 4.32 
8 ND ND ND 
9 0.1 2 4.17 
10 0.1 1 3.58 
11 0.1 3 4.8 
12 0.1 3 4.8 
13 0.1 2 4.39 
14 0.1 2 4.58 
 
nMSC XF (HPL) 
DONOR ID 
SEEDED  
(X 106) (B) 
HARVESTED   
(X 106) (A) P1  
PD  
[log (A/B)] / 0.301 
GMP_03 0.1 7 6.12 
GMP_04 0.1 3 4.96 
GMP_05 0.1 1 3.67 
 
nMSC dXF  
DONOR ID 
SEEDED  
(X 106) (B)  
HARVESTED   
(X 106) (A) P1 FROM T75 FLASK 
PD  
[log (A/B)] / 0.301 
7 ND ND ND 
8 0.1 1 3.23 
9 0.1 1 6.78 
10 0.1 3 4.75 
11 0.1 3 5.08 
12 0.1 2 4.58 
13 0.1 4 5.28 



























[log (A/B)] / 0.301 PD 
P3 1.7 1 1.765 1.76 
P10 0.3 0 1 2.76 
P11 1.4 1 1.485 4.245 
P12 2.5 1 2.322 6.567 
P14 0.8 1 0.678 7.245 
P15 0.45 0 0.585 7.83 










[log (A/B)] / 0.301 PD 
P5 2.4 1 1.585 1.585 
P6 3.1 1 2.632 4.217 
P7 1.4 1 1.485 5.702 
P8 2.8 1 2.222 7.924 
P9 6.2 1 3.632 11.556 
P10 3.2 0 3.415 14.971 
P11 1.25 0 2.059 17.03 
P12 0.72 0 1.848 18.878 
 
 









[log (A/B)] / 0.301 PD 
P1 0.3 0.072 (after cell sorting) 2.059 2.059 
P2 0.96 0 1.678 3.737 









[log (A/B)] / 0.301 PD 
P1 0.6 0.15  (after cell sorting) 2 2 
P2 1.9 1 1.663 3.663 









[log (A/B)] / 0.301 PD 
P1 0.46 0.12  (after cell sorting) 1.938 1.938 
P2 0.78 0 0.761 2.699 













[log (A/B)] / 0.301 PD 
P1 2.5 0.47  (after cell sorting) 2.411 2.411 
P2 3 1 1.819 4.23 









[log (A/B)] / 0.301 PD 
P1 2.4 0.72   (after cell sorting) 1.737 1.737 
P2 1.4 1 0.807 2.544 









[log (A/B)] / 0.301 PD 
P1 2.1 0.62    (after cell sorting) 1.76 1.76 
P2 1.9 1 1.44 3.2 





Table 6.3.6 Percentage of sub-populations for MSC surface markers in Fibroblasts (%) 
Fibroblasts CD29 CD44 CD73 CD90 CD105 CD56 MSCA1 
DONOR/ 
PASSAGE               
BJ P4 99.7 99.1 97.2 99.1 90.1 3.3 0 
BRCA1 P6 99.5 98.1 96.1 91.1 56.7 11.9 0 
EB P7 99.1 98.8 98.4 89.8 87 1.7 0 
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WJ MSC FLOW CYTOMETRY MARKERS  
Table 6.3.7 Percentage of sub-populations for MSCs surface markers with mean, SD 
and SEM (%) (Prism Graphpad 6). BM MSC was used as comparison with WJ MSC. ND, 
non-determined. 
BM MSC  CD29 CD44 CD73 CD90 CD105 CD56 MSCA1 
BM MSC 01  97.7 97.4 97.9 65.3 97.4 15.53 2.73 
BM MSC 02  97.5 95.4 92.9 92.3 67.3 11 7.5 
BM MSC 03  96.4 78.7 71.5 54.9 74.5 1 0.4 
MEAN 97.2 90.5 87.4 70.8 79.7 9.2 3.5 
SD 0.7 10.27 14 19.3 15.72 7.435 3.619 
SEM 0.4041 5.928 8.1 11.15 9.075 4.292 2.09 
STD (FBS) CD29 CD44 CD73 CD90 CD105 CD56 MSCA1 
8 97.6 91.4 65.9 35.9 72.8 63.6 0 
12 98.4 97.3 69.9 48.3 87.3 82.9 0.1 
13 98 96.9 60.5 21.4 63.1 21.3 0 
MEAN 98 95.2 65.4 35.2 74.4 55.9 0.0333 
SD 0.1 3.297 4.7 13.46 12.18 31.51 0.05774 
SEM 0.05774 1.904 2.7 7.773 7.032 18.19 0.03333 
 dXF (STG) CD29 CD44 CD73 CD90 CD105 CD56 MSCA1 
8 99 98.5 99.2 34.6 71.1 5 15.8 
9 98.7 96.5 98 31 51.5 8.1 4.4 
10 98.1 98.8 98.7 33.9 70.1 5 23.5 
11 98.7 98.9 99.5 21.2 65.4 7.1 13.5 
12 99.3 95.1 97.8 29.5 61.5 14.3 20.4 
13 98.8 97.1 99.2 8.4 49.8 14.5 86.1 
14 99.2 87.8 97.9 24.4 43 12.6 19.4 
GMP 03 STG 97.3 96 93.2 60.2 22.3 0.6 25 
GMP 04 STG 99.2 91.1 98.6 20.3 62.7 12.8 30 
GMP 05 STG 99.2 98.6 98.5 70.8 42.7 0.2 7.3 
MEAN 98.75 95.84 98.06 33.43 54.01 8.02 24.54 
SD 0.4 3.69 1.6 18.76 15.24 5.381 23.01 
SEM 0.2309 1.167 0.95 5.931 4.82 1.701 7.277 
nXF (HPL) CD29 CD44 CD73 CD90 CD105 CD56 MSCA1 
GMP 03 HPL 99.6 99.7 99.3 99.9 89.1 66.4 0.1 
GMP 04 HPL 99.5 99.3 99.2 99.2 63.7 30.5 0 
GMP 05 HPL 99.4 98.4 96.4 93.5 15.1 6.9 0 
MEAN 99.5 99.1 98.3 97.5 55.9 34.6 0.0333 
SD 0.6241 0.6658 1.6 3.51 37.6 29.96 0.05774 




PERCENTAGE OF SUB-POPULATIONS FOR MSCS SURFACE MARKERS  
 
 
Figure 6.3.1 CD34 expression in WJ MSCs cultured under standard (STD, n=4) and 
chemically defined xeno-free (XF, n=5) conditions. Clinical grade BM MSCs and Kasumi 




Figure 6.3.2 CD45 expression in WJ MSCs cultured under standard (STD, n=4) and 
chemically defined xeno-free (XF, n=5) conditions. Clinical grade BM MSC and Kasumi cell 








Figure 6.3.3 CD29 expression in WJ MSCs cultured under standard (STD, n=4) and 





Figure 6.3.4 CD44 expression in WJ MSCs cultured under standard (STD, n=4) and 










Figure 6.3.5 CD56 expression in WJ MSCs cultured under standard (STD, n=4) and 





Figure 6.3.6 CD73 expression in WJ MSCs cultured under standard (STD, n=4) and 










Figure 6.6.6 CD90 expression in WJ MSCs cultured under standard (STD, n=4) and 





Figure 6.6.7 CD105 expression in WJ MSCs cultured under standard (STD, n=4) and 









Figure 6.6.9 MSCA-1 expression in WJ MSCs cultured under standard (STD, n=4) and 
chemically defined xeno-free (XF, n=5) conditions. Clinical grade BM MSCs are used as a 
control. 
 
Table 6.3.8 Percentage of sub-populations for MSCs surface markers in different passages 
of iPSC MSC lines (%) 
DONOR P CD44 CD29 CD90 CD73 CD105 MSCA1 CD56 CD34 CD45 
12 ARG P1 52.9 98.4 46.9 60.4 12.9 31.2 6.9 2.7 0.4 
P9 96.9 99.6 12.8 99.5 18.2 0.3 0.4 1.2 0.1 
13 ARG P1 97.8 98.4 23.7 95.6 46.4 3.1 0.6 0.1 0.2 
P8 77.6 97.6 18.3 85.7 13.3 16.6 0.3 0.1 0.1 
34 ARG P1 98.4 99.8 71.6 96.6 57.6 0.3 10 0.9 0.1 
P9 94.8 98.7 13.5 99.2 6.6 0.2 1.2 0.3 0.1 
12 TEX 
P1 96.7 99.8 51.2 97.9 73.1 1 22.1 2.2 0.1 
P6 98.1 97.1 39.5 92.4 25.9 0.4 9.8 1.1 0.1 
P11 94.7 96.1 86.7 96 7.1 44 5.1  1.0 0.4 
13 TEX 
P1 95.9 99.6 16.4 94.5 62 5.9 32.3 0.5 0.4 
P9 95.7 97 75.7 96.3 72.5 54.6 0.3 0.3 0.1 
P11 95.7 97.2 59.8 96.6 45.4 61.7 0.3 0.1 0.1 
34 TEX 
P2 99 99.9 78.1 99 69.8 0.2 10.4 0.2 0.3 
P6 90.1 99.8 23.4 94.8 35.4 0.2 9.6 0.1 0.2 
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8. PUBLISHED PAPERS 
Since I joined Dr Ilic laboratory as a research technician and part-time PhD student, I co-
authored 15 publications. Five of them were directly related to my PhD project, whereas for all 
others I contributed the data as a technician. 
 
Publications directly related to my PhD thesis project: 
(1) Devito L, Petrova A, Miere C, Codognotto S, Blakely N, Lovatt A, Ogilvie C, Khalaf Y, Ilic D. 
Cost-effective master cell bank validation of multiple clinical-grade human pluripotent stem cell lines 
from a single donor. Stem Cells Translational Medicine, 3:1116-1124, 2014. 
Through this work I learned the principles of GMP cell culture and generated a research 
grade of hESC line KCL034 that I used as a positive control for numerous experiments in my 
thesis.  
 
(2) Badraiq H, Devito L, Ilic D. Isolation and expansion of mesenchymal stromal/stem cells from 
umbilical cord under chemically defined conditions. Methods in Molecular Biology 1283:65-71, 2015. 
In this method publication, we described isolation and expansion of MSC under 
chemically-defined xeno-free conditions (dXF medium). This is described in detail in the thesis 
(see Results, section 3.1).  
 
(3) Devito L, Badraiq H, Galleu A, Taheem DK, Codognotto S, Siow R, Khalaf Y, Briley A, Shennan 
A, Poston L, McGrath J, Gentleman E, Dazzi F, Ilic D. Wharton's jelly mesenchymal stromal/stem cells 
derived under chemically defined animal product-free low oxygen conditions are rich in MSCA-1(+) 
subpopulation. Regenerative Medicine, 9:723-732, 2014. 
 222 
At the beginning of the project, while I was comparing different culture conditions, I 
found that expression of MSCA-1 marker is markedly increased only under dXF conditions. 
This is described in detail in the thesis (see Results, sections 3.1 and 3.2).  
 
(4) Miere C, Devito L, Ilic D. Sendai Virus-Based Reprogramming of Mesenchymal Stromal/Stem Cells 
from Umbilical Cord Wharton's Jelly into Induced Pluripotent Stem Cells. Methods in Molecular 
Biology, 1357:33-44, 2016. 
In this method publication, we described SeV-mediated reprogramming of WJ MSC 
into iPSC. I used the same approach to reprogram nMSC12 and nMSC13 into iPSC12 and 
iPSC13, respectively. This is described in detail in the thesis (see Results, sections 3.5 and 3.6).  
 
(5) Ilic D, Devito L, Miere C, Codognotto S. Human embryonic and induced pluripotent stem cells in 
clinical trials. British Medical Bulletin, 116:19-27, 2015. 
A review paper describing clinical trials involving hESC and hiPSC. Some of the 
aspects were discussed in my thesis. 
 
(6) Miere C, Hewitson H, Devito L, Wood V, Kadeva N, Cornwell G, Codognotto S, Stephenson E, Ilic 
D. Generation of KCL018 research grade human embryonic stem cell line carrying a mutation in the 
DMPK gene. Stem Cell Research 16:342-434, 2016. 
 
(7) Devito L, Petrova A, Wood V, Kadeva N, Cornwell G, Codognotto S, Stephenson E, Ilic D. 




(8) Devito L, Jacquet L, Petrova A, Miere C, Wood V, Kadeva N, Cornwell G, Codognotto S, 
Stephenson E, Ilic D. Generation of KCL034 clinical grade human embryonic stem cell line. Stem Cell 
Research, 2016;16:184-288, 2016. 
 
(9) Devito L, Wood V, Kadeva N, Cornwell G, Codognotto S, Stephenson E, Ilic D. Generation of 
KCL039 clinical grade human embryonic stem cell line. Stem Cell Research 16:170-217, 2016. 
 
(10) Canham MA, Van Deusen A, Brison DR, De Sousa PA, Downie J, Devito L, Hewitt ZA, Ilic D, 
Kimber SJ, Moore HD, Murray H, Kunath T. The Molecular Karyotype of 25 Clinical-Grade Human 
Embryonic Stem Cell Lines. Scientific Reports, 5:17258, 2015. 
As a technician, I participated in characterization of multiple hESC lines derived in our 
laboratory. The work involved the same experiments as I have done for characterization of mu 
iPSC12 and iPSC13 lines, which are described in detail in the thesis (see Results, section 3.7). 
 
(11) Petrova A, Celli A, Jacquet L, Dafou D, Crumrine D, Hupe M, Arno M, Hobbs C, Cvoro A, 
Karagiannis P, Devito L, Sun R, Adame LC, Vaughan R, McGrath JA, Mauro TM, Ilic D. 3D In vitro 
model of a functional epidermal permeability barrier from human embryonic stem cells and induced 
pluripotent stem cells. Stem Cell Reports, 2:675-689, 2014. 
 
(12) Petrova A, Capalbo A, Jacquet L, Hazelwood-Smith S, Dafou D, Hobbs C, Arno M, Farcomeni A, 
Devito L, Badraiq H, Simpson M, McGrath JA, Di WL, Cheng JB, Mauro TM, Ilic D. Induced 
Pluripotent Stem Cell Differentiation and Three-Dimensional Tissue Formation Attenuate Clonal 
Epigenetic Differences in Trichohyalin. Stem Cells Development, 25:1366-1375, 2016. 
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One of the ongoing projects in the lab is bioengineering of 3D model of epidermis using 
keratinocytes differentiated from hESC and iPSC lines. As the lab technician, I was involved 
in cell culture aspects of the project. 
 
(13) Cvoro A, Devito L, Milton FA, Noli L, Zhang A, Filippi C, Sakai K, Suh JH, H Sieglaff D, Dhawan 
A, Sakai T, Ilic D, Webb P. A thyroid hormone receptor/KLF9 axis in human hepatocytes and 
pluripotent stem cells. Stem Cells 33:416-428, 2015. 
This was a collaboration project with a group from Houston working on thyroid 
hormone signalling. Our group provided hESC/iPSC-related data. As the lab technician, I have 
performed cell culture, including T3-treatment time course, gene expression knock down using 
siRNA transfections, differentiation into endodermal progenitors as described in Cheng et al. 
(2012), and immunostaining. 
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(14) Shahbazi MN, Jedrusik A, Vuoristo S, Recher G, Hupalowska A, Bolton V, Fogarty NNM, 
Campbell A, Devito L, Ilic D, Khalaf Y, Niakan KK, Fishel S, Zernicka-Goetz M. Self-organization of 
the human embryo in the absence of maternal tissues. Nature Cell Biology, 18:700-708, 2016. 
 
(15) Shahbazi MN, Scialdone A, Skorupska N, Weberling A, Recher G, Zhu M, Jedrusik A, Devito L, 
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These two publications are coming from ongoing collaboration with a group from 
Cambridge working on the earliest stages of human development. Since I am trained 
embryologist, one of my duties as a technician is to take care of supranumerary embryos 
donated for research. For this collaboration, I was thawing the embryos the embryos used in 
the experiments in Guy’s Assisted Conception Unit and assuring that the documentation is up 
to HFEA standards. 
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ABSTRACT
Standardization guidelines for human pluripotent stem cells are still very broadly defined, despite
ongoing clinical trials in theU.S.,U.K., and Japan. The requirements for validationofhumanembryonic
(hESCs) and induced pluripotent stem cells (iPSCs) in general follow the regulations for other clinically
compliant biologics already in place but without addressing key differences between cell types or
final products. In order to realize the full potential of stem cell therapy, validation criteria, method-
ology, and, most importantly, strategy, should address the shortfalls and efficiency of current
approaches; without this, hESC- and, especially, iPSC-based therapy will not be able to compete
with other technologies in a cost-efficient way. We addressed the protocols for testing cell lines
for human viral pathogens and propose a novel strategy that would significantly reduce costs. It
is highly unlikely that the multiple cell lines derived in parallel from a tissue sample taken from
one donor would have different profiles of endogenous viral pathogens; we therefore argue that
samples from the Master Cell Banks of sibling lines could be safely pooled for validation. We illus-
trate this approachwith tiered validationof two sibling clinical-gradehESC lines, KCL033andKCL034
(stage 1, sterility; stage 2, specific human pathogens; and stage 3, nonspecific human pathogens).
The results of all testswere negative. This cost-effective strategy could alsobeapplied for validation
of Master Cell Banks of multiple clinical-grade iPSC lines derived from a single donor. STEMCELLS
TRANSLATIONAL MEDICINE 2014;3:1116–1124
INTRODUCTION
Optimism that human embryonic stem cells
(hESCs) would provide a virtually unlimited source
of selected cell types for future cell therapies and
drug screening and development has resulted in
considerable progress in stem cell biology since
the first hESCs were derived in 1998 [1]. The initial
difficulties in obtaining embryos for stem cell re-
search has largely been overcome, especially in
theU.K.,where a regulatory routemap to facilitate
clinical researchapplicationhasbeenproducedrel-
atively quickly [2, 3]. By theendof 2009,more than
1,000 hESC lines had been derived worldwide;
however, only a few had been thoroughly charac-
terized [4, 5].With the discovery of induced plurip-
otent stem cells (iPSCs) in 2006 [6], interest in
hESCs started to wane.
An Investigational New Drug application for
the first clinical trial of hESC-based therapy re-
ceived initial Food andDrug Administration clear-
ance in January 2009. The company, Geron Corp.
(Menlo Park, CA, http://www.geron.com), gener-
ated aMaster Bank from hESC line H1, which was
derived as a research grade line in the presence of
animal products [1]. The inner cell mass was iso-
lated by immunosurgery with a rabbit antiserum
and plated on mitotically inactivated mouse em-
bryonic fibroblasts in a medium supplemented
with 20% fetal bovine serum. The Master Bank
used forproductionof hESC-derivedoligodendro-
cyteprogenitorsGRNOPC1had tobe “re-derived”
under current good manufacturing practice
(cGMP) conditions and subjected to validation,
not only for the presence of human viral patho-
gens but also for the presence of animal patho-
gens, significantly increasing the costs.
Similarly, the hESC line MA-09 used in clinical
trials for Stargardt’s macular dystrophy and age-
related macular degeneration was also derived
as a research grade line in the presence of animal
components [7, 8] and had to undergo a similar
process and costly validation for the presence of
animal pathogens to be used for cellular therapy.
The first clinical-grade hESC lines were de-
rived at a cGMP facility in Brisbane, Australia,
from frozen embryos donated at Sydney IVF
Ltd., under sponsorship of the Singapore-based
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company ES Cell International Pte. Ltd. (ESI Bio, BioTime, Inc.,
Alameda, CA, http://www.biotimeinc.com) [9]. To promote the
lines, the company was willing to make them easily accessible
in a research grade version through the A*STAR Singapore Stem
Cell Consortium (SSCC). The intentionwas that the StemCell Bank
within the SSCCwould expand and distribute the cells under non-
cGMP conditions for minimal reimbursement. Despite interna-
tional efforts and multimillion investments, they did not gain
the popularity of the H1 and H9 hESC lines derived by Thomson
et al. [1] and the cells were never used in clinical trials. In May
2010, the California-based BioTime acquired ESI, including a bank
of six clinical-grade hESC lines. Five of them the company charac-
terized further [10]. BioTime has also recently acquired Geron’s
hESC portfolio; there might, therefore, be long-term plans for
using these cell lines in the clinic.
In the U.K., the Medical Research Council systematically
invested in derivation of clinical-grade hESC lines in five centers
across the country. Currently, more than 30 such lines have been
derived. At King’s College London, in our purpose-built cGMP
laboratory, we derived, under animal product-free conditions
[11–14], eight clinical-grade lines: KCL031–KCL034 and KCL037–
KCL040. All eight clinical-grade lines will be available through
the U.K. Stem Cell Bank, which will conduct further validation
of these lines before releasing them. The lines are also under con-
sideration for placement on the NIH hESC registry [15], which will
make them eligible for use in NIH-supported research.
In the next step, following cGMP, we adapted four clinical-
grade hESC lines, KCL033, KCL034, KCL037, and KCL040, to
feeder-free conditions using methods described previously [12].
However, owing to the high costs of running a cGMP facility and
Master Cell Bank validation, we were not able to proceed with
all the lines. Of the four lines, KCL040 and KCL037 had haplotypes
that matched ∼0.016% and ∼0.019% of the population, respec-
tively, and were therefore potentially more clinically useful than
the other two, which only matched ∼0.004% [13]. However, the
lines KCL033 and KCL034 were sibling lines, meaning that they
were derived from embryos donated by the same couple. In ad-
dition, these embryos had been generated and cryopreserved as
supernumerary in a single in vitro fertilization (IVF) cycle. Further-
more, the embryos had been thawed at the same time, and the
lines were generated in parallel under the same conditions using
the same reagents. The embryos were thus coming from a single
source and were undergoing all procedures in parallel until initial
stock cryopreservation. We, therefore, reasoned that if one line
had been positive for any human pathogens, itwas highly unlikely
that the other line would have a different status. Testing of only
one cell line should therefore theoretically be sufficient to ex-
clude or confirm the presence of pathogens in all sibling lines;
however, regulations require that all lines should be tested. We
therefore considered the strategy of pooling samples from such
Master Cell Banks, thereby reducing costs without compromising
the detection of human viral pathogens.
Hence, KCL033 and KCL034 were taken further, and Master
Cell Banks were generated and validated in vitro for the presence
of human viral pathogens. All validation studies were conducted
by SGS Vitrology (Glasgow, U.K., http://www.sgs.com), in compli-
ancewith theprinciples ofGMPas setout inDirective 2003/94/EC
for medicinal products for human use [16] and 91/412/EEC for
veterinary medicinal products [17]. In the present study, we de-




The present work was ethically approved (U.K. National Health
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Human Fertilization and Embryology Authority (license no. R0133)
and the U.K. Human Tissue Authority (license no. 22621).
Cell Culture
The methods have been previously described in detail [11–14].
Sterility Testing
Five vials each of KCL033 and KCL034 from the respective Master
Cell Banks were pooled and tested for sterility. The presence of
microorganisms was assessed after 14 days of incubation at the
appropriate temperature. Tryptone soya broth (TSB) was used
for the growth of aerobic bacteria and fungi at 20°C–25°C. Fluid
thioglycolate (THIO) medium was used for the growth of both
anaerobic and aerobic bacteria at 30°C–35°C.
The experiment controls were as follows. Uninoculated TSB
and THIO in duplicate served as the negative control (NC) and
when inoculated with 1 ml of sterile demineralized water served
as the operator/assay technique control. TSB inoculated with
10–100 colony forming units of Bacillus subtilis, Aspergillus
brasiliensis, andCandidaalbicans andTHIO inoculatedwithClostri-
duim sporogenes, Pseudomonas aeruginosa, and Staphylococcus
aureus served as the positive controls (PCs). Environmental mon-
itoring was performed in the sample isolator (settle plates) and
before and after manipulation (contact plates).
Sterility testingwasperformed inaccordancewith thecurrent
requirements of the European Pharmacopoeia, Section 2.6.1 Ste-
rility, U.S. Pharmacopeia,71. Sterility Tests, and International
Conference on Harmonisation Topic Q5D guidelines.
Mycoplasma Testing
One vial each of KCL033 and KCL034 from the respective Master
Cell Banks were pooled and increased to 5 ml volume by adding
sterile Dulbecco’s modified Eagle’s medium. The pooled sample
was sonicated on ice for 2 minutes, increased to a final vol-
ume of 15 ml, and tested for Mycoplasma without additional
treatment.
Vero indicator cell cultures were inoculated with the test ma-
terial and cultured for 3 days. Then, the cells were mechanically
transferred into thechamber slideandcultured for anadditional 3
days. At day 6, the cells were stained with DNA-binding Hoechst
33258 fluorescent dye for Mycoplasma detection.
Testmaterialwas also inoculated into broth known tohavenu-
tritive properties forMycoplasma species and either cultured fur-
ther in broth or plated on agar plates, which were then observed
microscopically for typical Mycoplasma colony morphology.
Mycoplasma testing was performed in accordance with the
current requirements of the European Pharmacopoeia, Section
2.6.7, Mycoplasmas.
Fluorescent-Product Enhanced Reverse Transcriptase
Assay for Retroviral Activity
Spentmedium from theKCL033 andKCL034 cultures, 8.7ml each,
was pooled and centrifuged at 11,000g for 10 minutes at 4°C.
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Then, the supernatant was filtered through a 0.45-mm filter. The
sample was spiked with 3.0 3 104 retroviral particles (ampho-
tropicmurine leukemia virus [A-MLV]) permilliliter, and retroviral
particles were purified by ultracentrifugation at 100,000g for
a minimum of 60minutes at 4°C. To release reverse transcriptase
(RT) activity from the retroviral particles, the pellets were resus-
pended in disruption buffer. Recovery of retroviral particles in
the absence of the test sample was assessed by ultracentrifuga-
tion of the same number of A-MLV in culture medium. Aliquots
(5 ml) of processed test sample and retrovirus particle recovery
control were added to the RT reactionmix containing all reagents
necessary for reverse transcription (dNTP,MgCl2, reverse primer,
RNase inhibitor) and Brome mosaic virus RNA as a template.
The mix also contained activated calf thymus (aCT) DNA to
reduce false-positive signals arising fromDNApolymerases. Toas-
sess the level of DNA polymerase activity, the sample was also
analyzed in the absence of aCT DNA. Synthesized cDNA was sub-
sequently amplified using TaqMan (Life Technologies, Carlsbad,
CA, http://www.lifetechnologies.com) real-time polymerase
chain reaction (PCR). The data were collected and analyzed
using an Applied BioSystems 7900HT Fast Real Time PCR
System (Applied BioSystems, Foster City, CA, http://www.
appliedbiosystems.com). The negative controls included PCR
no-template control (PNTC), NC, and medium only control. The
positive controls included PC and spike positive control (SPC).
SPC consisted of retroviral particles at or near the limit of detec-
tion spiked into the test sample before processing. The cycling
parameterswere as follows: for reverse transcription: 30minutes
at 37°C (reverse transcription) and 5 minutes at 95°C (reverse
transcription inactivation), and 5 minutes at 25°C (reaction cool-
ing); for c-DNA PCR: 2 minutes at 50°C (uracil-DNA glycosylase
[UNG] activation) and 10 minutes at 95°C (AmpliTaq Gold activa-
tion; Life Technologies), followed by 40 cycles of 15 seconds at
95°C (denaturation) and 1 minute at 60°C (annealing/extension).
Themethods usedwere compliant with the current edition of
the European Pharmacopoeia, 2.6.21, Nucleic Acid Amplification
Techniques.
Real-Time PCR
For detection of the enteroviruses, hepatitis A virus (HAV), and
hepatitis C virus (HCV), RNA was extracted using RNA easy kit
(Qiagen, Venlo, The Netherlands, http://www.qiagen.com) from
3.03 106 cells in 200 ml of phosphate-buffered saline (PBS) per
column. Eluted RNA frommultiple columns was pooled together.
During theRNAextraction procedure, the samplewas spikedwith
cucumber mosaic virus (CrMV) interference control RNA from an
unrelated species. From the pooled RNA, 3ml (67 ng/ml) was used
per replicate in testing for pathogens in real-time PCR assays. This
is equivalent to approximately 1.23 105 cells per reaction assum-
ing 100% recovery from the extraction process.
Fordetectionof sexually transmitteddisease (STD)pathogens
and all other viruses, DNA was extracted using the QIAamp DNA
mini-kit (Qiagen) from either 3.0 3 106 cells (for detection of
viruses) or 3.6 3 106 cells (for bacterial pathogen detection) in
200 ml of PBS per column. Eluted DNA from multiple columns
was pooled together. During the DNA extraction procedure,
the sample was spiked with CrMV interference control DNA from
an unrelated species. From the pooled DNA, 3 ml (280 ng/ml for
viruses, 238.3 ng/ml for STD pathogens) was used per replicate
in testing for pathogens in real-time PCR assays. This is equivalent
to approximately 1.23 105 cells for viruses and 1.03 105 cells for
STD pathogens.
Extracted nucleic acidswere tested in real-time PCRs contain-
ing either CrMV interference control specific primers and probe
or pathogen target specific primers and probe. The accumulation
of the PCR products was monitored and data collected using an
Applied Biosystems 7900HT Fast Real Time PCR System. Real-
time PCR controls included PNTC, NC, PC, postspike control, exog-
enous internal positive control, extraction no-template control,
and extraction recovery and contamination control. The cycling
parameters were as follows.
For the HAV, HCV, and enteroviruses, we used initial steps
of 10 minutes at 50°C (reverse transcription) and 10 minutes at
95°C (reverse transcription inactivation), followed by 40 cycles
of 15 seconds at 95°C (denaturation) and 1 minute at 60°C
(annealing/extension).
For HIV-1, HIV-2, human T-lymphotropic virus (HTLV) type 1
and 2, hepatitis B virus (HBV), human herpesvirus (HHV)-6,
HHV-7, HHV-8, human cytomegalovirus (hCMV), Epstein-Barr vi-
rus (EBV; also known asHHV-4), B19 virus, Simian virus 40, human
polyomavirus JC, human polyomavirus BK, and Treponema pal-
lidum,weused2minutes at 50°C (UNGactivation) and10minutes
at95°C(AmpliTaqGoldactivation), followedby40cyclesof15sec-
onds at 95°C (denaturation) and 1 minute at 60°C (annealing/
extension). For Chlamydia species and Neisseria gonorrhoeae,
the number of cycles was increased to 50.
The methods used were compliant with the current edition
of the European Pharmacopoeia, 2.6.21, Nucleic Acid Amplifica-
tion Techniques.
In Vitro Assay for Detection of Virus Contaminants
Using Indicator Cell Lines
The cell lines used in this assay were normal human fetal lung
fibroblasts MRC-5, African green monkey Cercopithecus aethiops
kidney Vero C1008 (Vero 76, clone E6, Vero E6), and human
cervical carcinoma HeLa. The control viruses used in the assay
were herpes simplex virus type 1, human adenovirus type 5, and
influenza A virus.
KCL033 and KCL034 in frozen culture medium (23 106 cells per
milliliter) were thawed, pooled together, and centrifuged at low
speed. The supernatant (SN)was removed and saved, and the pellet
was resuspended ina small volumeofSNandsubjected to twocycles
of freezing and thawing to facilitate release of cell-associated viral
particles. Following low-speedcentrifugation, the SNwas removed
and pooled with the original SN. The pooled SNwas diluted with
appropriate maintenance medium at a ratio of 1:4 and used for
inoculation of the indicator cell lines. Subconfluent monolayers
of indicator cell lines in T80 flasks were inoculated with the test
item or with relevant controls in duplicate (2.5 ml inoculum per
flask). MRC-5 cultures were fed on days 7, 14, and 21, VeroC1008
on day 14, and HeLa on days 11, 18, and 25 after inoculation. The
HeLa cells were also subcultured on days 7, 14, and 21. The cul-
tures were monitored for 28 days for cell health and evidence
of a virus-induced cytopathic effect (CPE). On day 28 after inocu-
lation, the test itemcultures and relevant controlswere tested for
hemadsorption with guinea pig erythrocytes, one half at 2°C–8°C
and the other half at 20°C–25°C.
Transmission Electron Microscopy
Cell pellets containing 13 107 cells fixed in glutaraldehyde solu-
tion were postfixed in OsO4, stained en bloc in uranyl acetate,
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dehydrated in anethanol series andpropylene oxide beforebeing
infiltrated to Araldite resin (Huntsman Corp., Salt Lake City, UT,
http://www.huntsman.com), and polymerized. Semithin sec-
tions (1mm)weremounted on glass slides, stainedwith toluidine
blue, and examined by light microscopy for general quality of fix-
ation, gross cellmorphology, and thepresenceofmitotic, dead, or
dying cells. Ultrathin sections (0.1mm)weremountedonelectron
microscope grids and stainedwith uranyl acetate and lead citrate
solutions. Aminimumof 100median cell profiles of the tested cell
culture were examined for the presence of viruses, virus-like
particles, and other extraneous agents.
RESULTS
Stage 1: Sterility and Mycoplasma Testing
Validation of theMaster Cell Banks was divided into three stages.
In order to proceed to the next stage, the samples had to pass
each validation test.
The first stage was to test for any contamination that might
havearisen fromourhandling, despite thecontinuousmonitoring
during sample processing in our cGMP-compliant facility. Pooled
samples from the KCL033 and KCL034 Master Cell Banks were
therefore tested first for sterility, to detect the presence of bac-
teria, fungi, andMycoplasma species and to ensure that no inhib-
itory materials were present that would mask the detection of
pathogens.
The growth of bacteria or fungi was not detected in the test
article after 14 days of incubation. Spiking the test material with
either bacteria or fungi resulted in growth at a similar rate as the
positive control, indicating thatno inhibitory factorswerepresent
in the tested sample (Table 1).
Mycoplasma validation was performed in the indicator cell
line and liquid (broth) and solid (agar) media known to have nu-
tritive properties for Mycoplasma species. Growth was not
detected, and no inhibitory factors were present in the tested
sample (Table 2A–2C).
Stage 2: Detection of Specific Human Pathogens
Having confirmed in stage 1 that our handling did not introduce
exogenouspathogens, in the second stage,we tested for thepres-
ence of human viral pathogens that might have been inherited
from the donor tissue. Two different types of assay were per-
formed: fluorescent-product enhanced reverse transcriptase
(F-PERT) fordetectionofreversetranscriptase,whichwould indicate
retroviral activity, and a series of real-time PCRs for detection of
various commonhuman viruses, including T. pallidum,Chlamydia
species, and N. gonorrhoeae.
Regulatory guidance recommends the use of reverse tran-
scriptase activity packaged into extracellular retroviral particles
as a marker for the potential presence of retroviral contamina-
tion. The assays are designed to detect conversion of RNA tem-
plate to cDNA when retroviral reverse transcriptase is present
in the test sample [18–21]. PERT assays are routinely required
for cell banks or any product originating from mammalian and
avian cell substratesmanufactured in aprocess that doesnot con-
tain endogenous retroviral activity. The F-PERT assay for KCL033
andKCL034pooled samplewasnegative toa sensitivity of approx-
imately 1,000 retroviral particles per reaction or 2,600 particles
per milliliter of pooled sample (Table 3).
Screening of embryo donors for STDs, mandatory in the U.S.
and most European Union (EU) countries, is not required in the
U.K. However, because the U.K., as a member of the EU, follows
the EUTissue andCells Directive [22–24],we validatedour samples
for the presence of STD pathogens, in addition to the list of spe-
cific human viral pathogens. Real-time PCR, commonly used to
detect human viruses in biological materials [20, 21], confirmed
that KCL033 and KCL034 were negative for all viruses tested
and for T. pallidum, Chlamydia species, and N. gonorrhoeae
(Table 4). Negative results were expected for some of the viruses
included in the panel (i.e., HIV-1 and -2, HBV, HCV, HTLV-1 and -2,
hCMV, EBV), either because the embryo donors were tested be-
fore IVF treatment, or because we had previously performed the
Table 1. Sterility testing
Sample Growth medium Inoculum Result
NC
TSB None No growth
detected
THIO None No growth
detected
OATC
TSB Water No growth
detected
THIO Water No growth
detected
PC





















KCL034 TSB None No growth
detected
THIO None No growth
detected
Spiked KCL033




















Abbreviations: NC, negative control; OATC, operator/assay technique
control; PC, positive control; THIO, thioglycollate; TSB, tryptone soya
broth.
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testwith a non-cGMP service provider at low cost tominimize un-
necessary spending.
Stage 3: Detection of Nonspecific Viral and Other
Adventitious Contaminants
The assays in stage 2 covered only specific types of human patho-
gens. In the third stage, we therefore performed two additional
tests for the detection of nonspecific viral contaminants: the
28-day in vitro assay and transmission electron microscopy
(TEM).
The 28-day in vitro assay was designed to meet the general
requirements of the tests for extraneous agents in cell culture
as described in European Pharmacopoeia, chapters 5.2.3 (“Cell
Substrates for Production of Vaccines for Human Use”) and
2.6.16 (“Tests for Extraneous Agents in Viral Vaccines for Human
Use”), with extension to 28 days to increase the sensitivity of the
assay for slowgrowing viruses, as suggested by the Food andDrug
Administration and later accepted by theWorld Health Organiza-
tion. MRC-5, Vero C1008, and HeLa cell cultures were inoculated
with the pooled samples from theKCL033 andKCL034Master Cell
Banks andmonitored for 28 days. None of the cultures inoculated
with the test material showed signs of a virus-induced cytopathic
effect or hemadsorption with guinea-pig red blood cells. The
KCL033 and KCL034 samples were therefore considered negative
for the presence of cytopathic or hemadsorbing adventitious
virus contaminants (Table 5A–5C).
Regulatory agencies recommend theuseof TEMonharvested
cells to ascertain the presence of viruses and adventitious agents.
TEMcan reveal the size, structure, and localization of viral, fungal,
bacterial, orMycoplasma contaminants in the sample. Obviously,
for this test, KCL033 and KCL034 could not be pooled, because
we would not be able to be sure how many cells from each cell
line were analyzed in a mixed sample. We tested only KCL034 in
the TEM assay and no viruses, virus-like particles, or extraneous
agents, including Mycoplasma, yeast, fungi, or bacteria were
detected in at least 100 random median cell profiles examined
(Fig. 1).
We have not tested for extraneous agents that might be
present without causing cytopathic or other apparent effects in
the cell culture. Such tests are done in vivo, commonly involving
embryonated eggs and suckling and adult mice; they generally
cost.$12,000 per sample. Multiple cell lines derived in parallel
from a tissue sample from a single donor could also be pooled for
these tests, as described above for our two clinical-grade hESC
lines.




NC Yes Yes Negative
KCL033 and KCL034
Flask A Yes Yes Negative
Flask B Yes Yes Negative
OATC Yes Yes Negative
PC
Mycoplasma orale Yes Yes Positive
Mycoplasma hyorhinis Yes Yes Positive
Abbreviations: NC, negative control; OATC, operator/assay technique
control; PC, positive control.
Table 2B. Mycoplasma testing: culture test in broth
Sample Result
NC Negative
KCL033 and KCL034 Negative
OATC Negative
Spiked KCL033 and KCL034
(Mycoplasma fermentans)
Positive
PC (M. fermentans) Positive
Abbreviations: NC, negative control; OATC, operator/assay technique
control; PC, positive control.
Table 2C. Mycoplasma testing: culture test on agar
Sample
Results
Plate A Plate B
Day of subculture
0 3 7 14 21 0 3 7 14 21
NC N N N N N N N N N N
KCL033 and
KCL034
N N N N N N N N N N




P P P P P P P P P P
PC (M. fermentans) P P P P P P P P P P
Abbreviations: N, negative (absence of Mycoplasma); NC, negative
control; OATC, operator/assay technique control; P, positive (presence
of Mycoplasma); PC, positive control.







KCL033/034 with aCT 2 2.63 103
KCL033/034 without aCT 1111 NA
KCL033/034 SPC 1111 NA
PC 1111 NA
CT = undetermined after 40 cycles of PCR. CT = # 39.99 after 40 cycles of
PCR.
aAssay sensitivity per milliliter was based on testing 5 ml of KCL033 or
KCL034 sample per replicate from the original sample resuspended in
100 ml of disruption buffer, after ultracentrifugation of 7.8 ml of the
original sample.
Abbreviations:2, negative to the sensitivity of the assay (i.e., no
amplification signals detected; assay sensitivity reported was based on
the sample SPC that has amplified in a minimum of three of four
replicates);1, potentially positive (amplification signals detected in
three or more replicates); aCT, activated calf thymus; F-PERT,
fluorescent-product enhanced reverse transcriptase; MOC, medium
only control; NC, negative control; PC, positive control; PCR, polymerase
chain reaction; PNTC, PCR no-template control; SPC, spike positive
control.
1120 Validation of Multiple Cell Lines From One Donor




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Devito, Petrova, Miere et al. 1121
www.StemCellsTM.com ©AlphaMed Press 2014
DISCUSSION
Oncehumanpluripotent stemcell (hPSC) therapy is approvedand
available, it will have to compete with other technologies over
a range of criteria, including costs. Even if the technology is at
least as beneficial as established alternatives, the high production
costs could become a major obstacle in successful dissemination
of the therapy and return of investments for developers and
investors. Nevertheless, it is essential for hPSC-based therapy
that quality control should be very rigorous for each step, from
isolation of the stem cells through to the final differentiated
product.
In order to decrease the costs of quality control while main-
taining rigorousmonitoring, we considered the possibility ofmix-
ing multiple lines derived in parallel from tissue of a single donor,
before testing for the presence of various human viruses and
other adventitious agents. The risks associatedwith this approach
seem very low, because (a) the tissue has been processed under
identical environmental conditions, exposed to identical cell cul-
ture media and reagents, cryopreserved and stored in the same
vacuum flask, and (b) the possibility of introducing any human
viruses from the controlled environment of a cGMP-compliant
laboratory is rather remote. Therefore, the only source of con-
tamination would be the donor tissue itself. Although possible,
it is unlikely that a part of tissue fromwhich one cell line is derived
would be positive for some virus or other pathogen and the other
part would not. Such a risk might be somewhat higher in the case
of embryos harvestedduring a single IVF cycle than itwould be for
multiple iPS cell clones obtained from reprogramming of a single
batch of donor cells.
Pooling the lines derived from different donors could be con-
sidered as potentially providing additional cost savings. However,
an important consideration in the testing of pooled lines using
PCR methods is the determination of sensitivity. For nucleic acid
testingmethods, the European Pharmacopoiea 2.6.21 states a re-
quirement of sensitivity at the95%confidence level. For example,
the assay sensitivity for the detection of T. pallidum is 10 copies
per reaction at 95% confidence, the minimum number of copies
detected in 95% of the reactions. Thus, we can follow that the re-
action containing 100,000 cells (or 714.9 ng of DNA, based on the
estimate that 7 pg of DNA corresponds to 1 genome equivalent)
Table 5A. Controls in the assay with indicator cell lines
Assay Control
Cell lines
InoculumMRC-5 Vero C1008 HeLa
CPE
Negative control Tissue culture
medium
Positive control N/A HSV-1a
N/A N/A Ad5a
HAD
Negative control N/A N/A Tissue culture
medium
Positive control N/A N/A Inf Aa
Negative and positive controls for CPE were inoculated on day 0, the
same day as inoculation of the test sample; negative and positive
controls for HAD were inoculated on day 14.
aOne hundred median tissue culture infective dose units per flask.
Abbreviations: Ad5, adenovirus type 5; CPE, cytopathic effect; HAD,
hemadsorption; HSV-1, herpes simplex virus 1; Inf A, influenza A virus;
N/A, not applicable.
Table 5B. Virus-induced cytopathic effect assay results
Sample
Cell lines
MRC-5 Vero C1008 HeLa
Negative control 2/2 2/2 2/2
KCL033/KCL034 2/2 2/2 2/2
Positive control
HSV-1 1/1 N/A 1 /1
Ad5 N/A 1/1 N/A
Abbreviations:2, negative result; 1, positive result;2/2 and1/1,
individual results obtained for duplicate flasks tested; Ad5, adenovirus
type 5; HSV-1, herpes simplex virus 1; N/A, not applicable.





HAD negative (MRC-5 T80 flask) 2 2




Negative control 2 2
KCL033/KCL034 2 2
Vero C1008
Negative control 2 2
KCL033/KCL034 2 2
HeLa
Negative control 2 2
KCL033/KCL034 2 2
Abbreviations:2, negative result; 1, positive result; gp, guinea pig
erythrocytes; HAD, hemadsorption; Inf A, influenza A virus; TCID50,
median tissue culture infective dose.
Figure 1. Typical KCL034 transmission electronmicroscopy cell pro-
files. The cells were generally adherent, with intercellular connec-
tions and a normal range of organelles and nuclei, with sparse
heterochromatin and prominent nucleoli. Abbreviations: des, des-
mosome; f, fibrils; tj, tight junction.
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will detect 10 copies of the pathogenwith a sensitivity of 95%, re-
gardless of thenumberof lines pooled. Therefore, if testing 10 cell
lines with 10,000 cells from each cell line in the reaction, all 10
pooled cell lines would need to have 1 copy of T. pallidum to give
a low-level positive result of 10 copies per reaction at the assay
detection limit.
It has been estimated that in the U.S., CMV infects 50%–80%
of the adult population [25] and nearly 95% of adults aged 35–40
years have been infected with EBV [26]. When considering the
cost of deriving hPSC lines, it would therefore seem vitally impor-
tant to prescreen potential donors for common viral pathogens
such as HIV, HBV, HCV, HTLV, CMV, and EBV, alongwith screening
for other health risks such as hereditary diseases or cancer. This
approach would diminish the risk of investing in lines that would
not be safe for therapeutic use and might reduce the pathogen
burden sufficiently to enable larger scale pooling. This strategy
would be impractical for hESC lines owing todonor confidentiality
but shouldbeeasily applicablewhen recruitingdonors for clinical-
grade iPSC lines. Alternatively, screening of biopsied samples
in non-GMP facilities before cell line derivation would exclude
contaminated material and reduce the overall derivation costs,
although the tests would have to be repeated once the cell lines
were derived to satisfy regulations.
CONCLUSION
The requirements for validation of hPSC lines are even more rig-
orous than for other biological material for human therapy, in-
cluding adult or fetal stem cells. The paramount issue is to
prove the safety of these cells. However, the costs associatedwith
validation of the products could render hESC- and iPSC-based
therapy prohibitively expensive. Using two clinical-grade hESC
lines, KCL033andKCL034, derived inparallel fromsiblingembryos
harvested in a single IVF cycle, we demonstrated as a proof-of-
principle that multiple cell lines can be safely tested together
and thus reduce the validation costs significantly without com-
promising safety and/or efficiency. This pooling strategy would
be especially cost-effective in the case of clinical-grade iPSC lines,
because three lines are generally derived from each donor. For
example, a clinical iPSC bank from 100 donors with 3 lines from
each donor, such as the Clinical iPSC Bank of Kyoto, could save
on validation $18 million using our approach of pooling the
samples from a single donor.
ACKNOWLEDGMENTS
This work was supported by the U.K. Medical Research Council
(Grant G0801061) and incentive funds to Y.K. and D.I. We thank
the hESC lines derivation team: Victoria Wood, Neli Kadeva,
Glenda Cornwell, and Dr. Emma Stephenson. We are especially
indebted to the patients who donated embryos and Dr. Peter
Braude, who set up the program.
AUTHOR CONTRIBUTIONS
L.D., A.P., and C.M.: experimental work; S.C., N.B., and A.L.: con-
ception and design, manuscript writing. Y.K.: conception and de-
sign, financial support; C.O. and D.I.: conception and design,
financial support, manuscript writing.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
N.B. and A.L. have compensated employment with SGS Vitrology.
REFERENCES
1 Thomson JA, Itskovitz-Eldor J, Shapiro SS
et al. Embryonic stem cell lines derived from
human blastocysts. Science 1998;282:1145–
1147.
2 StephensonEL, BraudePR,MasonC. Inter-
national community consensus standard for
reporting derivation of human embryonic stem
cell lines. Regen Med 2007;2:349–362.
3 Available at http://www.advisorybodies.
doh.gov.uk/genetics/gtac/InterimUKSCroutemap
120309.pdf.
4 Lo¨ser P, Schirm J, Guhr A et al. Human em-
bryonic stem cell lines and their use in inter-
national research. STEM CELLS 2010;28:240–
246.
5 Strulovici Y, Leopold PL, O’Connor TP et al.
Human embryonic stem cells and gene therapy.
Mol Ther 2007;15:850–866.
6 Takahashi K, YamanakaS. Inductionof plu-
ripotent stem cells from mouse embryonic and
adult fibroblast cultures by defined factors. Cell
2006;126:663–676.
7 Schwartz SD, Hubschman JP, Heilwell G
et al. Embryonic stem cell trials for macular de-
generation: A preliminary report. Lancet 2012;
379:713–720.
8 Klimanskaya I, Chung Y, Becker S et al. Hu-
manembryonic stemcell lines derived fromsin-
gle blastomeres. Nature 2006;444:481–485.
9 Crook JM, Peura TT, Kravets L et al.
The generation of six clinical-grade human
embryonic stem cell lines. Cell StemCell 2007;
1:490–494.
10 Funk WD, Labat I, Sampathkumar J et al.
Evaluating the genomic and sequence integrity
of human ES cell lines: Comparison to normal
genomes. Stem Cell Res (Amst) 2012;8:154–
164.
11 Ilic D, Stephenson E, Wood V et al. Deri-
vation and feeder-free propagation of human
embryonic stem cells under xeno-free condi-
tions. Cytotherapy 2012;14:122–128.
12 Stephenson E, Jacquet L, Miere C et al.
Derivation and propagation of human embry-
onic stem cell lines from frozen embryos in an
animal product-free environment. Nat Protoc
2012;7:1366–1381.
13 Jacquet L, Stephenson E, Collins R et al.
Strategy for the creation of clinical grade hESC
line banks that HLA-match a target population.
EMBO Mol Med 2013;5:10–17.
14 Health Explained: How to make stem
cells. BBC News. Available at http://www.bbc.
co.uk/news/health-18496355.
15 NIH Human Embryonic Stem Cell Regis-
try. NIH. Available at http://stemcells.nih.
gov/research/registry/Pages/Default.aspx.
16 Directive 2002/94/EC of the European
Parliament and of the Council of October 08,
2003 laying down the principles and guidelines
of good manufacturing practice in respect of
medical products for human use and investiga-
tional medicinal products for human use. Offi-
cial Journal of the European Union October
14, 2003;L262:22–26. Available at http://ec.
europa.eu/health/files/eudralex/vol-1/dir_2003_
94/dir_2003_94_en.pdf.
17 Commission Directive 91/412/EEC of
July 23, 1991 laying down the principles and
guidelines of good manufacturing practice for
veterinary medicinal products. Official Journal




18 Lovatt A, Black J, Galbraith D et al. High
throughput detection of retrovirus-associated
reverse transcriptase using an improved fluo-
rescent product enhanced reverse transcrip-
tase assay and its comparison to conventional
detection methods. J Virol Methods 1999;82:
185–200.
19 BrorsonK, Swann PG, Lizzio E et al. Use of
a quantitative product-enhanced reverse tran-
scriptase assay to monitor retrovirus levels in
mAb cell-culture and downstream processing.
Biotechnol Prog 2001;17:188–196.
20 Lovatt A. Applications of quantitative
PCR in thebiosafety andgenetic stability assess-
ment of biotechnology products. J Biotechnol
2002;82:279–300.
21 Xu Y, Brorson K. An overview of quantita-
tive PCR assays for biologicals: Quality and
safety evaluation. Dev Biol (Basel) 2003;113:
89–98.
22 Directive 2004/23/EC of the European
Parliament and of the Council of March 31,
Devito, Petrova, Miere et al. 1123
www.StemCellsTM.com ©AlphaMed Press 2014
2004 on setting standards of quality and safety
for the donation, procurement, testing, pro-
cessing, preservation, storage and distribution
of human tissues and cells. Available at http://
eur-lex.europa.eu/LexUriServ/LexUriServ.do?
uri=OJ:L:2004:102:0048:0058:EN:PDF.
23 Commission Directive 2006/17/EC of
February 8, 2006 implementing Directive
2004/23/EC of the European Parliament and of
the Council as regards certain technical require-
ments for thedonation,procurementandtesting
of human tissues and cells. Available at http://
eur-lex.europa.eu/LexUriServ/LexUriServ.do?
uri=OJ:L:2006:038:0040:0052:EN:PDF.
24 Commission Directive 2006/86/EC of
October 24, 2006 implementing Directive
2004/23/EC of the European Parliament and
of the Council as regards traceability require-
ments, notification of serious adverse reactions
and events and certain technical requirements
for the coding, processing, preservation, stor-




25 Cytomegalovirus (CMV) and congenital
CMV infection. U.S. Centers for Disease Control
and Prevention. Available at http://www.cdc.
gov/cmv/overview.html.
26 Epstein-Barr virus and infectious mono-
nucleosis. U.S. Centers for Disease Control
and Prevention. Available at http://www.cdc.
gov/epstein-barr/index.html.
1124 Validation of Multiple Cell Lines From One Donor
©AlphaMed Press 2014 STEM CELLS TRANSLATIONAL MEDICINE
Isolation and Expansion of Mesenchymal Stromal/Stem
Cells from Umbilical Cord Under Chemically
Defined Conditions
Heba Badraiq, Liani Devito, and Dusko Ilic
Abstract
From a perspective of manufacturer, procurement of bone marrow aspirates for isolation of mesenchymal
stromal/stem cells (MSC) is challenging. The MSC isolated from adult donors have lower proliferation
capacity than the cells isolated form young donors of pediatric age. To obtain more MSC from young
healthy donors for allogeneic therapy on multiple patients, umbilical cord (UC) seems to be the best
alternative. Here, we describe an easy, cost-effective and reproducible protocol of isolation of theMSC from
Wharton’s Jelly (WJ) in UC.
Keywords: Umbilical cord, Mesenchymal stem cells, Explant culture
1 Introduction
The use of animal derived supplements, such as fetal bovine serum
(FBS), should be eliminated for clinical grade cells to avoid the risks
in transmitting animal pathogens and to avoid immunogenic reac-
tions after clinical transplantations. The optimization of a xeno-free
(XF) culture represents a positive step for the future production of
these cells in a clinical grade scale. In addition, content and con-
centration of cytokines, growth, and other soluble factors greatly
varies from batch to batch of FBS and even for purpose of basic
research, the trend is to culture cells in serum-free medium. Differ-
ent research groups have established a range of protocols for isola-
tion and characterization of stromal cells from WJ. However,
defined XF culture systems allow for a better multipotent differen-
tiation and expansion rates of adipose tissue- and BM-MSCs,
serving as a preferred alternative to FBS containing medium for
the production of large scale, functionally competent, clinical grade
MSCs (1–3).
Isolation of MSCs from WJ has been poorly investigated and
the techniques vary depending on the laboratories. The enzymatic
treatment with a combination of various collagenases is widely
used; however this treatment fluctuates in the literature. Trypsin
Methods in Molecular Biology (2015) 1283: 65–71
DOI 10.1007/7651_2014_116
© Springer Science+Business Media New York 2014
Published online: 24 August 2014
65
and other proteases such as hyaluronidase are frequently added in
different concentrations, and the incubation time also changes
from 4 to 24 h at room temperature or at 37 C (4–8). The yield
of MSC often varies and enzymes containing no animal product are
difficult to obtain and they are expensive.
The method of WJ MSCs isolation from UC explants possesses
advantages over the enzymatic method: (a) cell damage by enzymes
is avoided, (b) WJ contains growth factors that support the prolif-
eration of MSC, and (c) it is a low cost protocol. The primary
cultures obtained by UC explants appear to be heterogeneous
(9, 10), with a population of fibroblast-like cells with a different
cell shape and size. In our experimental setting, MSCs outgrowing
from explants in chemically defined, animal product-free medium
were also relatively heterogeneous initially. However, heterogeneity
was substantially decreased after the first passage and it was gone
after several population doublings (PD), yielding uniform popula-
tion of the MSC.
2 Materials
2.1 UC The UC is collected only from patients who gave their informed
consent (see Note 1). Only one UC should be collected at a time
to avoid and minimize risk of contamination (see Note 2). After
delivery and inspection of placenta and UC by a nurse, the UC
is cut and placed immediately inside a sterile 500-ml bottle contain-
ing PBS supplemented with Gentamicin + Amphotericin B
(Gibco). The bottle is placed inside the tissue carrier bag and
transported to the laboratory (see Note 3).
2.2 CELLstart-
Coated Dishes
Survival of anchorage-dependent cells is determined by signals
from their environment. These signals are primarily derived from
soluble factors present in serum and from cell interactions with
extracellular matrix (ECM). When serum factors are withdrawn,
cells can still survive on certain matrices, whereas they undergo
apoptosis on others. Fibronectin is the most effective survival-
promoting ECM ligand for both primary fibroblasts and endothe-
lial cells after serum withdrawal (11, 12). CELLstart, xeno-free
coating reagent, is mostly fibronectin. Cell culture dishes should
be coated the day of use following the manufacturer’s recommen-
dation (see Note 4).
2.3 Equipment 1. 100-μl pipetman.
2. 1,000-μl pipetman.
3. Autoclaved surgical tweezers.
4. Biosafety cabinet.
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5. Cryobox/“Mr Frosty”/(Nalgene; Cat. No. 5100-001) (see
Note 5).
6. Disposable scalpels (Swann-Morton, Cat. No. 0503).
7. Hemocytometer (Hausser).
8. Phase contrast microscope.
9. Pipette gun.





1. 100-mm Cell culture dish (Corning, Cat. No. 430293).
2. 100-μl Filter tips (SLS, Cat No. 171403).
3. 1,000-μl Filter tips (SLS, Cat No. 171703).
4. 500-ml Storage bottle (Corning, Cat. No. CLS430282).
5. 75-cm2 Flask (Corning, Cat No.430641).
6. γ-irradiated individually wrapped polystyrene 5-ml pipettes
(Falcon; Cat. No. 357543).
7. γ-irradiated individually wrapped polystyrene 10-ml pipettes
(Falcon; Cat. No. 357551).
8. γ-irradiated individually wrapped polystyrene 25-ml pipettes
(Falcon; Cat. No. 357525).
9. γ-irradiated 15-ml conical tube (BD Falcon; Cat no. 352096).
10. γ-irradiated 50-ml conical tube (BD Falcon; Cat no. 352070).
11. Cryotube (Thermo Scientific; Cat No. 377224).




1. CELLstart (Life Technologies, Cat. No. 07930).
2. Cryostor CS10 (STEMCELL Technologies, Cat. No.
A10142-01).
3. DMEM (Life Technologies, Cat No. 41965-039).
4. DPBS with Ca2+/Mg2+ (Lonza, Cat No. BE17 513F).
5. Gentamicin/Amphotericin B 500X (Gibco/Life Technolo-
gies, Cat. No. R-015-10).
6. Isopropanol (Shield Medicare; Cat. No. 3035300).
7. PBS, Ca2+/Mg2+-free (Life Technologies CatNo. 10010-023).
8. Stemgro (Corning, Cat. No. 40-410-KIT).
9. Tryple (Life Technologies, Cat No. 12604-021).
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3 Methods
3.1 Receiving the UC 1. Assure that the UC is accompanied with signed donor consent
and a proof that the donor has no blood-borne diseases.
2. The UC is received inside a storage bottle containing sterile
PBS supplemented with Gentamicin/Amphotericin B (see
Note 7). The bottle should be wiped with IPA cleaning wipes
and placed inside the biosafety cabinet.
3.2 Plating UC
Explants
1. The cords should be then transferred into a non-coated
100-mm dish.
2. The cord can be cut into 3–5 cm pieces and thoroughly washed
with PBS to eliminate any remains of blood (a new storage
bottle can be used to wash the cord pieces).
3. Place one piece in a new non-coated 100-mm dish. While
holding the UC piece with surgical tweezers, cut it longitudi-
nally with a sterile scalpel to expose the Wharton’s jelly (WJ)
and then slice it into 0.5–1 cm2 pieces.
4. Ten to fifteen pieces (explants) can be transferred per dish into
a pre-labeled 100-mm dish coated with CELLstart.
5. Plate the umbilical cord explants on the bottom of the plate
and wait 2–5 min before covering slowly with 10 ml Stemgro
medium supplemented with Gentamicin/Amphotericin B.
6. Set as many explants as possible. Unused UC discard as medical
waste.
7. Place dishes into tissue culture incubators at 37 C.
3.3 MSC Derivation 1. The medium (Stemgro with Gentamicin/Amphotericin B) in
explant culture needs to be exchanged every 2–3 days.
2. The cells are ready for subculture about 10–14 days after initial
outgrowths were observed.
3. Remove remaining explants and discard them into medical
waste.
4. Wash outgrowths in each 10-mm dish with 5 ml PBS,
Ca2+/Mg2+-free
5. Add 5 ml TripLE in each 10-mm dish. Incubate 3–5 min at
37 C. Detach the cells with vigorous pipetting or, if needed,
scrape the cells off with cell scraper. Add equal amount of
DMEM and transfer into 15- or 50-ml conical tube. Pool cell
suspension from up to four plates in one 50-ml tube.
6. Spin down for 5 min at 700  g. Pool pellets from all tubes and
resuspend in 10-ml Stemgro with Gentamicin/Amphotericin B.
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7. Count cells using a hemocytometer. This number is population
doubling (PD) ¼ 0.
8. Plate the cells in T75 coated with CELLstart in 10 ml Stemgro
with Gentamicin/Amphotericin B. Approximate density for
optimal growth should be 7,000 cells/cm2 (525,000
cells/T75). Lesser density may slow cell proliferation (see
Note 8).
9. Change medium every 2–3 days. Use Stemgrow w/o Genta-
micin/Amphotericin B (see Note 9).
10. Once when the cells reach 80 % density, repeat steps 4–8 if
needed. Target is to have 2  107 cells in total.




1. For cryopreservation, cell monolayer is washed with PBS and
incubated in TrypLE for 3–5 min at 37 C. TrypLE is then
diluted with an equal amount of pre-warmed DMEM. Separate
20 μl for cell counting before centrifuging the cells at 700  g
for 5 min.
2. The cell pellet is then resuspended at a concentration of 1
 106 cells/ml with Cryostor CS10. Add 0.5 ml in each cryo-
vial (500,000 cells in 0.5 ml/vial). Cryovials should be placed
inside precooled Mr Frosty (see Note 10)
3. Place Mr Frosty at 20 C for 2 h and then in 80 C for
another 2 h. After that, transfer the Cryovials from the freezer
into liquid nitrogen dewar.
4 Notes
1. Assure that you have the following information:
(a) Copy of signed consent.
(b) Time of delivery.
(c) Hospital ID number.
(d) Results of tests for: HIV1/HIV2, HepA, HepB, HepC,
HTLV1/2, and Syphilis tests. The mandatory tests are
different from country to country; assure that you follow
regulations set for your country.
(e) Ask if there is clean medical history. If not, write down the
conditions.
2. UC can be collected from healthy donors either after vaginal
delivery or from Caesarean section deliveries. UC obtained
from Caesarian sections are sterile and risk of contamination
in the culture is low in comparison with UC collected from
natural vaginal deliveries.
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3. The tissue carrier bag should not be carried in public transport.
Private car, hired car, or specialized courier services should be
used to transport the tissue carrier bag containing the UC
between the collection site and the laboratory.
4. Avoid drying of coated surface.
5. Each isopropanol freezing cryobox can hold 18 cryovials.
Check level of isopropanol in each cryobox before usage. If
not sufficient, fill it up to the fill line
6. Isopropanol, disposable culture, and plasticware of the equiva-
lent quality can be purchased from different manufacturers
without altering the outcome of the procedure.
7. If you are not sure that PBS is supplemented with antibiotic/
antimycotic mix, wash the cord 3 in 150 ml of PBS supple-
mented with antibiotic/antimycotic mix, gently stirring for
5 min each time.
8. Use smaller vessels if needed (i.e., T25).
9. Since all cells were mixed at step 6 (Section 3.3), the medium
sample can be taken from any of culture flasks and it will
represent the whole population. The following two tests are
recommended:
(a) To assess sterility of the culture, spread 1 ml of spent
medium w/o Gentamicin/Amphotericin B in which cells
were at least 48 h and spread over agar plate and send to
microbiology laboratory for analysis.
(b) For testing mycoplasma, plate 10,000 cells in Maktek
dish and stain with Hoechst 24 h later.
10. Do not leave cells in cryopreservant for extended period at
room temperature. That will affect their viability upon
thawing.
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Aim: Umbilical cord contains, within Wharton’s jelly (WJ), multipotent mesenchymal 
stromal/stem cells (MSCs) of fetal origin that can be isolated and expanded in vitro 
with a minimal manipulation and very high efficiency. Our aim was to develop a highly 
reproducible protocol that has the unique potential to be scaled up and adapted to 
cGMP requirements for the use in cellular therapy. Results: We found that derivation 
of WJ MSCs under defined conditions in low oxygen resulted in several folds higher 
populations of MSCA-1+ cells (6.0–19.2%) when compared with WJ MSCs derived in 
the presence of serum (0.1–2.8%) or clinical-grade bone marrow (BM) MSCs cultured 
under atmospheric O2 (20%). We demonstrate that WJ MSCs derived following our 
protocol display antiproliferative activity similar to clinical-grade BM MSCs. We also 
show that these WJ MSCs can be differentiated into adipo-, chondro- and osteo-
genic lineages. Conclusion: Easy accessibility, abundance and genetic ‘naivety’ make 




Traditional isolation of mesenchymal stem 
cells (MSCs) from bone marrow (BM) is 
dependent on adherence to tissue culture 
plastic. When mononuclear cells from BM 
aspirate are plated in a dish, MSCs will 
attach and in approximately 2 weeks form 
colonies of fibroblast-like cells that can be 
propagated in vitro in either serum or platelet 
lysate supplemented culture medium [1]. The 
method is still widely used even though yield 
is very low – only about one in 80,000 plated 
cells are MSCs. Extensive characterization of 
cell surface markers on BM MSCs led to the 
discovery of multiple prospective ‘markers’ 
that were actually not really MSC-specific, 
although could enrich yield, if used for puri-
fication of BM aspirate before cell plating [2]. 
Among them, CD271 and MSC antigen-1 
(MSCA-1) seem to be the most promising, 
increasing yield of colony forming units 
over >100-fold [3–7]. MSCA-1, which was 
previously associated only with cells of the 
osteoblasts lineage may, therefore, also rep-
resent a marker of multipotent BM stromal 
stem cells [7].
Donor procurement makes the logistics 
of obtaining BM as a source of MSCs com-
plicated. Although BM MSCs from adult 
donors still have satisfactory abilities to be 
used for regenerative medicine purposes, 
from the manufacturing prospective, the 
best donors are in the pediatric age range. 
In addition, the procedure requires planning 
and involves some pain for the donor. There-
fore, the MSCs therapy field is constantly 
looking for alternative sources. Among the 
various options (peripheral blood, placen-
tal, amniotic, dental pulp and nasal mucosa, 
among others), adipose tissue-derived (AD) 
MSCs have proven to be the most suitable, 
although a somewhat restricted, source for 
cell therapies [8]. Since for allogeneic therapy 
AD MSCs are harvested from people with 
extra fat tissue undergoing cosmetic surgery, 
there is a plausible preoccupation that the 
Wharton’s jelly mesenchymal stromal/stem 
cells derived under chemically defined 
animal product-free low oxygen conditions 
are rich in MSCA-1+ subpopulation
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abnormal metabolic environment related to excessive 
body weight bears consequences for these cells, per-
haps rendering them unsuitable for clinical use on 
multiple recipients [9]. Ideally, the cells for allogeneic 
therapy on multiple recipients should be isolated from 
a healthy young donor, with a clean, well-documented 
health history. Cord blood and umbilical cord (UC) 
are clearly an obvious choice. They are easily obtain-
able shortly after birth and therefore less likely to con-
tain acquired, potentially deleterious mutations con-
tained in cells derived from adult tissues. Nevertheless, 
the possible transmission of pathogens from mother to 
child necessitates a careful screening of donors.
Indeed, in the last few years, stromal cells isolated 
from UC’s Wharton’s jelly (WJ), are becoming more 
and more popular as a potentially promising alterna-
tive source for cellular therapy. Their advantage in 
comparison with BM MSCs is in the number of cells 
obtainable, extended retention of stem cell properties 
in vitro and the reported presence of surface markers 
involved in immune tolerance [10–14]. A subpopulation 
of WJ MSCs expressing CD29, CD73, CD90 and 
CD105 and negative for CD34, CD45 and HLA-DR 
displayed low immunogenicity and could be isolated 
in large numbers form >90% of UC [14]. Earlier studies 
demonstrated that WJ MSCs secrete IL-6 and VEGF, 
cytokines known for their role in immunosuppres-
sive activity of MSCs, and are negative for immune 
response-related co-stimulatory molecules CD40, 
CD80 and CD86, suggesting further their therapeutic 
potential [14].
WJ is composed of water (90%), sulphated glycos-
aminoglycans (GAGs) and a collagen-rich 3D extra-
cellular matrix (ECM) network. The most abundant 
GAG is hyaluronic acid (∼70%), whereas collagen 
type I and III are more prevalent than IV, VI and VII 
[15]. The composition of the 3D matrix suggests three 
distinct zones, sub-amnion, WJ per se, and perivascular 
zone, and even though different types of stromal cells 
are dispersed in different zones, the term WJ MSCs is 
often extended to all UC stromal cells [16]. They share 
common features with MSCs from adult tissues, such 
as being positive for CD44, CD73, CD90, CD105, 
α-smooth muscle actin and vimentin [17,18]. In spite of 
recent surge in publications, there is very little, or no, 
information about CD271 and MSCA-1 in WJ MSCs.
Methods
UC collection
The National Health Service Research Ethics Com-
mittee approved the protocol (12/NE/0371). Follow-
ing informed consent, UCs were collected from Cesar-
ean section deliveries of otherwise healthy women 
at the gestational age ≥37 weeks. After delivery and 
inspection of placenta and UC by a nurse, a 10–20 cm 
piece of the UC was cut and placed immediately inside 
a sterile 100-ml bottle. The cord was washed twice to 
remove remaining blood in warmed PBS supplemented 
with antibiotics and antimycotic (Life Technologies, 
NY, USA) and processed for explant culture in ≤4 h.
Plating UC explants
The cords were transferred into a 145-mm dish, cut 
into three to four smaller pieces and thoroughly 
washed with PBS. The cord was cut longitudinally 
with a sterile scalpel to expose WJ and then sliced 
into 0.5–1 cm2 pieces. A total of 10–12 blood vessel-
free pieces (explants) were transferred, inner side of 
the explant facing the bottom of the dish, per a pre-
labeled 100-mm dish coated with CellSTART (Life 
Technologies). To facilitate the attachment of the 
explants to the plastic surface, they were left exposed 
to air for 5–10 min before adding 15 ml of cell cul-
ture medium [19]. The medium was either StemGro® 
hMSC Medium (Corning) or DMEM supplemented 
with 10% fetal calf serum (FCS; Hyclone, UT, USA). 
The plates with explants were then transferred to the 
incubator (Thermo Scientific Heraeus®, MA, USA) 




. The initial 
evaluation of suitable conditions for the long-term WJ 
MSC cultures under defined low O
2
 were performed 
within a gas environment-regulated workstation (SCI-





 and 75% relative humidity.
WJ stromal cells derivation
Explant media was changed every 3 days until cell out-
growth was observed under the microscope. The cells 
were allowed to expand for an additional 7–10 days 
before the first passaging.
To passage the cells, cell monolayers were washed 
with PBS (Invitrogen, Paisley, UK) and incubated in 
Tryple Select (Invitrogen) for 3–5 min at 37°C. Tryple 
was then diluted with an equal amount of prewarmed 
DMEM (Invitrogen). Cells were centrifuged for 5 min 
and the cell pellet resuspended in complete media for 
replating or in a freezing solution for cryopreservation. 
The cells were passaged at 60–80% confluence.
For cell counting, the cells were completely resus-
pended in growth medium and counted using a 
hemocytometer (Hausser). Population doublings 
were calculated according to the formula: PD = [log 
(A/B)]/0.301, where A is the number of cells that were 
harvested and B, the number of cells seeded into the 
plate. The first harvest from explants is termed P0.
Trypan blue was used routinely to assess cell sur-
vival when the cells were counted for passaging or flow 
cytometry analyses.
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Cells grown under standard conditions were fro-
zen in 10% DMSO (Sigma-Aldrich, MO, USA) in 
fetal bovine serum (FBS), whereas cells grown under 
defined xeno-free (XF) conditions were frozen in 
Synth-a-Freeze® (Life Technologies) and stored in 
liquid nitrogen.
Flow cytometry analyses
Expression of cell surface molecules was assessed using 
a FACS CANTO II (BD, Oxford, UK). To this pur-
pose, 1 × 106 cells were resuspended in 100 μl of ice-
cold PBS supplemented with 10% FBS then mixed 
with the appropriate primary antibody 1:50 and then 
incubated in the dark for 15 min at room temperature. 
After washing with PBS, the cells were resuspended in 
500 μl of ice-cold PBS with 10% FBS. The data were 
analyzed using the DIVA software. All antibodies used 
in flow cytometry were purchased from Miltenyi Bio-
tec (Cologne, Germany): PE-conjugated anti-CD34, 
anti-CD73 and anti-MSCA-1, APC-conjugated anti-
CD56, anti-CD29 and anti-CD105, FITC-conjugated 
anti-CD44, anti-CD90 and anti-CD271, and Vio-
Blue-conjugated anti-CD45. Titration was done for 
each of antibody used and unstained cells were used as 
negative control. Fluorescence minus one (FMO) was 
also performed to avoid any nonspecific binding.
Acute myeloid leukemia cell line Katsumi, used 
as a CD34+CD45+ control for flow cytometry, was 
a kind gift from Eric So (King’s College London, 
UK). The cells were cultured in RPMI-1640 medium 






Clinical grade human BM MSCs were manufac-
tured according to the validated GMP protocol from 
the BM aspirates of healthy individuals donating BM 
for their siblings. Donors were consented to release 
unused materials for research. Briefly, 2 ml of BM 
unfractionated cell suspension was plated at a density 
of 10–25 × 106/636 cm2 in α-modified Eagle’s medium 
(αMEM) supplemented with 5% human platelet lysate 
and incubated for 3 days at 37°C in 5% CO
2
. Non-
adherent cells were then discarded and the remaining 
cells left to grow until confluence (90–100%). After 
usually 3 weeks, MSCs were detached with Tryp-
sin 0.05% and EDTA 4Na 0.2 g/l. BM MSCs were 
distributed for compassionate use under the hospital 
exemption scheme (EC No 1394/2007).
Differentiation assay
To assess adipogenenic potential of WJ MSCs 
derived under defined XF conditions, the cells were 
cultured first under standard conditions for 3 days. 
The medium was then replaced with supplemented 
complete STEMPRO® adipogenesis differentiating 
medium (GIBCO®, Invitrogen) and changed every 
3–4 days for 14 days. The cells were fixed with 4% 
paraformaldehyde for 30 min and to detect cellular 
lipids incubated for 20 min in 1:100 dilution of Lipid-
TOXTM Green Neutral Lipid Stain. Samples mounted 
in VECTASHIELD® (Vector, CA, USA) were exam-
ined under a Nikon epifluorescence microscope. Nuclei 
were visualized with Hoechst 33342 (Invitrogen).
To assess chondrogenic potential of WJ MSCs 
derived under defined XF conditions, cells were seeded 
at a density of 2 × 104 cells/cm2 and cultured for 21 
day in StemGro supplemented with 2 mM L-gluta-
mine, 347 μM L-Proline, 100 nM dexamethasone, 1% 
insulin–transferrin–selenium solution, 137 μM ascor-
bate-2-phosphate and 0.38 μM (10 ng/ml) recombi-
nant human TGF-β1/3 (PeproTech, Hamburg, Ger-
many). Medium was changed every 3–4 days. Cells 
fixed in 4% paraformaldehyde were stained with 1% 
Alcian Blue solution to detect glycosaminoglycans.
To assess osteogenic potential of WJ MSCs derived 
under defined XF conditions, the cells were seeded at 
a density of 2 × 104 cells/cm2 and cultured for 21 day 
in StemGro supplemented with 2 mM L-glutamine, 
100 nM dexamethasone, 50 μM ascorbate-2-phos-
phate and 2.5 mM β-glycerophosphate. Medium was 
changed every 3–4 days. Cells fixed in 4% paraformal-
dehyde were stained with 1% alizarin red solution to 
detect calcium-containing mineral.
The stained samples were examined under Olym-
pus CK40 inverted phase contrast microscope. Images 
were recorded with ProgRes CT5 camera (Jenoptik, 
Thuringia, Germany).
Mitogen-induced proliferation assay
Human peripheral blood mononuclear cells (PBMCs) 
were isolated from leukocyte cones purchased from the 
National Blood Service (Colindale, UK). Leukocyte 
cones were diluted 1/1 with PBS (Invitrogen Life Tech-
nologies) and layered on Histopaque (Sigma-Aldrich) 
for density gradient separation.
PBMCs proliferation assays were performed in 0.2 ml 
of medium (RPMI supplemented with 10% FBS and 
penicillin/streptomycin) per well of 96-well flat-bot-
tom plates (Costar®, Sigma-Aldrich). WJ MSCs from 
four donors derived under defined XF conditions and 
clinical-grade BM MSCs from three donors were plated 
overnight at serial dilutions. A total of 5 × 105/well 
PBMCs were then added to MSCs to obtain co-cultures 
with increasing PBMC/MSC ratios from 10:1 to 80:1. 
PBMCs were then stimulated with 5 μg/ml phyto-
hemagglutinin (PHA; Sigma-Aldrich) and after 72 h 
proliferation was measured by incorporation of radio-
labeled [3H]-thymidine (TdR) during the final 18 h 
of incubation. Briefly, cell cultures were pulsed with 
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0.5 μCi/well of [3H]-TdR (Amersham, UK) 18 h before 
harvesting onto glass fiber filter mats (Wallac, Perkin-
Elmer, MA, USA) using a 96-well plate automated cell 
harvester (Skatron; Molecular Devices, CA, USA). 
Scintillation fluid was added and [3H]-TdR incorpora-
tion was measured by liquid scintillation spectroscopy 
on a β-counter (Wallac). The results were expressed in 
counts per minute (cpm) or percentage of control pro-
liferation for triplicate cultures. Cultures of stimulated 
PBMCs without MSCs were used as positive control.
Statistical analyses
Statistical analyses to determine differences between 
STD and XF conditions were carried out by unpaired 
t-test unless otherwise noted. Differences were 
considered significant when p < 0.05.
Results
WJ MSCs grown from UC explants under XF 
conditions are morphologically similar to 
clinical-grade BM MSCs
Overall, after several passages WJ MSCs were spindle 
shaped with a flat polygonal morphology characteristic 
of BM MSCs (Figure 1A). Early evidence of WJ MSCs 
growth from the UC explants was typically observed 
within 8–11 days (9.3 ± 0.3) following initial plating 
under standard conditions (STD; 10% FBS/DMEM) 
and 10 to 14 (12.1 ± 0.5) for chemically defined, XF 
conditions (Figure 1B). Population doublings were cal-
culated between the two first passages (P1 and P2) to 
establish the proliferative rate among the conditions 
used. No significant cell death was observed (>90% of 
trypan blue-negative cells at any experiment). The assay 
demonstrated that the cells cultured under STD condi-
tions have a significantly higher proliferative rate than 
those under XF conditions (40.8 ± 4.8 vs 55.2 ± 2.6 h; 
n = 7; Figure 1C).
WJ MSCs isolated & grown under XF conditions 
have capacity of multipotent stem cells
First, we wanted to determine whether the isolated stro-
mal cells (PD 5) have differentiation potential into the 
three mesenchymal lineages by testing their response 
to adipogenic, chondrogenic and osteogenic induction 
media. After 2 weeks of culture in adipogenic medium, 
we could detect fat droplets, while it took 3 weeks to 
induce Alcian Blue-positive glycosaminoglycan depo-
sitions (cartilage) or mineralized nodules (bone) by 
Alizarin Red staining (Figure 2A). Control cells cul-
tured under chemically defined XF conditions without 
the addition of differentiation supplements showed no 
change in cell morphology and no cells were positive 














































Figure 1. Derivation of mesenchymal stem cells from 
umbilical cord explants. (A) The cells in initial outgrowth 
from attached umbilical cord (UC) explants grown 
under STD conditions (10% fetal calf serum/DMEM) 
looked more like typical fibroblasts, whereas cells 
grown under chemically defined XF conditions were 
less elongated and never as tightly packed as cells in 
standard culture. Interestingly, after three passages, the 
WJ MSCs cultured under XF conditions resembled more 
phenotypically clinical-grade BM MSCs than WJ MSCs 
cultured under STD conditions. (B) First outgrowth from 
UC explants. The first outgrowth was observed sooner 
(9.3 ± 0.3 days; n = 7) under STD than under XF conditions 
(12.1 ± 0.5 days; n = 8). The p-value was analyzed by 
two-tailed unpaired t-test with significant difference 
observed (*p ≤ 0.05). (C) Population doubling time of 
WJ MSC (P1–P2). The mean doubling time of cells derived 
under STD condition was shorter (40.8 ± 4.8 h; n = 7) than 
under XF conditions (55.2 ± 2.6 h; n = 7). The p-value was 
analyzed by a two-tailed unpaired t-test with significant 
difference between the groups (*p ≤ 0.05). 
BM: Bone marrow; MSC: Mesenchymal stem cell; 
STD: Standard; WJ: Wharton’s jelly; XF: Xeno-free.
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Immunomodulatory potential of WJ MSCs 
isolated & grown under defined XF conditions
MSCs are known for their ability to exert potent 
immuno suppressive and immunoregulatory effects 
on a variety of cell types mediating both adaptive 
and innate immunities [20]. Next, we compared the 
immunomodulatory effect of clinical-grade BM MSCs 
(n = three donors) and WJ MSCs isolated and grown 
under XF condition (n = four donors) by adding them 
to PHA-stimulated PBMCs. WJ MSCs inhibited 
PHA)-stimulated PBMCs proliferation in a dose-
dependent manner in a similar fashion as BM MSCs, 
although there was a significantly higher antiprolifera-
tive activity at 1/20 ratio (Figure 2B). These data sug-
gest that WJ MSCs isolated and grown under XF con-
ditions retain similar immunosuppressive activities to 
the ones originally described in BM MSCs.
WJ MSCs subpopulations profile is dependent 
on culture conditions
As the next step of characterization, we assessed the 
effect of chemically defined, animal product-free cul-
ture conditions on WJ MSCs surface marker profile 
(CD29, CD34, CD44, CD45, CD56, CD73, CD90, 
Figure 2. Characteristics of Wharton’s jelly mesenchymal stem cells. (A) Adipogenic, chondrogenic and osteogenic 
differentiation of WJ MSCs. Cells rich in intracellular lipid droplets visualized with a fluorescent LipidTOX™ Green 
Neutral Lipid Stain indicate successful adipogenic induction. Cartilage proteoglycans detected with 1% Alcian Blue 
after chondrogenic and calcium phosphate mineral accumulation detected with 1% Alizarin red after osteogenic 
induction confirmed the multipotent nature of WJ MSCs. (B) Immunomodulatory potential of WJ MSCs. WJ 
MSC (n = four donors) inhibited phytohemagglutinin-stimulated human PBMC proliferation in dose-dependent 
manner in a similar fashion as BM MSC (n = 3 donors), with significantly higher antiproliferative activity at 
20/1 ratio. The relative proliferation at each PBMC/MSC ratio was calculated as percentage of the proliferation 
obtained in the positive control as described by the following formula: A/B × 100, where A is the proliferation at 
one specific PBMS/MSC ratio and B is the proliferation of the corresponding PBMC/MSC ratio, but in the absence 
of phytohemagglutinin (negative control), and C is the proliferation of the positive control. The percentage of 
inhibition was then calculated by subtracting the percentage of proliferation to 100 (maximum of inhibition). 
Statistics: two-tailed unpaired t-test. 95% CI; *p < 0.05. WJ MSC used in the assay were PD 5–6, whereas BM MSC 
were at P2 or P3. 
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Figure 3. Xeno-free culture conditions induce MSCA-1 expression (see facing page). (A) Expression profile of WJ MSCs’ surface 
markers. XF (red) and STD (blue) were negative for hematopoietic stem cell markers CD34 (mucosialin, gp 105–120) and CD45 
(leukocyte common antigen, Ly-5). Similarly to BM MSCs (97.7%), nearly all WJ MSCs from all five donors expressed CD29, regardless 
of culture conditions (98.4 ± 0.4% of cells under STD vs 98.7 ± 0.3% under XF conditions). CD44 expression also did not differ 
regardless of donor or culture conditions (BM MSCs: 97.4%, STD: 96.1 ± 1.6%, XF: 98.2 ± 0.5%). In contrast, CD56 expression varied 
ostensibly from donor to donor (range 5.0–27.6% under XF conditions; range 21.3–82.9% under STD conditions). CD73, ecto-5’-
nucleotidase, has been expressed in almost the entire population of clinical-grade BM MSCs (97.9%) and WJ MSCs cultured under 
XF conditions (98.7 ± 0.3%), whereas WJ MSCs cultured under STD conditions were about 25% less positive for CD73 (74 ± 8.8%). 
CD90 expression, also known as thymocyte differentiation antigen (Thy-1), was in general lower in WJ MSCs (XF: 20.2 ± 5.6%; STD: 
38.6 ± 6.4%) than in BM MSCs (65.3%), varying among donors regardless of the condition of culture (i.e., 7.2% in donor #14 to 33.9% 
in donor #10 under XF conditions). A higher proportion of BM MSCs were positive for CD105, endoglin, (97.4%) than WJ MSCs. 
Although CD105+ cells varied amongst donors, it was found generally lower in WJ MSCs cultured under XF conditions (57.6 ± 4.3% in 
XF vs 80.28 ± 7.7 in STD). CD271, nerve growth factor receptor (NGFR) was detected only in a very small subpopulation of WJ MSCs 
(0.0–3.9%) regardless of culture conditions. MSCA-1, however, displays a curious pattern. Whereas this marker was barely detectable 
in BM MSCs (0.1%) and in WJ MSCs cultured under STD conditions (0.13 ± 0.1%), more than 13.5–38.8% of cells were positive under 
XF conditions. Donor #9 was an exception with only 4.4% MSCA-1+ cells under XF conditions. An unpaired two-tailed t-test was 
performed for statistical analyses (n = 4; *p ≤ 0.05). All analyses on WJ MSCs presented here were performed at PD4–5 for each of 
donors. (B) MSCA-1 expression is induced by exposing WJ MSCs to XF conditions. WJ MSCs derived and expanded under STD condition 
(n = 2 donors) were exposed to XF condition for 14 days (STD–XF), which was sufficient to significantly induce an increase of the 
MSCA-1+ subpopulation from 0.1 to 0.9% in donor #12 and from 0 to 9.9% in donor #14. 
BM: Bone marrow; MSC: Mesenchymal stem cell; STD: Standard; WJ: Wharton’s jelly; XF: Xeno-free. 
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CD105, CD271 and MSCA-1) in cells isolated from 
five donors (Donor ID: #9, #10, #11, #12 and #14). 
Approximately half of the explants from each UC were 
cultured under standard (STD) conditions (DMEM 
supplemented with 10% FCS), whereas the other half 
were cultured under chemically defined XF condi-
tions. Kasumi cells were used as positive control for 
hematopoietic markers. Clinical-grade BM MSCs were 
used for comparison of the expression of cell surface 
molecules with WJ MSCs derived under STD and XF 
conditions (Figure 3A).
The profiling of cell surface markers from five inde-
pendent donors, cultured under two different condi-
tions, confirmed that WJ MSCs isolated in this study 
expressed all MSC markers seen in BM MSCs. Sig-
nificant differences in the expression of CD56, CD73, 
CD105 and MSCA-1 were noted between WJ MSCs 
cultured under STD and XF conditions. Interestingly, 
it seems that XF condition favors the expression of the 
MSCA-1 marker, which was barely detectable in STD 
conditions or in clinical-grade BM MSCs. Neverthe-
less, there were large differences in the size of MSCA-1+ 
subpopulation amongst donors (donor #9 [4.4%] vs 
the other four donors (13.5–38.8%). Neither age nor 
any obvious health-related condition could be linked to 
variations in size of MSCA-1+ population (Figure 3B). 
Expression profile did not vary over the time spent in 
culture; there were no difference between cells at PD 
4–5 (Figure 3B) and PD 9–11 (data not shown).
Isolation & expansion of MSCA-1+ 
subpopulation is dependent on culture 
conditions
To confirm that chemically defined XF culture condi-
tions described here selectively privileged the expansion 
of MSCA-1+ cells, we transferred WJ MSCs derived 
and expanded under STD conditions (n = two donors) 
into defined XF medium for 14 days and assessed 
the proportion of MSCA-1+ cells. For both donors, 
the numbers of MSCA-1+ cells increased from 0.1 to 
0.9% in donor #12 and from undetectable (0%) to 
9.9% in donor #14. Since population doubling time of 
WJ MSCs under XF conditions is slightly over 2 days 
(55.2 ± 2.6 h; Figure 1C) and the cells were cultured for 
only 14 days, this increase is likely due to stimulation 
of MSCA-1 expression, not higher cell proliferation 
of already present MSCA-1+ cells. The cells cultured 
in parallel under STD conditions had no detectable 
increase of the MSCA1+ subpopulation (data not 
shown).
Discussion
In this study we characterized the features of MSC 
isolated from UC explants under chemically defined 
XF conditions. For isolation of the MSCs, we opted to 
use an explant technique because aside from being less 
harsh for cells and less cumbersome for researchers, in 
the long run it is much more cost effective. In addi-
tion, we opted to isolate and expand WJ MSCs under 
physiological (‘hypoxic’) culture conditions [21].
Cell outgrowth from the explants was observed 
sooner under STD than XF conditions. Cells also pro-
liferated faster under STD conditions. Neither result 
was surprising – STD medium contains FBS, which is 
by definition rich in growth factors and nutrients that 
stimulate cell growth and proliferation.
Thorough comparative phenotype analysis between 
UC tissue in in vivo and in vitro expanded stromal 
cells demonstrated protocol-dependent variations 
in the size of subpopulations positive for multiple 
730 Regen. Med. (2014) 9(6) future science group
Methodology    Devito, Badraiq, Galleu et al.
putative MSC markers. After primary culture, how-
ever, there were no significant differences between 
expression of MSC markers in cells isolated by enzy-
matic digestion and by explant isolation [21,22]. We 
found that stromal cells cultured on CellSTART-
coated dishes in StemGro medium at 5% O
2
 have 
unusually large MSCA-1+ subpopulations, whereas the 
cells from the same donor derived and cultured under 
STD conditions (1% FCS/DMEM) had scarcely any. 
Interestingly, in BM MSCs, expression of MSCA-1 is 
restricted to CD271 bright population [5,6]. However, 
this is not the case with WJ MSCs where <5% of cells 
are CD271+ across multiple donors and regardless of 
culture conditions (Figure 3A).
MSCA-1 epitope recognized by W8B2 antibody was 
shown to be identical to a tissue nonspecific alkaline 
phosphatase (TNAP) ectoenzyme expressed at high 
levels in liver, bone and kidney as well as in embryonic 
stem (ES) cells [3]. MSCA-1/TNAP is a repressor of 
NFκB-inducing kinase (NIK) activity and regulates 
both the classical and alternative NFκB-mediated sig-
naling [22,23]. In general, alkaline phosphatases dephos-
phorylate various substrates implicated specifically 
in the promotion of inflammation and in such a way 
exhibit potent anti-inflammatory effects [23,24]. TNAP 
is also involved in skeletal and dental mineralization 
[24–27], as well as in the brain and activity-dependent 
neurodevelopmental processes including myelination 
and synaptogenesis [26,28–30]. Whether presence of 
large MSCA-1/TNAP+ subpopulations in WJ MSCs 
might provide an additional benefit in MSC-based cel-
lular therapy of inflammatory diseases such as graft 
vs host disease [25,27–29], or for development of novel 
cellular therapies for regeneration of skeletal damage, 
remains to be investigated.
Multiple factors can influence the behavior of cells 
in vitro. Indeed, mimicking the physical environment 
of the manipulated tissue in vitro may result in bet-
ter outcomes in both clinical practice and for tissue 
engineering. For example, in vitro fertilization labora-
tories routinely manipulate human embryos under oxy-
gen tension similar to that of the oviduct and uterine 
environments because the embryos cultured in low 
oxygen yield a better quality blastocyst and marked 
improvement in birth rate [30,31]. Similarly, exposure to 
sequential high-to-low humidity environments in an 
air/liquid interface culture mimicking transition from 
an aquatic environment (amniotic fluid) to the open air 
post partum was essential in generating human epider-
mal tissue with a normal epidermal permeability barrier 
equivalent to that of normal skin [32,33]. Hypoxic envi-
ronments were also superior for long-term expansion 
of human adipose-derived stem cells [34], and a physi-
ological oxygen environment has also been beneficial 
for WJ MSCs culture. Moreover, reducing the oxygen 
concentration from ambient to 5% O
2
 increased signif-
icantly the yield of MSCs from WJ without affecting 
their capacity for osteogenic or chondrogenic differen-
tiation [35,36]. Low oxygen also supported a more primi-
tive phenotype of WJ MSCs, which was dependent on 
hypoxia-inducible factor [37,38].
Conclusion
Several protocols for isolation and scale-up of clinically 
compliant WJ MSCs have been published [27,39,40]. Our 
protocol is, however, the first one to combine chemi-
cally defined, animal product-free culture conditions 
with a low oxygen environment. Although it has been 
suggested that the low oxygen may support expression 
of pluripotency marker OCT4 [37], we could not con-
firm this finding under our culture conditions (data 
not shown). Further studies are needed to confirm 
the hypothesis that WJ MSCs isolated by this method 
might have an advantage in replacement of BM and 
AD MSCs for cellular therapy.
Future perspective
The best donors for allogeneic MSC-based cellular 
therapy are in the pediatric age range. Logistically, it 
is difficult to identify suitable child donors and the 
MSC therapy field is constantly looking for alternative 
sources. Among the various options, UC is clearly an 
obvious choice. UC cells are easily obtainable shortly 
after birth and therefore less likely to contain acquired, 
Executive summary
Wharton’s jelly mesenchymal stem cells isolated & grown under xeno-free conditions have capacity of 
multipotent stem cells
•	 Wharton’s jelly (WJ) mesenchymal stem cells (MSCs) derived under defined conditions in low oxygen display 
adipo-, osteo- and chondro-genic potential typical for MSCs.
Immunomodulatory potential of WJ MSCs isolated & grown under defined xeno-free conditions
•	 Immunomodulatory potential of WJ MSCs isolated and grown under defined xeno-free conditions is similar to 
bone marrow MSCs.
Isolation & expansion of MSCA-1+ subpopulation is dependent on culture conditions
•	 Derivation of WJ MSCs under defined conditions in low oxygen resulted in several folds higher populations of 
MSCA-1+ cells that can be easily isolated/purified and further expanded.
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potentially deleterious mutations that are contained in 
cells derived from adult tissues. We believe that over 
time, WJ MSCs will prevail as a source for the cellular 
therapy. Currently, MSCs used for cellular therapy are, 
in general, a mixed population of not well-character-
ized primary cells expanded under conditions that vary 
from laboratory to laboratory. We hope that our work 
highlights that the profile of surface markers on MSCs 
can be changed under different culture conditions and 
that, therefore, there is a need for standardization of 
MSCs used for cellular therapy.
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Sendai Virus-Based Reprogramming of Mesenchymal
Stromal/Stem Cells from Umbilical Cord Wharton’s Jelly
into Induced Pluripotent Stem Cells
Cristian Miere, Liani Devito, and Dusko Ilic
Abstract
In an attempt to bring pluripotent stem cell biology closer to reaching its full potential, many groups have
focused on improving reprogramming protocols over the past several years. The episomal modified Sendai
virus-based vector has emerged as one of the most practical ones. Here we describe reprogramming of
mesenchymal stromal/stem cells (MSC) derived from umbilical cord Wharton’s Jelly into induced plurip-
otent stem cells (iPSC) using genome non-integrating Sendai virus-based vectors. The detailed protocols of
iPSC colony cryopreservation (vitrification) and adaption to feeder-free culture conditions are also
included.
Keywords: Umbilical cord, MSC, Sendai virus, Reprogramming, iPSC, Vitrification, Adaption to
feeder-free culture conditions
1 Introduction
Since its emergence in 2006, reprogramming of somatic cells to
pluripotency has revolutionized cell biology by opening new ave-
nues and bypassing many hurdles researchers were struggling with.
Significant progress has been made from basic research (1), drug
development (2, 3), toxicity screening (4), and disease modeling
(5, 6) to promise for cell therapy. The first patient with macular
degeneration of retina has been treated with induced pluripotent
stem cell (iPSC)-derived retinal pigment epithelium cells in Sep-
tember 2014, in the world’s first iPSC clinical trial in Kobe, Japan.
The original proof-of-concept studies used retroviral transduc-
tion of four transcription factors, Oct4, Sox2, Klf-4, and c-Myc,
later known as the Yamanaka factors, into human dermal fibroblasts
(7). After several weeks in culture, colonies with embryonic stem
cell (ESC)-like morphology and properties emerged in the culture
dish. Known today as iPSC, these cells are the man-made equivalent
to ESC. Much research has compared the two cell types (8), in an
attempt to further pluripotent stem cell biology and to get closer to
the promise of regenerative medicine. Several alternative methods
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have been attempted to increase efficiency or bypass problems with
the original protocol based on genome-integrating viral vectors and
presence of c-Myc oncogene (reviewed in (9)).
The modified Sendai virus method (10) is based on a non-
integrating vector that is also replication deficient, so that upon
several passages, the newly derived iPSC lines become transgene-
free. The reasons for choosing this method include a straightfor-
ward, not labor-intensive protocol, the non-integrating nature of
the vector, low cytotoxicity elicited in culture, broad range of target
cells accessible, and highly reproducible protocol.
The CytoTune®-iPS Sendai Reprogramming Kit (Life Tech-
nologies) contains four SeV-based reprogramming vectors, each
encoding one of the four Yamanaka factors. The kit has been
shown to reprogram several cell types, including human CD34+
cord blood cells (11), nasal epithelial cells (12), dermal fibroblasts
(13, 14), peripheral blood mononuclear cells (15), and
T-lymphocytes (16).
Mesenchymal stromal/stem cells (MSC) are multipotent stem
cells, capable of differentiating into osteoblasts, chondrocytes, and
adipocytes. In the human body exist multiple sources of MSC and
the most frequently used for clinical applications are bone marrow
MSC. They are also present in extraembryonic perinatal tissue,
having been isolated from placenta, fetal membrane, Wharton’s
Jelly (WJ) umbilical cord, cord blood, and amniotic fluid (17).
Routinely discarded after birth, these tissues do not pose any ethical
problems and are readily available for processing (18).
The characteristics of MSCs include plastic adherence and
expression of a set of surface markers including CD90, CD73,
and CD105. Although MSCs have been harvested from multiple
different tissues, recent evidence points toward different properties
based on the tissue of origin. Due to their developmental stage,
extraembryonic derived MSCs are considered to have a broader
differentiation ability and faster proliferation rate than adult tissue-
derived MSCs (19).
Due to their low immunogenicity, one of the main uses of
WJ-MSCs could be allogeneic transplantation. The multipotency
and immunomodulatory properties make them ideal candidates for
this purpose. WJ-MSCs have been reported to be useful in cancer
therapy, liver disease, cardiovascular disease, cartilage regeneration,
and peripheral nerve repair (reviewed in (17)).
We have recently reported a protocol for derivation of
WJ-MSCs under chemically defined (20) and xeno-free conditions
(21). Here we describe in detail the reprogramming protocol of
WJ-MSC into iPSC using the CytoTune Kit from Life
Technologies.
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2 Materials
2.1 Feeder Cells Reprogramming-Qualified Newborn Foreskin Fibroblasts (NuFF;
Global Stem, GSC-3006G) (see Note 1).




5. Phase contrast microscope.
6. Pipette gun.





1. 75-cm2 Flask (Corning; Cat. No.430641).
2. Six-well culture plate (Costar-VWR; Cat. No. 734-1596).
3. P60 (60-mm) TC-Treated Culture Dish (Corning; Cat. No.
430166).
4. Open pulled straws for vitrification (MTR; Cat. No. 19050/
0050).
5. 0.22-μM syringe filter (VWR; Cat. No. 6896-2502).
6. Four-well dish (Nunc; Cat. No. 1256572).
7. 5-ml cryogenic vial (Nalgene; Cat. No. 5000-0050).
8. 100-μl Filter tips (SLS; Cat. No. 171403).
9. 1,000-μl Filter tips (SLS; Cat. No. 171703).
10. γ-Irradiated individually wrapped polystyrene 5-ml pipettes
(Falcon; Cat. No. 357543).
11. γ-Irradiated individually wrapped polystyrene 10-ml pipettes
(Falcon; Cat. No. 357551).
12. γ-Irradiated individually wrapped polystyrene 25-ml pipettes
(Falcon; Cat. No. 357525).
13. γ-Irradiated 15-ml conical tube (BD Falcon; Cat. No.
352096).




1. EmbryoMax® 0.1 % Gelatin Solution (Millipore; Cat. No.
ES-006-B).
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2. Pluriton™ Reprogramming Medium (Stemgent; Cat. No.
00-700).
3. Recombinant Human Fibroblast Growth Factor (FGF) basic
(146 aa) (R&D Systems; Cat. No. 233-FB-025).
4. DMEM, high glucose, Glutamax™, pyruvate (Life Technolo-
gies; Cat. No. 31966-021).
5. MEM Non-Essential Amino Acid Solution (100) (Life Tech-
nologies; Cat. No. 11140-035).
6. Fetal Bovine Serum, ES Cell Qualified (Life Technologies; Cat.
No. 16141-079).
7. CytoTune®-iPS Sendai Reprogramming Kit (Life Technolo-
gies; Cat. No. A1378001).
8. DPBS, Ca2+/Mg2+-free (Life Technologies; Cat. No. 14190).
9. CTS™TrypLE™ Select (LifeTechnologies;Cat.No. 12859-01).
10. KnockOut DMEM/F12 (Life Technologies; Cat. No. 12660-
012).
11. KnockOut™ Serum replacement (KOSR) (Life Technologies;
Cat. No. 10828010).
12. HEPES 1 M Buffer Solution (Life Technologies; Cat. No.
15630-056).
13. Sucrose (Sigma; Cat. No. S0389).
14. Ethylene glycol (Sigma; Cat. No. 10246-6).
15. Dimethyl sulfoxide (DMSO) (VWR; Cat. No. 23500.26).
16. Ethanol, absolute (Sigma; Cat. No. E7023).
17. Rock inhibitor Y-27632 (Sigma; Cat. No. Y0503).
18. Growth Factor Reduced (GFR)Matrigel (BD Biosciences; Cat.
No. 354239).
19. PBS-EDTA (Lonza; Cat. No. BE02-017F).
20. TeSR™-E8™ basal medium (STEMCELL Technologies; Cat.
No. 05941).
21. TeSR™-E8™ supplement (STEMCELL Technologies; Cat.
No. 05942).
22. Alkaline Phosphatase Staining Kit II (Stemgent; Cat. No.
00-0055).
23. ReadyMix™ Taq PCR Reaction Mix (Sigma; Cat. No. P4600).
24. HyperLadder™ 100 bp (BioLine; Cat. No. BIO-33056).
25. Agarose (Life Technologies; Cat. No. 16500).
26. CryoStor CS10 (STEMCELL Technologies; Cat. No.
A10142-01).




1. Coat one T75 flask with 5 ml of 0.1 % Gelatin Solution for 1 h
at 37 C.
2. Plate 3–4  106 NuFF in 30 ml DMEM supplemented with
5 % FBS for 24 h. Wash the cells thoroughly 3–5x with DMEM
without FBS before adding Pluriton medium supplemented
with 4 ng/ml bFGF.
3. Change Pluriton medium supplemented with 4 ng/ml bFGF
daily for 7–10 days. Keep spent medium at +4 C.
4. The last day of conditioning, Pool all spent medium and pass
through a 0.22-μm filter; aliquot the Pluriton-conditioned
medium.
5. Aliquots are kept at20 C and should be used within Pluriton
expiry date.
3.2 Reprogramming Day: 2
6. Coat desired number of wells of a six-well plate dish with 0.1 %
Gelatin Solution, 1 ml per well, for 1 h at 37 C.
7. Plate MSC at several different densities (i.e., 1.5, 2.0,
2.5  105 cells/well) in 2 ml of DMEM high glucose, with





9. Choose 70 % confluent well for reprogramming. The cells from
other wells can be collected and snap frozen as cell pellets
serving as a negative control in Sendai virus detection
RT-PCR later (Section 3.6).
10. Transduce the cells with Sendai virus encoding reprogramming
factors at an multiplicity of infection (M.O.I.) of 3 per cell
according to the certificate of analysis (see Note 3). Follow
the manufacturer’s protocol step by step exactly.
Day: 1–7
11. Refresh medium on a daily basis. High cell death is normal (see
Note 4).
Day: 5
12. Coat with 2 ml of 0.1 % Gelatin Solution, for 1 h at 37 C, two
P60 culture dishes for each well of the six-well dish undergoing
reprogramming.
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13. Plate 3  105 NuFF feeders per P60 in 5 ml of DMEM high
glucose, with Glutamax and pyruvate, supplemented with 10 %
FCS and 1 Non-Essential Amino Acids.
Day: 7
14. Wash cells undergoing reprogramming with 3 ml of DPBS
(Ca2+/Mg2+-free) and incubate in 1 ml TrypLE for 3–5 min
at 37 C. TrypLE is then diluted with 11 ml of pre-warmed
DMEM.Mix well and separate cells into three tubes, 4 ml each.
Centrifuge the cells at 1,200 rpm for 5 min.
15. Resuspend the cell pellet in 5 ml of conditioned Pluriton
medium in each of two tubes and plate cell suspension from
one tube into one P60 with NuFF feeders (see Note 5).
16. Remove supernatant from the third tube and snap freeze cell
pellet. This will be your positive control in Sendai virus detec-
tion RT-PCR later (Section 3.6)
Day: 8–28
17. Exchange medium daily and allow iPSC colonies to grow and
expand in culture.
Day: 18 (see Note 6)
18. Coat the vessel with 5 ml of 0.1 % Gelatin Solution for 1 h at
37 C.
19. Plate 2  104 NuFF feeders per each well in 0.5 ml of DMEM
high glucose, with Glutamax and pyruvate, supplemented with
10 % FCS and 1 Non-Essential Amino Acids.
20. Refresh culture medium every 2–3 days.
Day: 21–28
21. Primary iPSC colonies from one of two P60 dishes with
the most uniform and compact cells are manually picked
(see Note 7) and passaged onto NuFF feeder cells in 0.5 ml
Pluriton (see Note 8).
22. The second P60 dish is used for assessing reprogramming
efficiency.
23. Collect the cells from the third P60 dish and snap-freeze the





iPSCs cultured on feeder cells were cryopreserved in pieces of about
100–200 cells using the open pulled straw (OPS) vitrification
method (22–24).
For vitrification you have to have prepared the following
solutions:




KnockOut™ SR (KOSR) 4.0
HEPES 1 M buffer solution 0.4
20.0
Mix the components, filter through a 0.22-μM syringe filter
and store at 4 C for up to 7 days.
1 M sucrose solution
1. Mix 3.42 g of sucrose with 6.0 ml ES-HEPES in a 15-ml
centrifuge tube and place in the incubator at 37 C.
2. When the sucrose had fully dissolved, add 2.0 ml of ES-HEPES
and 2.0 ml KOSR. Mix well by flipping the tube.
3. Filter the solution through a 0.22-μM syringe filter and store at
4 C for up to 7 days.






Mix the components and store at 4 C for up to 7 days.
20 % vitrification solution (VS2)
Component Volume (ml)
ES-HEPES 0.75




Mix the components and store at 4 C for up to 7 days.
The procedure goes as follows:
1. Submerge straws in 70 % ethanol for at least 20 min and then
allow them to dry in biosafety cabinet.
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2. Label a 5-ml cryogenic vial with the cell line identification code,
passage number, and the date of freezing, remove the top, and
place in a cane. Place the cane into a container with liquid N2,
ensuring that the 5-ml cryogenic vial and most of the cane are
submerged.
3. Place 500 μl of ES-HEPES in well #1 of four-well dish, CS1 in
well #2, and VS2 in well #3. The well #4 remains empty.
4. Equilibrate the dish in the incubator at 37 C for 10–15 min.
5. Place the dish in the biosafety cabinet and invert the lid.
6. Place several 30–40 μl drops of each VS1 and VS2 on the inner
surface of the inverted lid of the four-well dish in two separate
areas.
7. Cut the colonies to be vitrified with a 21 G syringe needle,
generating a grid-like pattern, which ensures evenly sized pieces.
8. Detach the pieces from the dish by gentle scraping with the tip
of a 200-μl micropipette
9. Transfer the detached pieces into well 1 containing ES-HEPES
using a pipette tip primed with ES-HEPES solution.
10. Set timer for 1 min 25 s (seeNote 9). Immediately transfer 4–8
pieces to one of VS1 drops on the lid.
11. When timer reaches 25 s, transfer them to VS2 using a pipette
tip primed with VS2 solution.
12. When timer reaches 0, aspirate the pieces into a narrow end of
the straw.
13. Hold the straw horizontally with a forceps and dip quickly into
liquid N2 for several seconds and then place into a 5-ml cryo-
genic vial (see Note 10).
14. Repeat the procedure until no pieces are left in the well #1.
15. Put lid on the 5-ml cryogenic vial and transfer into dewer with
liquid N2 for extended storage.
Thawing of the vitrified cells:
1. To thaw vitrified cells, you have to have ready four-well dishes
with feeder cells (see Section 3.2, steps 17–21). A day before
thawing replace feeder medium with Pluriton (see Note 8).
2. Just before thawing, add into the 24-h conditioned medium on
feeders Rock inhibitor Y-27632 in a final concentration of
10 μM. Mix well.
3. Place 500 μl of DMEM into each of two wells of four-well dish.
4. Take straw to be thawed form the liquid N2 and place the tip
directly into well 1 to release frozen pieces.
5. After 30 s, transfer the pieces into well 2.
6. After 5 min, transfer the cells into well with feeders.
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7. Two days later, refresh the medium. There is no need for
adding Y-27632.
3.4 Adapting iPSC to
Feeder-Free
Conditions
1. Thaw GFR-Matrigel stock overnight at 4 C (see Note 11).
2. Check for the presence of any gel formation. If there were no
visible clumps, GFR-Matrigel stock dilute to a final concentra-
tion of 0.34 mg/ml with cold DMEM.
3. Coat one well of a six-well plate with 750 μl of GFR-Matrigel
working solution per well for 1 h at 37 C.
4. Remove the GFR-Matrigel and replace with DMEM until use
(see Note 12).
5. Rinse three to four wells of the iPSC cultured on feeders with
500 μl PBS-EDTA.
6. Incubate the cells with 500 μl PBS-EDTA per well for 3–5 min
at 37 C.
7. When the edges of the colonies visibly detach from the sub-
strate (keep checking under the microscope), remove all PBS-
EDTA.
8. Add 500 μl of complete TeSR-E8 supplemented with 10 μMY-
27632 and detach cells by pipetting up and down.
9. Transfer the suspension from all wells of the same cell line into
one well of a six-well plate pre-coated with GFR-Matrigel.
10. Rinse the four-well dish wells with another 500 μl of medium
and transfer into the same six-well plate well.
11. The following day change the culture medium with complete
TeSR-E8 without Y-27632.
12. Passage cells using PBS-EDTA, by adjusting the volumes




We assess reprogramming approximately 20 days after passaging on
NuFF feeder cells. Leaving the emerging colonies too long will lead
to merger of some of them and will have a negative impact on the
efficiency rate observed. We use Alkaline Phosphatase Staining Kit
II and follow the manufacturer’s recommendation. We count colo-
nies using OpenCFU software.
3.6 Sendai Virus
Detection PCR
1. In our experience Sendai virus becomes undetectable in 100
days of continuous cell culture since viral transduction on day
0 of reprogramming. Collect cells at day 100. Extract RNA
with any commercially available column-based kit or alternative
methods; perform reverse-transcription using any of kits suitable
for nanogram-range of RNA. Negative control: non-transduced
cells (Section 3.2, step 9); positive control: transduced cells 7 day
post transduction (Section 3.2, step 16).
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2. Perform end-point PCR with 5 μl of cDNA in 50 μl Ready-
Mix™ Taq PCR Reaction Mix.
3. Use the following primers to detect for the presence of Sendai
virus vector (10):
β-Actin forward CAA CCG CGA GAA GAT GAC
β-Actin reverse AGG AAG GCT GGA AGA GTG
Sendai virus forward GGA TCA CTA GGT GAT ATC GAG C
Sendai virus reverse ACC AGA CAA GAG TTT AAG AGATAT GTATC
4. Cycling conditions: One cycle of 95 C for 5 min, [95 C 30 s,
55 C 30 s, 72 C 30 s] for 35 cycles, and one cycle of 72 C
for 5 min.
5. Analyze PCR products on 2 % agarose gel. To determine size of
the product, we used 100 bp molecular weight ladder.
6. The expected size of the PCR product is 181 bp for SeV and
455 bp for β-actin.
4 Notes
1. Reprogramming efficiency depends also on quality of the fee-
ders. It is important to choose reprogramming-qualified feeder
cells.
2. Disposable culture and plasticware of the equivalent quality can
be purchased from different manufacturers without altering the
outcome of the procedure.
3. Viral titer varies from vector to vector and from batch to batch
of the CytoTune kit. You will have to calculate for each vector
independently, the specific volume to add per well.
4. Highest cytotoxicity is observed 48–72 h post transduction.
5. Before plating the cells, wash feeders 2 with DMEM/F12 to
remove traces of the FBS.
6. This step does not have to be done exactly at day 18. It could be
done a day or two earlier or later, depending on other work-
load. The main point is that it has to pass 72 h from the plating
before the feeders could be used. The dishes with feeders
should be used within the maximum of 7–10 days after plating.
7. Dissecting and picking colonies could be done with different
tools (needle, Pasteur pipette, loading tip for Western blot-
ting), it depends on personal preferences. Important: change
tools between colonies.
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8. For this step, we also validatedNutriStem™ (Stemgent, Cat. No.
01-005), TeSR™-E8™ with its supplement, and KnockOut
DMEM/F12 (Life Technologies, Cat No 10829-018) with its
supplement (Life Technologies, Cat No 10828-028).
9. It is essential to do this process quickly, following indicated
timing.
10. Do not take the straw out of liquid N2 while doing that.
11. Work on ice. Precool tubes, pipettes, and tips.
12. Do not let GFR-Matrigel dry or results may vary. Just before
use, remove DMEM and plate cells.
13. iPSCs adapted to feeder-free conditions do not require vitrifi-
cation. They can be treated as any other adherent cells. We
cryopreserve them in CryoStor CS10 following the manufac-
turer’s protocol.
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Abstract
Background: Human embryonic and induced pluripotent stem cells (hESC and hiPSC) have
tremendous potential for clinical implementation. In spite of all hurdles and controversy,
clinical trials in treatment of spinal cord injury, macular degeneration of retina, type 1 dia-
betes and heart failure are already ongoing.
Sources of data: ClinicalTrials.gov database, International Clinical Trials Registry Platform,
PubMed and press releases and websites of companies and institutions working on hESC-
and iPSC-based cellular therapy.
Areas of agreement: The initial results from multiple clinical trials demonstrate that hESC-
based therapies are safe and promising.
Areas of controversy: Are iPSC cells safe in the clinical application? Is there a room for both
hESC and iPSC in the future clinical applications?
Growing points: Increasing number of new clinical trials.
Areas timely for developing research: Development of hESC- and/or iPSC-based cellular
therapy for other diseases.
Key words: human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), macular degeneration,
spinal cord injury, diabetes, heart repair
Introduction
Since they were isolated for the ﬁrst time,1 human
embryonic stem cells (hESC) remain at the centre of
controversy.Whereas scientists clearly have seen their
potential in the treatment of debilitating disease, the
regulators and public became widely divided, from
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being very supportive to seeking a regulatory ban on
hESC research. In spite of all the obstacles, the hESC-
based therapies moved to clinical trials very quickly.
Only 12 years later, the ﬁrst patient has been treated
with hESC-based cellular therapy. Just to remind
you, the ﬁrst antibody was commercially produced
in 1978, and the ﬁrst antibody-based treatment was
approved in 1998. It took 20 years to reach that step
and we knew a lot of about antibodies already.
About hESC we did not know anything. ‘The new
kid on the block’, human induced pluripotent stem
cells (hiPSC) seemed to hold even more potential
than hESC.2–4
The review article is aiming to provide an over-
view of the studies conducted in human subjects
using hESC- or iPSC-based cellular therapies in treat-
ment of diseases (Table 1).
Spinal cord injury
Geron
Geron (CA, USA; www.geron.com) is considered to
be the pioneer in the business of hESC and regenera-
tive medicine. For years Geron opened new areas of
research and development and took a lead in bring-
ing hESC towards therapeutic application. The com-
pany exclusively licensed fundamental hESC-related
patents from Wisconsin Alumni Research Founda-
tion and learned how to manufacture several differ-
ent types of functional cells derived from hESC. In
collaboration with researchers at the University of
California, Irvine, Geron had shown that in animal
models hESC-derived oligodendrocyte progenitor
cells (GRNOPC1) could improve functional loco-
motor behaviour after implantation in the injury site
7 days after injury. Histological analysis also pro-
vided evidence for the engraftment and function of
these cells.5 The reliability and reproducibility of
their differentiation protocols for these speciﬁc hESC-
derived GRNOPC1 cells were probably behind the
decision to embark on a risky task: repair of spinal
cord injury.
After the completion of extensive animal toxi-
cology testing, including 24 separate studies in rats
and mice, that required more than ﬁve billion
GRNOPC1 cells, Geron ﬁled a 21 000 page Investi-
gational New Drug (IND) application with the FDA
containing data from the animal and in vitro testing
of the cells to ensure the highest possible degree of
Table 1Ongoing clinical trials with hESC and iPSC
Indication Cell
source
Institution Country Start date Finish date Subjects
Spinal cord injury hESC Geron USA October 2010 July 2013 5
Asterias USA March 2015 June 2018 13
Immunotherapy vaccine for
lung cancer




hESC Ocata USA April 2014 April 2015 Not deﬁned
Stargardt macular
degeneration of retina
hESC Ocata USA July 2012 December 2030 13
UK November 2011 December 2015 16
Dry macular degeneration
of retina
hESC Ocata USA July 2012 December 2030 13
Cell Cure
Neurosciences
Israel April 2015 August 2017 15
iPSC RIKEN CBD Japan October 2013 Not deﬁned 6
Wet macular degeneration
of retina
hESC The London Project
to Cure Blindness
UK August 2015 October 2016 10
Diabetes type I hESC ViaCyte USA September 2014 August 2017 40
Heart failure hESC APHP France June 2013 June 2017 6
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safety of the product before initiating human clinical
trials. In January 2009, Geron received FDA clear-
ance to begin the world’s ﬁrst human clinical trial
of a hES cell-based therapy. On news of the FDA
approval, stocks jumped from $4.81 to $8.05
(68%). However, a few weeks later, when the
company realized that its worldwide license for its
stem cell technology was not valid in Europe, shares
plummeted 16.7%, from $1.30 down to $6.47 in
midday trading in New York. The same month a
group in Israel reported that following neural stem
cell transplantation in Russia, the unexpected devel-
opment of a multifocal brain tumour in the recipient.
Although this was nothing to do with Geron’s
trial, it caused their stock value to drop further.6 In
August 2009 Geron announced that its IND had
been placed on clinical hold by the FDA pending the
agency’s review of new nonclinical animal study
data submitted by the company. In this study, the
injected animals developed a higher frequency of
microscopic cysts in the regenerating injury site.
A year later, on July 30, 2010, the FDA notiﬁed the
company that the clinical hold had been lifted and
the Phase I clinical trial of GRNOPC1 in patients
with acute spinal cord injury could proceed.
The ﬁrst patient was treated at the Shepherd
Center in Atlanta in October 2010. Data on the ﬁrst
two patients with neurologically complete American
Spinal Injury Association (ASIA) impairment scale
grade A thoracic spinal cord injuries were presented
at the two conferences in June 2011. According
to Geron’s press release, these patients received
GRNOPC1 at a dose of 2 million cells, 7–14 days
post-injury, delivered by injection into the lesion site
between T3 and T10, using a specially designed
syringe-positioning device. None had either surgical
complication during or after procedure, nor adverse
events related to the injection procedures or to
GRNOPC1. Low-dose tacrolimus was given for tem-
porary immune suppression from the time of injec-
tion for 46 days, at which point the dose was tapered
and withdrawn completely at 60 days. Initial ana-
lyses showed no evidence of immune responses to
GRNOPC1 through until Day 90, which includes
the 30-day period after complete withdrawal of
immune-suppression. There was also no evidence of
cavitation in the spinal cord at the injury site on MRI
through until Day 180. Following this report, Geron
received clearance from the FDA to expand eligibility
criteria to include patients with injuries down to
T11. In addition, the FDA approved that the current
30-day period between subjects in the trial could be
reduced to 10 days. In October 2011, safety data on
four patients presented at two symposia showed that
the results were fulﬁlling all expectations.
So, why then was Geron switching gears and
closed the promising GRNOPC1 clinical trial only
a month later, in November 2011, and ostensibly
giving up on their stem cell programme, which was
one of the most innovative in the world? The
answer is simple: money. Although the prime goal
of the clinical trial was safety, public expectations
were driven by a Geron’s short movie of a rat with
a spinal cord injury that could walk after being
treated with GRNOPC1. No matter how many
times the Company emphasized that their trial
was speciﬁcally only about safety, almost everyone
expected that the treated patients would walk
shortly after the GRNOPC1 injection. Of course,
this did not happen and Geron’s stock started to
slide. With each new patient enrolled and each day
that passed it became clear that there would be
no miracle, and from January till September 2011
shares dropped nearly 60%.
As a medium size enterprise, Geron did not have
readily available resources to bring a potential drug
from bench to bedside. For example, they conducted
in total 28 animal studies, involving >3500 rodents
and pigs. In the recent economic climate, without
government or Big Pharma wading in to help cope
with enormous regulatory and manufacturing costs,
small and medium enterprises are incapable of
bringing a new drug to market. The fact that even if
injection of GRNOPC1 cells could make people
walk, the costs would leave no room for proﬁt,
did not help Geron’s case. In order to survive, lack
of investment and support forced the company to
do the only sensible thing: temporarily close their
stem cell programme. Their action has brought to
light ethical and social questions about prematurely
ended trials and compromising the contract between
participants and trial sponsor.7
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In total, they treated ﬁve patients 21–32 year-old,
four males and one female. All participants received
2 × 106 GRNOPC1 cells within 2 weeks of injury.
None of them developed antibodies or cellular
immune response to GRNOPC1 through a year post
treatment even though some had complete HLA mis-
match with GRNOPC1; the closes match was 5 out
of 10 alleles. The treatment per se caused no serious
adverse events. However, no motor or sensory
neurological changes were observed.
Asterias
In January 2013, Geron entered into Asset Contribu-
tion Agreement with BioTime (CA, USA; www.
biotimeinc.com) and its subsidiary Asterias Biothera-
peutics (http://asteriasbiotherapeutics.com). The trans-
actions were closed 10 months later with Geron
contributing to Asterias both intellectual property
and tangible assets related to its discontinued hESC
programmes. Asterias received multiple lots of OPC1
cells used in the clinical trial as well as multiple lots
of hESC manufacturing cell banks from which add-
itional lots of OPC1 cells could be made.
In May 2014, Asterias received USD 14.3 million
as a strategic partnership award from the California
Institute for Regenerative Medicine (CIRM) to rein-
itiate clinical development of hESC-derived OPC1
cells, now renamed AST-OPC1, in a dose-escalating
trial. Additional USD 13 million was raised shortly
after in an equity ﬁnancing. With enough money on
the account and a green light from the US FDA,
Asterias has initiated a Phase 1/2a open-label, single-
arm dose-escalation clinical trial and the ﬁrst patient
was treated in Atlanta in June 2015. With the third
patient treated in Chicago in August 2015, the trial
ﬁnalized initial low-dose (2 × 106 cells) safety cohort.
The study, conducted at a total of up to eight centres
in the United States, will test three sequential escalat-
ing doses with highest being 20 × 106 cells. The
AST-OPC1cells will be administered in 13 patients
with sub-acute, C-5 to C-7, neurologically complete
cervical spinal cord injury. These patients are quadri-
plegic, have lost all sensation and movement below
their injury site. AST-OPC1 will be administered 14–
30 days post-injury. Additional information on this
study, including trial sites, can be found at www.
clinicaltrials.gov (ID: NCT02302157) and at the
SCiStar Study Website www.scistarstudy.com
Immunotherapy vaccine for lung cancer
In addition to OPC1 and spinal cord injury, Geron
contributed to Asterias all the documents related to
antigen-presenting dendritic cells GRNVAC1 and
GRNVAC2. GRNVAC2, now called AST-VAC2, is
hESC-derived cancer vaccine designed to stimulate
patients’ immune systems to attack telomerase, a
protein that is expressed in majority of cancers but is
rarely expressed in normal adult cells (http://www.
businesswire.com/news/home/20140911006326/en/
BioTime-Subsidiary-Asterias-Biotherapeutics-Cancer-
Research-UK#.VbR2Y3iyXTR). The vaccine was de-
veloped following successful early phase clinical
trials of a similar, autologous vaccine GRNVAC1,
now called AST-VAC1. GRNVAC1 were autologous
mature dendritic cells transfected with mRNA encoding
human telomerase reverse transcriptase (hTERT) and a
portion of the lysosome-associated membrane protein
LAMP-1. Dendritic cell-based telomerase immunother-
apy GRNVAC1 showed telomerase-speciﬁc immune
responses in 55% of acute myeloid leukaemia and
95% of prostate cancer patients. In September 2014,
Asterias teamed up with the UK charity Cancer
Research UK and its development and commercial-
ization arm Cancer Research Technology to bring
AST-VAC2 into clinical trials in patients with non-
small lung cancer.
Macular degeneration of retina
Ocata (former Advanced Cell Technologies)
Ocata Therapeutics (MA, USA; https://www.ocata.
com) reported derivation of retinal pigment epithe-
lial (RPE) cells from hESC more than 10 years ago.8
At that time, the report did not catch much attention
and nobody could predict that this would be actually
the seminal paper for what is today considered the
ﬁrst hESC-based therapy that successfully demon-
strated clinical beneﬁts in clinical trials.9–11 Two
years later, the group showed reproducible generation
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of RPE cells from 18 different hESC lines.12,13 Fur-
thermore, RPE cells derived from one of the hESC
lines were tested in animal model of retinal disease—
the Royal College of Surgeons rat, in which photo-
receptor loss is caused by a defect in the adjacent
retinal pigment epithelium. The improvement in
visual performance of treated rats was stunning and
in November 2009, the company ﬁled an IND with
the US FDA to treat patients with Stargardt’s macular
dystrophy. The US FDA cleared application a year
later, in November 2010. The IND to treat dry age-
related macular degeneration (AMD), was cleared by
the FDA in January 2011. Shortly after, in July
2011, the ﬁrst two patients, a 77-year-oldwomanwith
dry AMD and a 27-year-old woman with Stargardt’s
macular dystrophy were enrolled at the Jules Stein Eye
Institute at the University of California, Los Angeles,
and about 50 000 RPE cells were administered into
one eye of each patient. Additional information on
these studies can be found at www.clinicaltrials.gov
(ID: NCT01344993, NCT01345006).
About the same time, in June 2011, EMEA grant-
ed orphan medicinal product designation to their
hESC-derived RPE cells and in January 2012, the
ﬁrst European patient suffering from Stargardt’s
macular degeneration was treated at the Moorﬁelds
Eye Hospital in London. Additional information on
this study can be found at www.clinicaltrials.gov
(ID: NCT01469832).
Each of the three studies will enrol 16 patients in
ﬁve cohorts: four low vision cohorts will contain
three patients each, whereas one better vision cohort
will contain four patients. In the low vision cohorts,
the patients will be transplanted with 50 000 (cohort
1), 100 000 (cohort 2), 150 000 (cohort 3) or 200 000
(cohort 4) hESC-derived RPE cells, whereas the
cohort with better vision patients (cohort 2a) was
transplanted with 100 000 cells. Each cohort will
be enrolled sequentially, with the exception of the
better vision cohort, which may be enrolled in paral-
lel with the other cohorts.
Although the results are preliminary and the num-
ber of treated patients is still too small, the initial
data are encouraging. Among 18 patients treated so
far, visual acuity improved in ten, remained the same
in seven and worsen in one.10 In addition, it seemed
that in dry AMD the improvement in visual acuity
has a dose trend—more cells injected, better vision.
This had not been observed in Stargardt’s macular
degeneration patients. Immunosuppression has been
given to the participants in the trials for total of 13
weeks, one week before the treatment and 12 weeks
after. Regardless, no signs of rejection were evident
in follow up.
The company also reported the data from two
Asian patients with dry AMD and two with Star-
gardt’s macular degeneration and one year and
follow up.11 No serious safety issues were noted and
visual acuity improved in three patients, whereas in
one remained stable. Asian patients may carry differ-
ent risk alleles for retinal disorders and the report
suggested that hESC-derived RPE cells seemed to be
safe for them too.
Long-term follow up of 15 years for both dry
AMD and Stargardt’s macular dystrophy trials in the
USA are registered as separate studies at www.
clinicaltrials.gov, NCT02463344 and NCT02445612
respectively. The ﬁrst visit of extended follow up will
be 12 months post-injection. In addition, Ocata is
embarking on a trial in patients with geographic
atrophy secondary to myopic macular degeneration
(ID: NCT02122159 at www.clinicaltrials.gov).
The ﬁrst patient with dry AMD has been enrolled
in the Phase 2 clinical trial in September 2015.
Cell Cure Neurosciences
Cell Cure Neurosciences (Israel; http://www.cell
cureneurosciences.com) was funded as a subsidiary
of Singapore-based ES Cell International. In 2010,
through acquisition of ES Cell International, BioTime
(CA, USA; www.biotimeinc.com) acquired a major-
ity in Cell Cure. Cell Cure generated under xeno-free
conditions a proprietary formulations of hESC-
derived RPE cells OpRegen® and OpRegen-Plus®
and it has an exclusive license agreement with Israeli
pharmaceutical giant Teva Pharmaceutical Industries
(http://www.tevapharm.com) to develop and com-
mercialize the hESC-derived RPE for the treatment
of dry AMD. In October 2014, Cell Cure ﬁlled an
IND application with the US FDA to initiate Phase
I1/2a clinical trial of OpRegen in patients with
hESC and iPSC in clinical trials, 2015, Vol. 116 23




geographic atrophy, the severe type of AMD. Only a
month later the US FDA gave them the green light.
The clinical trial running in Hadassah Ein Kerem
University Hospital in Jerusalem is now recruiting
the patients. The study will enrol 15 patients, divided
in four cohorts, which will, following vitrectomy,
receive 50 000–500 000 RPE cells into subretinal
space. Additional information on this study can be
found at www.clinicaltrials.gov (ID: NCT02286089).
The US FDA has granted Fast Track designation
for OpRegen in September 2015.
The London Project to Cure Blindness
As the result of a partnership between the Moor-
ﬁelds Eye Hospital (www.moorﬁelds.nhs.uk), the
University College London Institute of Ophthal-
mology (www.ucl.ac.uk/ioo), the National Institute
for Health Research (NIHR; www.nihr.ac.uk) and
Pﬁzer (NY, USA; www.pﬁzer.com) under umbrella
named the London Project to Cure Blindness (www.
thelondonproject.org), theﬁrst patientwithwetAMD
was treated in August 2015 and there have been no
complications to date. The trial will recruit 10
patients in total over a period of 18 months. Each
patient will be followed for a year to assess the safety
and stability of the cells and whether there is an
effect in restoring vision.
More recently, The London Project has secured
funding to examine the use of iPSC technology for
transplantation.
RIKEN CBD
Following a successful launching of clinical trials
with hESC-derived RPE cells, Japanese researcher
Masayo Takahashi from Riken Centre for Develop-
mental Biology in Kobe (http://www.cdb.riken.jp/en/),
seized the opportunity and initiated the ﬁrst-in-man
study with iPSC-derived RPE cells. Rigorous in vitro
and preclinical experiments in animals were satisfac-
tory enough for the Japanese Ministry of Health,
Labour and Welfare to give the green light in July
2013 to the open-label study, designed to evaluate
safety of the autologous iPSC-derived RPE cell sheets
in patients with wet AMD. Enrolment started the next
month. The iPSC were generated from a 4-mm skin
biopsy from upper arm, differentiated into RPE cells
and prepared as cell sheets for transplantation. An
estimate for the entire process, Quality Control (QC)
included, has been 10 months for each participant.
Post-transplantation patients will be monitored each
month for 6 months and then every 2 months up to
one year. Follow up examinations will occur once a
year for the next 3 years.
The study is planning to enrol six participants.
The ﬁrst three will be transplanted with the 1.3 mm
× 3 mm RPE sheet, whereas the following three will
receive either larger sheet or multiple smaller sheets.
In case of multiple sheets, the maximum number per
participant will be three. The ﬁrst patient, a 70-year-
old female received the treatment in September 2014.
The patient did not receive any immunosuppression
and 6 month later there were still no signs of rejection
or other adverse effects. However, the study was tem-
porarily halted in March 2015, when the investigators
found three single nucleotide variations (SNVs) and
three copy-number variants (CNVs) present in the
second patient iPSC and not detectable in the original
ﬁbroblasts. Additional information on the study can be
found at http://www.riken-ibri.jp/AMD/english/index.
html, the International Clinical Trials Registry Plat-
form (ICTRP; http://www.who.int/ictrp/en/) under ID:
JPRN-UMIN000011929 and at the Japan Primary
Registries Network (JPRN; http://www.umin.ac.jp/ctr/
index.htm) under ID: UMIN000011929. The promis-
ing result and availability of the iPSC lines homozy-
gous for HLA haplotype14–16 is taking the trial toward
different direction—use of allogeneic iPSC lines.
Type 1 diabetes
Viacyte (former Novocell)
Viacyte (CA, USA; www.viacyte.com), a privately
held company, invested more than a decade to bring
hESC-based therapy for type 1 diabetes from bench
to patients with a goal of achieving long-term insulin
independence without immune suppression. The
company was founded in 1999 under name Novocell
and merged with CyThera and Bresagen in 2004.
Mimicking pancreatic organogenesis in vitro, they
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were able to deduce a protocol to differentiate hESC
into pancreatic hormone-expressing endocrine cells.17
These cells, when implanted into mice, reacted to
glucose stimulation; human insulin and C-peptide
were detected in sera at levels similar to those of
mice transplanted with approximately 3000 human
islets.18 Using surface markers, they were able to sep-
arate pancreatic hormone-expressing endocrine cells
into different subtypes. Enriched pancreatic endo-
derm, CD142+ cells, when transplanted into mice,
gave rise to all pancreatic lineages, including func-
tional insulin-producing cells, demonstrating that
they are indeed pancreatic progenitors.19 Next, the
company developed manufacturing process on a
scale amenable to clinical entry. The cells produced
in such a way, upon implantation in mice, formed
neo-pancreatic tissue sufﬁcient to protect against
streptozotocin-induced hyperglycaemia.20,21 In par-
allel, the company developed Encaptra®, an encap-
sulating drug delivery system made from porous
cell-impermeable membrane. The company ﬁled an
IND and device master ﬁle with the US FDA in July
2014. The application was approved relatively quickly,
only a month later, and the ﬁrst patient was im-
planted with hESC-derived islet replacement product
candidate in October 2014 at University of California
San Diego. The second site at the University of Alberta
Hospitals in Edmonton in Canada was opened in
July 2015.
The product candidate, called VC-01™, is placed
under patient’s skin and actually represents Encap-
tra-250 pouch/device ﬁlled with hESC-derived pan-
creatic precursor cells PEC-01™. After surgical
implantation, the cells differentiate further into fully
functioning insulin-producing β-cells, as well as to
other endocrine cell types that make up the normal
human pancreatic islet. The Phase 1/2 open-label,
dose-escalation study will enrol about 40 participants
with a diagnosis of type 1 diabetes mellitus for at least
3 years. All the patients will be C-peptide negative and
thus have essentially no ability to produce insulin.
They will be divided into two cohorts. The ﬁrst cohort
is sub-therapeutic and each of six participants will
receive two VC-01 implants, placed in the lower
back, aiming to evaluate safety and tolerability. The
patients in the second cohort will receive four to six
dose-ranging VC-01 implants to achieve efﬁcacy. The
participants will be also implanted with sentinels,
Encaptra-20 pouches, which can be periodically with-
drawn from the patients and analysed. Their size is
about 10-folds smaller than VC-01 implant, which is
about half the size of business card (http://www.ipscell.
com/2015/03/viacyte/). Additional information on this
study can be found at www.clinicaltrials.gov (ID:
NCT02239354). Therapy development was supported
substantially by the CIRM (www.cirm.ca.gov) and
JDRF (www.jdrf.org), a global organization focussed
on type 1 diabetes research.
Heart failure
APHP
The world-ﬁrst hESC-based trial for the heart
repair commenced in autumn 2014 in France
under the sponsorship of the Assistance Publique –
Hôpitaux de Paris (APHP; http://www.aphp.fr).
The study is planning to recruit six patients who
have severe left ventricular systolic dysfunction
with left ventricular ejection fraction (LVEF)
≤35% and history of myocardial infarction, older
than 6 months, with a residual akinesia involving
more than 2 out of 16 contiguous segments. A
ﬁbrin patch embedding hESC-derived cardiac-
committed CD15+ ISL-1+ progenitors will be
transplanted into epicardium of the infarcted area
and covered with an autologous pericardial ﬂap.
The ﬂap is designed to provide nutrients to the
underlying graft with the idea of improving via-
bility of embedded cells.22 The objective of this
study is to assess both the feasibility and safety of
this approach. Efﬁcacy will be assessed on the fol-
lowing end points: left ventricular function, via-
bility of the grafted area, functional status and
major adverse cardiovascular events.
The ﬁrst patient, a 68-year-old insulin-dependent
diabetic woman, with an indication for a surgical
anterior myocardial revascularization, has received in
addition to planned coronary artery bypass, also aﬁbrin
patch embedded with hESC-derived cardiac-committed
CD15+ ISL-1+ progenitors. At 3-month follow-up
time point, the patient showed marked improvement.
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Echocardiographic LVEF improved from 26 to 36%.
At the time of the treatment, the patient had
New York Heart Association (NYHA) Class III
symptoms, whereas after the treatment the symp-
toms matched NYHAClass I. Furthermore, the akin-
etic infarct zone, under the patch, has become
moderately hypokinetic.23 Additional information
on this study can be found at www.clinicaltrials.gov
(ID: NCT02057900).
Conclusion
In spite of signiﬁcant challenges, hESC and iPSC-
based cellular therapies are reaching clinical applica-
tion in an extraordinary short time, especially given
challenges and obstacles that at certain time seemed
to be insurmountable. To fully realize their potential,
ﬁrst is necessary to demonstrate their safety and only
then efﬁcacy. This can be achieved only by careful
planning and with adequate resources in a regulatory-
friendly environment. Initial data from all trials are
promising and they are likely to incite new trials for
other diseases. One of the closest to the clinical trial
might be Parkinson’s disease.
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Fig. 1. Genetic pedigree tree. The couple undergoing IVF had only on embryo in this
particular cycle. The embryo carried the mutation and was donated for research.
Fig.
ﬁbe
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(immunostaining)
(Fig. 3)2. Expression of pluripote
rs, visualized with rhodam(tubulin, β3 class III); Mesoderm: ACTA2 (actin, α2,
smooth muscle) (Ilic et al., 2012)bling lines available NoSiWe generated KCL018 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012). Thency markers. Pluripotency is conﬁrmed by immunostaining (Oct
ine-phalloidin (red), are present in both feeders and hES cell colexpression of the pluripotency markers was tested after freeze/thaw
cycle (Ilic et al., 2012). Differentiation potential into three germ layers
was veriﬁed in vitro (Ilic et al., 2012).Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in themeantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to resign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.6) were created on Aug. 10, 2007.
HFEA Code of Practice that was in effect at the time of document
creation: Edition 7 — R.1 (http://www.hfea.gov.uk/2999.html). The
donor couple signed the consent on Oct. 15, 2009. HFEA Code of Practice
that was in effect at the time of donor signature: Edition 8 — R.1. HFEA
Code of Practice Edition 7 — R.1 was in effect until Dec. 09, 2007 and
Edition 8 — R.1 was in effect: Oct. 01, 2009–Apr. 06, 2010.Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007; Ilic et al., 2010). hESC
colonies were expanded and cryopreserved at the third passage.4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress
onies, whereas AP activity (green) is detected only in hES cells. Scale bar, 50 μm.
Fig. 3.Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smoothmuscle actin (red) formesoderm, β-III tubulin (red) for ectoderm andα-fetoprotein (red)
for endoderm. Nuclei are visualized with Hoechst 33,342 (blue). Scale bar, 50 μm.
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Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).Chr1
1














D21S1437 331 335Author disclosure statement
There are no competing ﬁnancial interests in this study.Acknowledgments
This workwas supported by the UKMedical Research Council grants
G0701172 and G0801061. We thank Dr. Yacoub Khalaf, Director of the
Assisted Conception Unit of Guy's and St Thomas' NHS Foundation
Trust and his staff for supporting the research program.We are especial-
ly indebted to Prof Peter Braude and to the patients who donated
embryos.
References
Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N.,
Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Deriva-
tion and feeder-free propagation of human embryonic stem cells under xeno-free
conditions. Cytotherapy 14 (1), 122–128.
Ilic, D., Caceres, E., Lu, S., Julian, P., Foulk, R., Krtolica, A., 2010. Effect of karyotype on
successful human embryonic stem cell derivation. Stem Cells Dev. 19 (1), 39–46.
Ilic, D., Genbacev, O., Krtolica, A., 2007. Derivation of hESC from intact blastocysts. Curr.
Protoc. Stem Cell Biol. (Chapter 1: Unit 1 A.2).
Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S.,
Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic
stem cell lines from frozen embryos in an animal product-free environment. Nat.
Protoc. 7 (7), 1366–1381.
Stem Cell Research 16 (2016) 296–299
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab Resource: Stem Cell LineGeneration of KCL033 clinical grade human embryonic stem cell lineLiani Devito, Anastasia Petrova, Victoria Wood, Neli Kadeva, Glenda Cornwell, Stefano Codognotto,
Emma Stephenson, Dusko Ilic ⁎
Stem Cell Laboratories, Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London and Assisted Conception Unit, Guys' Hospital, London, United Kingdom⁎ Corresponding author.
1. Resource table
Name of stem cell
line
KCL033
Institution King's College London, London, UK









Type of resource Biological reagent: cell line




Pluripotent stem cell markers: NA
TRA-1-81, alkaline phosphatase (A






1) Jacquet, L., Stephenson, E., Coll
Al-Bedaery, R., Renwick, P., Og
2013. Strategy for the creation
banks that HLA-match a target
Med. 5 (1), 10–17.
doi: 10.1002/emmm.20120197
http://www.ncbi.nlm.nih.gov/
2) Canham, A., Van Deusen, A., B
Downie, J., Devito, L., Hewitt, Z
Moore, H.D., Murray, H., Kuna
http://dx.doi.org/10.1016/j.scr.2015.12.047
1873-5061/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 28 December 2015
Accepted 29 December 2015
Available online 15 January 2016The KCL033 human embryonic stem cell linewas derived from a normal healthy blastocyst donated for research.
The ICM was isolated using laser microsurgery and plated on γ-irradiated human foreskin ﬁbroblasts. Both the
derivation and cell line propagation were performed in an animal product-free environment and under current
Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were conﬁrmed
by in vitro assays. The line was also validated for sterility and speciﬁc and non-speciﬁc human pathogens.






ins, R., Patel, H., Trussler, J.,
ilvie, C., Vaughan, R., Ilic, D.,




rison, D.R., De Sousa, P.,
.A., Ilic, D., Kimber, S.J.,
th, T., 2015. The molecular
karyotype of 25 clinical-grade human embryonic stem
cells lines. Sci. Rep. 5, 17258.
doi: 10.1038/srep17258
http://www.ncbi.nlm.nih.gov/pubmed/26607962
3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson,
D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H.,
Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012.
Derivation and feeder-free propagation of human em-
bryonic stem cells under xeno-free conditions.
Cytotherapy. 14 (1), 122–128.
doi: 10.3109/14653249.2011.623692
http://www.ncbi.nlm.nih.gov/pubmed/22029654
4) Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N.,
Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D.,
2012. Derivation and propagation of human embryonic
stem cell lines from frozen embryos in an animal
product-free environment. Nat. Protoc. 7 (7), 1366–1381.
doi: 10.1038/nprot.2012.080
http://www.ncbi.nlm.nih.gov/pubmed/22722371
5) Devito, L., Petrova, A., Miere, C., Codognottom S., Blakely,
N., Lovatt, A., Ogilvie, C., Khalaf, Y., Ilic, D., 2014.
Cost-effective master cell bank validation of multiple
clinical-grade human pluripotent stem cell lines from a






KCL033 is a National Institutes of Health (NIH) registered hESC
line
NIH Registration Number: NIHhESC-14-0267
http://grants.nih.gov/stem_cells/registry/current.htm?id=653
Ethics The hESC line KCL033 is derived under license from the UK
Human Fertilisation and Embryology Authority (research li-
cense numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Committee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the ex-
periments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.
297L. Devito et al. / Stem Cell Research 16 (2016) 296–2992. Resource detailsConsent signed May 26, 2009
Embryo thawed Jul 11, 2011
UK stem cell bank deposit approval Mar 08, 2012
Reference: SCSC12-54
Sex Female 46, XX
Grade Clinical
Disease status Healthy/Unaffected
Karyotype (aCGH) No copy number changes detected.
SNP array Gain in regions 5p14.3 and 12p11.21
(Canham et al., 2015)
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Ectoderm: TUBB3 (tubulin, beta 3 class
III)
Mesoderm: ACTA2 (actin, alpha 2,
smooth muscle)
Sibling lines available KCL032, KCL034
Fig. 1. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining
(Oct. 4, Nanog, TRA-1-60, TRA-1-81). Scale bar, 50 μm.We generated KCL033 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation po-
tential into three germ layers was veriﬁed in vitro (Fig. 2).
Molecular karyotyping identiﬁed a novel 2.4 Mb gain on chromo-
some 5p14.3 and a gain on chromosome 12p11.21, which was also
found in KCL040.
The gain on chromosome 5p14.3 containing a single gene, CDH18
(Cadherin-18), was also present in one of two sibling cell lines,
KCL032, but not in KCL034, a third sibling. A duplication of this size
has not been reported to date, but its presence in two sibling hESC
lines strongly suggests that it was inherited from one of the parents
rather than by acquisition during hESC derivation and culture
(Canham et al., 2015). The 2498.8 bp gain starts at bp 19086546
and ends at bp 21585311 as referred to Human Genome Build 38.
The gain on chromosome 12p11.21 contains no genes and it has
been also reported in at least 14 submissions at Database of Genomic
Variants (DGV; http://dgv.tcag.ca), which has collected structural
variations in more than 14,000 healthy individuals from worldwide
population (MacDonald et al., 2014). Estimated frequency in the
human population is 4.70% (Canham et al., 2015).
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens (Devito et al., 2014) conformed that the cells in the Master Bank
were sterile, mycoplasma-free, and negative for Treponema pallidum,
chlamydia, Neisseria gonorrhoeae, human immunodeﬁciency virus-1 and 2 (HIV-1 and -2), human T-lymphotropic virus types-1 and 2
(HTLV-1 and 2), hepatitis A, B and C (HAV, HBV and HCV), human
herpes simplex virus HHV-4 (Epstein–Barr virus, EBV), -6, -7, and -8,
human cytomegalovirus (hCMV), human parvovirus B19, SV40, JCV,
BKV, enterovirus, HAV, HCV, nonspeciﬁc viral and other adventitious
contaminants.
We also generated research grade of KCL033 line that is adapted to
feeder-free conditions.
3. Materials and methods
3.1. Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to re-
search embryos that were stored for 5 or 10 years. They mail signed
consent back to us and that might be months after the PIS and consent
were mailed to them. If in meantime new versions of PIS/consent are
implemented, we do not send these to the patients or ask them to re-
sign; the whole process is done with the version that was given them
initially. The PIS/consent documents (FRO-V.6) were created on Dec.
18, 2008. HFEA Code of Practice that was in effect at the time of docu-
ment creation: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html).
The donor couple signed the consent on May 26, 2009. HFEA Code of
Practice that was in effect at the time of donor signature: Edition 7 —
R.4. HFEA Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–
30 Sep. 2009.
3.2. Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in detail (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
3.3. Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed me-
chanically from the outgrowth (Ilic et al., 2007; Ilic et al., 2010). hES col-
onies were expanded and cryopreserved at the third passage.
Fig. 2. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
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Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cells were part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).3.5. Pluripotency markers
Pluripotency was assessed with immunostaining for pluripotency
markers as described (Ilic et al., 2012; Stephenson et al., 2012).3.6. Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephenson
et al., 2012).3.7. Genotyping
DNA was extracted from hES cell cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.3.8. Array comparative genomic hybridization (aCGH)
aCGH was performed as described in detail (Ilic et al., 2012).3.9. Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in detail (Canham et al.,
2015).3.10. HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS) Pa-
thology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).3.11. Validation for sterility and speciﬁc and non-speciﬁc human pathogens
Validation for sterility and speciﬁc and non-speciﬁc human path-
ogenswas performed as described (Devito et al., 2014). All validation
studies were conducted by SGS Vitrology (Glasgow, U.K., http://
www.sgs.com), in compliance with the principles of GMP as set out
in Directive 2003/94/EC for medicinal products for human use
(Directive 2003/94/EC, 2003) and 91/412/EEC for veterinary medic-
inal products (Directive 91/412/EEC, 1991).
Sterility testing was performed in accordance with the current re-
quirements of the European Pharmacopoeia, Section 2.6.1 Sterility,
U.S. Pharmacopeia, 71. Sterility Tests, and International Conference on
Harmonisation Topic Q5D guidelines.
Mycoplasma testing was performed in accordance with the cur-
rent requirements of the European Pharmacopoeia, Section 2.6.7,
Mycoplasmas.
All PCR-based assays used were compliant with the current edition
of the European Pharmacopoeia, 2.6.21, Nucleic Acid Ampliﬁcation
Techniques.
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rs, visualized withThe hESC line KCL034 is derived under licence from the UK
Human Fertilisation and Embryology Authority (research li-
cence numbers: R0075 and R0133) and also has local ethical
approval (UK National Health Service Research Ethics Commit-
tee Reference: 06/Q0702/90).
Informed consent was obtained from all subjects and the
experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the NIH Belmont Report. No ﬁnan-
cial inducements are offered for donation.Resource detailsonsent signedpluripotenc
rhodamineMay 26, 2009
mbryo thawed Jul. 11, 2011
K Stem Cell Bank
Deposit ApprovalMar. 08, 2012
Reference: SCSC12-54x Male 46, XY
rade Clinical
isease status Healthy/unaffected
aryotype (aCGH) No copy number changes detected.
P Array Gain in region 6p22.1 (Canham et al., 2015)NA ﬁngerprint
Allele sizes (in bp) of 16 microsatellite
markers speciﬁc for chromosomes 13, 18
and 21 (Jacquet et al., 2013)LA typing
HLA-A 11,29; B 44,51; Bw 4; C 04,16;
DRB1 04,07; DRB4 01; DQB1 02,03









Ectoderm: TUBB3 (tubulin, beta 3 class III)
Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)ree germ layer
differentiation in vivo
(teratomas) (Fig. 3)Endoderm: AFP, GATA4
Ectoderm: TUBB3, GFAP (glial ﬁbrillary acidic
protein)
Mesoderm: DES (desmin), Alcian Blue and periodic
acid–Schiff (PAS)-stained cartilagergeted differentiation
(Fig. 4)Endoderm: deﬁnitive endoderm — GATA4
(Cvoro et al., 2015).y markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) a
–phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (greenEctoderm: keratinocytes — p63, KRT14
(Petrova et al., 2014)
Mesoderm: cardiomyocytes — TNNT2bling lines available KCL032, KCL033SiWe generated KCL034 clinical grade hESC line following protocols,
established previously (Ilic et al., 2012; Stephenson et al., 2012), and
now adapted to cGMP conditions. The expression of the pluripotency
markers was tested after freeze/thaw cycle (Fig. 1). Differentiation
potential into three germ layers was veriﬁed in vitro (Fig. 2), in vivo
(Fig. 3) and with targeted differentiation into speciﬁc endoderm, ecto-
derm and mesoderm cell types (Fig. 4).
Molecular karyotyping identiﬁed a gain on chromosome6p22.1. The
gain on chromosome 5p14.3 containing the following genes:
HIST1H2BL, HIST1H2AI, HIST1H3H, HIST1H2AJ, HIST1H2BM, HIST1H4J,
HIST1H4K, HIST1H2AK, HIST1H2BN, HIST1H2AL, HIST1H1B, HIST1H3I,
HIST1H4L, HIST1H3J, HIST1H2AM, HIST1H2BO, OR2B2 and OR2B6
(Canham et al., 2015). The 330.8 kb gain starts at bp 27627265 and
ends at bp 27958049 as referred toHumanGenomeBuild 38. This dupli-
cation that contained part of the Histone 1 gene cluster was not fully
present on the database of genomic variants (DGV; http://dgv.tcag.ca),
which has collected structural variations in more than 14,000 healthy
individuals from worldwide population (MacDonald et al., 2014). It is
probable that this gain represents a benign event as other histone clus-
ters have been shown to be preferentially duplicated during evolution
(Canham et al., 2015; Braastad et al., 2004).
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens (Devito et al., 2014) conformed that the cells in Master Bank
were sterile, mycoplasma-free, and negative as well as for Treponema
pallidum, Chlamydia, Neisseria gonorrhoeae, Human immunodeﬁcien-
cy virus-1 and 2 (HIV-1 and -2), Human T-lymphotropic virus type-1
and 2 (HTLV-1 and 2), Hepatitis A, B and C (HAV, HBV and HCV),
Human herpes simplex virus HHV-4 (Epstein–Barr virus, EBV), -6, -7,
and -8, Human cytomegalovirus (hCMV), human parvovirus B19,
SV40, JCV, BKV, Enterovirus, HAV, HCV, nonspeciﬁc viral and other ad-
ventitious contaminants.
We also generated research grade of KCL034 line that is adapted to
feeder-free conditions.nd alkaline phosphatase (AP) activity assay. Actin stress
) is detected only in hES cells. Scale bar, 50 μm.
Fig. 2. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm and α-
fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 50 μm.
186 L. Devito et al. / Stem Cell Research 16 (2016) 184–188Materials and methods
Consenting process
We distribute Patient Information Sheet (PIS) and consent form to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in meantime new versions of PIS/consent are imple-
mented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (FRO-V.6) were created on Dec. 18, 2008.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 7 — R.4 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on May 26, 2009. HFEA Code of Practice
that was in effect at the time of donor signature: Edition 7 — R.4. HFEA
Code of Practice Edition 7 — R.4 was in effect: 02 Oct. 2008–30 Sep.
2009.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).Fig. 3. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not
speciﬁc stains are brown (immunohistochemistry) or light blue (Alcian blue). Germ layer m
ectoderm, GATA4 and AFP for endoderm. Positive immunostaining for complex IV type II m
desmin). Scale bars are 100 μm.Cell culture
ICMplated onmitotically inactivatedHFFwere cultured as described
(Ilic et al., 2012; Stephenson et al., 2012). TE cells were removed
mechanically from outgrowth (Ilic et al., 2007, 2010). hES colonies
were expanded and cryopreserved at the third passage.
Viability test
Strawswith the earliest frozen passage (p. 2–3) are thawed and new
colonies are counted three days later. These colonies are then expanded
up to passage 8, atwhich point cellswere part frozen and part subjected
to standard battery of tests (pluripotency markers, in vitro and in vivo
differentiation capability, genetics, sterility, mycoplasma).
Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo as described (Petrova et al., 2014; Stephensoninvade surrounding tissue. Sections are counterstained with hematoxylin and eosin and
arkers: Alcian blue–PAS-stained cartilage and DES for mesoderm, TUBB3 and GFAP for
arker conﬁrms the human origin of the tumor (adjacent section of the one stained for
Fig. 4. Targeted differentiation into speciﬁc cell types of endoderm (deﬁnitive endoderm), extoderm (keratinocytes) andmesoderm (cardiomyocytes). Deﬁnitive endoderm:GATA2 (red),
nuclei (blue). Ectoderm: p63 (red), KRT14 (green), nuclei (blue). Mesoderm: TNNT2 (green), nuclei (blue). Scale bar, 125 μm.
187L. Devito et al. / Stem Cell Research 16 (2016) 184–188et al., 2012). Targeted differentiation in cardiomyocytes (Jacquet et al.,
2015; Laﬂamme et al., 2007) and deﬁnitive endoderm (Cvoro et al.,
2015; Cheng et al., 2012), keratinocytes (Petrova et al., 2014), followed
the protocols described earlier. Nuclei are visualized with Hoechst
33342.
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions. Ampliﬁ-
cation of polymorphic microsatellite markers was carried out as de-
scribed (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
Whole-genome single nucleotide polymorphism (SNP) array
SNP array was performed as described in details (Canham et al.,
2015).
HLA typing
HLA-A, -B and -DRB1 typing was performed with a PCR sequence-
speciﬁc oligonucleotide probe (SSOP; Luminex, Austin, TX, USA) hybrid-
ization protocol at the certiﬁed Clinical Transplantation Laboratory,
Guy's and St Thomas' NHS Foundation Trust and Serco Plc. (GSTS)
Pathology (Guy's Hospital, London, UK) as described (Jacquet et al.,
2013). HLA typing was also performed independently by other group
(Canham et al., 2015).
Validation for sterility and speciﬁc and non-speciﬁc human pathogens
Validation for sterility and speciﬁc and non-speciﬁc human patho-
gens was performed as described (Devito et al., 2014). All validation
studies were conducted by SGS Vitrology (Glasgow, U.K., http://www.
sgs.com), in compliance with the principles of GMP as set out in Direc-
tive 2003/94/EC for medicinal products for human use (Directive
2003/94/EC, 2003) and 91/412/EEC for veterinary medicinal products
(Directive 91/412/EEC, 1991).
Sterility testing was performed in accordance with the current re-
quirements of the European Pharmacopoeia, Section 2.6.1 Sterility,
U.S. Pharmacopeia, 71. Sterility Tests, and International Conference on
Harmonisation Topic Q5D guidelines.
Mycoplasma testing was performed in accordance with the cur-
rent requirements of the European Pharmacopoeia, Section 2.6.7,
Mycoplasmas.All PCR-based assays used were compliant with the current edition
of the European Pharmacopoeia, 2.6.21, Nucleic Acid Ampliﬁcation
Techniques.
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ig. 1.Genetic pedigree tree. The c
cle. Three embryos were norma
onated for research. We derivedJul 21, 2011ex Male 46, XY
rade Researchisease status
(Fig. 1)Mutation affecting one allele of the HTT gene
encoding huntingtin (~38 CAG repeats; 14 for the
normal allele) associated with Huntington's
disease (Ilic et al., 2015)aryotype (aCGH)Decreased copy number at 2q37.3
(242,930,599–242,948,040) and at 3q25.1
(151,368,847–151,542,568). The imbalances are
considered to be benign copy number variants. The
chromosome 3 imbalance was not called by
software.NA ﬁngerprint
Allele sizes (in bp) of 17 microsatellite markers
speciﬁc for chromosomes 13, 18 and 21 (Jacquet
et al., 2015)iability testing Pass
luripotent markers
(immunostaining)
(Fig. 2)NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
(Jacquet et al., 2015)hree germ layers
differentiation in vitro
(immunostaining)
(Fig. 3)Endoderm: AFP (α-fetoprotein); Ectoderm: TUBB3
(tubulin, β3 class III); Mesoderm: ACTA2 (actin,
α2, smooth muscle) (Jacquet et al., 2015)hree germ layer
differentiation in vivo
(teratomas)
(Fig. 4)Endoderm: AFP, GATA4. Ectoderm: TUBB3, GFAP
(glial ﬁbrillary acidic protein). Mesoderm: DES
(desmin), Alcian Blue and periodic acid–Schiff
(PAS)-stained cartilage (Jacquet et al., 2015)argeted differentiation
(Fig. 5)Cardiomyocytes: TNNT2 (cardiac troponin T)
immunostainingibling lines available NoneSWe generated KCL036 research grade hESC line following protocols
established previously (Ilic et al., 2012; Stephenson et al., 2012;
Jacquet et al., 2013). The expression of the pluripotency markers was
tested after freeze/thaw cycle (Fig. 2; Jacquet et al., 2015). Differentia-
tion potential into three germ layers was veriﬁed in vitro (Fig. 3 and
Fig. 5; Jacquet et al., 2015) and in vivo (Fig. 4; Jacquet et al., 2015).
Validation for sterility and speciﬁc and non-speciﬁc human
pathogens conﬁrmed that the cells in Master Bank were sterile,
mycoplasma-free, and negative for human immunodeﬁciency virus 1
(HIV-1), Human T-lymphotropic virus type 1 (HTLV-1), hepatitis B
and C (HBV and HCV), human herpes simplex virus HHV-4 (Epstein–
Barr virus, EBV), and human cytomegalovirus (hCMV).ouple undergoing IVF had 16 embryos in this particular
l, whereas those that carried the mutation in HTTwere
hESC lines from two of them.We also generated research grade of KCL036 line that is adapted to
feeder-free conditions (Jacquet et al., 2015).
Materials and methods
Consenting process
We distribute patient information sheets (PIS) and consent forms to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in themeantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.9) were created on Feb. 09, 2011.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 8—R.2 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Jul. 21, 2011. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 8—R.3. HFEA Code
of Practice Edition 8—R.2 was in effect: Apr. 07, 2010–Apr. 06, 2011.
HFEA Code of Practice Edition 8—R.3 was in effect: Apr. 07, 2011–Oct.
01, 2011.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICM plated on mitotically inactivated HFF were cultured as de-
scribed (Ilic et al., 2012; Stephenson et al., 2012). TE cells were re-
moved mechanically from outgrowth (Ilic et al., 2007; Ilic et al.,
2010). hESC colonies were expanded and cryopreserved at the third
passage.
Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and
new colonies are counted 3 days later. These colonies are then ex-
panded up to passage 8, at which point cells were part frozen and
part subjected to standard battery of tests (pluripotency markers,
in vitro and in vivo differentiation capability, genetics, sterility,
mycoplasma).
Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo (Jacquet et al., 2015) as described (Ilic et al., 2012;
Stephenson et al., 2012; Petrova et al., 2014). Targeted differentiation
in cardiomyocytes followed the protocols described earlier (Jacquet
et al., 2015; Laﬂamme et al., 2007).
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions.
Fig. 3. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm,
and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 25 μm.
Fig. 2. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar,
20 μm.
347L. Jacquet et al. / Stem Cell Research 16 (2016) 345–348Ampliﬁcation of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
Special pathology
The Doctors Laboratory London (UK) tested the line for HIV1, HepB,
HepC, CMV, and EBV by PCR.Fig. 4. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not
speciﬁc stains are brown (immunohistochemistry). Germ layer marker: DES for mesoderm, TUAuthor disclosure statement
There are no competing ﬁnancial interests in this study.
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The Molecular Karyotype of 25 
Clinical-Grade Human Embryonic 
Stem Cell Lines
Maurice A. Canham1, Amy Van Deusen1, Daniel R. Brison2, Paul A. De Sousa3,4, 
Janet Downie3, Liani Devito5, Zoe A. Hewitt6, Dusko Ilic5, Susan J. Kimber7, 
Harry D. Moore6, Helen Murray3 & Tilo Kunath1
The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now 
becoming a reality. Although the vast majority of hESC lines have been derived for research purposes 
only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. 
Cell types differentiated from these designated lines may be used as a cell therapy to treat macular 
degeneration, Parkinson’s, Huntington’s, diabetes, osteoarthritis and other degenerative conditions. 
It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. 
We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single 
nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) 
greater than 100 kb were detected, most of which were found to be naturally occurring in the human 
population and none were associated with culture adaptation. In addition, three copy-neutral loss 
of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small 
and interstitial suggesting they did not arise in culture. The large number of available clinical-grade 
hESC lines with defined molecular karyotypes provides a substantial starting platform from which the 
development of pre-clinical and clinical trials in regenerative medicine can be realised.
Since the derivation of human embryonic stem cells (hESCs) from blastocysts in 19981, and the more 
recent production of human induced pluripotent stem cells (iPSCs) from adult tissues2, anticipation has 
been growing with regard to their potential as cell therapies for a number of incurable conditions. As 
with any new medicine, Good Manufacturing Practice (GMP) is required to produce hESC/iPSC-derived 
cell products for clinical use in humans3. However, while over 1200 hESC lines have been established 
and reported worldwide4, the majority are suitable only for research purposes due to the sourcing of 
embryonic material, derivation process and subsequent handling procedures. Frequently, derivation and 
culture methods employ mouse feeder cells or poorly defined media containing animal-based products1,5, 
which may render these cell lines unusable as a starting material for any cell-based clinical application.
In recent years, there have been advances in the derivation of hESC lines whereby fully defined media 
devoid of animal-derived products is used6,7, and the traditional mouse feeders have been replaced with 
GMP-qualified human feeders8–10 or recombinant human proteins as a substrate on which to culture 
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hESCs11–14. Furthermore, animal-based enzymes and guinea pig complement used to isolate the inner 
cell mass for hESC derivation have been replaced with mechanical isolation or laser microdissection15–19. 
These efforts have culminated in the derivation of approximately 50 clinical-grade hESC lines from var-
ious centres across the world20–23 (www.mrc.ac.uk/research/facilities/stem-cell-bank; stemcells.nih.gov).
Remarkably, 38 of these lines have been derived among five different centres in the United Kingdom 
through funding from the Medical Research Council (MRC), Scottish Enterprise, the North West 
Development Agency and the Juvenile Diabetes Research Foundation. The MRC launched an initiative in 
2005 to provide infrastructure funding to UK in vitro fertilization (IVF) units to provide GMP-compliant 
embryos for hESC line derivation and further funded the Human Embryonic Stem Cell Co-ordinators 
(hESCCO) network, subsequently the National Clinical hESC Forum. This allowed the derivation centres 
to work with the Human Fertilisation and Embryology Authority and the UK Stem Cell Bank to estab-
lish common parameters for patient consent, screening and embryo procurement for the derivation of 
clinical-grade hESC lines. Ultimately this farsighted policy has yielded a cohort of hESC lines which have 
benefited from the shared implementation of GMP-compliant IVF laboratory standards, hESC derivation 
procedures and ethical principles for donor consenting24. A list of clinical-grade hESC lines conforming 
to the European Union Tissue and Cells Directives (Directives 2004/23/EC and 2006/17/EC) is shown 
in Table 1. These directives introduced common safety and quality standards across European member 
states to ensure that all tissues and cells used in patient treatment are traceable from donor to recipient, 
thus implementing key principles of GMP.
The value of a large number of different cell lines as starting material for clinical applications is 
three-fold: (a) different hESC lines have varying propensities to generate specific cell lineages during in 
vitro differentiation25, (b) hESC lines may harbour or acquire genetic anomalies potentially excluding 
them from clinical use26, and (c) in order to accommodate human leucocyte antigen (HLA) matching 
to a broad section of potential patients a sizeable number of hESC lines would be required. It has been 
estimated that approximately 150 different lines with particular HLA haplotypes would be required to 
cover ~93% of potential UK recipients27. With the advent of iPSC technology, the latter issue will be 
addressed by derivation of hiPSC lines from individuals homozygous for common HLA loci. An inter-
national effort is currently underway to address this28, but the issues of line-to-line variation and genetic 
stability of hESC and iPSC lines will remain29.
In accordance with GMP standards applicable to the sourcing and the application of raw materials 
used during production processes, such as hESC/iPSC cell derivation and differentiation into desired cell 
types, there is emerging evidence that equal scrutiny should be undertaken to account for the genetic 
health of cells at all stages of production3,30. Some characteristics of self-renewal and multipotency that 
define pluripotent stem cells (PSCs) are also shared by tumour stem cells31. This has been exemplified 
by the identification of non-random genetic changes, particularly gains of chromosomes 12, 17 and 
X, common to embryonal carcinoma cell lines and PSCs following prolonged culture26,32. Moreover, 
recent studies using high-resolution single nucleotide polymorphism (SNP) analysis of PSCs have shown 
copy number variations (CNVs) that can lead to gene expression alterations functionally linked to can-
cer33. One such microduplication associated with oncogenic transformation was detected on chromo-
some 20q11.2134,35. A comprehensive survey of 125 different PSC lines from many different laboratories 
across the world showed that about one third of lines acquired a culture-induced genomic variation 
upon prolonged culture, the most common of which was chromosome 20q11.21 microduplication36. The 
anti-apoptotic gene, BCL2L1, within this region has been shown to be a driver of growth advantage36,37. 
In addition to anomalies acquired during self-renewal, the process of in vitro differentiation from genet-
ically healthy PSCs can also lead to genomic instability38.
However, most CNVs are benign and relatively large duplications and deletions (> 100 kb) are com-
mon in healthy individuals39. Such parent-of-origin CNVs will also be present in blastocysts and hESC 
lines derived from them. The ideal way to determine if a CNV identified in a hESC line is naturally 
occurring is to genotype the parents of the donated blastocyst. This is indeed possible in cases involving 
Derivation Centre EUTCD Grade Cell Lines Number
King’s College London1 KCL031, KCL032, KCL033, KCL034, KCL037, KCL038, KCL039, KCL040 8
The University of Manchester Man11, Man12, Man13, Man14, Man15, Man16 6
Newcastle University NCL14 1
Roslin Cells Ltd, Edinburgh RC9, RC11, RC12, RC13, RC14, RC15, RC16, RC17 8
The University of Sheffield
MasterShef1, MasterShef2, MasterShef3, MasterShef4, MasterShef5, MasterShef6, 




Table 1.  List of 38 EUTCD compliant (clinical-grade) hESC lines. The 25 hESC lines analysed by SNP 
analysis are shown in bold. 1All eight (8) of the KCL hESC lines are listed on the NIH Stem Cell Registry 
(escr.nih.gov) making them available for NIH-funded projects in the USA.
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preimplantation genetic diagnosis40. However, the vast majority of blastocysts, including all within the 
UK, are donated under conditions that prohibit access to parental DNA. An alternative method to deter-
mine if a particular CNV observed in a hESC cell line might be parent-of-origin is to compare it to 
known CNVs present on the Database of Genomic Variants (DGV)41. The DGV has catalogued a collec-
tion of published CNVs from over 14,300 healthy individuals. Although not exhaustive, the collection is 
highly curated and covers a significant number of CNVs and other genomic structural variants known 
to exist in the general population. However, if a hESC CNV is found to be present on this database it 
does not exclude the possibility that it is a de novo genomic alteration that arose during development of 
the blastocyst or during establishment and maintenance of the cell line.
As well as CNVs, copy-neutral loss of heterozygosity (CN-LOH) represent another form of genomic 
structural variation characterised by a stretch of homozygosity along part of a chromosome42. If the 
affected alleles contain recessive mutations or lie within regions of the genome subject to imprinting, 
there can be either a net loss or a net gain of gene function and expression42. CN-LOH regions can also 
be due to the presence of persistent ancestral recombination ‘cold spots’ or be the consequence of recent 
consanguinity43,44. While these changes would be considered parent-of-origin if found in hESC lines, there 
are examples of somatic or acquired CN-LOH regions found during the progression of many cancers, 
particularly those of haematopoietic origin45. Whole genome SNP arrays are useful to detect CN-LOH 
events instead of regions, and regions greater than 1 Mb in length warrant further investigation42.
In this study, we sought to examine the genetic integrity of 25 clinical-grade hESC lines utilising 
whole-genome SNP genotyping analysis. While karyology is sufficient for establishing genetic normalcy 
within current regulatory standards, advances in technology and an increasing cytogenetic knowledge 
base demand higher resolution investigation of cell lines and cell products designed for clinical use.
Results and Discussion
Human ES cell lines were cultured in feeder-free conditions prior to the isolation of genomic DNA 
(Fig. 1). The DNA from 25 hESC lines (Table 1) was assayed for single nucleotide polymorphisms (SNPs) 
using the Illumina HumanCytoSNP-12 array and data was analysed for large CNVs with GenomeStudio 
and KaryoStudio software. Our SNP analysis of 25 clinical-grade hESC lines found 15 unique CNVs 
greater than 100 kb and 3 CN-LOH regions greater than 1 Mb in size among 16 hESC lines, with results 
summarised in Table 2. Nine clinical-grade hESC lines did not harbour any structural genomic variants 
of this size. The percentage of cell lines we found to have CNVs greater than 100 kb (72%) is in agreement 
with the percentage of healthy individuals (~70%) in the population found to harbour CNVs of at least 
this size39. Additionally, the percentage of cell lines with CN-LOH events between 2.5 and 5 Mb (12%) is 
similar to the percentage of individuals in outbred populations with CN-LOH of this size range43. Since 
we have restricted our search to large structural changes, we are reporting a considerably lower number 
of CNVs and CN-LOH regions identified in other studies that have examined hESC or hiPSC lines33,36,46. 
Approximately 5%–10% of the normal human genome contains CNVs averaging a few kilobases in 
Figure 1. Culture of 3 clinical-grade hESC lines. (A) Man11, Man12, and Shef6 hESCs were cultured in 
Laminin-521 in Essential 8 medium prior to collection of genomic DNA. (B) Human ESC lines maintained 
expression of the pluripotent marker, NANOG, during expansion. Scale bar, 90 μm.
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length47, and high resolution arrays can produce large data sets dominated by such naturally occurring 
small events48,49. Thus, we chose to use the HumanCytoSNP-12 array and KaryoStudio software, tailored 
to identify CNVs greater than 75 kb and CN-LOH regions greater than 1 MB, a resolution adequate for 
common molecular cytogenetic interpretation and applicable in a clinically relevant setting42,49–51.
Of the 15 unique CNVs detected, 12 were heterozygous duplications, 2 were heterozygous deletions, 
and 1 was a homozygous deletion (Table 2). We asked whether these structural genomic variants were 
hESC Line Passage
Detected 





KCL031 21 8q24.23 Loss2 136718037 136837768 119.7 20 NONE
KCL032 7 5p14.3 Gain 19086546 21585311 2498.8 252 CDH18 
KCL033 17 5p14.3 Gain 19031726 21440254 2408.5 256 CDH18 
KCL033 17 12p11.21 Gain2 31116366 31248444 132.1 19 NONE
KCL034 19 6p22.1 Gain 27627265 27958049 330.8 13
HIST1H2BL; HIST1H2AI; HIST1H3H; HIST1H2AJ; 
HIST1H2BM; HIST1H4J; HIST1H4K; HIST1H2AK; 
HIST1H2BN; HIST1H2AL; HIST1H1B; HIST1H3I; 
HIST1H4L; HIST1H3J; HIST1H2AM; HIST1H2BO;  
OR2B2; OR2B6 
KCL037 8 18q23 Gain 78611768 79153453 541.7 84 SALL3; ATP9B 
KCL040 21 2q11.1-11.2 CN-LOH 94871756 98412364 3540.6 345
TEKT4; MAL; MRPS5; ZNF514; ZNF2; PROM2; KCNIP3; 
FAHD2A; TRIM43; ANKRD36C; GPAT2; ADRA2B; 
ASTL; DUSP2; STARD7; TMEM127; CIAO1; SNRNP200; 
ITPRIPL1; NCAPH; NEURL3; ARID5A; KANSL3; FER1L5; 
LMAN2L; CNNM4; CNNM3; ANKRD23; ANKRD39; 
SEMA4C; FAM178B; FAHD2B; ANKRD36; ANKRD36B; 
COX5B; ACTR1B; ZAP70; TMEM131; VWA3B; CNGA3 
KCL040 21 12p11.21 Gain2 31116366 31248444 132.1 19 NONE
KCL040 21 16p11.2 Loss2 32491547 33993220 1501.7 34 TP53TG3; TP53TG3C; TP53TG3B
Man11 21 15q25.3 Gain2 85376921 85597560 220.6 39 AKAP13
MasterShef2 18 17q21.31 Gain2 46138530 46710944 572.4 22 KANSL1; LRRC37A; ARL17B; LRRC37A2; ARL17A; NSF 
MasterShef3 22 6q27 Gain2 167908790 168175598 266.8 59 MLLT4; KIF25; FRMD1 
MasterShef3 22 17p11.2 Gain 21358248 21593333 235.1 31 KCNJ12; C17orf51 
MasterShef5 37 12q21.31-21.33 CN-LOH 85929477 89347087 3417.6 397 MGAT4C; C12orf50; C12orf29; CEP290; TMTC3; KITLG 
MasterShef7 16 14q21.3 Gain 46731743 47047175 315.4 18 MDGA2 
MasterShef7 16 16p11.2 Gain 29672266 30188484 516.2 94
QPRT; C16orf54; ZG16; KIF22; MAZ; PRRT2; PAGR1; MVP; 
CDIPT; SEZ6L2; ASPHD1; KCTD13; TMEM219; TAOK2; 
HIRIP3; INO80E; DOC2A; C16orf92; FAM57B; ALDOA; 
PPP4C; TBX6; YPEL3; GDPD3; MAPK3; CORO1A 
MasterShef11 17 19p12 Loss2,3 20423851 20532555 108.7 9 NONE 
Shef6 45 8p22 Gain 14634612 15188066 553.5 93 SGCZ 
RC9 17 8q24.23 Loss2 136718037 136837768 119.7 20 NONE
RC11 18 2p16.2-16.1 CN-LOH 53624707 57243565 3618.9 499
GPR75-ASB3; CHAC2; ERLEC1; GPR75; PSME4; ACYP2; 
TSPYL6; C2orf73; SPTBN1; EML6; RTN4; CLHC1; 
RPS27A; MTIF2; CCDC88A; CFAP36; SMEK2; PNPT1; 
EFEMP1; CCDC85A 










Table 2.  Summary of SNP array analysis of clinical-grade hESC lines. 1Nucleotide numbers refer to 
Human Genome Build 38. 2denotes that the frequency of this CNV in the human population has been 
estimated (Supplementary Table S2). 3denotes a homozygous deletion.
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likely to be parent-of-origin CNVs, that is, naturally occurring, or if they could have arisen during the 
hESC derivation process or during expansion in culture. We first checked each CNV on the DGV (http://
dgv.tcag.ca) to determine whether the CNVs have been previously observed in healthy individuals41,52.
Amongst the 15 large hESC CNVs, we found 10 had clear evidence of being present in healthy indi-
viduals. For example, a duplication of 267 kb on chromosome 6q27 observed in MasterShef3 containing 3 
protein-encoding genes—MLLT4, KIF25, FRMD1—was represented on the DGV and has been reported 
in the healthy population at a frequency of over 1 in 50 individuals (Fig.  2A) 48,51,53. RC17 hESCs har-
boured a single 144 kb duplication on chromosome 12p13.31 encompassing the SLC2A14 and SLC2A3 
genes (Fig.  2B). Although this is close to the NANOG locus, we do not believe it confers a growth 
advantage since this CNV is commonly found (1 in 25) in healthy individuals39,51,54. A 132 kb duplica-
tion on chromosome 12p11.21 was detected in both KCL033 and KCL040 hESC lines (Supplementary 
Fig. S1). This region does not contain any protein-coding genes, and there are at least 14 submissions 
of this duplication on the DGV39,51,53–55. Man11, MasterShef2, and MasterShef7 also harboured genomic 
duplications of greater than 100 kb that are represented on the DGV (Supplementary Fig. S1). Man11 
harboured a 220 kb gain on chromosome 15q25.3 that has been reported several times39,51,56. This dupli-
cation contains one gene, AKAP13, and this CNV was not found in the sibling hESC line, Man12. One 
of the CNVs detected in MasterShef7, a 315 kb duplication present on chromosome 14q21.3, contains a 
single gene, MDGA, and this CNV is also present on the DGV51. A 572 kb gain on chromosome 17q21.31 
encompassing 5 genes in MasterShef2 was also found to be present in the normal population at high 
frequency (9.8%)53.
Both heterozygous deletions and the homozygous deletion were found to be naturally occurring in 
the human population. Two unrelated cell lines, KCL031 and RC9 hESCs harboured the same 120 kb 
deletion on chromosome 8q24.23 (Fig. 3). This CNV is estimated to have a frequency of about 1 in 26 
people and has been reported numerous times to occur in healthy individual39,48,51,53,55,56. This region 
does not contain any protein-coding genes. KCL040 and MasterShef11 also possessed genomic deletions 
greater than 100 kb that were present on the DGV (Supplementary Fig. S2). KCL040 harbours a previ-
ously reported 1.5 Mb deletion on chromosome 16p11.2 that contains 3 related genes56,57. MasterShef11 
has a 109 kb homozygous deletion on chromosome 19p12 that has been widely reported to occur in 
healthy individuals (~1 in 9) and does not contain any genes39,48,51,55,56.
We identified a novel 2.4 Mb gain on chromosome 5p14.3, containing a single gene, Cadherin-18, that 
was present in two sibling cell lines, KCL032 and KCL033 (Fig.  4), but not in KCL034, a third sibling 
line20,58. A duplication of this size has not been reported to date, but its presence in two sibling hESC 
lines strongly suggests it was inherited from one of the parents of the donated blastocysts rather than by 
acquisition of an identical CNV during hESC derivation and culture.
The remaining 5 CNVs, all duplications, were not fully represented on the DGV. For example, a 
516 kb duplication was detected on chromosome 16 in MasterShef7 hESCs that encompassed over 20 
genes (Fig. 5). A similarly sized duplication of this region has not been reported to date, but the DGV 
is not exhaustive and this CNV may represent a novel, but rare naturally-occurring genomic variant. 
This duplication is not known to confer a selective growth advantage, and has not been reported to be 
associated with hESC culture adaptation36. We also checked this CNV on the DECIPHER database59 of 
microdeletion and microduplication clinical syndromes to determine if it was associated with a known 
disorder. This CNV was not associated with a described clinical syndrome, nor were any of the other 14 
CNVs identified here.
The four other unique CNVs that were not fully represented on the DGV were present in KCL034, 
KCL037, MasterShef3, and Shef6 hESC lines (Supplementary Fig. S3). KCL034 harboured a duplication 
of a 331 kb region on chromosome 6 (chr6q22.1) that contained part of the Histone 1 gene cluster. 
While this region was not fully present on the DGV, it is probable that this gain represents a benign 
event as other histone clusters have been shown to be preferentially duplicated during evolution60. A 
542 kb gain on chromosome 18q23 in KCL037 containing two coding genes, SALL3 and ATP9B, has 
not been previously reported. However, a smaller duplication covering the same two genes has been 
observed51. A 235 kb duplication was detected on chromosome 17 in MasterShef3 hESCs. Although, a 
duplication of this size is not present on the DGV, four slightly smaller duplications of the region have 
been reported39,51,53,55. A 553 kb gain on chromosome 8p22 in Shef6 hESCs within an intron of the SGCZ 
gene is an unreported novel structural duplication, but a deletion of this region has been observed51. 
While the 5 novel CNVs detected in our study were not fully present on the DGV, they were also not on 
the ‘ESC-associated’ culture-adaptation list of CNVs from the International Stem Cell Initiative survey 
of 125 different hESC and hiPSC lines36. Based on the available evidence, these CNVs likely represent 
novel, but rare, structural variants found in the human population. However, we do not know the health 
status of the individuals that may harbour these novel CNVs, so we cannot assume they are benign. 
Furthermore, we cannot definitively exclude the possibility that these CNVs arose during blastocyst 
development or during the early stages of hESC line derivation.
In addition to the 15 CNVs identified, our analysis detected 3 regions of CN-LOH greater than 1 
MB among three different hESC lines, KCL040, MasterShef5, and RC11 (Table 2 and Fig. 6). All three 
regions ranged in size between 3.4 and 3.7 Mb, two of which were on chromosome 2 and the other on 
chromosome 12. Due to their interstitial nature and relatively small genetic size, it is unlikely any of these 
CN-LOH regions would represent examples of acquired CN-LOH. The vast majority of CN-LOH events 
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Figure 2. Duplications found in hESC lines that are present on the DGV. (A) Chromosome 6 ideograms 
from SNP array analysis of MasterShef3 revealed a 267 kb duplication near the telomere, which contained 3 
genes, MLLT4, KIF25, and FRMD1. Duplications of this size, or greater, have been reported and annotated 
on the DGV with an estimated frequency of 2.82% in the human population. (B) A 144 kb duplication 
was observed on chromosome 12p13.31 of RC17 hESCs. This region contained two genes, SCL2A14 and 
SLC2A3, and is represented on the DGV (3.9% frequency in humans).
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documented in cancers are telomeric in nature and while examples of acquired interstitial CN-LOH 
do exist61,62, the double recombination event required to achieve this would be difficult to explain for 
sizes less than 25 Mb63,64. Since hESCs are known to maintain monoallelic expression in some imprinted 
regions65, we cross-referenced the 3 CN-LOH regions we identified to the Genomic Imprinting data-
base (http://www.geneimprint.com)66. None of the CN-LOH regions reside in known imprinted regions, 
although CCDC85A in the CN-LOH of RC11 is predicted, but not validated, to be an imprinted gene 
on this database.
While none of the CNV and CN-LOH regions observed in the hESCs appear to harbour genomic 
anomalies associated with culture adaptation at the passages reported here (Table 2), we have detected 
the presence of the culture-adapted microduplication on chromosome 20q11.21 at higher passages of 4 
Figure 3. A common deletion observed in two unrelated hESC lines. Chromosome 8 ideograms from 
SNP array analysis of KCL031 and RC9 hESC lines revealed a 120 kb deletion on chromosome 8q24.23 (red 
arrow). This deletion is relatively common in the human population (3.85%), and does not contain any 
protein-coding genes.
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clinical-grade hESC lines. This microduplication was reported to be found in ~20% of research-grade 
hESC lines36,37. Thus, it is with prudence that each cell line should be re-evaluated frequently and cer-
tainly before the production of any differentiated cell product67. These results also illustrate that the het-
erogeneity of molecular karyotypes in the human population will be reflected in the cell lines produced 
from human embryos. A perfect genome is unlikely to exist, so an appreciation of human genomic diver-
sity will lend itself to a more measured interpretation of molecular karyotype and genome sequencing 
data of cell lines destined for clinical use.
Our molecular karyotypic evaluation of 25 clinical-grade hESC lines has established a valuable plat-
form for the development and manufacture of cell therapy products for clinical application in regener-
ative medicine.
Figure 4. An identical duplication found in sibling KCL hESC lines, but not present on the DGV. 
Chromosome 5 ideograms from SNP array analysis of KCL032 and KCL033 hESC lines with the common 
CNV indicated by blue arrows. This 2.4 Mb duplication on chromosome 5p14.3 included the CDH18 gene. 
A duplication of this size was not present on the DGV, but a smaller duplication (nsv597424) covering most 
of the CDH18 exons was present, and a number of smaller deletions have been observed in this region. Only 
published CNVs greater than 100 kb are represented here.
www.nature.com/scientificreports/
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Materials and Methods
Clinical-grade hESC Samples. Approval for the use of all hESC lines used in this study was granted 
by the MRC Steering Committee for the UK Stem Cell Bank and for the Use of Stem Cell Lines. The fol-
lowing clinical-grade hESC lines were kindly provided by the following derivation centres: The University 
of Sheffield (12 lines) MasterShef2, MasterShef3, MasterShef4, MasterShef5, MasterShef7, MasterShef8, 
MasterShef10, MasterShef11, MasterShef12, MasterShef13, MasterShef14 and Shef6; King’s College 
London (8 lines) KCL031, KCL032, KCL033 KCL034, KCL037, KCL038, KCL039, and KCL040; Roslin 
Cells Ltd (3 lines) RC9, RC11, and RC17; and Central Manchester NHS Foundation Trust/The University 
of Manchester (2 lines) Man11 and Man12. Most of the cell samples were provided as frozen cell pellets, 
which were directly processed for genomic DNA isolation. However, Man11 and Man12, sibling hESC 
lines, were provided as cryopreserved hESC lines, and Shef6 was obtained directly from the UK Stem 
Cell Bank (UKSCB Accession No. R-05-031). These three lines were thawed and cultured in Essential 8 
media (Life Technologies) on Laminin-521 substrate (Biolamina) for less than 10 passages before pellet-
ing by centrifugation for genomic DNA isolation. Human ES cell morphology and pluripotent marker, 
NANOG, expression were maintained during this expansion (Fig.  1). NANOG immunostaining was 
performed with anti-NANOG antibody (1:500) from R&D Systems (cat no. AF1997).
Figure 5. A novel duplication observed in MasterShef7. A 516 kb duplication on chromosome 16p11.2 
was detected in MasterShef7 by SNP array analysis. This region contained 26 protein-coding genes, and 
a duplication of this size has not been reported to date. Smaller duplications have been observed in this 
region, including a duplication (esv2758642) spanning 7 of the genes. Only published CNVs greater than 
10 kb are represented here.
www.nature.com/scientificreports/
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Isolation of Genomic DNA. Genomic DNA was isolated from cell pellets using the MasterPure™ 
Complete DNA and RNA Purification Kit (Epicentre) according to the manufacturer’s instructions. 
Briefly, cell pellets were lysed with Tissue and Cell Lysis Solution, followed by Proteinase K and RNase 
A treatment. Proteins were precipitated with MPC Protein Precipitation Reagent and removed by cen-
trifugation. Genomic DNA was precipitated with isopropanol, pelleted by centrifugation and then resus-
pended in TE buffer to a final concentration of 50 ng/μ l. Purity was checked by spectrophotometry using 
the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific).
HLA typing. All samples were subjected to HLA typing at the Histocompatibility and Immunogenetics 
(H&I) Laboratory of the Scottish National Blood Transfusion Service (SNBTS). The HLA typing data 
(Supplementary Table S1) was used for identification purposes by comparing it to the HLA typing data 
for each cell line provided by the hESC derivation centres. The H&I Laboratory at SNBTS is accredited 
through Clinical Pathology Accreditation (UK) Ltd (CPA), and all CPA labs are subjected to UK National 
External Quality Assessment Schemes (UK NEQAS).
Genotyping and Analysis. Genomic DNA samples were assayed using the Illumina 
HumanCytoSNP-12 v2.1 BeadChip, at either AROS (Aarhus, Denmark) or the Wellcome Trust Clinical 
Research Facility (Edinburgh, UK). The data have been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series accession number GSE68508. Genotyping was initially assessed 
using GenomeStudio genotyping module (v1.94, Illumina). KaryoStudio (v1.4, Illumina) was employed 
to perform automatic normalisation and to identify genomic aberrations utilising default settings of the 
built-in cnvPartition algorithm (3.07, Illumina) to generate B-allele frequency and smoothened Log R 
ratio plots for detected regions. These parameters are designed to detect CNVs greater than 75 kb and 
CN-LOH regions larger than 1 MB with a confidence value greater than 35. All identified duplication 
and deletions were first cross-matched to the Database of Genomic Variants (DGV; http://dgv.tcag.ca) 
to identify naturally-occurring structural variations in the human genome41,52. We also determined the 
Figure 6. Interstitial CN-LOH regions detected in clinical-grade hESC lines. Chromosome ideograms 
from SNP array analysis showing CN-LOH regions indicated by green arrows: (A) A 3.6 Mb region on 
chromosome 2p16.2-16.1 in RC11. (B) A 3.5 Mb region on chromosome 2q11.1-11.2 in KCL040. (C) A 
3.4 Mb region around chromosome 12q21.31-21.33 in MasterShef5.
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estimated frequency of 8 common CNVs in the human population (Supplementary Table S2) by access-
ing the DGV Gold Standard track of a highly curated and accurate CNV map of the human genome47. 
All CNVs were inputted into the DECIPHER database (https://decipher.sanger.ac.uk/) to determine if 
they were associated with any clinical syndromes59. The CN-LOH regions were cross-referenced with 
the Genomic Imprinting database (http://www.geneimprint.com) to determine if the genomic variants 
occurred in known imprinted regions66. CNVs that were not identified on the DGV were then checked 
against a list of ES cell-associated culture adaptation genomic variants published by the International 
Stem Cell Initiative36.
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A B Bw C DRB1 DRB3 DRB4 DRB5 DQB1 
KCL031 02, 24 51, 52 4 12, 14 11, 15 02   01 03, 06 
KCL032 02, 11 15, 51 4, 6 03, 04 04, 13 03 01   03, 06 
KCL033 11, 29 44, 51 4 04, 16 04, 07   01   02, 03 
KCL034 11, 29 44, 51 4 04, 16 04, 07   01   02, 03 
KCL037 02, 03 35, 40 6 03, 04 01, 13 03     05, 06 
KCL038 03, 11 07, 15 6 03, 07 14, 15 02   01 05, 06 
KCL039 01, 24 35, 49 4, 6 04, 07 03 01/02     02 
KCL040 03, 24 07, 15 6 03, 07 04, 15   01 01 03, 06 
Man11 02, 24 35, 44 4, 6 04, 05 04, 11 02 01   03 
Man12 01, 02 37, 44 4 05, 06 04   01   03 
MasterShef2 01, 68 44 4 07 01, 11 01/02/03     03, 05 
MasterShef3 02, 24 40, 44 4, 6 03, 05 04, 15   01 01 03, 06 
MasterShef4 01, 08 44 4, 6 05, 07 03, 15 01   01 02, 06 
MasterShef5 03, 24 27 4 02 03, 11 02     03, 02 
MasterShef7 01, 29 08, 44 4, 6 07, 16 03, 07 01 01   02 
MasterShef8 03, 23 14, 44 4, 6 04, 08 07, 13 03 01   02, 06 
MasterShef10 01, 03 07, 27 4, 6 01, 07 04, 15   01 01 03, 06 
MasterShef11 02, 03 07 6 07 15     01 06 
MasterShef12 01, 03 38, 40 4, 6 02, 12 03, 13 01, 02     02, 06 
MasterShef13 02, 11 18, 44 4, 6 05, 12 11, 15 02   01 03, 06 
MasterShef14 03, 26 07, 38 4, 6 07, 12 09, 13 01 01   03, 06 
Shef6 02, 23 15, 44 4, 6 03, 04 04, 07   01   02, 03 
RC9 01, 02 07, 08 6 07 01, 15     01 05, 06 
RC11 01, 24 07, 08 6 07 03, 15 01   01 02, 06 
RC17 01, 03 07, 08 6 07 03, 11 01, 02     02, 03 
 
Supplementary Table S1: HLA typing of 25 clinical-grade hESC lines. Two-digit 
HLA typing was performed on genomic DNA isolated from 25 hESC lines.  
 
Supplementary Table S2 
 
Human ESC Line(s) Region Variation GSSV No. NR_freq 
KCL031 and RC9 8q24.23 Loss gssv179004 3.85% 
KCL033 and KCL040 12p11.21 Gain gssv32361 4.70% 
KCL040 16p11.2 Loss gssv62559 5.14% 
Man11 15q25.3 Gain gssv58152 0.30% 
MasterShef2 17q21.31 Gain gssv71248 9.82% 
MasterShef3 6q27 Gain gssv157263 2.82% 
MasterShef11 19p12 Loss gssv81932 10.94% 
RC17 12p13.31 Gain gssv32355 3.90% 
 
Supplementary Table S2: Common CNVs in the human population. The 
accession number of the DGV Gold Standard CNV (gssv no.) and the estimated 
frequency (NR_freq) in the human population are listed.
 

















Supplementary Figure S1: Duplications found in hESC lines that are present on 
the DGV. (A) A 132.1 kb duplication on chromosome 12p11.21 was observed in two 
unrelated hESC lines, KCL033 and KCL040. This region does not contain any 
protein-coding genes, and is well represented on the DGV and relatively common 
(4.7%). (B) A 220.6 kb duplication was observed in Man11 hESCs spanning most of 
the AKAP13 gene, but was not present in the sibling line Man12. This is a known 
CNV and is present on the DGV at a low frequency (0.3%). (C) A 315.4 kb 
duplication on chromosome 14q21.1 was observed in MasterShef7 hESCs. This 
CNV is not apparent in the whole chromosome 14 ideogram, but is significantly 
called by the KaryoStudio software. The region contains the MDGA2 gene and is 
represented on the DGV by one entry. (D) A 572.4 kb duplication on chromosome 
17q21.31 was observed in MasterShef2 hESCs. This CNV contained 5 coding 
genes, and a number of duplications and deletions have been reported on the DGV 
within this region and is common (9.82%). 
 




Supplementary Figure S2B 
 
 
Supplementary Figure S2: Deletions found in hESC lines that are present on 
the DGV. (A) A 1.5 Mb deletion was observed on chromosome 16p11.2 of KCL040 
hESCs containing 3 protein-coding genes. Two deletions and one duplication of this 
region have been reported and are present on the DGV at a relatively common 
frequency of 5.14%. (B) A homozygous deletion of 108.7 kb was observed on 
chromosome 19p12 in MasterShef11 hESCs. This region has been frequently 
observed to be deleted and duplicated in the human population (10.94%), and it does 
not contain any coding genes. 
 
Supplementary Figure S3A,B 
 
Supplementary Figure S3C,D 
 
 
Supplementary Figure S3: Duplication in hESCs that are not fully represented 
on the DGV. (A) A 330.8 kb duplication on chromosome 6p22.1, containing part of 
the Histone 1 gene cluster, was detected in KCL034 hESCs. A duplication of this size 
has not been reported, but a deletion (nsv601208) spanning most of the Histone 1 
cluster has been observed. (B) A 541.7 kb duplication on chromosome 18q23 was 
found in KCL037 hESCs. Although a duplication of this size has not been reported, a 
smaller duplication (nsv577794) spanning the two coding genes in the region has 
been observed. Only published CNVs larger that 10 kb are represented on this plot. 
(C) MasterShef3 harboured a 235.1 kb duplication on chromosome 17p11.2 
spanning the KCNJ12 and C17ORF51 genes. Although a duplication of this size has 
not been reported, a deletion of this region is on the DGV (esv2660756), as well as 
several duplications covering the majority of this CNV. (D) A 553.5 kb duplication was 
detected within an intron of SGCZ on chromosome 8p22 in Shef6 hESCs. Small 
duplications within this CNV have been reported, and a full deletion of the region is 
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYCornification and epidermal barrier defects are associated with a number of clinically diverse skin disorders. However, a suitable in vitro
model for studying normal barrier function and barrier defects is still lacking. Here, we demonstrate the generation of human epidermal
equivalents (HEEs) from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). HEEs are structurally similar
to native epidermis, with a functional permeability barrier. We exposed a pure population of hESC/iPSC-derived keratinocytes, whose
transcriptome corresponds to the gene signature of normal primary human keratinocytes (NHKs), to a sequential high-to-low humidity
environment in an air/liquid interface culture. The resulting HEEs had all of the cellular strata of the human epidermis, with skin barrier
properties similar to those of normal skin. Such HEEs generated from disease-specific iPSCs will be an invaluable tool not only for
dissecting molecular mechanisms that lead to epidermal barrier defects but also for drug development and screening.INTRODUCTION
The major function of the skin is to form a permeability
barrier between an organism and its external environment.
Integrity and cohesion of the ‘‘bricks andmortar’’ structure
of the outermost layer of epidermis, the stratum corneum
(SC), is essential for terrestrial life, the survival of which ul-
timately depends on maintenance of permeability barrier
homeostasis (Elias, 1983; Kalinin et al., 2002; Segre 2003).
The SC is composed of corneocytes (‘‘bricks’’) encased in
a lipid-rich extracellular matrix (ECM; ‘‘mortar’’) (Nemes
and Steinert, 1999).
Corneocytes, which are composed of keratin microfi-
brils surrounded by cornified envelopes (CEs), are the
final products of a linear keratinocyte differentiation
pathway from a mitotically active stratum basale (SB)
through a transcriptionally active stratum spinosum (SS)
and a stratum granulosum (SG) that transitions into anu-
cleate SC cells. The CEs are formed from precursor pro-
teins directly beneath the plasma membrane. Following
membrane disintegration, Ca2+ influx activates transgluta-
minase, which irreversibly crosslinks CE proteins around
filaggrin-associated keratin filaments. These CEs combineStewith secreted and processed lipids to form a functional
epidermal barrier.
The lipids are packaged into lamellar bodies in the SG
cells. The lamellar body, with all its contents, is secreted
in response to barrier perturbation. The secreted lipids of
the SC are processed into lamellar membranes (Figures 1A
and 1B). Lamellar bodies also contain proteolytic enzymes
and antimicrobial peptides, which when secreted along
with lipid contribute to permeability barrier function
(reviewed in Elias, 2012).
Ichthyoses and atopic dermatitis are due to polymor-
phisms or mutations in genes that control keratinocyte
differentiation, cornification, or lipid metabolism. These
changes lead to defects in epidermal permeability barrier
homeostasis that range from mild (can be easily mistaken
for normal dry skin) to life threatening (Segre 2006; Smith
et al., 2006; Richard, 2004). Although ichthyosis-like dis-
eases are also present in animals and can be mimicked
in transgenic mouse models, there are still no suitable
in vitro models for these diseases.
Human epidermal equivalents (HEEs) are in-vitro-gener-
ated 3D models that are widely used in experimental set-
tings. However, their utility for addressing themechanismsm Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authors 675
Figure 1. Epidermal Permeability Barrier within the SC of Normal Human Skin
(A) Schematic drawing of normal human skin, depicting the epidermal permeability barrier within the SC.
(B–F) TEM demonstrates the components of a competent permeability barrier in normal human skin. Lipids are packaged into lamellar
bodies (LBs) in the SG cells.
(B) LBs (arrows) are present in the uppermost SG cells. These LBs are not discrete droplets, but rather are part of a tubular network
extending from the Golgi.
(C) LBs, with all their contents, are secreted into extracellular space (asterisks) between the uppermost SG cells. De, desmosome.
(D) Close-up of LB morphology.
(E) Lipid from LBs is processed into lipid bilayers (asterisk) by SC enzymes that require acidity, thus forming lipid structures that are
impermeable to passage of water and ions.
(F) Ceramide-based lipids bind to the CE (asterisk), forming the cornified lipid envelope (CLE).
Scale bars are noted in each panel.
Stem Cell Reports
Epidermal Permeability Barrier 3D In Vitro Modelof various skin disorders, or for drug development and
testing, has been limited by the fact that previously engi-
neered HEEs do not form a fully developed epidermal
barrier. In spite of advances in HEE engineering, such as
integratingmelanocytes (Nissan et al., 2011), macrophages
(Linde et al., 2012), or dermal fibroblasts (Itoh et al., 2013)
and pluristratified epidermis, issues involving the genera-
tion of a functional permeability barrier in vitro remain
unresolved. Further, in vitro studies have been limited
by the fact that only a limited number of HEEs can be
generated from one sample of epidermis, and the primary
keratinocytes generated from this sample may contain pre-
viously unidentified polymorphisms in genes that modify
epidermal growth, differentiation, or barrier development.
HEEs generated from immortalized keratinocytes develop
even less well than those generated from primary keratino-
cytes (Go¨tz et al., 2012). Therefore, in order to develop a
HEE model that can be produced in an unlimited number
of genetically identical units, we turned to human embry-
onic stem cells (hESCs) and induced pluripotent stem
cells (iPSCs), primary cells that are capable of infinite
proliferation and whose genetic footprint can be fully
characterized.
We demonstrate here that by following an integrated,
highly reproducible four-step protocol, we were able to
differentiate hESCs/iPSCs into keratinocytes with gene-
expression profiles similar to those of normal human676 Stem Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authorskeratinocytes (NHKs, i.e., primary keratinocytes isolated
from biopsies of normal healthy skin). These hESC/iPSC-
derived keratinocytes were then used to generate HEEs
in an air/liquid interface culture exposed to sequential a
high-to-low humidity environment. HEEs generated from
hESC/iPSC-derived keratinocytes have a functional perme-
ability barrier similar to native human skin and are indis-
tinguishable from HEEs generated from NHKs under the
same condition. We are not aware of any other protocols
resulting in this functional endpoint.RESULTS
Reprogramming
Since the first iPSCs were derived, different reprogramming
approaches aimed at increasing their efficiency and mini-
mizing the potential for DNA damage have been developed
(reviewed in Bellin et al., 2012; Robinton and Daley 2012).
We used a nonintegrating, nonviral, synthetic, modified
mRNA system (Yakubov et al., 2010; Warren et al., 2010)
to reprogram human newborn fibroblasts (Figure S1 avail-
able online). In our hands, the reprogramming efficiency
was 0.76% (Figures 2A and S2), which is lower than that
reported byWarren et al. (2010).We chose two iPSC clones,
iKCL004 and iKCL011, that had a population doubling
time (PDT) similar to that of KCL034, a clinical-grade
(legend on next page)
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ments. Both iKCL004 and iKCL011 had a methylation
signature of PSCs, expressed pluripotency markers, and
were able to differentiate into cells of all three germ layers
in vivo (Figures 2B–2G and S3). Array comparative genomic
hybridization (CGH) did not detect any copy number
changes, using Promega male as a standard, over an
extended period of cell culture (>3 months) under feeder-
free conditions.
Efficient and Reproducible Differentiation of hESCs
and iPSCs into Keratinocytes
To recapitulate epidermogenesis, in the first step of kerati-
nocyte differentiation, which we termed ‘‘induction,’’ we
transferred a clinical-grade hESC line (KCL034) and two
iPSC lines (iKCL004 and iKCL011) from 5% O2 to atmo-
spheric O2, and exposed them to 25 ng/ml BMP4 and
1 mM of the carboxylic acid form of vitamin A, all-trans
retinoic acid (ATRA), for 7 days (Figure 3A). The lines did
not respond similarly to induction. Both iPSC lines ex-
pressed higher mRNA levels of the epidermal markers
integrin b4 (ITGB4) and keratin 14 (KRT14), suggesting
differentiation toward an epidermal lineage, whereas
hESC line KCL034 seemed to remain ‘‘undecided,’’ having
similar mRNA levels of these two epidermal markers and
a neural marker, oligodendrocyte lineage transcription
factor 2 (OLIG2; Figure 3B). In the next step, termed ‘‘selec-
tion,’’ we used native 3D decellularized human dermal
fibroblast (HDF) ECM as a growth-supporting platform.
This was done to mimic basement membrane (BM), which
is formed soon after epidermal induction during embr-
yogenesis (Figure S4). A week later, we purified epidermal
progenitor stem cells based on their preferential adherence
to collagen IV (Murray et al., 1979; Bickenbach and Roop,
1999). During the next ‘‘enrichment’’ step of our differenti-
ation protocol, the purified cells gave rise to a homoge-
neous population of keratin 14 (K14)+p63+ colonies, whichFigure 2. Generation and Characterization of Normal Human iPSC
(A) Trypan blue staining of colonies in one well of a six-well dish. Th
ments was 0.76%.
(B–D) DNA methylation analyses. Hierarchical clustering (B), methyla
both iKCL004 and iKCL011 have the methylation signature of PSCs. BJ,
for each cell line.
(D) Undifferentiated iKCL004 and iKCL011 cultured on HFF feeders
of PSCs.
(E) Expression of pluripotency markers is confirmed by alkaline phos
TRA-160, and TRA-1-81 in iKCL004 and iKCL011 lines.
(F) Differentiation of iKCL004 and iKCL011 into all three germ layers in
encapsulated and did not invade surrounding tissues. All sections w
brown (immunohistochemistry) or light blue (Alcian). Positive stainin
the teratoma tissue. Germ layer markers: Alcian blue/periodic acid Sc
and glial fibrillary acidic protein (GFAP) for ectoderm, and GATA4 and
See also Figures S1–S3.
678 Stem Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authorswas further amplified in the final ‘‘expansion’’ step of the
protocol (Figure 3C). p63 is a transcription factor that plays
a major role in maintaining the proliferative potential of
epithelial progenitors (reviewed in Blanpain and Fuchs,
2007). Whereas plating of cells on 3D HDF ECM rapidly
increased p63 mRNA expression, pluripotent markers,
such as the transcription factors Oct4 and nanog, steadily
decreased during differentiation (Figure 3D). K18, which
is expressed earliest during embryonic development, and
with its binding partner K8 can serve as a marker of simple
epithelium, was expressed at higher levels only during the
induction and selection steps, suggesting that the cells sub-
jected to our differentiation protocol were following a fate
similar to that which occurs for epidermal morphogenesis
during embryonic development. This four-step protocol
was highly reproducible. KRT14 expression increased
steadily during differentiation and there were no signifi-
cant differences among the three lines in multiple rounds
of the differentiation process (Figure 3E). The PD of
hESC/IPSC-derived keratinocytes did not differ much
from that of NHKs over a period of 5 weeks in culture
(Figure 3F).
hESC/iPSC-Derived Keratinocytes Are Very Similar to
Primary NHKs
Next, we compared enriched and expanded populations
(T3) of hESC/iPSC-derived keratinocytes with NHKs from
different donors in several different ways, and did not
find anymajor discrepancies. Differences in the expression
levels of KRT14 and p63 in multiple T3 populations of
hESC/iPSC-derived keratinocytes (n = 9; three biological re-
peats for each of three lines) and NHKs from three donors
were not statistically significant (Figure 4A). Flow-cytome-
try analysis of NHK and T3 populations of hESC/iPSC-
derived keratinocytes using K14 and integrin b4 as markers
did not identify any marked difference in the percentage
of double-positive (DP) cells; 95% of NHK, 87.8% ofs
e average reprogramming efficiency from two independent experi-
tion portrait (C), and principal component analysis (D) suggest that
parental HFFs. n = 3 biological replicates (rounds of differentiation)
and under feeder-free conditions display the typical morphology
phatase (AP) activity assay and immunostaining for NANOG, OCT4,
vivo is confirmed by detection of specific markers. Teratomas were
ere stained with hematoxylin and eosin (H&E). Specific stains are
g for mitochondrial complex IV type II confirms the human origin of
hiff (PAS)-stained cartilage and desmin for mesoderm, bIII tubulin
a-fetoprotein for endoderm.
Figure 3. Efficient and Reproducible Dif-
ferentiation of hESCs and iPSCs into Ker-
atinocytes
(A) Schematic of the differentiation proto-
col. T0 (day 0), T1 (day 7), T2 (day 14), and
T3 (day 28) represent time points at which
the cells were switched to a new culture
condition and/or collected for analyses.
(B) qPCR analysis measuring the expres-
sion of differentiation markers (epidermal:
ITGB4 and KRT14; neural: OLIG2) suggests
a difference in commitment toward epi-
dermal lineage at time point T1. n = 9 for
each cell line; each of three rounds of
differentiations (biological replicates) had
three technical replicates.
(C) Diversity is lost at later stages, and cell
colonies at the enrichment step are uni-
formly positive for keratinocyte markers
K14 (red) and p63 (green).
(D) qPCR analyses measuring expression of
differentiation markers at T0, T1, T2, and T3
of the differentiation protocol. Expression
of pluripotency markers OCT4 and NANOG
is diminished by the end of differentiation,
whereas KRT18 and p63 mRNA levels reflect
stages during epidermogenesis. n = 9 for
each cell line; each of three rounds of
differentiations (biological replicates) had
three technical replicates.
(E) Levels of KRT14 mRNA expressed during
three rounds of differentiation at four
different time points for each of lines
demonstrate the reproducibility of the
protocol. Absolute quantification was per-
formed using the ddCt method. GOI ex-
pression was normalized to the geometrical
mean of two HK genes (GAPDH and ElF4A2).
The SEM was calculated for mean expression
in KCL034, iKCL004, and iKCL011. n = 9 for
each cell line; each of three biological
replicates/rounds of differentiations had
three technical replicates.
(F) The proliferation rate of hESC/iPSC-
derived keratinocytes shows no marked
difference compared with freshly isolated primary NHKs over a period of 5 weeks. Statistical significance was calculated for each passage
using two-way ANOVA with Sidak’s multiple comparison test. Data are presented as a blank adjusted mean with SD (n = 3 biological
replicates for each cell line).
See also Figure S4.
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were K14+/integrin b4+ (Figures 4B and S5). Finally, we used
the HumanHT-12 Expression BeadChip whole-genome
expression array, which provides coverage for more than
47,000 transcripts and known splice variants, to compare
the transcriptomes of undifferentiated hESCs/iPSCs (T0),
hESC/iPSC-derived keratinocytes (T3), and NHKs fromStetwo different donors. The T0 and T3 transcriptomes were
analyzed as biological replicates from three independent
differentiation runs for each of three cell lines (KCL034,
iKCL004, and iKCL011). Principal component analysis
identified an expected pattern: hESC/iPSC-derived kera-
tinocytes at T3 were grouped together with NHKs and
were dissimilar to undifferentiated hESCs/iPSCs at T0m Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authors 679
Figure 4. Profiling of hESC/iPSC-Derived Keratinocytes
(A) qPCR analyses measuring expression of KRT14 and p63 in hESC/iPSC-derived keratinocytes at T3 (n = 9; three rounds of differentiation
for each of three lines) and NHKs (n = 2) found no significant difference between the two groups. Multiple t tests. Statistical significance
was determined using the Holm-Sidak method. For KRT14, p = 0.120881; for p63, p = 0.155472.
(B) Populations of hESC/iPSC-derived keratinocytes at T3 have a similar percentage of K14+/integrin b4+ cells as NHKs. The percentage is
an average from three rounds of differentiation for each of the three lines. At T0, no K14+/integrin b4+ cells were detected. Fluorescence-
activated cell sorting (FACS) images represent one of the three rounds.
(C and D) Scatterplots showing the relative expression of all genes on the chip.
(C) Global gene-expression profiles of NHKs from two donors (NHK1 and NHK2) shown as a scatterplot against each other.
(legend continued on next page)
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transcriptome of iKCL011-derived keratinocytes at T3 was
closer to the transcriptome of NHKs than to keratinocytes
derived from iKCL004 or KCL034. A scatter analysis of
gene expression in NHKs from two different donors
(NHK1 and NHK2) found that 939 transcripts (2.00%)
differed by >2-fold (Figure 4C). An average of these two
was then compared with an average of three biological
replicates from each of the three lines at T3. The keratino-
cytes derived from iKCL011 differed by >2-fold in only
155 transcripts (0.33%) from NHKs by >2-fold, whereas
iKCL004 (636 transcripts, 1.35%) and KCL034 (1,604
transcripts, 3.41%) were more distinct (Figure 4D). Among
all transcripts that were different from NHKs, only 122
(0.26%) were common to all hESC/iPSC-derived keratino-
cytes at T3 (Figure 4E). We profiled these 122 transcripts
using the GeneGo database (Thomson Reuters) for
Pathway Maps, Process Networks, Gene Ontology Net-
works, and Disease Biomarkers list, and found that 34
(0.07%) of them might have relevance to keratinocyte
biology (Tables S1–S5, S6, and S7).
We also looked at how reprogramming and differentia-
tion changed human leukocyte antigen (HLA) gene expres-
sion (Figure 4F). Although parental HDFs do express HLA
class I, the reprogrammed clonal lines iKCL004 and
iKCL011 do not, similarly to hESC line KCL034. Differenti-
ation into keratinocytes changed the global pattern.
Notably, HLA class I genes were turned on, implying that
the recipients of epidermis generated from the hESC-
derived keratinocytes as an off-shelf product would be in
need of immunosuppressive therapy, whereas that may
not be the case with iPSC-based autografts.
hESC-derived keratinocytes exhibit an epidermal tran-
scription program, and p63 is considered to be the main
transcription regulator of epidermogenesis and essential
for epidermal commitment of hESCs (Blanpain and Fuchs,
2007; Aberdam et al., 2007; Medawar et al., 2008; Pozzi
et al., 2009; Crum and McKeon 2010; Vanbokhoven
et al., 2011). Therefore, we compared the expression
profiles of 96 genes that, according to the NCI Pathway(D) Global gene-expression profiles of hESC/iPSC-derived keratinocyt
tiation for each line) shown in scatterplots against NHKs (average of n
as XY coordinates for each sample. Yellow lines indicate boundaries o
(E) Venn diagram of the transcripts with a 2-fold relative expression
keratinocytes at T3 shows that 122 out of >47,000 were common to
(F) Heatmaps showing relative expression patterns across multiple
searching for ‘‘HLA’’ within the ‘‘Gene Symbol’’ annotation, and p63-r
in the NCI Pathway Interaction database. The colors of the heatma
average for that gene across the samples. The values are the average
and T3. Transcripts for NHKs from two different donors are shown in
transcriptional network heatmap.
See also Figures S5 and S6, and Tables S1–S5, S6, and S7.
SteInteraction Database, constitute the p63 transcriptional
network. Of these genes, only three (ADA [OMIM: 608958],
SMARCD3 [OMIM: 601737], and YWHAQ [OMIM: 609009]
had R2-fold higher expression in NHK from two donors
than in all biological replicates of hESC/iPSC-derived
keratinocytes at T3. Similarly, only three of those 96 genes
(BBC3 or PUMA [OMIM: 605854], CDKN1A or p21 [OMIM:
116899], and SP1 [OMIM: 189906]) had R2-fold higher
expression in hESC/iPSC-derived keratinocytes at T3 than
in NHKs from two donors. None of these six genes are
known to be essential for epidermogenesis, although they
may be indirectly involved.
HEEs with a Functional Epidermal Permeability
Barrier Generated In Vitro
Molecular characterization suggested that our highly
reproducible protocol for differentiating hESCs/iPSCs into
keratinocytes yields a fairly pure population of cells that
are very similar to NHK. To test the capability of hESC/
iPSC-derived keratinocytes to generate multilayered
epithelium in vitro, we used the HEE model developed by
R.S., A.C., D.C., M.H., L.C., S.D. Peckenpacker, K. Park,
Y. Uchida, K.R. Feingold, P.M. Elias, D.I., and T.M.M.
(unpublished data). The HEEs generated using this proto-
col developed in vitro all of the cellular strata seen in the
human epidermis. Since they also developed normal
barrier properties in vitro, there was no need to implant
the organotypic cultures into immunodeficient mice,
which is a commonly used technique (Del Rio et al.,
2002). We assessed the integrity of the stratifying cultures
by measuring the transepithelial electric resistance (TEER),
which indicates changes in the transcellular and para-
cellular permeability of epithelial/epidermal in vitro cell
cultures. Within 2 weeks, the TEER in all cultures reached
>1,000 U, indicating the formation of a permeability
barrier and multilayered epithelia (Figures 5A and 5B).
Differentiation markers were normally expressed and
located (Figures 6A–6D). Since our system does not contain
mixed fibroblast-keratinocytes cultures, the basement
membrane zone (BMZ) generated by this system cannotes at T3 (average of n = 3 biological replicates/rounds of differen-
= 2). Normalized linear expression levels for each probe are plotted
f a 2-fold relative expression difference.
difference from NHKs in KCL034-, iKCL004-, and iKCL011-derived
all three lines.
samples for specific gene lists. HLA genes were selected by text
elated genes were identified from the p63 transcriptional network
ps indicate high (yellow) or low (blue) expression relative to the
of three independent runs for KCL034, iKCL004, and iKCL011 at T0
dependently on the HLA heatmap, and as an average on the p63
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Figure 5. Pluristratified HEEs Generated In Vitro from hESCs and iPSCs
(A) The TEER during HEE formation over a period of 14 days reflects permeability barrier formation (n = 4 for NHK, n = 12 for each of lines;
each point represents an average of measurements from three different spots). Error bars represent SD. Only 14-day-old HEE cultures that
displayed a TEER of >1,200 ohm cm2 were used for subsequent analyses unless indicated otherwise.
(B) H&E staining demonstrates normal morphology with the presence of all epidermal layers regardless of the source of keratinocyte
population. SB, stratum basale; SS, stratum spinosum.
Stem Cell Reports
Epidermal Permeability Barrier 3D In Vitro Modelbe equivalent to the BMZ of human skin. Nevertheless, in
our 3D cultures, basal-layer keratinocytes were secreting
ECM proteins, such as laminin, and assembling a BMZ-
like structure (Figures 6E and 6F).
Next, we examined the epidermal permeability barrier.
Lipid secretion appeared normal. Lamellar bodies and
extensive intercellular bilayers were detected in all cultures
(Figure 7A). The endoplasmatic reticulum (ER) Ca2+ store,
which is essential for normal keratinocyte signaling and
differentiation (Callewaert et al., 2003; Celli et al., 2012),
was detectable at day 8 of the culture (Figure 7B). Typically,
the Ca2+ gradient for normal epidermis has low levels in
the SB and lowest levels in the SS, followed by an increase
in extra- and intracellular Ca2+ that peaks within the SG
(Elias et al., 2002). In terminally differentiated air-lifted
cultures at day 14, HEEs generated from NHKs and hESC
(KCL034)-derived keratinocytes had the greatest density
of Ca2+ precipitates in the SG, whereas precipitates were
somewhat more diffuse in HEEs generated from iPSC-
derived keratinocytes (Figure 7C). However, the lanthanum
perfusion assay, which is used to depict pathways of water
movement through epidermis, demonstrated a functional
permeability barrier in all cultures: the passage of elec-
tron-dense lanthanum tracer was blocked by the epidermal
lipid barrier at the SG/SC interface and was not detected
in the SC (Figure 7D).DISCUSSION
We have described a stepwise protocol for manufacturing
in vitro HEEs, with all of the cellular strata and apparently682 Stem Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authorsnormal barrier properties seen in the human epidermis,
from hESCs and iPSCs.
When manipulating the cellular fate of pluripotent cells
in vitro, it is crucial to have a thorough understanding of
the embryonic morphogenesis of the target tissue in order
to achieve efficient production of the desired cell type (Hay
et al., 2008; Cheng et al., 2012). Epidermal morphogenesis
andhomeostasis are relativelywell described (Blanpain and
Fuchs, 2009; Simpson et al., 2011). After gastrulation, the
embryo surface emerges as a single layer of neuroectoderm,
which will ultimately specify the nervous system and skin
epithelium. This decision is guided by Wnt signaling,
which blocks the ability of the ectoderm to respond to
fibroblast growth factors (FGFs). In the absence of FGF
signaling, the cells express bone morphogenetic proteins
(BMPs) and become fated to develop into epidermis. In
contrast, neural fate develops when, in the absence of a
Wnt signal, the ectoderm is able to receive and translate
activating cues by FGFs, which then attenuate BMP
signaling through inhibitory cues (Chang and Hemmati-
Brivanlou, 1998; Stern, 2005). Similarly to our protocol,
most of the published protocols for differentiation of
PSCs (either mouse or human) into keratinocytes follow
this strategy (referenced in Figure S6). We introduced a
step in which we purified epidermal progenitor stem cells
based on their preferential adherence to collagen IV (Mur-
ray et al., 1979; Bickenbach and Roop, 1999). In our hands,
this step, which is a kind of physiological purification
step that puts a minimal stress on the cells, resulted not
only in a higher yield of hESC/iPSC-derived keratinocytes
but also in a purified population that was highly homo-
geneous and similar to NHKs (Figure 2). Homogeneous
Stem Cell Reports
Epidermal Permeability Barrier 3D In Vitro Modelpopulations of keratinocytes differentiated from disease-
specific iPSCs would be advantageous for addressing the
effects of suchmutations on keratinocyte biology (Mildner
et al., 2010; Simpson et al., 2010).
Although a link between the level of ambient humidity
and barrier development has been described in both ani-
mals (Hanley et al., 1997; Ko¨mu¨ves et al., 1999) and human
premature infants (Agren et al., 2006), and then recapitu-
lated in vitro with NHKs (Thakoersing et al., 2010), the
exact molecular mechanism is still unclear. A limited num-
ber of studies have addressed the relationship between
environmental humidity and barrier function in postnatal
epidermis (Takei et al., 2013; Katagiri et al., 2003; Sato et al.,
2002; Denda et al., 1998), and the results warrant further
work. Regardless, the model that we describe here would
have an unprecedented advantage for elucidating the
molecular mechanisms of barrier development, perturba-
tion, and recovery, as well as how mutations of genes
involved in cornification and lipid metabolism affect
permeability barrier homeostasis (Mildner et al., 2010;
Simpson et al., 2010).
Previous HEE models have developed some barrier prop-
erties (Gschwandtner et al., 2013; Thakoersing et al., 2012;
Ponec et al., 2001). The technique presented here is an
advance from previously published HEEs because it is
able to produce a HEE that not only shows morphologic
changes associated with barrier establishment but also
demonstrates the essential functional properties seen in
skin with a functional barrier. The HEEs described above
provide an effective block against water permeation, as
evidenced by their ability to block lanthanum and form a
calcium gradient. Further, this 3D model of HEEs with a
functional permeability barrier is highly reproducible
and has the potential to be easily scaled up and adapted
to cGMP requirements for the use in regenerative and
aesthetic medicine, as well as drug development. The
recent (March 2013) European Union ban on the import
and sale of cosmetics containing ingredients tested on
animals will increase the demand for efficient and cost-
effective alternative in vitro models that would not com-
promise consumer safety. HEEs with a functional perme-
ability barrier generated completely in vitro from either
hESCs or iPSCs, as described here, might present the best
available answer (Ku¨chler et al., 2013).EXPERIMENTAL PROCEDURES
mRNA Synthesis and Modifications
The intronless coding sequences (CDSs) of OCT4, SOX2, KLF4,
c-MYC, and LIN28 were retrieved from the National Center for
Biotechnology Information (NCBI). As previously described by
Warren et al. (2010), a KOZAK translational initiation signal was
added in the 50 UTR, whereas the 30 UTR was terminated with anStealpha-globin-driven oligo(dT) sequence for templated addition
of a polyA tail. The CDSs were then codon optimized with the
use of GeneOptimizer expert software (GENEART/Life Technolo-
gies). Codon optimization allows more efficient transcription
by avoiding RNA secondary structures, adjusting GC content,
and removing splice-sites. The gene encoding the destabilized
enhanced GFP (d2EGFP) codon from pRVGP-d2EGFP vector
(Addgene) and optimized OCT4, SOX2, KLF4, c-MYC, and LIN28
CDSs were synthesized and subcloned (GENEART/Life Technolo-
gies) into the pTNT plasmid vector, which was specifically de-
signed for in vitro expression (Promega). Plasmids were linearized
with BamHI. PCR templates were generated from the linearized
plasmids using the same upstream primers for all six constructs
and six different gene-specific, downstream T120-heeled reverse
primers for addition of the poly(A) tail. Quality control of the
PCR reaction was performed by capillary electrophoresis (Agilent
Bioanalyzer). The templates were transcribed with T7 polymerase
and further modified according to Warren et al. (2010). Modifica-
tions included the complete substitution of 5-methylcytidine
(5mC) for cytidine and the substitution of pseudouridine (psi)
for uridine to increase mRNA viability and ectopic protein expres-
sion. Furthermore, to promote efficient translation and increase
mRNA half-life, a synthetic 50 guanine cap 30-0-Me-m7G(50)
ppp(50)G was added and 50-triphosphates were eliminated by
Antarctic phosphatase treatment. The DNA template was removed
with DNase, and single-strand RNA (ssRNA) was purified with
spin columns. Quality control of the purified ssRNA product was
performed by capillary electrophoresis (Agilent Bioanalyzer; Fig-
ure S1). An ‘‘mRNA cocktail’’ containing OCT4, SOX2, KLF4,
C-MYC, LIN28, and d2eGFP in molar ratios of 3:1:1:1:1:1 at a final
concentration of 100 ng/ml was prepared (AmsBio), aliquoted for
single use, and frozen in single-use aliquots.Reprogramming
Mitotically inactivated foreskin fibroblasts (NuFF from donor 11;
AmsBio) were used as feeder cells and plated at a density of
2.5 3 105/well of a six-well dish coated with CELLstart (Life
Technologies). Human neonatal foreskin fibroblasts BJ (ATCC,
CRL-2522) were plated onto feeders 24 hr later at a density of
7,000/well. For each four wells to be transfected, 25 ml of RNAiMAX
(Sigma), a lipofectamine transfection reagent, was diluted in 225 ml
of Opti-MEM (Life Technologies) and mixed with 50 ml of mRNA
cocktail diluted in 200 ml Opti-MEM. The complex was incubated
at room temperature for 15min before 120ml was added dropwise
into each of four wells to be transfected. The culture medium was
refreshed 4 hr later with complete Pluriton medium (Stemgent)
supplemented with 300 ng/ml B18R (eBioscience). Transfection
was repeated for 17 consecutive days. On days 6–17, Pluriton was
preconditioned with NuFF feeders for 24 hr and supplemented
with 300 ng/ml B18R and 0.5 mM Na-butyrate. On days 18–21,
potential iPSC colonies were left to expand in complete Pluriton
with no other supplements. Ten colonies were picked based on
morphology on day 21, transferred onto human foreskin fibroblast
(HFF) feeders in KOSR-XF medium (Life Technologies), and
expanded. Two clones with a similar growth rate, iKCL004 and
iKCL011, were further characterized. The cells were cultured at
5% O2, 37
C, 5% CO2 throughout the reprogramming.m Cell Reports j Vol. 2 j 675–689 j May 6, 2014 j ª2014 The Authors 683
(legend on next page)
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hESC line KCL034 was derived and characterized as previously
described (Jacquet et al., 2013; Stephenson et al., 2012). Expression
of pluripotency markers and capability to differentiate into cells
of three germ layers were confirmed for both iKCL004 and
iKCL011 by methods that are routinely used for hESC lines in
our derivation center.
PSC lines were cultured under standard feeder-free conditions
on BD Matrigel hESC-qualified matrix (Becton Dickinson) in
mTESR1 medium (StemCell Technologies) under hypoxic (5% O2)
conditions.Methylation Assay
Genomic DNA was isolated from BJ parental fibroblasts (negative
control), KCL034 (positive control), iKCL004, and iKCL011. Each
sample of 500 ng DNA was bisulfite treated (EZ Zymo DNA Kit)
according to the manufacturer’s recommendations optimized
for 450k array. Epigenome-wide methylation (>480,000 CpG sites)
was analyzed using the Infinium Human Methylation 450 Bead-
ChipKit (Illumina) inbiological triplicates for each line.GenoSplice
Technology performed quality control, processing, and further
analyses of the data.3D HDF ECM
Preparation of decellularized 3D ECMwas performed as previously
described (Ilic et al., 2012).Differentiation Protocol
To induce differentiation, undifferentiated PSCs were transferred
into a 20%O2 atmosphere environment and treated with mTESR1
basal media supplemented with 1 mM ATRA (Sigma-Aldrich) and
25 ng/ml BMP4 (R&D) for 7 days (Induction). To select for cells
with early acquisition of ectodermal fate, the cells were harvested
and replated onto freshly prepared 3D HDF ECM at a density of
5–103 103 cells per cm2 and grown in Dulbecco’s modified Eagle’s
medium/Ham F12 (3:1; Life Technologies) supplemented with
1 mM ATRA and 25 ng/ml BMP4 for a further 7 days (Selection).
To enrich for putative epidermal progenitors, rapid adhesion to
type IV collagen-coated dishes was used, and the rapidly adhering
cells were cultured in defined keratinocyte-SFM supplemented
with 1 mM ATRA for 7 days (Enrichment). After that, the cells were
cultured in EpiLife medium (Life Technologies) for a further
7 days (Expansion) before final harvest and analysis.Proliferation Assay
All three lines andNHKswere seeded in six-well plates in triplicates
at a constant density of 4 3 105 per well. Every 7 days, cells wereFigure 6. The Distribution of Epidermal Markers in HEEs Mirrors t
(A) Immunostaining for three markers of keratinocyte terminal differe
expressed at the appropriate site, denoting normal epidermal differe
(B–D) Immunostaining for K14 (basal layer) and K10 (suprabasal layer
general) (D) demonstrates normal epithelial stratification in all HEE
(E and F) Basal layer keratinocytes express laminin (E) and form BM
stratum basale; TM, transwell membrane. Yellow arrowheads point to
Steharvested and the total number was counted. The cells were
then subcultured at the density described above. This cycle was
repeated for five passages. Average PDs were calculated for each
line and control at each passage according to the following
formula:
PD = (log 2)  1(logNt  logN0), where Nt = cell number at
harvest and N0 = cell number plated (4 3 105). The total PD level
was calculated as the cumulative of average PDs for five passages.
The PDT was calculated according to the following formula:
PDT = I/PD, where I = interval (days) between the passages (7).
Immunostaining
Samples were processed as previously described (Ilic et al., 2007;
Stephenson et al., 2012). The following antibodies were used:
rabbit anti-K14, rabbit anti-filaggrin, rabbit anti-involucrin, and
rabbit anti-loricrin (all from Covance); rabbit anti-laminin
(DAKO); mouse anti-p63 (Santa Cruz Biotechnology); rabbit anti-
fibronectin, mouse anti-collagen IV, mouse anti-collagen VII, and
rabbit anti-desmocollin 1 (all from Sigma-Aldrich); and rabbit
anti-p63, mouse anti-K10, and rabbit anti-collagen I (all from
Abcam). Secondary antibodies were obtained from Jackson Immu-
noResearch and Life Technologies.
Flow Cytometry with Confocal Imaging
Cells were incubated with PE-conjugated rat anti-CD104 (integrin
b4) antibody (BD PharMingen) for 1 hr, washed, fixed with 4%
(v/v) paraformaldehyde, and permeabilized with 0.1% Triton
X-100 in PBS. The samples were then incubated with fluorescein
isothiocyanate (FITC)-conjugated mouse anti-K14 antibody
(Abcam) for 1 hr, washed and incubated with Hoescht 33342
(Life Technologies) for 5 min. To set the gating, fluorescence
minus one (FMO) and single-stained compensation controls
were also prepared. For acquisition, 1 3 106 cells/per sample
were resuspended in 100 ml of 1% BSA/PBS. The data were acquired
on an ImageStreamX analyzer and analyzed with IDEAS software
(Amnis).
Quantitative RT-PCR
Data for quantitative PCR (qPCR) analysis were collected from
three independently performed differentiation rounds for each
of the cell lines. Total RNA extraction was performed at T0, T1,
T2, and T3 time points using the RNeasy kit (QIAGEN). For
cDNA preparation, the QuantiTect Reverse Transcription Kit (-
QIAGEN) was used. The primers are listed in Figure S7. KAPA
SYBR FAST Universal 23 qPCR Master Mix (Kapa Biosystems)
was used to set up the qPCR and run on a real-time PCR 7900HT
system (Applied Biosystems). All reactions were run in triplicates.
The data were collected and analyzed using GUSB and b-actinhat in Human Skin
ntiation: filaggrin, loricrin, and involucrin. Each of these markers is
ntiation.
s) (B), desmocollin 1 (suprabasal layers) (C), and p63 (basal layer in
cultures.
Z-like structure (F). BM, basement membrane; Cy, cytoplasm; SB,
laminin-positive staining of BM.
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Figure 7. HEE with a Functional Permeability Barrier
(A) Lipid bilayer formation assessed with TEM. Arrows, lamellar bodies; asterisks, lipid bilayers. Upper row: normal lipid secretion between
the SG and SC is seen in all cultures. Middle row: LBs are seen in the SG of all cultures (arrows). LB morphology was normal in all cultures,
although it appeared slightly smudged in KCL034. Bottom row: lipid was successfully processed into lipid bilayers (asterisks) in all cultures.
Like LB morphology, lipid bilayer morphology was normal in all cultures, although it seems slightly disrupted in KCL034.
(B) ER Ca2+ sequestration at day 7 of HEE culture in cells transfected with the ER-targeted Ca2+ sensor D1ER. Data are presented as the mean
of the intensity ratio (I) between the yellow-channel (higher Ca2+) and blue-channel (lower Ca2+) images (I(yfp)/I(cfp)) ± SEM. Higher
ratios denote higher Ca2+ stores in the ER. n = 10–14 cells from two biological replicates in each group. Significance was calculated using a
one-way ANOVA. Distributions with p < 0.05 were assumed to be statistically different based on unpaired t tests between the populations.
(C) The epidermal Ca2+ gradient captured on TEM as electron-dense Ca2+ deposits at day 14. Arrows indicate the direction from the basal
layer toward the SC. Ca2+ precipitates (black deposits) denote the presence of Ca2+ in the tissue. Precipitates are seen in the viable SG but
are absent from the SC, denoting a functional barrier to the passage of water and ions.
(D) Permeability barrier integrity assessed by lanthanum perfusion. Lanthanum is visualized as electron-dense deposits in the extracellular
spaces of the viable SG (arrowheads), demonstrating that lanthanum and, by extension, water and other small ions can pass between
keratinocytes in this stratum. In contrast, lanthanum spreads along the base of the SC, but cannot penetrate further into the SC because a
functioning lipid barrier is blocking its movement upward. All cultures demonstrated a functional permeability barrier.
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Epidermal Permeability Barrier 3D In Vitro Modelor GAPDH as the reference genes. The results were analyzed and
quantified using the ddCT method.Whole-Genome Gene-Expression Array
Total RNA from T3 cell populations and control primary NHKs
were reverse transcribed into cDNA using SuperScript III Reverse
Transcriptase (Life Technologies). In vitro transcription of
biotin-labeled antisense RNA (aRNA) was performed with the
TargetAmp-Nano labeling kit (Epicenter), and purification was
performed with the RNeasy Mini Kit (QIAGEN). The quality and
quantity of the resultant biotin-labeled aRNAs were assessed using
a Bioanalyzer (Agilent) and Qubit Fluorometer (Life Technologies).
A total amount of 750 ng of biotin-labeled aRNA in a 5 ml volume
was then used for the HumanHT-12 Expression BeadChip
whole-genome, gene-expression direct hybridization assay system
(Illumina) according to the manufacturer’s instructions and run
on the iScan system (Illumina).HEEs
A suspension of 0.25 3 106 neonatal NHKs or hESC/iPSC-derived
keratinocytes was seeded on a CELLstart CTS (Invitrogen)-
coated 12-well 0.4 mm PET Millicell Hanging Cell Culture Insert
(Millipore) in CnT.BM.1 medium with CnT-07 supplement
(CELLnTEC). Three days after seeding, the medium was switched
to CnT-BM.3 medium with CnT-02-3DF with supplement
(CELLnTEC). On day 4, the HEEs were air exposed by feeding
the insert from bottom of the well only. HEEs were grown in
a humidified (3100% relative humidity) or dry (30%–50%
relative humidity) incubator at 37C (R.S., A.C., D.C., M.H.,
L.C., S.D. Peckenpacker, K. Park, Y. Uchida, K.R. Feingold,
P.M. Elias, D.I., and T.M.M., unpublished data). The TEER was
measured with an epithelial voltohmmeter (EVOM; World Preci-
sion Instruments).ER Ca2+ Sequestration
Cells were transfected with the ER-targeted cameleon-based Ca2+
sensor D1ER (a gift from Dr. Amy Palmer; Palmer and Tsien,
2006) using the lipid-based TransIT transfection reagent (Mirus)
at a 1:3DNA/TransIT ratio. Transfection complexeswere assembled
30 min prior to cell plating by adding 1 ml D1ER (at a 1.3 mg/ml
concentration) and 3 ml transfection reagent per 100 ml serum-
free OptiMem. Cells were resuspended in low-calcium 154 CF
medium supplemented with 0.03 mM Ca2+ (GIBCO) at a density
of 0.5 3 106 cells per 1.5 ml. Transfection complexes were added
to the suspension at a 100 ml:1 ml complex/cell suspension ratio
and gently mixed by pipetting. The cells were then plated into
12-well inserts precoated with CELLstart at a 0.5 3 106 cells per
insert density and left with the transfection complexes overnight.
The medium was then switched to CnT.BM.1 medium with
CnT-07 supplement (CELLnTEC) for 3 days. Dual-channel fluo-
rescence measurements were recorded using a Zeiss LSM Meta
confocal system (Zeiss).Transmission Electron Microscopy
Samples were processed for transmission electron microscopy
(TEM) as previously described (Ilic et al., 2007; Tu et al., 2012).SteACCESSION NUMBERS
The methylation data have been deposited in the Gene Expres-
sion Omnibus under accession number GSE55006, and expres-
sion array data have been deposited under accession number
GSE55898.
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Synthetic modified mRNA quality control. All transcripts were generated with and without the 
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some sequence-context dependent “stuttering” of T7 RNA polymerase, quite similar to the 
physiological situation where mRNAs carry poly(A) tails of variable lengths. The high 
percentage (100%) of modified m5CTP and pseudo-UTP did not lead to premature termination 
with short products. Homogeneous highly modified in-vitro-transcribed mRNA products with 5’-
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Representative morphology of BJ fibroblasts plated on NuFF-feeders undergoing mRNA 
reprogramming. Day 1: Healthy cells after the first transfection. Day 3: Cell loss and cell 
rounding indicate high apoptotic rate. Day 5: Cells start undergoing MET and adopt an epithelial 
morphology. Day 7 and 9: Increase in cell death. Surviving cells are transitioning. Day 11: First 
sign of compaction and colony formation. Day 13: Increased compaction. Cells become smaller 
and more hESC-like. Day 15. Increase in colony size. Day 17: Last transfection. Only 
reprogrammed cells survived all 17 transfections and colonies keep increasing in size. Day 19: 
Cells are fed with NuFF-conditioned Pluriton. Colony center (arrow) keeps compacting as cells 
continue to reprogram and adopt morphology typical for hESC. Day 20: The colony center is 
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plating: All the colonies plated have attached start to expand. Scale bar in all panels is 50 µm, 
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Genotyping. Microsatellite markers specific for chromosomes 13, 18, 21, X and Y were 
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sizes in bp for markers on chromosomes 13, 18, and 21 are listed in the tables. The occasional 
1bp size difference is due to the size differentiation by capillary electrophoresis. 
	Figure S4 (related to Figure 3) 
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and assembled in 3D HDF ECM. 
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Confocal images of cells undergoing flow cytometry. DN, double negative (K14-/integrin 4-); SP, 
single positive (either K14+/integrin 4- or K14-/integrin 4+); DP double positive (K14+/integrin 
4+).  
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(A-C) Expression level averages shown for the sample groups in a principal component analysis 
plot (A and B). A single sphere represents each group and its 3D position is dictated by its value 
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represented by that component. (C) Distance measures between groups of samples. Euclidean 
distances for samples were calculated using Omics Explorer (Qlucore). 
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Gene Primer sequence 
ACTB Forward: 5′-CCATGTACGTTGCTATCCAG-3′ 
Reverse: 5′-CCTCGTAGATGGGCACAG-3′ 
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GUSB Forward: 5′-AAACGATTGCAGGGTTTCAC -3′ 
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OLIG2 Forward: 5′-GAAACTACCCCACCGACTCA-3′ 
Reverse: 5′-ACCCAAACTGTTTCCACAGC-3′ 
OCT4 Forward: 5′- GCCGTGAAGCTGGAGAAG -3′ 
Reverse: 5′- GTGTATATCCCAGGGTGATCC-3′ 
TAp63 Forward: 5′-GTCATTTGATTCGAGTAGAGGGG-3′ 
Reverse: 5′-CTGGGGTGGCTCATAAGGT-3′ 
 
The Primer3 website (http://frodo.wi.mit.edu/) was used to design the primers. The optimal 
annealing and extension temperature of the DNA Polymerase contained in the SYBR® Green 
PCR Master Mix (Roche) is 60°C, hence primers had to be chosen that were compatible with 
reagents to be used. Specificity of the primer pairs for relevant genes was verified by performing 
nucleotide alignment searches using BLAST.  
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Classification of 122 transcripts with 2-fold relative expression difference from NHK in all 
hESC/iPSC-derived keratinocytes at T3 using GeneGo database (Thomson Reuters) for 
Pathway Maps ranked using an enrichment score (p-value). Groups that have a relevance to 
keratinocyte biology are highlighted in yellow. 
  
	Table S2 (related to Figure 4) 
 
Classification of 122 transcripts with 2-fold relative expression difference from NHK in all 
hESC/iPSC-derived keratinocytes at T3 using GeneGo database (Thomson Reuters) for 
Process Networks ranked using an enrichment score (p-value). Groups that have a relevance to 
keratinocyte biology are highlighted in yellow. 
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Classification of 122 transcripts with 2-fold relative expression difference from NHK in all 
hESC/iPSC-derived keratinocytes at T3 using GeneGo database (Thomson Reuters) for Gene 
Ontology Processes ranked using an enrichment score (p-value). Groups that have a relevance 
to keratinocyte biology are highlighted in yellow. 
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Classification of 122 transcripts with 2-fold relative expression difference from NHK in all 
hESC/iPSC-derived keratinocytes at T3 using GeneGo database (Thomson Reuters) for 
Disease Biomarkers list, ranked using an enrichment score (p-value). None of them had a 
relevance to keratinocyte biology. 
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Genes that were 2-folds or greater expressed higher in NHK than in hESC/iPSC-derived 
keratinocytes at T3 (n=3 independent differentiation rounds for each of the line). 
  
	Table S7 (related to Figure 4) 
Genes that were 2-folds or greater expressed in hESC/iPSC-derived keratinocytes at T3 than in 
NHK (n=3 independent differentiation rounds for each of the lines). 
  
	Supplementary references: 
Aberdam, E., Barak, E., Rouleau, M., de LaForest, S., Berrih-Aknin, S., Suter, D.M., Krause, K.H., 
Amit, M., Itskovitz-Eldor, J., and Aberdam, D. (2008). A pure population of ectodermal cells 
derived from human embryonic stem cells. Stem Cells. 26, 440-444. 
Bilousova, G., Chen, J., and Roop, D.R. (2011). Differentiation of mouse induced pluripotent stem 
cells into a multipotent keratinocyte lineage. J. Invest. Dermatol. 131, 857-864. 
Guenou, H., Nissan, X., Larcher, F., Feteira, J., Lemaitre, G., Saidani, M., Del Rio, M., Barrault, 
C.C., Bernard, F.X., Peschanski, M., et al. (2009). Human embryonic stem-cell derivatives for 
full reconstruction of the pluristratified epidermis: a preclinical study. Lancet. 374,1745-1753. 
Hewitt, K.J., Shamis, Y., Carlson, M.W., Aberdam, E., Aberdam, D., and Garlick, J.A. (2009). 
Three-dimensional epithelial tissues generated from human embryonic stem cells. Tissue 
Eng Part A. 15, 3417-3426. 
Itoh, M., Kiuru, M., Cairo, M.S., and Christiano, A.M. (2011). Generation of keratinocytes from 
normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. Proc. 
Natl. Acad. Sci. USA. 108, 8797-8802. 
Iuchi, S., Dabelsteen, S., Easley, K., Rheinwald, J.G., and Green, H. (2006). Immortalized 
keratinocyte lines derived from human embryonic stem cells. Proc. Natl. Acad. Sci. USA. 103, 
1792-1797. 
Ji, L., Allen-Hoffmann, B.L., de Pablo, J.J., Palecek, S.P. (2006). Generation and differentiation of 
human embryonic stem cell-derived keratinocyte precursors. Tissue Eng. 12, 665-679. 
Metallo, C.M., Azarin, S.M., Moses, L.E, Ji, L., de Pablo, J.J. and Palecek, S.P. (2010). Human 
embryonic stem cell-derived keratinocytes exhibit an epidermal transcription program and 
undergo epithelial morphogenesis in engineered tissue constructs. Tissue Eng. Part A 16, 
213-23. 
Selekman, J.A., Grundl, N.J., Kolz, J.M., and Palecek, S.P. (2013). Efficient Generation of 
Functional Epithelial and Epidermal Cells from Human Pluripotent Stem Cells Under Defined 
Conditions. Tissue Eng. Part C Methods. [Epub ahead of print] 
van de Kamp, J., Kramann, R., Anraths, J., Schöler, H.R., Ko, K., Knüchel, R., Zenke, M., Neuss, 
S., and Schneider, R.K. (2012). Epithelial morphogenesis of germline-derived pluripotent 
stem cells on organotypic skin equivalents in vitro. Differentiation. 83, 138-147. 
Yoshida, S., Yasuda, M., Miyashita, H., Ogawa, Y., Yoshida, T., Matsuzaki, Y., Tsubota, K., 
Okano, H., Shimmura, S. (2011). Generation of stratified squamous epithelial progenitor cells 
from mouse induced pluripotent stem cells. PLoS One. 6, e28856. 
Induced Pluripotent Stem Cell Differentiation
and Three-Dimensional Tissue Formation Attenuate
Clonal Epigenetic Differences in Trichohyalin
Anastasia Petrova,1–3,* Antonio Capalbo,4,* Laureen Jacquet,1,* Simon Hazelwood-Smith,5
Dimitra Dafou,5,{ Carl Hobbs,6 Matthew Arno,7 Alessio Farcomeni,8 Liani Devito,1 Heba Badraiq,1
Michael Simpson,5 John A McGrath,2 Wei-Li Di,3 Jeffrey B Cheng,9 Theodora M Mauro,9 and Dusko Ilic1
The epigenetic background of pluripotent stem cells can influence transcriptional and functional behavior. Most of
these data have been obtained in standard monolayer cell culture systems. In this study, we used exome sequencing,
array comparative genomic hybridization (CGH), miRNA array, DNA methylation array, three-dimensional (3D)
tissue engineering, and immunostaining to conduct a comparative analysis of two induced pluripotent stem cell
(iPSC) lines used in engineering of 3D human epidermal equivalent (HEE), which more closely approximates
epidermis. Exome sequencing and array CGH suggested that their genomewas stable following 3 months of feeder-
free culture. While the miRNAome was also not affected,&7% of CpG sites were differently methylated between
the two lines. Analysis of the epidermal differentiation complex, a region on chromosome 1 that contains multiple
genes involved in skin barrier maturation (including trichohyalin, TCHH), found that in one of the iPSC clones
(iKCL004), TCHH retained a DNA methylation signature characteristic of the original somatic cells, whereas in
other iPSC line (iKCL011), the TCHH methylation signature matched that of the human embryonic stem cell line
KCL034. The difference between the two iPSC clones in TCHH methylation did not have an obvious effect on its
expression in 3D HEE, suggesting that differentiation and tissue formation may mitigate variations in the iPSC
methylome.
Introduction
Reprogramming somatic cells back to a pluripotentstate, similar to embryonic stem cells (ESCs), initially
required insertion of reprogramming transgenes and their viral
vectors into the host genome [1]. Previous studies demon-
strated that the effect of reprogramming on terminally differ-
entiated somatic cells was strikingly similar to that seen in
neoplastic transformation. Profound epigenetic changes led to
pluripotent plasticity and indefinite self-renewal of cells that
were previously committed to differentiation and had a limited
proliferation capacity. Although reprogramming-associated
point mutations might arise during the initial stages of
conversion [2], it instead appears that these point mutations are
predominantly a consequence of cloning individual cells with
different mutation histories [3]. In addition, induced pluripo-
tent stem cell (iPSC) clones might carry not only epigenetic
memory of their parental somatic cell origin [4] but also have a
unique pattern of DNA methylation as a result of nonuniform
epigenome transformation during reprogramming [5–7]. Spe-
cific genetic and epigenetic footprints influence the molecular
and functional properties of each iPSC clone. Altered gene
expression and distinct differentiation propensity among early
passage iPSC clones are likely to be largely attenuated through
continuous passaging [7]. In contrast, human pluripotent stem
cells, both human ESC (hESC) and especially iPSC, kept for
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extended period of time in culture are prone to genomic in-
stability [8,9]. It is unknown to what extent the cellular genetic
and epigenetic makeup or culture conditions contribute to ge-
nomic instability over time.
We reprogrammed human foreskin BJ fibroblasts (HFFs)
into iPSC using modified synthetic mRNA. Two iPSC clones,
iKCL004 and iKCL011, that we used to build human skin
equivalents [human epidermal equivalent (HEE)] with a func-
tional permeability barrier [10] showed subtle differences,
which prompted us to investigate in depth the genetic and epi-
genetic footprint of both lines. Since the focus of our work was
keratinocyte differentiation culminating in the stratum corneum
derived epidermal permeability barrier, we concentrated on the
epidermal differentiation complex (EDC) on chromosome 1,
which contains multiple genes involved in epidermal cornifi-
cation [11–19]. One of our clinical grade lines, KCL034, was
used as a control in most analyses [20].
Materials and Methods
Reprogramming
Human neonatal foreskin fibroblastsBJ (ATCC,CRL-2522)
were reprogrammed using modified synthetic mRNA as de-
scribed [10]. At day 2–17 of reprogramming, some cells also
were treated with 1mM pifithrin-a. Two clones with a similar
growth rate, one derived in the absence (iKCL004) and one in
the presence of 1mM pifithrin-a (iKCL011), were further
characterized; pluripotency marker expression and differenti-
ation into three germ layers in vitro and in vivo (teratomas)
revealed no obvious difference between the lines [10].
Cell culture
Undifferentiated hESC line KCL034 and iPSC lines,
iKCL004 and iKCL011, were cultured under standard feeder-
free conditions on Matrigel (Becton Dickinson) in mTeSR1
medium (STEMCELL Technologies) under hypoxic (5% O2)
conditions. Differentiation into keratinocytes and generation of
HEEs were described previously [10]. Transepithelial electrical
resistance was measured with epithelial voltohmmeter EVOM
(World Precision Instruments) as described [10,21]. Normal
human keratinocytes (NHK) were cultured in EpiLife (Life
Technologies). Human neonatal foreskin fibroblasts BJ were
cultured in Dulbecco’smodified Eagle’smedium supplemented
with 10% fetal bovine serum (Hyclone).
Quantitative reverse transcriptase–polymerase
chain reaction
Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN) following the manufacturer’s instructions. A 20-
min DNase I (Qiagen) treatment stepwas included to eliminate
the potential contamination of genomic DNA. cDNA was
generated by reverse transcription of total RNA (350ng) using
theRT2First StrandKit (Qiagen) following themanufacturer’s
instruction. The quantitative reverse transcriptase–polymerase
chain reaction (qPCR) consisted of 3mL of cDNA diluted 1:10
in water, 6.25mL of RT2 Real Time SYBR Green qPCR
Master Mix (Qiagen), and 400nM of each primer for a final
volume of 12.5mL. qPCR cycling conditions were as follows:
one cycle 95C for 10min; 40 cycles 95C for 15 s, 61C for 30 s
followed by melt curve acquisition from 59C to 95C with
0.5C increment. The BAX (Fw: CGGGTTGTCGCCCTTTTC
TA;Rv:CGGGGATTGATCAGACACGTA) and p21 (Fw:GC
ACTTTGATTAGCAGCGGA; Rv: AAGACAACTACTCCC
AGCCC) primers were designed using Primer3 software. The
GAPDH and ACTB primers were from PrimerDesign Ltd. All
samples were analyzed in triplicate, Ct values were determined,
and the expression was calculated by the 2-DDCt method.
GAPDH and ACTB were used for internal normalization.
Array comparative genomic hybridization
Array comparative genomic hybridization (CGH) was per-
formed following strict protocols for each of the different steps
as provided by themanufacturers of the reagents. CGHLabeling
Kit (Enzo Life Sciences) was used to label 1mg DNA. Post
labeling, DNA was purified with QIAquick PCR Purification
Kit (Qiagen). Labeling efficiency and yield were assessed by
spectrophotometry (NanoDrop). For hybridization, washing,
and scanning of arrays, we used an Agilent 4· 44K platform.
Image quantification, array quality control (QC), and aberration
detection were performed using feature extraction and DNA
Analytics software packages (Agilent); 95% of array data were
required to pass QC. The ADM-2 algorithm at threshold 6 (with
a three-probe sliding window providing a mean detection in-
terval of 200 kb) was used for aberration calling.
Exome sequencing
Exome sequencing was undertaken using genomic DNA
extracted from BJ parental fibroblasts before and after re-
programming (two clones: iKCL004 and iKCL011). Li-
braries were prepared using the SureSelect Human All Exon
Capture v4 (Agilent) and sequenced with 100-bp paired end
reads on the HiSeq platform (Illumina).
The resulting sequence reads were aligned to the reference
genome (hg19) with NovoAlign (Novocraft Technologies).
Duplicate reads, resulting from PCR clonality or optical du-
plicates, and readsmapped tomultiple locationswere excluded
fromdownstream analysis. Single-nucleotide substitutions and
small insertions or deletions were identified and quality filtered
within the SAMtools software package and in-house software
tools. Variants were annotated with respect to genes and
transcripts with the ANNOVAR tool.
To identify differentially arising new mutations, we un-
dertook a series of pairwise comparisons with the VarScan 2
tool. Comparison was limited to protein coding regions and
associated splice sites of genes defined by the GENCODE
project and sites at which >20 reads were observed in all
three samples (*90% of the targeted exome).
The resulting differentially called variants were filtered with
the following criteria to retain high quality changes; presence
of the new allele in >20% of reads in the sample in which the
variant was identified, absence of any reads representing the
alternative allele in the other two samples. Variants located
within repeat elements or segmentally duplicated regions were
excluded as likely alignment artifacts. The sequence align-
ments spanning each candidate variant were checkedmanually
using the Integrative Genomics Viewer 2.3.
miRNA expression analysis
miRNA expression was evaluated in biological triplicates of
undifferentiated hESC and iPSC using TaqMan Array
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MicroRNA Cards (Panel A and Panel B; Applied Biosystems).
The cards contain primer sets for 736 humanmiRNA sequences
(667 unique miRNAs), two sequences from Arabidopsis, eight
measurements of MammU6, and 22 RNU sequences.
The cell sampleswere collected in 200mLof total volume of
lysis buffer. MicroRNA isolation and purification were con-
ducted through the TaqManmiRNAABC (Anti-miRNABead
Capture) Purification Kit (Applied Biosystems). This system is
designed for rapid and specific purification of humanmiRNAs.
The Human Panel A or Panel B v3.0 Beads are super-
paramagnetic Dynabeads covalently bound to a unique set of
377 anti-miRNA oligonucleotides for each panel. The miRNA
isolation relies on hybridization of endogenous miRNAs to
the corresponding anti-miRNA oligonucleotides attached to the
beads. The purification protocol was followed according to
the manufacturers’ instructions. The bead hybridization and
the miRNA elution steps were conducted on the Thermo-
mixer R (Eppendorf). All the washing steps were performed
through the DynaMag-2 magnet (Applied Biosystems), to
clear up the solution from DNA, proteins, contaminants, and
residual binding solution, while keeping the miRNAs bound to
the beads.MicroRNAswere eluted in 20mL of final volume, to
concentrate them in the smallest possible volume. The cDNA
was then generated using the specific Megaplex RT Primer
pools A and B v3.0 (Applied Biosystems), which include 377
primer sets for each specific miRNA isolated in the previous
step, according to the manufacturer protocol. Preamplification
was performed according to manufacturer instructions and
protocol using the specific Megaplex PreAmp Primer pools A
and B v3.0 (Applied Biosystems). Briefly, 25mL of pre-
amplification products were added to 425mL nuclease-free
water and mixed with 450mL TaqMan Universal Master Mix
II, No UNG, then dispensed into the 384 wells by centrifuga-
tion on a Heraeus Megafuge 40 (Thermo Scientific) with the
proper TaqMan Low Density Arrays card adapters. The reac-
tions were incubated in a 384-well plate at 95C for 10min
followed by 40 cycles of 95C for 15 s and at 60C for 1min on
a ViiA 7 Real-Time PCR System (Applied Biosystems).
Raw data were analyzed using SDS software (Applied
Biosystems), and Ct values were used as a readout. Manual
inspection of all amplification plots was performed andmiRNAs
were excluded from the analysis if: Ct values were too high
(above 35, indicating a miRNA expression too low for ac-
curate detection) or if amplification was not achieved in at
least two samples (biological replicates). Datawere processed
through the RealTime StatMiner 5.0 software (Integromics).
Presence/absence indicators were compared among groups
through a logistic mixed model, with a slide specific intercept
to capture any overdispersion. TheP-values arising fromWald
tests on the group indicator coefficients were then adjusted
using Benjamini–Hochberg (BH) correction. The global false
discovery rate (FDR)was guaranteed below the rate of 5%.We
then proceeded to compare expression levels after Loess nor-
malization as this normalization approach has been shown to
effectively reduce standard deviations, increase sensitivity and
improve accuracy of differential miRNA expression detection,
and increase interplatform concordance [22]. Once again we
controlled for multiplicity using BH correction. Effect sizes
of miRNAs relative concentration were measured by means
of fold changes. Pearson’s correlation was used to generate
a heatmap for intragroup correlation plot among all biological
samples.
Hierarchical clustering analysis exploiting complete
linkage clustering method and Euclidean distance similarity
measure was performed on fold changes using KCL034 cell
lines as a calibrator to compare similarity of miRNA ex-
pression profile between iPSC and hESC lines. A Volcano
plot was generated using significance versus fold change on
the y- and x-axes, respectively.
Whole epigenome methylation array
Epigenome-wide methylation (>480,000CpG sites) was
analyzed using Infinium Human Methylation 450 BeadChip
Kit (Illumina) in biological triplicates of 500 ng bisulfite
treated DNA for each: BJ parental fibroblasts (negative
control), KCL034 (positive control), iKCL004, and iKCL011
line. GenoSplice Technology performed QC of the data, their
processing, and further analyses. Microarray data have been
deposited in the NCBI Gene Expression Omnibus (GEO)
with the accession number GSE55006.
Whole genome gene-expression array
Total RNA fromundifferentiated hESC and iPSC, aswell as
control primary (NHK) and hESC/iPSC-differentiated kerati-
nocytes (NHK), was reverse transcribed into cDNA using
SuperScript III Reverse Transcriptase (Life Technologies). A
total amount of 750 ng of biotin-labeled aRNA in a 5mL vol-
ume was then used for HumanHT-12 Expression BeadChip
whole-genome gene expression direct hybridization assay
system (Illumina) according to manufacturer’s instructions,
run on iScan system (Illumina) and analyzed as described [10].
All samples were analyzed as biological replicates from three
independent experiments. Microarray data have been depos-
ited in the NCBI GEO with the accession number GSE55898.
Immunostaining
Immunostaining has been performed as previously de-
scribed [23,24]. The following antibodies were used: rabbit
anti-KRT14 (Covance), -Oct4 (Santa Cruz Biotechnology),
-Sox2 (GeneTex), -LCE2B (Bioss), -p63 (Abcam), mouse
anti-cMyc (Santa Cruz Biotechnology), -Klf4 (ATGen),
-TCHH (ImmuQuest), and goat anti-LIN28 (R&D Systems).
Secondary antibodies were purchased from Jackson Im-
munoResearch. Actin stress fibers were visualized with
rhodamine-conjugated phalloidin and DNA with a nuclear
stain Hoechst 33342, both from Life Technologies.
Results
Reprogramming had no effect on mutation rate
and genomic stability of iKCL004 and iKCL011 lines
We first reprogrammed HFFs using synthetic modified
mRNA and following a modified version of the protocol
originally described by Warren et al. [25]. mRNA trans-
fection efficiency was on average >75% (Fig. 1A, B). We
increased the B18R concentration from 200 to 300 ng/mL to
further suppress the innate immune response triggered with
the exogenous mRNA cocktail. We also added B18R to the
medium 4 h prior the first transfection to precondition the
cells. Regardless, a regime of daily transfection had a del-
eterious effect on the cells; the vast majority did not survive
(Fig. 1C). At day 4 of reprogramming, we assessed the
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FIG. 1. Reprogramming HFFs using synthetic modified mRNA. (A) Synthetic modified mRNAs are translated into proteins.
Cells transfected with mRNA cocktail expressing reprogramming factors Klf4, cMyc, Oct4, LIN28, and Sox2. The 15-h time
point was chosen for analysis as it corresponds to the average peak expression time post-transfection of the different
reprogramming factors [25]. (B)More than 75% cells express reprogramming factors 15 h after mRNA transfection. The cells
were fixed and immunostained for Oct4, Klf4, Sox2, c-Myc, and LIN28 15h post-transfection with mRNA reprogramming
cocktail. Nuclei were visualized with Hoechst 33342. Total cell number was calculated. Data are presented as the mean of cells
positive for Oct4, Klf4, Sox2, c-Myc, and LIN28– standard error of the mean (n= 3). (C) Daily transfection had a deleterious
effect on the cells; vast majority did not survive. Day 0: the cells before the first transfection demonstrate normal morphology
and density. Day 3: decreased cell density and cell rounding indicate a high apoptotic rate. Day 6: massive apoptosis is seen.
Surviving cells start undergoing mesenchymal epithelial transformation and adopt an epithelial morphology. Day 9: surviving
cells continue to transition to an epithelial morphology. Day 12: first signs of compaction and colony formation are noted. Day
15: increased compaction. Cells become smaller and more hESC like. (D) Inhibitory effect of pifithrin-a on p53-mediated
transcription. qPCR expression analyses of the two p53 target genes, BAX, and p21 at Day 4 of reprogramming showed
decrease in BAX, but not p21 mRNA levels (n= 3 biological replicates). Transfected samples are compared with the negative
control (untransfected BJ cells). Data are given by normalized mean – standard error of the mean (n= 3); statistical sig-
nificance was calculated by two-way analysis of variance with Tukey post hoc test. ****P < 0.0001. (E) An average
reprogramming efficiency from two independent experiments was calculated as number of trypan blue positive colonies per
total number of cells plated per well of six-well dish. HFF, human foreskin fibroblast; hESC, human embryonic stem cell;
qPCR, quantitative reverse transcriptase–polymerase chain reaction.
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inhibitory effect of pifithrin-a on p53-mediated transcription
using qPCR. Transcription of two p53 target genes BAX and
CDKN1A (known as p21) was elevated > sixfold in cells
subjected to daily mRNA transfections, suggesting that p53
activation is induced by reprogramming itself. Pifithrin-a
treated cells had reduced levels of BAX, but no effect on
p21 transcription was observed (Fig. 1D). Daily mRNA
transfections caused massive cell death in both conditions,
although cell survival seemed to be somewhat higher in the
presence of pifithrin-a. Although reprogramming efficiency
was about 30% higher in the presence of 1 mM pifithrin-a
(0.86% vs. 0.66%), in our hands, it was still lower than the
reprogramming efficiency reported by Warren et al. [25]
regardless of the p53 inhibition (Fig. 1E).
Harsh conditions in cell culture might result in survival of
clones that carry growth-promoting mutation(s) associated
with tumorigenesis. To assess the genomic integrity of our
lines, we subjected iKCL004 and iKCL011 to array CGH at
two different time points, one at early passages (<10) and
the other about 3 months after the lines were adapted to the
feeder-free culture. Even though it is widely known that
extended periods of cell culture under feeder-free conditions
are linked to higher rates of chromosomal abnormalities in
pluripotent stem cells, especially iPSC [8,9], we did not
FIG. 2. hESC/iPSC miRNA profiling.
(A) Volcano plot showing no significant
miRNA differentially expressed between
two iPSC lines (n= 3 biological replicates
per group). Significance versus fold change
on the y- and x-axes, respectively, is plot-
ted. Horizontal black lines represent the
statistical significance threshold. Green
and red lines represent the upper and lower
fold changes thresholds, respectively. (B)
Correlation heatmap among the profiles of
miRNA expression of all the samples an-
alyzed (three biological replicates per each
of two iPSC and one hESC line). Superior
to the heatmap and on the left of it three
biological replicates and their relative
grouping are reported. The color intensity
varies in function of the Pearson correla-
tion index ranging from green to red for a
lower or a higher correlation, respectively.
The proper numerical value of correlation
between each couple of sample is reported
within the squares at the intersections.
(C) Volcano plot showing no significant
miRNA differentially expressed between
two iPSC lines, iKCL004 and iKCL011,
and a control hESC line KCL034. (D)
Hierarchical clustering of fold-change
values obtained from the comparison of the
two iPSC lines against hESC line used as a
calibrator. The analysis was performed
exploiting complete linkage, Euclidean
distance, and z-score normalization, and
the heatmaps, beside reporting four clusters
of genes showing a similar behavior
(highlighted by the four groups of dendo-
grams with the same colored halo below
the heatmaps), do not reveal significant
differences among the samples analyzed.
(E) Hierarchical clustering of fold-change
values obtained from the comparison of the
two iPSC lines against hESC line used as a
calibrator. The analysis was performed
exploiting complete linkage, Euclidean
distance, and z-score normalization and the
heatmaps, beside reporting four clusters of
genes showing a similar behavior (high-
lighted by the four groups of dendograms
with the same colored halo below the
heatmaps), do not reveal significant dif-
ferences among the samples analyzed.
iPSC, induced pluripotent stem cell.
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detect any copy number changes using array CGH in either
iKCL004 or iKCL011 over 3 months of culture on Matrigel
in mTeSR1 medium [10], suggesting that the genome of
both lines is relatively stable. Next, we subjected iKCL004,
iKCL011, and parental BJ fibroblast to exome sequencing.
The comparative analysis did not identify any alleles that
had arisen during the reprogramming, which suggested that
the rate of mutation was not substantially affected during
reprogramming of BJ fibroblasts.
miRNAome is similar in both iPSC lines
Recently, it has been demonstrated that miRNAs can
contribute to iPSC somatic donor memory [26]. Therefore,
we evaluated miRNA expression in biological triplicates
of iKCL004 and iKCL011 using TaqMan Array Micro-
RNA Cards containing primer sets for 736 human miRNA
sequences. This miRNA profiling technology is a me-
dium throughput approach that holds the advantage of high
FIG. 3. Whole epigenome methylation profile. (A) Comparative analysis of iKCL004 and iKCL011 methylome found that
35,550 (7%) of CpGs are differently methylated between the two lines. Nearly a half of them were hypermethylated (18,815 or
53%) and the other half was hypomethylated (16,737 or 47%). Nearly twice more hypomethylated sites (3,516 or 18%) were
found in body than hypermethylated sites (1,924 or 9%). Both hyper- and hypomethylated CpG sites were predominantly
distributed in islands, shores, and shelves, across all chromosomes. (B) Manhattan plot, color-coded by chromosomes.
FIG. 4. DNA methylation of EDC genes. (A) EDC on chromosome 1. Pale yellow background indicates genes involved in
keratinocyte terminal differentiation which with methylation we analyzed individually. (B) DNA methylation of TCHH
family shown as lollipop diagram and bar charts. In the lollipop diagram, black circles represent CpG sites that have Beta
value ‡0.5 and white circles represent CpG sites with Beta value <0.5. The difference of 0.4 (40%) is considered significant
(star) in a bar chart diagram. EDC, epidermal differentiation complex; TCHH, trichohyalin.
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accuracy thanks to the use of single assay TaqMan chem-
istry [27]. After filtering, as described in ‘‘Materials and
Methods’’ section, and Loess-based normalization, we com-
pared 383 miRNA expressed in iKCL004 and iKCL011. We
found that the average fold change was 0.9998, with a con-
fidence interval 0.995–1.004, P= 0.702. Kendall’s Tau rank
correlation coefficient was 0.860, P< 0.0001 (if the two
rankings are the same, the value is 1 and if they are com-
pletely independent, the value is 0). No miRNA was flagged
as differentially expressed after multiplicity correction with
Benjamini–Hochberg FDR method at the 5% level (Fig. 2A).
Considering that even minimal cellular variation of miRNA
concentration can be biologically significant, we next re-
peated every single miRNA analysis at the 10% and 20%
levels, which are less stringent. Even with these larger values
for the Type I error, no miRNA was selected as statistically
significant in any analysis.
We then analyzed the relative expression miRNA profiles
of iKCL004 and iKCL011 against the hESC line KCL034 to
see if one of the two iPSC lines was more similar to hESC.
Pearson’s correlation showed high similarity between all
cell samples analyzed (>0.78; Fig. 2B). No significance was
found between miRNA signature of KCL034 compared with
iKCL011 and iKCL004 (Fig. 2C, E).
iKCL004 and iKCL011 have a different
methylation signature
During reprogramming, to acquire pluripotency potential,
the DNA of somatic cells undergoes a global epigenetic
transformation. Variability of methylation in iPSC lines very
often influences the molecular and functional properties of
iPSC lines [2,7,28]. Although epigenome-wide methylation
analysis suggested that both iKCL004 and iKCL011 display
the methylation signature of pluripotent stem cells [10],
about 7% of CpG sites (35,550 out of >480,000) were dif-
ferentially methylated (difference >0.2) between iKCL004
and iKCL011, suggesting that these iPSC lines are likely to
harbor spots of aberrant epigenetic reprogramming (Fig. 3A, B).
Although the differences in DNA methylation signature
appeared to have no effect on miRNA expression profile
(Fig. 2), they may influence the differentiation propensity of
these two iPSC lines.
Since our group is primarily interested in differentiation of
hESC and hiPSC into keratinocytes, especially the formation of
the epidermal permeability barrier, we next focused on the EDC
on chromosome 1. EDC is a &2-Mb region at chromosome
band 1q21, which contains multiple conserved gene encoding
stratum corneum proteins [11–19] (Fig. 4A). We found no dif-
ference in DNA methylation of regions associated with either
late cornified envelope or small proline-rich region (SPRR)
families, as well as with filaggrin, filaggrin 2, involucrin, and
loricrin (Supplementary Table S1; Supplementary Figs. S1–S3;
FIG. 5. hESC/iPSC-derived keratinocytes. (A, B) Heat-
map and principal component analysis of EDC genes in
undifferentiated (T0) hESC (KCL034) and iPSC (iKCL004
and iKCL011), hESC/iPSC-derived keratinocytes (T3), and
NHK and fibroblasts (BJ) parental to iPSC lines. (C) KRT14
and p63 expression in hESC/iPSC-derived keratinocytes
suggest that they would be comparable with cells in basal
layer of epidermis. NHK, normal human keratinocytes.
‰
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Supplementary Data are available online at www.liebertpub
.com/scd). However, in iKCL004, but not in iKCL011, tricho-
hyalin (TCHH) retained a DNA methylation signature charac-
teristic of somatic cell origin (Fig. 4B). TCHH, an intermediate
filament-associated protein, similar to involucrin, is transiently
expressed during late stages of skin development, as well as in
development of the inner root sheath of the hair follicle [29–32].
TCHH expression pattern in HEE resembles
neonatal, not adult, skin
Next, we investigated whether the difference in methylation
signature of TCHH in iKCL004 had an effect on expression of
EDC genes and hESC/iPSC differentiation into keratinocytes.
We compared the transcriptome of EDC genes in undifferenti-
ated hESC/iPSC (T0), hESC/iPSC-derived keratinocytes (T3),
and NHK from skin biopsies of two donors. The T0 and T3
transcriptomeswere analyzed as biological replicates from three
independent sets of differentiation experiments. Heatmaps
showing relative expression for EDC genes and the principal
component analysis clearly demonstrate that (i) hESC/iPSC-
derived keratinocytes at T3 cluster together with NHK; and that
(ii) no significant difference was observed between iKCL004
and iKCL011 (Fig. 5A, B). hESC/iPSC-derived keratinocytes,
in general, express keratin 14 (KRT14) and TP63 (p63)
(Fig. 5C), which are markers of keratinocytes in the stratum
basale of human epidermis. No TCHH expression at protein
levelwas detected in any of the samples (data not shown),which
suggested that aberrant DNA methylation of TCHH gene did
not affect hESC/iPSC differentiation into keratinocytes and did
not induce its expression in KRT14+/p63+ cells.
TCHH is not normally seen in interfollicular adult skin, but
is found only in the stratum granulosum (SG) of neonatal skin
[30]. To examine TCHH expression in a neonatal model of
SG cells, we generated multilayered HEEs from the hESC/
iPSC-derived keratinocytes and primary human foreskin
keratinocytes following our high-to-low humidity protocol
[10,21]. All resulting HEEs, regardless of the keratinocytes’
origin, had a similar TCHH expression, which resembled the
pattern seen in the neonatal skin (Fig. 6). The data suggest
that a difference between two iPSC clones in DNA methyl-
ation of TCHH gene did not have an obvious effect at TCHH
expression pattern in three-dimensional (3D) HEEs.
Discussion
Exome sequencing of both iPSC lines and parental HFFs BJ
confirmed that the reprogramming used to generate these cells
did not lead to increased number of mutations. Moreover, both
lines were genetically identical to their parental line. Kar-
yotype of both iPSC lines was stable over the extended periods
of in vitro culture under feeder-free conditions. Cytogenetic
resilience of iKCL004 and iKCL011 lines might arise from
particular aspects of cell culture, as well as reflect a genetic
predisposition to chromosomal stability/instability, commonly
noted with hESC lines [8,9,33,34]. hESC is derived from
embryos created by in vitro fertilization, often from donors
that have problems with fertility. Prevalence of balanced
structural chromosomal abnormalities in patients seeking as-
sisted conception is higher than in general population and it is
reasonable to speculate that undiagnosed genetic mutations
might be underlying cause of infertility, and consequently,
genomic instability in the hESC lines.
Although ideally, hiPSC should be functionally and mo-
lecularly indistinguishable from hESC, often that is not the
case [35]. These differences may manifest only upon dif-
ferentiation, not in the pluripotent state; miRNA profile [36]
and residual DNA methylation [28] are likely to influence
differentiation propensity. For example, upon induction of
keratinocyte differentiation with bone morphogenic protein
4 and all-trans retinoic acid, none of the three lines used in
the study (iKCL004, iKCL011, and KCL034) responded
equally [10]. Over time, by end of the differentiation, these
differences were diminished, probably through selection and
purification by selective attachment to collagen IV-coated
surface as described [10]. Indeed, the miRNA profile of both
iPSC lines, iKCL004 and iKCL011, was not significantly
different from control hESC KCL034 line (Fig. 2). Inter-
estingly, epigenome-wide methylation (>480,000CpG sites)
analysis using Infinium Human Methylation 450 BeadChip
Kit found more differences between iKCL004 and iKCL011
(7%) than between either iKCL004 and KCL034 (5%) or
iKCL011 and KCL034 (4%) (Fig. 3) [10].
Differently methylated CpG sites are in general randomly
scattered across the genome. Within one gene, DNA methyl-
ation often is significantly different on only one or two CpG
sites (Supplementary Table S1; Supplementary Figs. S1–S3).
FIG. 6. The expression pattern of TCHH in human epidermal equivalents is similar to human neonatal skin. Localization
in the granular layer corresponds to expression of other proteins involved in cornification such as LCE2B.
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One of the few genes in which DNA methylation was signifi-
cantly different on most of its CpG sites (12 out of 21) was
TCHH (Supplementary Table S1; Fig. 4). TCHH is normally
expressed in the inner root sheet and medulla of hair follicles
and transiently in the SG and corneum of the epidermis during
late stages of fetal skin development [30]. It is also present in
isolated cells of the SG of some regions of epidermis (Sup-
plementary Fig. S4) [37]. While in normal skin, TCHH ex-
pression correlateswith expression of filaggrin, this correlation
is lost in psoriatic skin [38]. By forming multiple complex
cross-links with itself and other structural proteins, including
epiplakin, involucrin, and SPRRs, TCHH is important for the
mechanical strength of the hair follicle and epithelial tissues
such as hard palate or filiform papillae of the tongue [39].
TCHH is also thought to be a potential major autoantigen in
alopecia areata [40]. CpG sites within TCHH were mostly
hypomethylated in HFFs and hypermethylated in the hESC
KCL034 line (Fig. 4). TCHH methylation pattern suggested
that iKCL004 retained methylation signature of the parental
fibroblasts, whereas iKCL011 matched the hESC line. We
found, however, no differences in TCHH expression pattern in
HEE (Fig. 6) suggesting that DNA methylation of the TCHH
gene in establishing an iPSC population may not play an
essential role.
The data presented in this study highlight our limited un-
derstanding of the epigenetic heterogeneity. It is generally
considered that faithful genetic and epigenetic reprogramming
is critical to obtain fully naive ‘‘ground state’’ of pluri-
potency.’’ Indeed, DNA methylation defects have been linked
to multiple human diseases [41]. However, as there are sig-
nificant differences among the genomes of healthy human in-
dividuals that do not affect normal fetal and postnatal growth, it
is quite plausible that the same rule can also be applied for the
epigenome–DNA methylation status may not be equally im-
portant for regulation of all genes. Differentiation and tissue
formation may, in some cases, attenuate variations in iPSC
methylome. These findings should enhance future research
using these 3D cultures, since iPSC methylome differences
produced by the transformation and culture techniques do not
result in phenotypic variation.
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Supplementary Data
SUPPLEMENTARY FIG. S1. DNA methylation of LCE family. DNA methylation of LCE gene family shown as
lollipop diagram and bar charts. In lollipop diagram, black circles represent CpG sites that have Beta value ‡0.5 and white
circles represent CpG sites with Beta value <0.5. The difference of 0.4 (40%) is considered significant (star) in bar chart
diagram. LCE, late cornified envelope.
SUPPLEMENTARY FIG. S2. DNA methylation of SPRR family. DNA methylation of SPRR gene family shown as
lollipop diagram and bar charts. In lollipop diagram, black circles represent CpG sites that have Beta value ‡0.5 and white
circles represent CpG sites with Beta value <0.5. The difference of 0.4 (40%) is considered significant (star) in bar chart
diagram. SPRR, small proline-rich regions.
SUPPLEMENTARY FIG. S3. DNA methylation of LOR, INV, and FLG family. DNA methylation of genes encoding
loricrin, involucrin, and filaggrin family shown as lollipop diagram and bar charts. In lollipop diagram, black circles
represent CpG sites that have Beta value ‡0.5 and white circles represent CpG sites with Beta value <0.5. The difference of
0.4 (40%) is considered significant (star) in bar chart diagram.
SUPPLEMENTARY FIG. S4. TCHH expression in adult
epidermis. Isolated cells of the stratum granulosum were
positive for TCHH in some regions of adult epidermis.
TCHH, trichohyalin.
Supplementary Table S1. Average Beta values
of CpG Methylation in Parental BJ Fibroblast,
iKCL004, iKCl011, and KCL034
CpG sites that have Beta value ‡0.5 are highlighted pink, whereas
CpG sites with Beta value <0.5 are highlighted green.
Illumina Target ID
Methylation Site 
Coordinate (hg18) Gene Name BJ iKCL004 iKCL011 KCL034
cg05388137 chr1:150323493 TCHHL1 0.54 0.78 0.50 0.48
cg10827479 chr1:150327987 TCHHL1 0.73 0.85 0.86 0.87
cg08918985 chr1:150328157 TCHHL1 0.32 0.86 0.81 0.78
cg01925883 chr1:150329191 TCHHL1 0.32 0.86 0.85 0.84
cg16689481 chr1:150346337 TCHH 0.85 0.92 0.95 0.96
cg15973171 chr1:150346978 TCHH 0.33 0.38 0.62 0.61
cg14661959 chr1:150347095 TCHH 0.17 0.48 0.81 0.74
cg04938315 chr1:150347167 TCHH 0.25 0.34 0.66 0.58
cg05523911 chr1:150347626 TCHH 0.21 0.30 0.74 0.63
cg04986781 chr1:150347941 TCHH 0.39 0.58 0.85 0.75
cg03438305 chr1:150349549 TCHH 0.15 0.40 0.58 0.57
cg05464302 chr1:150349653 TCHH 0.04 0.19 0.46 0.36
cg10234068 chr1:150349900 TCHH 0.14 0.40 0.69 0.74
cg24645670 chr1:150349916 TCHH 0.08 0.35 0.65 0.72
cg24880024 chr1:150350333 TCHH 0.10 0.16 0.66 0.40
cg05642734 chr1:150350971 TCHH 0.07 0.17 0.71 0.39
cg18287591 chr1:150351757 TCHH 0.10 0.36 0.76 0.52
cg20795569 chr1:150351760 TCHH 0.08 0.34 0.83 0.55
cg00584000 chr1:150351811 TCHH 0.11 0.24 0.90 0.60
cg20592707 chr1:150353247 TCHH 0.54 0.77 0.80 0.81
cg26685752 chr1:150353316 TCHH 0.75 0.89 0.75 0.80
cg02211983 chr1:150353503 TCHH 0.35 0.65 0.44 0.36
cg22603037 chr1:150353891 TCHH 0.30 0.67 0.50 0.41
cg11166365 chr1:150353939 TCHH 0.79 0.83 0.83 0.82
cg23021650 chr1:150354513 TCHH 0.72 0.85 0.83 0.80
cg10321714 chr1:150546692 FLG 0.77 0.87 0.86 0.87
cg01880149 chr1:150551225 FLG 0.73 0.87 0.84 0.87
cg07548383 chr1:150551451 FLG 0.70 0.78 0.78 0.77
cg12136906 chr1:150552501 FLG 0.86 0.94 0.93 0.93
cg03465714 chr1:150552535 FLG 0.64 0.76 0.76 0.76
cg22719314 chr1:150556958 FLG 0.74 0.77 0.67 0.71
cg19855573 chr1:150564497 FLG 0.61 0.75 0.72 0.69
cg13447818 chr1:150565508 FLG 0.70 0.80 0.64 0.67
cg10500702 chr1:150565665 FLG 0.53 0.62 0.51 0.45
cg26390526 chr1:150565702 FLG 0.68 0.85 0.74 0.63
cg20825532 chr1:150588873 FLG2 0.75 0.83 0.73 0.69
cg07134486 chr1:150597372 FLG2 0.77 0.82 0.83 0.84
cg20694572 chr1:150598153 FLG2 0.51 0.84 0.83 0.79
cg17542852 chr1:150599275 FLG2 0.42 0.82 0.80 0.81
cg03957898 chr1:150600047 FLG2 0.24 0.51 0.27 0.16
cg23812489 chr1:150600220 FLG2 0.77 0.90 0.87 0.87
cg03439811 chr1:150600546 FLG2 0.69 0.78 0.76 0.72
Average	  Beta	  Value
cg05248781 chr1:150749823 LCE5A 0.57 0.82 0.78 0.75
cg16320885 chr1:150749828 LCE5A 0.74 0.88 0.86 0.90
cg01868128 chr1:150750299 LCE5A 0.27 0.58 0.51 0.47
cg00011513 chr1:150751010 LCE5A 0.16 0.53 0.51 0.49
cg23724738 chr1:150805004 LCE3E 0.31 0.71 0.71 0.67
cg07476201 chr1:150805050 LCE3E 0.18 0.47 0.42 0.38
cg24000437 chr1:150805481 LCE3E 0.27 0.79 0.75 0.75
cg23110514 chr1:150805512 LCE3E 0.28 0.69 0.60 0.64
cg22519158 chr1:150818799 LCE3D 0.44 0.69 0.65 0.66
cg20676475 chr1:150819118 LCE3D 0.38 0.78 0.77 0.76
cg02054568 chr1:150819720 LCE3D 0.42 0.67 0.63 0.65
cg18116418 chr1:150819868 LCE3D 0.24 0.65 0.62 0.57
cg26135325 chr1:150861946 LCE3A 0.63 0.83 0.81 0.80
cg20634798 chr1:150861975 LCE3A 0.60 0.80 0.75 0.76
cg27206522 chr1:150862253 LCE3A 0.30 0.63 0.59 0.59
cg26466858 chr1:150862466 LCE3A 0.26 0.69 0.84 0.77
cg13071333 chr1:150862506 LCE3A 0.07 0.60 0.88 0.80
cg08732526 chr1:150862606 LCE3A 0.33 0.71 0.89 0.91
cg09895009 chr1:150862616 LCE3A 0.38 0.71 0.87 0.89
cg07821297 chr1:150862801 LCE3A 0.43 0.72 0.74 0.73
cg16046605 chr1:150863037 LCE3A 0.35 0.45 0.44 0.42
cg11680857 chr1:150901824 LCE2D 0.48 0.56 0.56 0.89
cg22044308 chr1:150901850 LCE2D 0.69 0.88 0.88 0.90
cg16361876 chr1:150902502 LCE2D 0.22 0.52 0.50 0.51
cg21312148 chr1:150902698 LCE2D 0.28 0.80 0.74 0.72
cg01433225 chr1:150903458 LCE2D 0.59 0.78 0.77 0.79
cg13844662 chr1:150913157 LCE2C 0.19 0.33 0.29 0.29
cg00406188 chr1:150913840 LCE2C 0.66 0.91 0.90 0.90
cg03960217 chr1:150914401 LCE2C 0.25 0.61 0.59 0.56
cg26919735 chr1:150914417 LCE2C 0.56 0.79 0.76 0.76
cg06198390 chr1:150915350 LCE2C 0.51 0.76 0.76 0.77
cg19371339 chr1:150923822 LCE2B 0.22 0.60 0.53 0.43
cg08279693 chr1:150924574 LCE2B 0.65 0.89 0.89 0.90
cg24332770 chr1:150924911 LCE2B 0.12 0.52 0.47 0.42
cg25098401 chr1:150925031 LCE2B 0.45 0.62 0.64 0.63
cg21754343 chr1:150925421 LCE2B 0.56 0.85 0.85 0.85
cg18855143 chr1:150926178 LCE2B 0.46 0.66 0.66 0.67
cg06619428 chr1:150926378 LCE2B 0.34 0.50 0.32 0.26
cg22616525 chr1:150936609 LCE2A 0.17 0.56 0.53 0.46
cg13974761 chr1:150937222 LCE2A 0.09 0.62 0.61 0.56
cg13705774 chr1:150937388 LCE2A 0.61 0.87 0.86 0.87
cg13697387 chr1:150937467 LCE2A 0.05 0.25 0.18 0.15
cg08166767 chr1:150937972 LCE2A 0.09 0.50 0.50 0.41
cg16354520 chr1:150938331 LCE2A 0.15 0.78 0.75 0.73
cg20823091 chr1:150947263 LCE4A 0.47 0.88 0.86 0.90
cg21846488 chr1:150947467 LCE4A 0.38 0.66 0.63 0.59
cg00981443 chr1:150947787 LCE4A 0.57 0.88 0.84 0.84
cg04221650 chr1:150948511 LCE4A 0.13 0.63 0.59 0.53
cg23413307 chr1:151014096 LCE1F 0.31 0.77 0.66 0.67
cg26302157 chr1:151014125 LCE1F 0.19 0.73 0.70 0.67
cg13493250 chr1:151014186 LCE1F 0.16 0.30 0.16 0.13
cg01915081 chr1:151015462 LCE1F 0.52 0.71 0.65 0.65
cg21535199 chr1:151015730 LCE1F 0.39 0.64 0.66 0.62
cg14528310 chr1:151024088 LCE1E 0.77 0.88 0.87 0.87
cg25610428 chr1:151025077 LCE1E 0.19 0.81 0.80 0.81
cg14792160 chr1:151025256 LCE1E 0.16 0.38 0.34 0.19
cg21065959 chr1:151025379 LCE1E 0.36 0.64 0.61 0.62
cg16987735 chr1:151026396 LCE1E 0.10 0.66 0.62 0.62
cg15923484 chr1:151026965 LCE1E 0.33 0.79 0.72 0.73
cg01406203 chr1:151034891 LCE1D 0.34 0.82 0.80 0.86
cg22365757 chr1:151035100 LCE1D 0.02 0.48 0.37 0.31
cg12725323 chr1:151035351 LCE1D 0.49 0.84 0.80 0.84
cg11583211 chr1:151035870 LCE1D 0.13 0.62 0.54 0.51
cg11835200 chr1:151036520 LCE1D 0.27 0.80 0.74 0.67
cg15531099 chr1:151037126 LCE1D 0.18 0.62 0.44 0.42
cg24325314 chr1:151037144 LCE1D 0.30 0.76 0.75 0.77
cg16011217 chr1:151044006 LCE1C 0.21 0.72 0.65 0.53
cg08895932 chr1:151045204 LCE1C 0.64 0.88 0.91 0.89
cg24304714 chr1:151045998 LCE1C 0.08 0.41 0.29 0.24
cg11067224 chr1:151046763 LCE1C 0.43 0.82 0.80 0.76
cg21434954 chr1:151049761 LCE1B 0.59 0.82 0.74 0.77
cg19250709 chr1:151050113 LCE1B 0.48 0.86 0.82 0.82
cg08878744 chr1:151050298 LCE1B 0.17 0.50 0.37 0.31
cg03881934 chr1:151050929 LCE1B 0.67 0.91 0.89 0.93
cg07090653 chr1:151051538 LCE1B 0.34 0.80 0.75 0.75
cg12449852 chr1:151052097 LCE1B 0.50 0.86 0.83 0.83
cg01975957 chr1:151065536 LCE1A 0.48 0.84 0.83 0.83
cg06221609 chr1:151065762 LCE1A 0.78 0.93 0.90 0.92
cg07330196 chr1:151066566 LCE1A 0.54 0.71 0.67 0.72
cg14696820 chr1:151066792 LCE1A 0.11 0.49 0.34 0.31
cg22124859 chr1:151080474 LCE6A 0.23 0.65 0.59 0.55
cg09417355 chr1:151080897 LCE6A 0.13 0.68 0.58 0.53
cg16265542 chr1:151081455 LCE6A 0.04 0.54 0.35 0.33
cg26531371 chr1:151081692 LCE6A 0.52 0.72 0.58 0.63
cg08101739 chr1:151081782 LCE6A 0.54 0.89 0.84 0.85
cg00998782 chr1:151082083 LCE6A 0.48 0.83 0.84 0.87
cg13366738 chr1:151082467 LCE6A 0.14 0.66 0.51 0.49
cg23624133 chr1:151082792 LCE6A 0.57 0.87 0.84 0.85
cg02060465 chr1:151208351 SPRR4 0.25 0.84 0.77 0.84
cg08948808 chr1:151208627 SPRR4 0.13 0.88 0.86 0.91
cg11066776 chr1:151209025 SPRR4 0.70 0.92 0.90 0.92
cg24316982 chr1:151209028 SPRR4 0.66 0.90 0.89 0.92
cg02202484 chr1:151209312 SPRR4 0.65 0.91 0.87 0.93
cg08763351 chr1:151209834 SPRR4 0.44 0.95 0.91 0.96
cg19602452 chr1:151209930 SPRR4 0.91 0.95 0.95 0.97
cg16738827 chr1:151209976 SPRR4 0.83 0.95 0.95 0.95
cg09902062 chr1:151210958 SPRR4 0.14 0.86 0.81 0.86
cg18805469 chr1:151211434 SPRR4 0.48 0.86 0.84 0.85
cg00922841 chr1:151221704 SPRR1A 0.50 0.88 0.85 0.93
cg06101324 chr1:151222167 SPRR1A 0.09 0.78 0.76 0.84
cg04505023 chr1:151222810 SPRR1A 0.36 0.89 0.85 0.90
cg04546999 chr1:151223053 SPRR1A 0.57 0.91 0.70 0.92
cg27569034 chr1:151223642 SPRR1A 0.37 0.83 0.88 0.87
cg07909128 chr1:151224003 SPRR1A 0.37 0.95 0.92 0.96
cg04841371 chr1:151224726 SPRR1A 0.52 0.86 0.85 0.89
cg24667326 chr1:151240344 SPRR3 0.55 0.89 0.83 0.88
cg04138756 chr1:151240473 SPRR3 0.27 0.88 0.84 0.86
cg25856811 chr1:151240581 SPRR3 0.11 0.85 0.80 0.85
cg13444842 chr1:151240903 SPRR3 0.79 0.94 0.93 0.96
cg21543102 chr1:151241395 SPRR3 0.49 0.90 0.85 0.90
cg20671415 chr1:151242899 SPRR3 0.29 0.93 0.91 0.93
cg18771659 chr1:151269386 SPRR1B 0.46 0.93 0.90 0.95
cg24884084 chr1:151269822 SPRR1B 0.02 0.84 0.78 0.84
cg02919982 chr1:151271745 SPRR1B 0.42 0.80 0.79 0.84
cg01011918 chr1:151280197 SPRR2D 0.41 0.69 0.71 0.75
cg14826683 chr1:151280454 SPRR2D 0.42 0.93 0.92 0.96
cg10812889 chr1:151280934 SPRR2D 0.04 0.88 0.85 0.90
cg03943115 chr1:151280991 SPRR2D 0.04 0.84 0.82 0.87
cg18087023 chr1:151281580 SPRR2D 0.62 0.92 0.95 0.95
cg14966325 chr1:151295629 SPRR2A 0.51 0.94 0.91 0.92
cg18766755 chr1:151296563 SPRR2A 0.09 0.87 0.86 0.87
cg04993112 chr1:151297138 SPRR2A 0.29 0.91 0.89 0.92
cg22014834 chr1:151297191 SPRR2A 0.73 0.94 0.93 0.96
cg09169531 chr1:151297218 SPRR2A 0.33 0.91 0.88 0.92
cg26059632 chr1:151297375 SPRR2A 0.25 0.89 0.87 0.93
cg20612962 chr1:151309984 SPRR2B 0.17 0.69 0.65 0.73
cg13950674 chr1:151310695 SPRR2B 0.21 0.62 0.61 0.65
cg08009265 chr1:151311081 SPRR2B 0.45 0.92 0.88 0.92
cg06400319 chr1:151311898 SPRR2B 0.49 0.90 0.88 0.90
cg27631593 chr1:151332237 SPRR2E 0.34 0.91 0.84 0.90
cg08555657 chr1:151334855 SPRR2E 0.46 0.81 0.75 0.80
cg00152644 chr1:151334860 SPRR2E 0.54 0.90 0.86 0.90
cg04121973 chr1:151351776 SPRR2F 0.80 0.86 0.85 0.86
cg03449150 chr1:151352273 SPRR2F 0.05 0.88 0.88 0.91
cg22946974 chr1:151352593 SPRR2F 0.73 0.88 0.89 0.89
cg22204954 chr1:151352622 SPRR2F 0.35 0.65 0.62 0.69
cg13401840 chr1:151379440 SPRR2C 0.30 0.85 0.84 0.86
cg00891995 chr1:151379886 SPRR2C 0.13 0.77 0.78 0.80
cg00535683 chr1:151380626 SPRR2C 0.54 0.88 0.88 0.92
cg25212571 chr1:151380739 SPRR2C 0.62 0.92 0.91 0.94
cg07804289 chr1:151381314 SPRR2C 0.13 0.94 0.90 0.95
cg10119001 chr1:151381390 SPRR2C 0.54 0.94 0.93 0.94
cg23606417 chr1:151381957 SPRR2C 0.40 0.68 0.65 0.66
cg03969260 chr1:151388827 SPRR2G 0.41 0.91 0.89 0.92
cg06034133 chr1:151389151 SPRR2G 0.35 0.77 0.72 0.77
cg11267802 chr1:151390217 SPRR2G 0.03 0.87 0.85 0.90
cg20141817 chr1:151391449 SPRR2G 0.43 0.93 0.92 0.93
cg27626424 chr1:151498972 LOR 0.58 0.85 0.76 0.84
cg05001111 chr1:151499903 LOR 0.55 0.41 0.44 0.37
cg08611411 chr1:151500661 LOR 0.04 0.02 0.23 0.03
cg21860629 chr1:151500892 LOR 0.03 0.02 0.12 0.02
cg11534293 chr1:151500966 LOR 0.04 0.04 0.30 0.06
cg10228283 chr1:151501011 LOR 0.28 0.15 0.30 0.15
cg21419383 chr1:152879586 IVL 0.61 0.86 0.79 0.84
cg02889647 chr1:152880108 IVL 0.72 0.89 0.88 0.90
cg15059851 chr1:152880324 IVL 0.50 0.82 0.82 0.85
cg25082710 chr1:152881119 IVL 0.45 0.91 0.83 0.86
cg05440289 chr1:152881815 IVL 0.79 0.88 0.84 0.88
cg15486123 chr1:152881930 IVL 0.48 0.88 0.80 0.84
cg02855850 chr1:152882420 IVL 0.31 0.81 0.75 0.77
A Thyroid Hormone Receptor/KLF9 Axis in Human
Hepatocytes and Pluripotent Stem Cells
ALEKSANDRA CVORO,a LIANI DEVITO,b FLORA A. MILTON,a LAILA NOLI,b AIJUN ZHANG,a
CELINE FILIPPI,c,d KEIKO SAKAI,e JI HO SUH,a DOUGLAS H. SIEGLAFF,a ANIL DHAWAN,d
TAKAO SAKAI,e DUSKO ILIC,b PAUL WEBBa
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ABSTRACT
Biological processes require close cooperation of multiple transcription factors that integrate dif-
ferent signals. Thyroid hormone receptors (TRs) induce Kr€uppel-like factor 9 (KLF9) to regulate
neurogenesis. Here, we show that triiodothyronine (T3) also works through TR to induce KLF9
in HepG2 liver cells, mouse liver, and mouse and human primary hepatocytes and sought to
understand TR/KLF9 network function in the hepatocyte lineage and stem cells. Knockdown
experiments reveal that KLF9 regulates hundreds of HepG2 target genes and modulates T3
response. Together, T3 and KLF9 target genes influence pathways implicated in stem cell self-
renewal and differentiation, including Notch signaling, and we verify that T3 and KLF9 cooper-
ate to regulate key Notch pathway genes and work independently to regulate others. T3 also
induces KLF9 in human embryonic stem cells (hESCs) and human induced pluripotent stem cells
(hiPSC) and this effect persists during differentiation to definitive endoderm and hiPSC-derived
hepatocytes. Microarray analysis reveals that T3 regulates hundreds of hESC and hiPSC target
genes that cluster into many of the same pathways implicated in TR and KLF9 regulation in
HepG2 cells. KLF9 knockdown confirms that TR and KLF9 cooperate to regulate Notch pathway
genes in hESC and hiPSC, albeit in a partly cell-specific manner. Broader analysis of T3 respon-
sive hESC/hiPSC genes suggests that TRs regulate multiple early steps in ESC differentiation. We
propose that TRs cooperate with KLF9 to regulate hepatocyte proliferation and differentiation
and early stages of organogenesis and that TRs exert widespread and important influences on
ESC biology. STEM CELLS 2015;33:416–428
INTRODUCTION
Thyroid hormone (TH) receptors (TRs a and b)
belong to the nuclear receptor superfamily.
TRs occupy thyroid response elements and
alter expression of genes in response to the
active form of TH (T3). Primary events involved
in TH-dependent changes in gene expression
are well understood; T3 induces TR conforma-
tional changes that facilitate interactions with
coregulators which enhance or repress TR-
regulated gene transcription [1, 2]. Down-
stream consequences of TR-dependent induc-
tion of genes that encode other transcription
factors (TFs) and interplay between TRs and
these TFs are less clear.
The Kr€uppel-like factors (KLFs) are a family
of conserved zinc ﬁnger TFs that act as tran-
scriptional activators or repressors in a
context-dependent manner and are implicated
in transcriptional networking and regulation of
balance between pluripotency, self-renewal,
and differentiation in mouse embryonic stem
cells (mESCs) [3, 4]. Expression of one member
of this family, Kr€uppel-like factor 9 (KLF9), is
often associated with differentiated states or
early stages of differentiation processes [5–7].
Furthermore, TR actions on neurite extension
and branching and neuronal differentiation of
mammalian and amphibian cells are mediated
by induction of KLF9 [5, 8, 9]. Thus, at least
one crucial developmental effect of TR signal-
ing involves KLF9. In mESC, simultaneous
depletion of three KLFs, KLF2, KLF4, and KLF5
inhibits self-renewal and triggers cell differen-
tiation [10]. KLF9 and KLF4 bind to the Notch1
gene and exert opposite effects on its tran-
scription, thereby inﬂuencing the Notch signal-
ing pathway [6]. Notch signaling works with
Wnt, FGF, TGFb/BMP, and Hedgehog signaling
pathways [11–15] and converges upon a core
transcriptional network that involves Oct4,
Nanog, and Sox2 to regulate stem cell mainte-
nance, differentiation, and cellular homeostasis
[16]. Thus, alterations in KLF9 levels could
greatly inﬂuence cell differentiation processes
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EMBRYONIC STEM CELLS/INDUCED
PLURIPOTENT STEM CELLS
There are reasons to suspect that the TR/KLF9 axis is
active in many cellular contexts, in addition to neural develop-
ment. First TRs and KLF9 are detected in multiple tissue types
and differentiating cells at different stages of development
[4, 17–19]. Second, T3 induces KLF9 in non-neuronal cell
types such as epithelial and erythroid cells [20, 21]. Third,
TRs and KLF9 play similar roles in particular tissues; both
TRa and KLF9 are active in intestinal stem cell regulation
[22–24]. Thus, some T3 actions that are ascribed to TR could
be results of KLF9 induction. Presently, little is known about
the existence and possible roles of TR/KLF9 networking in
non-neuronal contexts.
In this study, we show that TR can induce KLF9 in multiple
cell types of hepatocyte origin and stem cells and sought to
understand roles of the TR/KLF9 signaling network in these
contexts using in vitro cell models. We demonstrate that TR
activation leads to KLF9 induction in HepG2 cells, nontrans-
formed liver cells, human induced pluripotent stem cells
(hiPSC), and in human embryonic stem cells (hESCs) and this
effect persists during hiPSC and hESC differentiation to deﬁni-
tive endoderm and mature hepatocytes. Dissection of TR/
KLF9 effects reveals important roles in key signaling pathways,
including the Notch pathway, in HepG2 and ESCs. T3 effects
upon KLF9 in ESCs occur in the context of widespread TR-
dependent effects on genes that are implicated in early stages
of ESC differentiation. Our data therefore suggest that the TR/
KLF9 axis plays important roles throughout several stages of




Triiodothyronine (T3) was from Sigma-Aldrich (Sigma, St. Louis,
MO, http://www.sigmaaldrich.com).
Cell Culture
Human HepG2 cells expressing TRa (HepG2-TRa) or TRb
(HepG2-TRb) were maintained as described [25]. hESC line
KCL034 and hiPSC lines iKCL004 and iKCL011 were maintained
in either TeSR2 (Stem Cell Technologies, Vancouver, BC; http://
www.stemcell.com/) or Nutristem medium (Stemgent, Cam-
bridge, MA, https://www.stemgent.com) on Matrigel-coated
six-well plates in the absence of feeder cells. Matrigel-coated
plates were prepared by incubating 1 ml of 0.33 mg/ml growth
factor reduced Matrigel (BD Biosciences, San Jose, CA, 354230,
http://www.bdbiosciences.com) in Dulbecco’s modiﬁed Eagle’s
medium (DMEM)/F-12 (Life Technologies, Carlsbad, CA, http://
www.lifetechnologies.com) per well for 1 hour at 37C.
Animals
Experiments were approved by Methodist Hospital IACUC fol-
lowing NIH guidelines for ethical use of animals in biomedical
research. C57B/6J mice were purchased from Jackson Labora-
tory (Bar Harbor, ME, http://www.jax.org) at 9 weeks of age.
Animals were maintained on a 12:12 hours light dark cycle,
with food and water available ad libitum and were divided into
two groups (n 5 4): control and T3. Animals were treated for
3 days by oral gavage 6 1 mg/kg T3. Three days after, animals
were killed and liver tissue collected for RNA puriﬁcation.
Isolation of Primary Mouse Hepatocytes
Primary mouse hepatocytes were isolated from male C57B/6J
mice using Life Technologies Protocol (Life Technologies, Carlsbad,
CA, http://www.lifetechnologies.com), plated in collagen-coated
plates (Invitrogen, Carlsbad, CA, http://www.invitrogen.com/) and
incubated at 37C for 2–3 hours using Williams’ Medium E, 1 5
ml penicillin-streptomycin (3100), and 5% fetal bovine serum
(FBS). Medium was then changed to HepatoZYME-SFM (Invitro-
gen, Carlsbad, CA, http://www.invitrogen.com/). Cells were
treated with 1 nM, 10 nM, or 100 nM T3 for 16 hours.
Primary Human Hepatocytes
Primary human hepatocytes were a gift from Prof. Dhawan,
Hepatocyte Biology and Transplantation Group, King’s College
London. Hepatocytes were isolated from donor organs rejected
for transplantation and consented for research. The research was
undertaken with full institutional ethical approval and conducted
according to the principles of the Declaration of Helsinki. The
procedure is based on papers by Berry and Friend, modiﬁed by
Seglen, on hepatocyte isolation from rat livers [26, 27]. Brieﬂy,
liver is perfused with 500 ml oxygenated HBSS-EGTA (Lonza, Wal-
kersville, MD, www.lonza.com) prior to perfusion with oxygen-
ated EMEM (Lonza, Walkersville, MD, www.lonza.com)
supplemented with collagenase-P for 15 minutes. Tissue is ﬁl-
tered and centrifuged at 50g for 5 minutes twice. The pellet con-
tains hepatocytes separated from nonparenchymal cells and
dead cells and are used fresh or cryopreserved in University of
Wisconsin solution supplemented with 10% DMSO and 4% glu-
cose, using a controlled-rate freezer.
Endoderm Differentiation
hESC (KCL034) and hiPSC (iKCL004 and iKCl011) were differenti-
ated as a monolayer into deﬁnitive endoderm [28]. Undifferen-
tiated cells, at 80% conﬂuence, were induced to differentiate
by culturing in RPMI-based serum-free medium 1 10% serum-
free deﬁned medium (SFD), Wnt3a (40 ng/ml), and Activin A
(100 ng/ml) for 1 day. For the next 2 days, media were
switched to RPMI supplemented with BMP4 (0.5 ng/ml), basic
ﬁbroblast growth factor (bFGF) (10 ng/ml), Activin A (100 ng/
ml), and vascular endothelialgrowth factor (VEGF) (10 ng/ml).
The last 2 days, cells were maintained in SFD 1 BMP4 (0.5 ng/
ml), bFGF (10 ng/ml), Activin A (100 ng/ml), and VEGF (10 ng/
ml). SFD serum-free medium consists of 75% Iscove’s modiﬁed
Dulbecco’s medium (IMDM) (Invitrogen, Carlsbad, CA, http://
www.invitrogen.com/), 25% Ham’s F-12 (Mediatech, Inc., Cell-
gro, Manassas, VA 20109, http://www.cellgro.com), 0.53 N2-
Supplememt (Gibco/Life Technologies, Carlsbad, CA, http://www.
lifetechnologies.com/ipac/en/home/brands/gibco.html), 0.53 B27
without retinoic acid, 0.1% bovine serum albumin (BSA) (Sigma,
St. Louis, MO, http://www.sigmaaldrich.com), 50 lg/ml ascorbic
acid, and 4.53 1024 Mmonothioglycerol.
Precommercial iCell highly puriﬁed iPSC-derived human
hepatocytes (iHep) were purchased from Cellular Dynamics Inter-
national (CDI; Madison, WI, http://www.cellulardynamics.com).
Cells were maintained according to iCell Hepatocytes User’s
Guide (CDI; Madison,WI, http://www.cellulardynamics.com).
Quantitative Real-Time PCR
Total RNA was prepared using the RNeasy mini-kits (Qiagen,
Venlo, Limburg, http://www.qiagen.com). For HepG2, Aurum
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Total RNA kit (Bio-Rad, Hercules, CA, http://www.bio-rad.com/)
was used. Reverse transcription reactions were performed
using 1 lg total RNA with an iScript cDNA Synthesis kit (Bio-
Rad, Hercules, CA, http://www.bio-rad.com). Quantitative real-
time PCR (qPCR) was performed with the Roche LightCycler
480 RT PCR Instrument using SYBR Green Mastermix (Roche,
Mannheim, Germany, www.roche.com). Primer sequences are
available per request. Data were collected and analyzed using
comparative threshold cycle method with b-actin and 18S
rRNA as reference. Experiments were performed at least three
times, and mean 6 SD was calculated and statistical analysis
was performed using Prism curve-ﬁtting program (GraphPad
Prism, version 6.01).
RNA Interference
HepG2-TRb cells were plated in 10% FBS-DMEM/F-12 media
and grown to 50% conﬂuence. Cells were transfected with
TRb or KLF9 ON-TARGET plus SMART pool siRNA (Dharmacon,
Waltham, MA, http://www.thermoscientiﬁcbio.com/Dharma-
con/) at 50 nM ﬁnal concentration. Positive and negative non-
targeting control siRNAs were also from Dharmacon. After
3 days, cells were treated with 100 nM T3 for 8 or 24 hours
and RNA or protein prepared.
hESC (KCL034) and hiPSC (iKCL004 and iKCL011) were
plated at 125,000/well of six-well dish and transfected with
5 lM nontargeting control or siKLF9 with DharmaFECT1
according to manufacturer’s protocol 2 days later. Cells were
exposed to 100 nM T3 for 18 hours 2 (for RNA) or 3 (for pro-
tein isolation) days post-transfection.
Western Blotting
Total proteins were separated with 4%–12% gradient Bis-Tris
gels (Invitrogen, Grand Island, NY, http://www.invitrogen.com/),
transferred to polyvinylidene ﬂuoride (PVDF) membranes (Bio-
Rad, Hercules, CA, http://www.bio-rad.com/), and incubated
with anti-KLF9 antibody (Santa Cruz Biotechnology, Dallas, TX,
www.scbt.com) followed by anti-mouse IgG Ab conjugated
with HRP (Santa Cruz Biotechnology, Santa Cruz Biotechnol-
ogy, Dallas, TX, www.scbt.com). A Luminata Classico Western
HRP Substrate (EMD Millipore, Billerica, MA, www.millipore.
com) was used for protein detection.
Microarray Analysis
Human HT-12_v4 whole genome expression arrays were from
Illumina (Illumina, San Diego, CA, http://www.illumina.com/).
cRNA synthesis and labeling were performed using Illumina
TotalPrep-96 RNA Ampliﬁcation Kit (Ambion/Life Technologies,
Carlsbad, CA, http://www.lifetechnologies.com/us/en/home/
brands/ambion.html). Labeling in vitro transcription reaction
was performed at 37C for 14 hours. Biotinylated cRNA sam-
ples were hybridized to arrays at 58C for 18 hours according
to manufacturer’s protocol. Arrays were scanned using Bea-
dArray Reader.
Unmodiﬁed microarray data obtained from GenomeStudio
were background-subtracted and quantile-normalized using
the lumi package [29] and analyzed with the limma package
[30] within R [31]. Effect of KLF9 knockdown was determined
through comparison between non-T3 treated control and
KLF9 knockdown. T3-response was determined by comparing
cells treated with T3 for 8 or 24 hours against their respective
untreated controls. All analyses were corrected for multiple
hypothesis testing [32], and effects determined as signiﬁcant
when more than or equal to twofold with an adjusted p-value
.05. To facilitate comparisons among datasets, all data were
uploaded into a SQLite3 database (http://www.sqlite.org/).
Pathway Enrichment Analysis (GeneCodis)
We used the GeneCodis analysis (http://genecodis.cnb.csic.es/
) to identify enriched pathways and functional themes. Gene-
Codis integrates different information resources (GO, Panther
pathways, SwissProt, etc.), searches, and arranges gene set
annotation by statistical signiﬁcance [33–35]. Genes of inter-
est, deﬁned as at least twofold differentially expressed accord-
ing to microarray, were uploaded as standard human gene
symbols and genes in the interaction network with false dis-
covery rate (FDR) <0.05 were taken into consideration.
GeneMANIA
We used GeneMANIA (http://www.genemania.org) to ﬁnd
genes related to input genes, using a very large set of func-
tional interaction data [36–38]. Inputs were differentially
expressed genes underlying speciﬁc functional themes and
pathways as identiﬁed by GeneCodis. We focus analysis on
high conﬁdence physical interactions (from various protein
interaction databases included in GeneMANIA) and pathway
interactions (from Reactome pathway database).
Ingenuity Pathway Analysis
Data were also analyzed using ingenuity pathway analysis
(Ingenuity Systems; IPA, Redwood City, CA, http://www.inge-
nuity.com). Genes of interest, deﬁned as at least twofold dif-
ferentially expressed, were uploaded. Each gene identiﬁer was
mapped to its corresponding gene object in the ingenuity
pathways knowledge base (IPKB). The IPKB, containing a large
network of curated molecular interactions and pathways, was
searched to ﬁnd subnetworks enriched in genes of interest.
Immunostaining
hESC/iPSC-derived deﬁnitive endoderm cells grown as a
monolayer were ﬁxed in 3.8% paraformaldehyde for 20
minutes, permeabilized in 0.5% Triton X-100/phosphate buf-
fered saline (PBS) for 5 minutes, washed in PBS, and incu-
bated with goat anti-GATA4 polyclonal Ab (R&D Systems cat.
no. 2606; Minneapolis, MN; www.rndsystems.com) overnight
at 14C. Samples were washed, incubated with rhodamine X-
conjugated donkey anti-goat IgG antibodies, and washed again
33 in PBS. In the second wash 10 lg/ml Hoechst 33342 (Life
Technologies, Carlsbad, CA, http://www.lifetechnologies.com)
was added to visualize nuclei. Samples were mounted in Vec-
tashield (Vector Laboratories, Burlingame, CA; www.vector-
labs.com) and analyzed with an epiﬂuorescence microscope
(Nikon, model E50i) equipped with Retiga 400R cooled mono-
chrome camera (QImaging, Surrey, BC; www.qimaging.com).
Images were processed using AdobePhotoshop CS5 software.
RESULTS
T3 Activates KLF9 in Hepatocytes
Our previous analysis of T3 response in parental HepG2 and
HepG2 cells that stably express either TRa or TRb [25] sug-
gested that KLF9 is a T3 inducible-target in this cell
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background. We used qRT-PCR to verify T3-activation of KLF9 in
these cells (Fig. 1A). T3 response was observed at 24 hours in
parental HepG2, which express very low levels of TRb [39] (Fig.
1A) but more rapid T3 induction was observed in both HepG2-
TR cell lines, occurring within one hour of T3 treatment and
maintained up to 24 hours (Fig. 1A). T3-induction of KLF9 per-
sisted after pretreatment with protein synthesis inhibitor cyclo-
heximide (CHX) in HepG2-TRb cells (Supporting Information Fig.
S1A). Thus, T3 induction of KLF9 is a direct effect that does not
require new protein synthesis. The speciﬁc role for TRb was
conﬁrmed by siRNA (Supporting Information Fig. S1B, S1C).
Since HepG2 cells are a liver carcinoma cell line, we veriﬁed
the effect of T3 on KLF9 expression in mouse liver. We treated 9
weeks old C57/Bl6 male mice 6 T3 by daily oral gavage. After 3
days, we isolated livers and showed that T3 induced KLF9 about
twofold (Fig. 1B). We conﬁrmed that KLF9 was not expressed in
cholangiocytes, as judged by absence of colocalization with the
cholangiocyte marker CK19 (Supporting Information Fig. S2). We
also conﬁrmed that T3 induced KLF9 in mouse primary hepato-
cytes in a dose-dependent fashion (Fig. 1C) and that T3 treatment
of human primary hepatocytes (adult and neonatal) resulted in an
increase in KLF9 expression (Fig. 1D). Thus, the TR/KLF9 axis is
active in transformed and nontransformed hepatocytes.
KLF9 Regulates Multiple Genes in HepG2 and
Influences T3 Response
To deﬁne roles of KLF9 and the TR/KLF9 network in HepG2, we
used siRNA to silence KLF9 expression in HepG2-TRb cells. We
veriﬁed that KLF9 levels were reduced in speciﬁc siRNA treated
cells versus cells that were treated with control siRNA (97% reduc-
tion of mRNA and protein) (Supporting Information Fig. S3A).
Although KLF9 levels were almost completely suppressed, some
T3 induction of KLF9 persisted (Supporting Information Fig. S3B).
Microarray analysis revealed 368 genes that displayed more
than twofold change after KLF9 knockdown, with 226 downregu-
lated and 142 upregulated (Fig. 2A). Effects were conﬁrmed by
qRT-PCR analysis of representatives of both classes of gene
(downregulated Lama1 and Aldoc, upregulated Snord 3A and 3D,
Fig. 2B). Thus, KLF9 regulates large numbers of genes in HepG2
and can act as a transactivator and transrepressor.
Figure 1. T3 induces KLF9 in HepG2 cells and in hepatocytes. (A): Parental HepG2, HepG2-TRb, and HepG2-TRa cells were treated with
100 nM T3 for the indicated times and KLF9 mRNA levels were determined by quantitative real-time PCR (qPCR). (B–D): Expression of
KLF9 after T3 treatment was assessed by qPCR in mice liver tissue (B), in isolated mice hepatocytes treated with increasing concentra-
tions of T3 (C), and human hepatocytes isolated from neonatal and adult livers (D).
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To understand whether KLF9 knockdown might inﬂuence
T3 response, we treated siControl and siKLF9 HepG2-TRb cells
with T3 for 8 and 24 hours and performed microarray analysis.
In accordance with previous results, 530 genes displayed T3
response (more than twofold) in siControl HepG2 cells, with
more genes displaying T3 response at 24 hours (Supporting
Figure 2. TR/KLF9 axis regulates multiple genes in HepG2 cells. (A): Differential gene regulation in HepG2-TRb cells after KLF9 silencing
revealed by microarray analysis. Microarray data obtained from human Illumina HT-12_v4 gene chips from control versus KLF9 knockdown
were analyzed using Limma package within R. Effects determined to be signiﬁcant when more than or equal to twofold with an adjusted
p-value  .05. (B): Effects of KLF9 knockdown conﬁrmed at representatives of both classes of gene by quantitative real-time PCR. (C):
Differential gene regulation by T3 in control and siKLF9 cells revealed by microarray analysis. (D–H): Cells were treated with 100 nM T3
and qRT-PCR was performed to verify patterns of KLF9-dependency of T3 response. Data are represented as mean 6 SD. Microarray data
are deposited in the Gene Expression Omnibus; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=sxkvckgwhxmfdgx&acc=GSE54699;
accession number GSE54699.
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Information Table S1). Comparison of genes that responded to
KLF9 knockdown or T3 in siControl cells revealed signiﬁcant
overlap between datasets, with 68 genes regulated by both
factors (Supporting Information Fig. S4). More surprisingly, KLF9
knockdown also altered the pattern of T3 response. Numbers of
T3 responsive genes were similar in control and KLF9 knockdown
cells (530 and 576 genes, respectively, Supporting Information
Table S1). While most T3 responsive genes were unaffected by
KLF9 knockdown (339 genes displayed similar responses in con-
trol and KLF9 knockdown cells), 191 T3 target genes displayed
reduced T3 response after KLF9 knockdown and 237 genes
gained T3 response (Fig. 2C). We conﬁrmed that genes that
responded to T3 in the presence and absence of KLF9 were truly
KLF9 independent (HR, Fig. 2D). We also conﬁrmed positive and
negative T3 responses that were dependent upon KLF9 (FoxO4
and DACT1; Fig. 2E, 2F) and T3 responses that emerged after
KLF9 knockdown (PPL and CLDN1, Fig. 2G, 2H). We also detected
genes that showed changes in overall expression after KLF9
knockdown, but retained similar T3 response (alkaline phospha-
tase, intestinal (ALPI), Supporting Information Fig. S5). Thus, T3
and KLF9 display overlapping effects upon gene expression in
HepG2 and many T3 responses are modulated by KLF9.
TR/KLF9 Axis Regulates Key Signaling Pathways
To deﬁne roles of deﬁned KLF9 target genes in HepG2 we
used GeneCodis software analysis (http://genecodis.cnb.csic.
es) [33–35] to examine functions of genes that displayed
altered expression after KLF9 knockdown. Candidate genes
were assigned to pathways and processes listed in Table 1
(upper section) and Supporting Information Table S2, respec-
tively, with differentially expressed genes listed in Supporting
Information Tables S3, S4. The main KLF9-dependent pathways
were TGFb signaling, Alzheimer’s disease-amyloid secretase
pathway, FGF and Wnt signaling (Table 1). The most important
processes were signal transduction, cell adhesion, aging, and
cell differentiation (Supporting Information Table S2).
We also analyzed T3 responsive pathways and processes
(Supporting Information Table S5). Interestingly, only two of the
top six KLF9-dependent pathways (TGFb and FGF pathway) and
three processes (transmembrane transport, cell death, and pro-
tein folding) were purely KLF9-responsive. Other KLF9 respon-
sive pathways and processes were also ﬂagged as T3 responsive
(Table 1-green, Supporting Information Table S2-green).
Analysis of an integrated gene set that included KLF9
responsive gene targets (Fig. 2A) and T3-regulated gene tar-
gets with altered response to KLF9 knockdown (Fig. 2C)
yielded more statistically enriched pathways (Table 1, lower
section) and processes (Supporting Information Table S6).
Together, T3 and KLF9 are active in the Notch pathway as well
as the EGF, Ras, and platelet-derived growth factor (PDGF)
regulated pathways (Table 1-blue). Furthermore, T3 and KLF9
inﬂuenced processes such as cell proliferation and metabolic
pathways (Supporting Information Table S6-blue; differentially
expressed genes in Supporting Information Tables S7, S8).
Thus, there are overlaps between KLF9- and T3-dependent
pathways and processes in HepG2, and TR and KLF9 cooper-
ate to inﬂuence signaling pathways that would not be identi-
ﬁed by consideration of actions of either T3 or KLF9 alone.
TR/KLF9 Axis Regulates Multiple Components of the
Notch Pathway
Since Notch signaling emerged as a major target pathway regu-
lated by T3 and KLF9 and because Notch signaling also plays
important roles in liver development and regeneration, we
Table 1. Pathway enrichment analysis of KLF9-dependent transcriptome. Canonical pathways obtained from GeneCodis using Panther
pathways database. Gene co-occurrence annotation found by GeneCodis for the genes differentially expressed (FC > 2, p < .05 cor-
rected for multiple testing) between siCtrl versus siKLF9 HepG2-TRb samples (KLF9 pathways) and integration of KLF9 targeted and TR/
KLF9 targeted pathways. p-Values have been obtained through hypergeometric analysis (Hyp) corrected by FDR method (Hyp*).
NGR NG Hyp Hyp* Annotations (panther pathways)
KLF9 pathways
91 7 1.86E-05 0.00011164 P00052: TGF-beta signaling pathway
66 5 0.0003218 0.00096552 P00003: Alzheimer disease-amyloid secretase pathway
109 5 0.0030787 0.00461811 P00021: FGF signaling pathway
280 8 0.0039947 0.00479375 P00057:Wnt signaling pathway
107 5 0.0028423 0.00568463 P00006: Apoptosis signaling pathway
198 6 0.0092045 0.00920453 P00031: Inﬂammation mediated by chemokine
and cytokine signaling pathway
TR/KLF9 pathways
91 9 4.60E-05 0.00103529 P00052: TGF-beta signaling pathway
280 16 7.02E-05 0.00105367 P00057: Wnt signaling pathway
107 9 0.000162 0.00182779 P00006: Apoptosis signaling pathway
66 7 0.000207 0.00186532 P00003: Alzheimer disease-amyloid secretase pathway
70 8 4.28E-05 0.00192706 P00016: Cytoskeletal regulation by Rho GTPase
114 9 0.000262 0.0019674 P00018: EGF receptor signaling pathway
118 9 0.000339 0.00218076 P00004: Alzheimer disease-presenilin pathway
36 5 0.000483 0.00271783 P00045: Notch signaling pathway
109 8 0.000924 0.00415905 P00021: FGF signaling pathway
72 6 0.002094 0.00589054 P00019: Endothelin signaling pathway
96 7 0.001980 0.00594038 P00036: Interleukin signaling pathway
198 10 0.003794 0.00898646 P00031: Inﬂammation mediated by chemokine
and cytokine signaling pathway
69 5 0.008789 0.0146485 P04393: Ras Pathway
126 6 0.029072 0.0408832 P00029:Huntington disease
128 6 0.031068 0.0411201 P00047: PDGF signaling pathway
NGR: Number of annotated genes in the reference list; NG: Number of annotated genes in the input list; Hyp: Hypergeometric pValue; Hyp*
Corrected hypergeometric pValue.
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explored links between T3, KLF9, and Notch in HepG2.We veriﬁed
regulation patterns of the ﬁve ﬂagged T3/KLF9 target genes with
qRT-PCR (HEY1, HEY2, NOTCH3, PSEN2, and HES1) (Table 1, Sup-
porting Information Table S7). This conﬁrmed that HEY1, HEY2,
and NOTCH3 all displayed T3 response and that expression levels
of these genes were changed by KLF9 knockdown (Fig. 3A–3C).
Furthermore, PSEN2 and HES1 transcript levels were, respectively,
greatly reduced and elevated by KLF9 knockdown (not shown).
Figure 3. TR/KLF9 axis and the Notch pathway. (A–C): Cells were treated with 100 nM T3 and qRT-PCR was performed to verify TR/
KLF9-dependency of identiﬁed Notch pathway genes. (D): Network of interactions among Notch pathway KLF9 targets, as retrieved by
the GeneMania. Circles represent genes and connecting lines represent interactions between genes. GeneMania retrieved known and
predicted interactions between these genes and added extra genes (gray circles) that are strongly connected to query genes. (E–G):
Quantitative real-time PCR veriﬁcation of genes identiﬁed by GeneMania as part of TR/KLF9-Notch network. All data are represented as
mean 6 SD.
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We next performed GeneMania analysis to identify Notch
networking partners (http://www.genemania.org); this
approach uncovers genes related to input genes, using a large
set of functional interaction data [36–38]. We generated the
network using a query of the ﬁve Notch signaling components
identiﬁed as T3 and/or KLF9 regulated (Fig. 3A–3C, Supporting
Information Table S7). We focused analysis only on high conﬁ-
dence pathway interactions (reactome pathway database; Fig.
3D, blue lines) and physical interactions (various protein inter-
action databases; GeneMANIA; Fig. 3D, red lines). This strat-
egy uncovered tight networking of the 5 input genes with 20
associated genes. Of these 20 genes, three were also ﬂagged
as T3 and/or KLF9 targets in microarray analysis (ID3, Furin,
ARNT), underscoring links between TR/KLF9 and Notch. We
used qRT-PCR to conﬁrm that ID3 exhibited strong regulation
by T3 and KLF9 response (not shown) and that Furin and
ARNT were responsive only to T3 and KLF9, respectively (Fig.
3E, 3F). A limited survey of additional genes implicated in
Notch signaling revealed that KLF9 and T3 also cooperate to
regulate HES4 (Fig. 3G). Thus, T3 and KLF9 regulate multiple
Notch pathway genes in HepG2 and TR/KLF9 targets are
involved in multiple aspects of Notch signaling (Discussion).
TR/KLF9 Axis Is Active in Embryonic Stem Cells and
Definitive Endoderm
Since TR regulates KLF9 in hepatocytes, we asked whether TR
might also regulate KLF9 during differentiation along the
hepatocyte lineage in culture. We assessed KLF9 expression in
two hiPSC lines, iKCL004 and iKCL011 [40] and the hESC line
KCL034 [41] (Fig. 4A). While KLF9 is detectable in all three cell
lines (iKCL004, iKCL011, and KCL034), its expression was pro-
foundly reduced in comparison to dermal BJ ﬁbroblasts from
which the iPSCs were reprogrammed (Fig. 4A). Even though
TRa was the predominant TR isoform in these cell lines (Sup-
porting Information Fig. S6), T3 treatment for 6 and 18 hours
resulted in robust increase in KLF9 mRNA in all three pluripo-
tent stem cell lines, but not BJ ﬁbroblasts (Fig. 4A).
We differentiated lines into deﬁnitive endoderm [28]. As
expected, expression of pluripotency markers Nanog and Oct4
decreased during deﬁnitive endoderm differentiation and
endoderm markers MIXL1 and SOX17 emerged (Supporting
Information Fig. S7A). We also conﬁrmed that the majority of
cells turned into endoderm by GATA41 immunostaining (Sup-
porting Information Fig. S7B). TRa remained the prevalent iso-
form during this process (Supporting Information Fig. S6) and
T3 treatment again induced KLF9 in deﬁnitive endoderm from
all stem cell lines (Fig. 4B).
Finally, we asked whether TR/KLF9 axis is active in highly
puriﬁed terminally differentiated hiPSC-derived hepatocytes.
Like mature hepatocytes, these cells predominantly expressed
TRb (Supporting Information Fig. S6) and, here, T3 also
increased KLF9 expression (Fig. 4C). Thus, T3 induces KLF9 in
human ESCs and at early and late stages of hepatocyte differ-
entiation in vitro in a manner that is independent of TR
subtype.
T3 Exhibits Cell-Specific Effects on Notch Genes in
ESCs
To explore TR function in ESCs, we performed microarray
analysis on KCL034, iKCL004, and BJ lines treated with T3 for
6 hours. The analysis revealed 820 and 826 genes changed in
KCL034 and iKCL004, respectively, and no change in BJ cells
(Supporting Information Table S9).
Analysis of T3 target genes using GeneCodis analysis con-
ﬁrmed that T3 regulates many key pathways previously recog-
nized as targets of TR or the TR/KLF9 axis in HepG2, including
Notch, Wnt, and FGF (Supporting Information Table S10) along
with others such as angiogenesis, cadherin, and endothelin
pathways. However, closer investigation of T3 effects upon
individual Notch pathway genes revealed differences from
HepG2. HEY2 and HES4 appeared as T3 targets in ESCs, as
seen in HepG2 (Supporting Information Table S11), but
Notch3, HEY1, and FURIN did not respond to T3 in any of plu-
ripotent stem lines tested (not shown). Conversely, several
Notch genes responded to T3 in stem cells and not in HepG2
(HES5, LFNG, and DLK1) (Fig. 4H, Supporting Information Fig.
S8). Thus, T3 displays cell-speciﬁc effects upon key Notch
pathway genes.
KLF9-Dependency of Notch Genes in ESCs
To determine whether KLF9 might regulate Notch signaling in
human pluripotent stem cells, we silenced KLF9 in iKCL004,
iKCL011 and KCL034 cells (Fig. 4D, 4E). RNA and Western anal-
ysis showed an average of 85%, 75%, and 72% knockdown of
KLF9 in iKCL004, iKCL011, and KCL034, respectively, relative to
scrambled siRNA control (Fig. 4D) with T3-dependent induc-
tion of KLF9 also signiﬁcantly reduced (Fig. 4E). In these cells,
KLF9 knockdown reduced basal levels and T3 response of T3/
KLF9 targets HES4 and HES5 (Fig. 4F, 4H). Additionally, PSEN2
and ARNT, pure KLF9-targets in HepG2 cells (Fig. 3), also
exhibited similar pure KLF9-dependency in stem cells (Fig. 4G
and not shown). There was no change in the expression of T3
target genes LFNG and DLK1 after KLF9 knockdown (not
shown). Thus, TR and KLF9 cooperate to regulate key Notch
pathway genes in stem cell lines, and work independently to
regulate others, but precise effects are cell type speciﬁc
(Discussion).
T3-Dependent Changes in Differentiation-Related Gene
Expression in Stem Cells
To gain insight into T3 regulated biological processes in ESCs,
we performed IPA (version Fall 2013) to determine functional
pathways of identiﬁed genes. IPA scans input genes to iden-
tify networks using the IPKB for interactions between “target
genes” and known and hypothetical interacting genes stored
in the IPA software (in our study, input genes were differently
expressed after T3 treatment). This revealed that T3 target
genes clustered into categories related to embryonic develop-
ment and differentiation (Table 2).
We used qRT-PCR to conﬁrm selected T3 responses. T3
induces important differentiation-related genes such as HHEX,
one of the earliest markers of anterior endoderm, which gives
rise to foregut organs such as the liver, ventral pancreas, thy-
roid, and lungs [42], HAND1, a TF that is critical for the devel-
opment of three embryologically distinct lineages: trophoblast
of the placenta, extraembryonic mesoderm derivatives and
cardiomyocytes [43], and the octamer TF POU3F1, which par-
ticipates in cell fate determination [44] (Fig. 5A). Conversely,
T3 represses the crucial ES pluripotency regulator Nanog (Fig.
5B, 5C). Thus, T3 triggers changes in genes involved in ESC
differentiation.
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Figure 4. TR/KLF9 axis is active in embryonic stem cells, deﬁnitive endoderm, and human induced pluripotent stem cell (hiPSC)-derived
hepatocytes. (A–C): Quantitative real-time PCR (qPCR) analysis of KLF9 expression levels 2/1T3 in BJ ﬁbroblasts, iKCL004, iKCL011, and
KCL034 cells (A), endoderm differentiated from iKCL004, iKCL011, and KCL034 (B), and terminally differentiated hiPSC-derived hepato-
cytes (C). KLF9 mRNA levels were expressed as fold change. All data are represented as mean 6 SD. (D–H): TR/KLF9 axis is involved in
regulation of Notch signaling in hiPSC and human embryonic stem cell. (D): Western blot for KLF9 from cell lysates from iKCL004,
iKCL011, and KCL034 transfected with Ctrl or KLF9 siRNA. (E–H): iKCL004, iKCL011, and KCL034 cells transfected with Ctrl or KLF9 siRNA
were treated with 100 nM T3 for 18 hours. KLF9, HES4, PSEN2, and HES5 mRNA levels were determined by qPCR. The data are pre-
sented as fold change of mRNA levels in Ctrl nontreated samples. All data are represented as mean 6 SD.
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DISCUSSION
It is important to understand how TR-dependent cascades of
alternate TFs contribute to T3 regulation of physiologic proc-
esses. This study was initially prompted by our observation
that TRs regulate KLF9 in HepG2 liver cells and nontrans-
formed hepatocytes. Previous studies implicate KLF9 in regula-
tion of the balance of cellular renewal and differentiation and
TR-dependent induction of KLF9 in neural development [5, 8,
9], but the role of their cooperation in hepatocytes is
unknown. TR activation regulates hepatocyte proliferation and
development [45, 46] and, conversely, induces regression of
carcinoma-induced hepatic nodules and reduce incidence of
hepatocarcinoma [47, 48]. Moreover, KLF9 regulates the bal-
ance between cell differentiation and self-renewal [6, 9].
Thus, investigation of the TR/KLF9 axis in hepatocytes could
yield insights into the ways that TRs inﬂuence liver regenera-
tion and cancer.
We used the HepG2 system to deﬁne TR/KLF9 effects in a
hepatocyte background. siRNA knockdown revealed hundreds
of KLF9-dependent genes in this cell type with 10%–15% of
T3 regulated genes identiﬁed in this study, and previous stud-
ies [25, 49], also being KLF9 targets (Supporting Information
Fig. S4). KLF9 knockdown also reduced T3 response of a large
proportion of TR target genes (Fig. 2C). Thus, we suggest that
some T3 responsive HepG2 target genes are regulated indi-
rectly through induction of KLF9. In this regard, 35% of T3
responses in HepG2 cells are indirect, as judged by sensitivity
to the protein synthesis inhibitor CHX [25]. Inspection of this
CHX sensitive dataset reveals many genes ﬂagged as KLF9 tar-
gets in this study (not shown).
Surprisingly, some genes displayed emergent T3 response
after KLF9 knockdown. We have not assessed mechanisms of
this effect, but we note that KLF9 knockdown often results in
large alterations of basal expression of this gene class (Fig.
2G, 2H). Thus, we suggest that emergent T3 responses may
occur at genes that display close to maximal KLF9 response in
HepG2; T3-dependent increases in remaining low levels of
KLF9 that persist after siRNA treatment are sufﬁcient to partly
rescue effects of KLF9 knockdown.
The fact that large numbers of genes respond to T3 and
KLF9 in HepG2 allowed us to deﬁne pathways that, respec-
tively, depend upon T3, KLF9, and T31KLF9. KLF9 target
genes are active in pathways implicated in stem cell pluripo-
tency and differentiation, including TGFb, FGF, and Wnt (Table
1, Fig. 5D). Analysis of an integrated dataset of KLF9- and T3-
target genes ﬂagged additional pathways, including Notch,
crucial for liver development and regeneration [50–56].
Detailed analysis of T31KLF9 targets in the Notch pathway
revealed multiple genes coordinately regulated by T3 and
KLF9 (HEY1, HEY2, HES4, Notch3, and ID3) and others that
were purely regulated by T3 (Furin) or KLF9 (PSEN2 and
ARNT).
Given connections between TR, KLF9, and Notch signaling
in hepatocytes, we determined whether T3 also regulates
KLF9 during hepatocyte differentiation from ESCs. Unexpect-
edly, T3 induced KLF9 in ESCs and hiPSC derived from BJ ﬁbro-
blasts, but not BJ ﬁbroblasts themselves, and this effect
persisted throughout differentiation to deﬁnitive endoderm
and mature hepatocytes (Fig. 4). Microarray analysis revealed
more than 800 T3-regulated genes in hiPSC and these genes
cluster into many of the pathways recognized as TR/KLF9
responsive in HepG2, including Notch, FGF, and Wnt. Silencing
of KLF9 in hESC and hiPSC conﬁrmed that the TR/KLF9 axis
regulates Notch pathway genes in ESCs, as seen in HepG2,
albeit in cell-type-speciﬁc fashion. Thus, the TR/KLF9 axis is
active in ESCs, remains active through early and late stages of
hepatocyte differentiation, and plays important cell-speciﬁc
roles in regulation of ESC Notch signaling genes.
Our studies do not yet allow us to precisely deﬁne how
T3 and KLF9 affect Notch-dependent behavior of different cell
types. We note, however, that T3 and/or KLF9 regulate genes
involved in upstream Notch signaling events (Notch3, Furin,
and PSEN2), members of the HES/HEY family of TFs that are
downstream targets of the Notch pathway and a gene that is
part of noncanonical Notch pathways (ARNT) (Supporting
Information Fig. S9) [57–59]. Thus, TR and KLF9 regulate mul-
tiple branches of the Notch pathway and the fact that T3 and
KLF9 cooperate to regulate genes of the HES/HEY family,
which constitute outputs of Notch signaling, in a cell-type-
speciﬁc manner suggests that T3 and KLF9 could inﬂuence
Notch pathway activity in a cell type-speciﬁc manner. HEY/HES
TFs are differentially and speciﬁcally expressed in different cell
types [60], display an oscillatory expression pattern, and con-
trol timing of biological events [61, 62]. Thus, TR/KLF9-
dependent changes in HES/HEY expression could have
Table 2. Functional categorization of T3 target genes in KCL034
and iKCL004 cells; pathway enrichment determination using inge-
nuity pathway analysis identify enriched development-related
functional themes The number of genes and statistical values are
shown for each cell line. Microarray data have been deposited in
NCBI’s gene expression omnibus; http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?tacc=GSE58273; accession number GSE58273
KCL034 IKCL004
Function NG p-Value NG p-Value
Gene expression 126 1.39E-10 103 7.08E-06
Transcription 146 7.90E-10 124 4.56E-06
Cellular development
Cell differentiation 178 1.09E-17 160 3.69E-14
Cell proliferation 271 1.02E-14 248 4.34E-12
Cell commitment 16 9.05E-05 16 4.39E-05
Cell cycle 73 2.87E-04 71 1.28E-04
Cell morphology 155 4.40E-10 154 6.62E-12
Cell death 242 6.23E-11 213 3.48E-07
Cell viability 104 5.55E-08 84 2.96E-04
Embryonic development
Development of body axis 86 1.96E-09 81 5.51E-09
Development of head 80 1.38E-09 76 2.31E-09
Lung development 33 8.85E-07 25 2.20E-08
Development of sensory organ 51 5.03E-07 51 7.57E-08
Cardiogenesis 39 1.56E-07 27 4.14E-04
Development of abdomen 28 1.15E-07 46 3.39E-06
Movement of neural crest cells 11 6.95E-06 29 5.22E-07
Eye development 42 1.88E-06 30 2.46E-06
Mesoderm development 31 1.59E-05 31 5.25E-04
Cell movement of embryonic cells 32 7.17E-04 32 4.03E-04
Development of epidermis 17 6.96E-04 22 7.73E-07
Skin development 34 6.35E-04 34 4.35E-08
Development of atrium 6 2.46E-04 6 1.76E-04
Development of lymphatic
system component
32 1.68E-04 30 2.83E-04
Development of brain 39 1.30E-04 45 1.85E-07
Development of forebrain 23 1.11E-04 21 3.30E-04
NG, Number of annotated genes in the input list.
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profound inﬂuences on cell fate, depending on cell type and
context.
While we focused on TR/KLF9-dependent effects upon the
Notch signaling pathway, such effects must be considered in
the context of widespread effects on differentiation-related
pathways (Fig. 5D). Indeed, IPA-based analysis of TR function
in ESCs provides strong evidence of T3 involvement in crucial
development-related processes (Table 2), suggesting that TR
may orchestrate transitions from the embryonic to adult tran-
scription programs (Fig. 5A–5C). While more experiments will
be needed to dissect mechanisms and consequences of these
effects, our data suggest that TR/KLF9 axis could orchestrate
key biological processes during differentiation through direct
transcription regulation or through signaling pathways such as
Notch (Supporting Information Fig. S9). It is not clear how the
TR/KLF9 axis inﬂuences dysregulated Notch signaling that
occurs in pathological conditions such as congenital disorders,
metabolic syndrome, and cancer [11, 12, 63]. We propose
Figure 5. Analysis of representative gene expression in KCL034 and iKCL004 cells. (A): T3-induced expression of HHEX, HAND1, and
POU3F1 in iKCL004 and KCL034. (B, C): Nanog display T3-dependent reduction in expression levels in KCL034 and iKCL004 as veriﬁed by
qPCR (B) and conﬁrmed by immunostaining in KCL034 cells (C). (D): A model for TR/KLF9 action. TR activates transcription of KLF9 and
both transcription factors modulate each other’s activity in multiple pathways leading to cell-speciﬁc responses to different signals.
Abbreviation: TR, thyroid hormone receptor.
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that it will be important to examine roles of KLF9 and Notch
pathway genes in T3-dependent enhancement of liver prolifer-
ation and inhibition of hepatocarcinoma proliferation using
gene ablation or knockdown.
CONCLUSIONS
TRs and KLF9 work together to regulate multiple genes and
important developmental processes. The TR/KLF9 axis is active
in ESCs and cell types that are representative of the hepatocyte
lineage and inﬂuences Notch signaling. Better understanding of
synergy between TR and KLF9 is crucial for understanding deci-
sions between stemness and differentiation and to uncover
regulatory patterns of cell homeostasis. Given the likely impor-
tance of KLF9 and Notch signaling in regulation of the balance
between proliferation and differentiation, we propose that it
will be important to further explore how the TR/KLF9 axis reg-
ulates hepatocellular cancer development and important physi-
ological processes such as liver regeneration.
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Self-organization of the human embryo in the absence
of maternal tissues
Marta N. Shahbazi1,5, Agnieszka Jedrusik1,5, Sanna Vuoristo1,5, Gaelle Recher1,6, Anna Hupalowska1,
Virginia Bolton2, Norah M. E. Fogarty3, Alison Campbell4, Liani G. Devito2, Dusko Ilic2, Yakoub Khalaf2,
Kathy K. Niakan3, Simon Fishel4 and Magdalena Zernicka-Goetz1,7
Remodelling of the human embryo at implantation is
indispensable for successful pregnancy. Yet it has remained
mysterious because of the experimental hurdles that beset the
study of this developmental phase. Here, we establish an
in vitro system to culture human embryos through implantation
stages in the absence of maternal tissues and reveal the key
events of early human morphogenesis. These include
segregation of the pluripotent embryonic and extra-embryonic
lineages, and morphogenetic rearrangements leading to
generation of a bilaminar disc, formation of a pro-amniotic
cavity within the embryonic lineage, appearance of the
prospective yolk sac, and trophoblast differentiation. Using
human embryos and human pluripotent stem cells, we show
that the reorganization of the embryonic lineage is mediated by
cellular polarization leading to cavity formation. Together, our
results indicate that the critical remodelling events at this
stage of human development are embryo-autonomous,
highlighting the remarkable and unanticipated self-organizing
properties of human embryos.
The development of a human embryo from a fertilized egg begins
with a series of cleavage divisions and morphogenetic rearrangements
that lead to the formation of a free-floating blastocyst. This blastocyst
comprises three distinct cell lineages: embryonic tissue (epiblast) and
two extra-embryonic tissues (hypoblast and trophectoderm) that, after
implantation into the uterus, will give rise to the yolk sac and pla-
centa respectively. This pre-implantation period has been extensively
studied using methods that pioneered in vitro fertilization1,2 (IVF).
However, on the seventh day of development, the human embryomust
implant into the uterus of the mother to survive, to establish the body
plan and to generate the germ layers. The failure of an embryo to
implant is a major cause of early pregnancy loss3 and yet the cellular
and molecular changes that take place in the human embryo at this
stage remain unknown. This is because experiments in vivo are not fea-
sible and there has been no system to culture human embryos ex vivo.
Monkey embryos have been used as a model for human
embryo development4,5 and the co-culture of human blastocysts and
endometrial cells6 has provided an experimental system to model
post-implantationmorphogenesis. However, the extent to which these
systems recapitulate post-implantation development of the human
embryo remains an open question. Moreover, the potential of human
blastocysts for self-organization has never been explored.
Here, to shed light on the early post-implantation phases of human
development, we have adapted our recently established protocol for
mouse embryos7,8. The culture system we have established allows
human embryos to undergo the pre- to post-implantation transition
in vitro, in the absence of any maternal tissues. By comparing human
embryos developing in vitro and the Carnegie series of in vivo
developing human embryos9, we have identified that the key hallmarks
of human embryogenesis take place in the absence of any maternal
tissues, uncovering the self-organizing properties of human embryos
at this stage.
RESULTS
Establishment of a method to culture human embryos through
implantation stages in vitro
To gain understanding of the developmental events undertaken by
the implanting human embryo, we reasoned that we needed an
in vitro culture system that would recapitulate these processes. To
this end, we adapted the culture conditions we had previously es-
tablished for mouse embryos at comparable stages7. Supernumerary
pre-implantation human embryos (at either cleavage or blastocyst
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Figure 1 Establishment of an in vitro system to study human implantation
and early post-implantation morphogenesis. (a) Human embryos were thawed
and cultured until the blastocyst stage (day 5–6 of development). The
zona pellucida was removed and embryos were transferred to plates in IVC1
medium for imaging. (b–d) On the second day of culture, medium was
changed for IVC2 with 30% KnockOut Serum Replacement (KSR). Shown
are representative bright-field images of human blastocysts developing in vitro
until day 12–13. All scale bars, 100 µm. These data involved the assessment
of a total of 5 embryos collected across 3 experiments, out of which 3 showed
correct development.
stage) donated for this project were thawed and placed in culture
medium to recover, before the zona pellucida was removed (Methods).
Embryos were scored by morphological criteria and those showing
abnormalities (fragmented blastomeres or developmentally arrested)
were discarded. We first plated human blastocysts on optical-grade
dishes in 21% O2 and in in vitro culture medium 1 (IVC1), which was
replaced by in vitro culture medium 2 (IVC2) after 48 h (Fig. 1a,b)7.
Time-lapse microscopy revealed that human blastocysts cultured in
IVC1 underwent a series of contractions and expansions reflecting
collapse and subsequent enlargement of the blastocyst cavity (Supple-
mentary Video 1), as observed in IVF clinics10. However, by the end of
day 7, the blastocyst cavity completely collapsed and embryos attached
to the dish (Fig. 1b–d). At this time the attached embryos started
to grow and this growth continued until day 12–13 (Fig. 1c,d and
Supplementary Video 2). We previously found that either human cord
serum or KnockOut Serum Replacement (KSR) in IVC2 permits peri-
implantation mouse development11. Here we show human embryos
develop in medium supplemented with KSR up to day 13 (Fig. 1b–d).
The experiment was stopped at this point because the internationally
recognized ethical limit for human embryo culture is up to day 14 or
to the first signs of development of the primitive streak12.
The trend in IVF clinics over recent years has been to culture pre-
implantation human embryos in hypoxic conditions (5% O2), as this
favours embryo survival13 and inhibits differentiation in embryonic
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Figure 2 Preservation of the pluripotent lineage in human embryos cultured
through implantation stages in vitro. (a) Bright-field images of day 5–6
blastocysts. Asterisks indicate the inner cell mass. (b) Day 5–6 blastocysts
were fixed and immunostained for lineage markers. Representative confocal
Z sections of human blastocysts stained for OCT4 and GATA6, and
OCT4 and CK7. (c) Human embryos cultured in either 21% or 5% O2
were analysed at the indicated time points. Representative confocal Z
sections of human embryos stained for OCT4, aPKC and F-actin. Note
the absence of OCT4-expressing cells and the presence of fragmented
nuclei in the embryos cultured in 5% O2. All scale bars, 50 µm. These
data involved the assessment of a total of 59 embryos in 21% O2
(out of which 29 embryos preserved the epiblast) and 20 embryos in
5% O2 (out of which none preserved the epiblast) collected across
3 experiments.
stem cells14,15. To investigate whether hypoxic conditions offer any
advantage to human embryos cultured through implantation, we
compared development of embryos cultured in 21% O2 to ones
cultured in 5% O2 in terms of preservation of the pluripotent lineage.
Initially, day 5–6 pre-implantation blastocysts had a group of inside
pluripotent cells as indicated by the presence of the transcription
factor OCT4 (Fig. 2a,b). However, after 4 days in culture, whereas
49% of embryos (N = 59) cultured in 21% O2 maintained a cluster
of epiblast cells showing expression of the pluripotency factor OCT4,
none of the embryos cultured in hypoxic conditions (N = 20) had
OCT4-expressing cells (Supplementary Table 1). In contrast, cells of
embryos in hypoxic conditions showed signs of cell death (Fig. 2c).
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Figure 3 Analysis of embryonic and extra-embryonic lineages in human
embryos cultured through implantation stages in vitro. Human embryos
developing in vitro until day 11 were fixed and stained at the indicated time
points. (a) Representative confocal Z sections of human embryos stained for
OCT4 and GATA6. Right panels show the centre of all OCT4-expressing (white)
and GATA6-expressing (green) cells. All positive cells were counted regardless
of the fluorescence intensity value. (b) Representative confocal Z section of
a day 9–10 embryo stained for OCT4, GATA6 and CK7. (c) Representative
confocal Z section of a day 8–9 embryo stained for PAR6 and CK7.
(d) Representative confocal Z section of human embryos stained for F-actin
and DAPI. Arrowheads point to multinucleated cells. (e) 3D reconstruction
of the cellular and nuclear shape of representative trophectoderm cells. Note
that cells in close proximity to the epiblast have a single nucleus, whereas
cells in the periphery of the embryo are multinucleated. All yellow rectangles
indicate the regions in the embryos that are shown with higher magnification.
All scale bars, 50 µm. These data involved the assessment of a total of 59
embryos collected across 6 experiments, out of which 29 showed preservation
of the embryonic lineage.
This suggests that preservation of the epiblast in vitro beyond day
7 might benefit from higher O2 concentrations possibly because of
the increase in embryo size, which may decrease the O2 pressure in
the core of the embryo. Hypoxia clearly has a complex influence on
embryonic development and its effects need to be better understood in
the intrauterine milieu to determine exactly how it affects both mouse
and human embryogenesis16. As a result of these findings, here we
cultured human embryos beyond day 7 in 21% O2, which we show
permits further development of the pluripotent lineage in vitro.
Development of the embryonic and extra-embryonic lineages
during human post-implantation morphogenesis in vitro
To gain temporal understanding of the cellular and developmental
events through early post-implantation development, we fixed and
immunostained human embryos at different time points of culture.
We used KnockOut Serum Replacement to supplement the medium
as it permits a more reproducible time course of development than
human cord serum7. We have focused on development between days
7 and 11, because during these 5 days the embryo undergoes a
major reorganization that is necessary for subsequent gastrulation9.
Shortly after attachment (day 7–8 of development), we observed a
clear separation between embryonic (OCT4-expressing, epiblast) and
extra-embryonic (GATA6-expressing, hypoblast) cells, the respective
progenitors for the fetus and yolk sac (Fig. 3a), whereas in the
unattached blastocysts, this segregation of epiblast and hypoblast
progenitors had not yet taken place (Fig. 2b). This contrasts with
mouse embryos, where the epiblast and the hypoblast-equivalent
(the primitive endoderm) segregate already before implantation17; but
agrees with observations in human embryos18–22. We found that at day
7–8, the epiblast was formed by a cluster of about 20 OCT4-expressing
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cells surrounded by approximately 50 GATA6-expressing hypoblast
cells (Fig. 3a and Supplementary Table 2). By day 8–9, GATA6-
expressing hypoblast cells preferentially localized to one side of the
epiblast, as occurs in human embryos developing in vivo9. This spatial
organization was maintained throughout subsequent developmental
stages (from day 9 to day 11; Fig. 3a and Supplementary Fig. 1a and
Supplementary Videos 3 and 4). By day 11, the number of OCT4-
expressing epiblast cells had significantly increased to an average of
328 cells, whereas the number of GATA6-expressing hypoblast cells
increased up to 79 (Supplementary Table 2).
To analyse development of trophectoderm, the progenitors of the
placenta, we followed cytokeratin 7 (CK7), which is highly expressed
in trophoblast derivatives23. We found that the trophectoderm cells
surrounding the epiblast and hypoblast (Fig. 3b) presented a polarized
epithelial phenotype, evident from the localization of the apical
determinant PAR6 (Fig. 3c). From day 8 onwards, we noted the
presence of CK7-expressing multinucleated cells in the outermost
region of the embryo (Fig. 3d). To determine their exact position
with respect to the epiblast–hypoblast cluster, we performed a three-
dimensional (3D) reconstruction of cellular shapes, based on the
computational segmentation of membranes and nuclei (Fig. 3e). This
revealed two trophectoderm subpopulations: cells in proximity to
the epiblast–hypoblast bilayer had a single nucleus, whereas those
in the periphery of the embryo were multinucleated and exhibited
characteristic lacunae (Fig. 3e and Supplementary Video 5). On the
basis of the expression of CK7, their position and their cellular and
nuclear shape, these two cell populations are likely to correspond to
the cytotrophoblast and syncytiotrophoblast respectively, indicating
that the development of post-implantation trophoblast derivatives
can be recapitulated in the absence of any maternal tissue. Together
these results demonstrate that the development of all three lineages
progresses as human embryos develop in vitro.
Human epiblast polarization and pro-amniotic cavity formation
Next, we focused on the development of the epiblast because it
undergoes its first major reorganization at implantation. One of the
hallmarks of epiblast transformation is the acquisition of a polarized
phenotype and the formation of a lumen, the prospective pro-amniotic
cavity9,24, essential for the subsequent development of the body plan.
However, the cellular mechanisms underlying lumen formation in
humans remain unknown. Whereas some reports in higher primates
point towards cell deathwithin the epiblast as themain driver of lumen
formation25, alternative reports suggest folding of the epiblast26, or
a change of polarity in epiblast cells4. Importantly, these hypotheses
are based on the observations of rhesus monkey embryos by electron
microscopy as, so far, it has not been possible to definitively identify
cell types and their features in human embryos at implantation. We
found that at day 7–8 of development, the epiblast was a cluster of cells
showing no signs of polarization (Fig. 4a and Supplementary Figs 1b
and 2).However, by day 8–9, a group ofOCT4-expressing epiblast cells
became radially organized around a small central lumen. These cells
were apico-basally polarized in 31% of the embryos (Supplementary
Table 1), as determined by the polarized apical localization of actin
and aPKC (the principal kinase of the apical Par polarity complex;
Fig. 4a and Supplementary Fig. 1b). The formation of a small lumen
at the exact site of incipient apical polarization indicates the onset of
pro-amniotic cavity formationwithin the epiblast. Importantly, we did
not observe any apoptotic cell, cellular debris or any other indication of
cell death in the incipient pro-amniotic cavity (Supplementary Fig. 3).
These results indicate that the epiblast becomes polarized by day 9 of
in vitro development and suggest that apoptosis is not the mechanism
driving lumenogenesis in human embryos.
Human bilaminar disc formation
The next expected remodelling event is the formation of the amniotic
epithelium and the epiblast disc. In contrast to the mouse, in which
the amnion is formed at gastrulation, the amnion is expected to
form in humans shortly after implantation with those epiblast cells
adjacent to the hypoblast acquiring a columnar shape, and those in
contact with cytotrophoblast differentiating into squamous and flat
amniotic epithelium. At this stage, both tissues line the pro-amniotic
cavity24. We observed that as development of embryos progressed
in vitro, the epiblast and the pro-amniotic cavity expanded in size
(Fig. 4a,b and Supplementary Fig. 4 and Supplementary Table 2 and
SupplementaryVideo 6), indicative of embryo growth. At day 10–11 of
development, we could detect two morphologically distinct groups of
OCT4-expressing cells. 3D reconstructions of cellular shapes revealed
that OCT4-expressing cells located near the hypoblast had a columnar
morphology whereas opposite-facing OCT4-expressing cells had a
distinct squamous and flat shape (Fig. 4c and Supplementary Video 7).
Moreover, these flat OCT4-expressing cells were in close proximity
to cells with a higher nuclear volume (on average 2.5 times bigger
than epiblast cells), a feature characteristic of trophoblast cells. These
observations suggest that the two types of OCT4-expressing cells may
represent the epiblast disc and the prospective amniotic epithelium.
Human prospective yolk sac formation
The next expected event of human embryo development is the
reorganization of hypoblast cells to give rise to a second cavity,
the primary yolk sac9,27, which will provide the blood supply to
the developing fetus. Remarkably, we found that human embryos
developing in vitro established a second cavity at day 11 of
development (Supplementary Video 8). This cavity was localized
below the epiblast and was surrounded by GATA6-expressing cells,
highlighting its hypoblast origin (Fig. 4d,e and Supplementary
Video 9). Thus, both expression of characteristic lineage markers
as well as morphological features suggest that formation of the
prospective yolk sac can be also recapitulated in human embryos
developing in vitro (Fig. 4f).
Human pluripotent stem cells (hPSCs) recapitulate the events
of polarization and lumenogenesis
As the above results revealed that epiblast polarization and lumen
formation are the first features of epiblast morphogenesis after
implantation, we next investigated the molecular pathways that
could be responsible for this critical remodelling. Given the ethical
restrictions and the limited number of human embryos available for
functional studies, we turned to human embryonic stem cells (hESCs)
and human induced pluripotent stem cells (hiPSCs) as alternative
models. First, to determine whether the extracellular matrix (ECM)
participates in inducing epiblast polarization and lumen formation, we
cultured individual hESCs in 3DMatrigel. We found that surrounding
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Figure 4 Remodelling of the epiblast in human embryos cultured through
implantation stages. Human embryos developing in vitro until day 11
were fixed and stained at the indicated time points. (a) Representative
confocal Z sections of human embryos stained for F-actin, aPKC and
OCT4. Arrowheads indicate the incipient pro-amniotic cavity. (b) 3D
reconstruction of the pro-amniotic cavity (shown in red). The nuclei of
OCT4-expressing epiblast cells are shown in grey. (c) 3D reconstruction of
the cellular shape of representative OCT4-expressing epiblast cells. (d) 3D
reconstruction of the prospective yolk sac (shown in blue). The nuclei of
OCT4-expressing epiblast cells are shown in grey. (e) Day 10–11 embryo
stained for F-actin, OCT4, GATA6 and aPKC. Note the presence of GATA6-
expressing cells on both sides of the cavity (arrowheads). The prospective
yolk sac is indicated with a dashed line. (f) Model of human embryo
implantation morphogenesis based on our results and the Carnegie series.
The main remodelling events that take place during this transition are:
segregation of epiblast and hypoblast progenitors (day 7); polarization and
pro-amniotic cavity formation in the epiblast (day 8–10); differentiation
of the trophectoderm (TE) into cytotrophoblast and syncytiotrophoblast
cells (day 8–10); formation of the prospective amniotic epithelium, the
prospective yolk sac and the bilaminar disc (day 10–11). All rectangles
indicate the regions in the embryos that are shown with higher magnification.
All scale bars, 50 µm. These data involved the assessment of a total of 59
embryos collected across 6 experiments, out of which 9 showed pro-amniotic
cavity formation.
cells with ECM enabled lumen formation by 24 h after cell plating,
and so it was sufficient to have two sister cells from a single cell
division for this to take place (Fig. 5a), in agreement with other
recent observations28. As the hESCs continued to divide, they self-
organized around a central lumen. These hESC cysts were apico-
basally polarized, as demonstrated by the polarized localization of
aPKC (Fig. 5a), PAR6 (Fig. 5b), centrosomes (Fig. 5c) and the Golgi
(Fig. 5d). They retained expression of pluripotency markers such
as OCT4 (Fig. 5a), mimicking the preservation of OCT4 in the
epiblast of in vitro-cultured human embryos (Fig. 3). To confirm
these results, we next plated hiPSCs into 3D Matrigel as we did with
hESCs. We found that hiPSCs also polarized and began to form
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Figure 5 Self-organization of hESCs in response to ECM signalling. hESCs
were plated in a 3D matrix of Matrigel and analysed at the indicated time
points. (a) hESCs stained for OCT4 as a marker of pluripotency, aPKC as a
marker of apical polarization and F-actin to reveal the general organization
of the cells. (b) hESCs stained for PAR-6 and F-actin. The size of the lumen
was quantified. Data are shown as average ± s.e.m. Note the increase in
lumen size with time (n=10 hESC cysts per time point). Unpaired two-tailed
Student’s t test with Welch’s correction, ∗∗P=0.0049. (c) hESCs stained
for the centrosome marker γ-tubulin and F-actin. Arrowheads indicate the
polarized apical localization of the centrosome. The nucleus centrosome
angle with respect to the nucleus–nucleus axis is shown. Each dot represents
an individual centrosome. Data are shown as average ± s.e.m. (n= 19
centrosomes). (d) hESCs stained for the Golgi marker GM130 and F-actin.
Arrowheads indicate the polarized apical localization of the Golgi. All
scale bars, 10 µm. These data involved the assessment of a minimum of
10 hESC cysts per panel, all of which showed the indicated phenotype.
Images are representative of a minimum of 2 independent experiments
per panel.
lumens between two cells, while retaining OCT4 expression (Fig. 6a).
Lumens formed on the apical side of polarized cells that exhibited
apical microvilli and a polarized distribution of aPKC, PAR6 and
the Golgi (Fig. 6a–c). This polarized organization was preserved in
the presence of the ROCK inhibitor Y-27632 (Fig. 6d), commonly
used to avoid cell death at the time of plating of hPSCs. We could
also detect lumen-directed secretion of the anti-adhesive protein
podocalyxin (PODXL), implicated in lumen formation through charge
repulsion29,30 (Fig. 6e,f). The observation that hPSC cysts develop
lumens between two cells as they become polarized suggests that
lumen formation is not a consequence of cell death. To test this
possibility directly, we treated hiPSCs with a caspase 3 inhibitor to
prevent cell death8 and found that polarization and lumen formation
were not affected (Fig. 6g,h). Taken together, our results indicate that
lumen formation is a consequence of cellular polarization and not cell
death and lead us to suggest that similarmolecular pathwaysmay drive
lumenogenesis in human embryos soon after implantation.
DISCUSSION
Implantation is a milestone in human development, as this is the
time when the embryo undergoes major remodelling, which is
absolutely required for correct gastrulation and therefore successful
body formation and pregnancy outcome. However, so far, the absence
of an in vitro culture system to visualize and model this critical
developmental transition has severely limited our understanding of
human embryogenesis. Here, we have established a system for the
in vitro culture of human embryos that offers a unique opportunity
to understand human development after implantation. This system
has allowed us to uncover the main morphogenetic events that
normally occur after human embryo implantation including: epiblast
and hypoblast segregation; epiblast polarization; formation of the pro-
amniotic cavity and the bilaminar disc; appearance of the prospective
amniotic ectoderm; appearance of yolk sac; and differentiation of the
trophoblast into cytotrophoblast and syncytiotrophoblast (Fig. 4f).
Although this system may not be able to fully recapitulate all of the
complex aspects of human embryogenesis in vivo, it has allowed us to
reveal a remarkable self-organizing capacity of human blastocysts that
has been previously unknown. The next stage in human development
corresponds to primitive streak formation but for ethical reasons we
are obliged to stop our cultures at day 14 of development or before the
primitive streak formation12. Thus, our studies have focused on the key
events of pre-gastrulation stages.
Our results indicate that the formation of the pro-amniotic cavity
in the human embryo is not triggered by apoptosis, as suggested25,
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Figure 6 Self-organization of hiPSCs in response to ECM signalling. hiPSCs
were plated in a 3D matrix of Matrigel and analysed at the indicated time
points. (a,b) hiPSCs stained for aPKC, OCT-4 and F-actin. (c) hiPSCs stained
for PAR-6, GM130 and F-actin. (d) hiPSCs cultured in the presence of the
ROCK inhibitor Y-27632 and stained for aPKC and F-actin. (e,f) hiPSCs
cultured in the presence (e) or absence (f) of ROCK inhibitor, and stained
for PODXL and F-actin. (g) hiPSCs were treated with the caspase 3 inhibitor
Z-DEVD FMK and lumen formation was analysed 24 and 48h after plating by
staining for aPKC and F-actin. (h) Quantification of lumen formation in the
presence of Z-DEVD FMK. Data are shown as a contingency table. Fisher’s
exact test. NS, not significant (n=12 hiPSC cysts per condition, 24 h time
point; n=10 hiPSC cysts per condition, 48 h time point). Data presented in
this figure involved the assessment of a minimum of 10 hESC cysts per panel
and per condition across a minimum of 2 independent experiments per panel.
but by the epiblast’s polarization, as proposed in monkey embryos4.
Owing to the limitations to perform functional studies in human
embryos, we have used hPSCs as an alternative model to test this
hypothesis, and demonstrate that the ECM participates in inducing
cell polarization and lumen formation through polarized secretion
(hollowing) and not programmed cell death (cavitation). This is
similar to the mechanism of epiblast polarization we have recently
found to operate in mouse embryos8. Thus, remarkably, despite
the significant differences in embryo morphology between these
different mammalian species, the initial steps of post-implantation
embryogenesis are evolutionarily conserved.
One of the most intriguing aspects of human implantation
development is the differentiation of the epiblast into the epiblast disc
and the amniotic epithelium24. Interestingly, we could not recapitulate
formation of the amniotic epithelium in our 3D hPSC culture possibly
because this developmental process requires interaction with extra-
embryonic tissues present in the whole embryo. It will be of interest
to determine the signalling pathways required for modelling amnion
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formation in vitro. Indeed, we anticipate that future studies using the
in vitro culture systems we report here for both human embryos and
hPSCs will shed new light on the cellular and molecular mechanisms
of this mysterious and yet critical stage of human development, which
will be of basic and clinical importance. 
METHODS
Methods and any associated references are available in the online
version of the paper.
Note: Supplementary Information is available in the online version of the paper
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METHODS
Ethics statement. Human embryo experiments were performed in three different
groups under three different licences obtained from the Human Fertilization and
Embryology Authority (HFEA):
(1) License reference R0193-1-a (University of Cambridge). Cryopreserved
human embryos were donated to this project, entitled ‘Filming of human
implantation in vitro’, after an informed consent of couples undergoing IVF
treatments. Before giving consent, people donating embryos were provided with all
of the necessary information about the research project and conditions that apply
within the licence and HFEA Code of Practice. In addition, an independent ethic
approval was obtained from the ‘Human Biology Research Ethics Committee’ of the
University of Cambridge.
(2) License reference R0075 (Kings College London, Guy’s Hospital). Informed
consent was obtained from all subjects and the experiments conformed to the
principles set out in theWMADeclaration of Helsinki and theNIHBelmont Report.
No financial inducements are offered for donation. This project has also a local
ethical approval (UKNational Health Service Research Ethics Committee Reference:
06/Q0702/90).
(3) License reference R0162 (The Francis Crick Institute). Informed consent was
obtained from all couples that donated spare embryos following IVF treatment.
Before giving consent, people donating embryos were provided with all of the
necessary information about the research project, an opportunity to receive
counselling and the conditions that apply within the licence and the HFEA Code
of Practice. No financial inducements are offered for donation. This project also has
ethical approval from the UK National Health Services Research Ethics Committee
Reference: 04/Q0108/99.
In the three locations involved in this project, all of the experiments on
human embryos were performed under the HFEA Codes of Practice and the
Human Fertilization and Embryology Act 1990 practices. Human embryos were not
maintained in culture past 14 days or appearance of the primitive streak.
Human embryonic stem cell work complies with the regulations of the UK Code
of Practice for the Use of Human Stem Cell Lines and UK Stem Cell Bank Steering
committee. An ethical approval for this project was obtained from the UK Stem Cell
Steering Committee.
Human embryo thawing and zona pellucida removal. Human blastocysts (day
5 and day 6) were thawed using Kitazato Thawing Media Kit VT802 (91182;
Kitazato Dibimed), or Quinn’s Advantage Thaw Kit (ART-8016; LifeGlobal Group)
depending on the protocol used for freezing and following the manufacturer’s
instructions. Cleavage-stage embryos (day 1, day 2 and day 3) were thawed
using Embryo Thawing Pack (10984010; Origio) and cultured in drops of human
embryo culture medium (LGGG-020; LifeGlobal Group) supplemented with 10%
(vol/vol) protein supplement (LPGS-605; LifeGlobal Group) under mineral oil
(9305; Irvine Scientific) until blastocyst stage. The zona pellucida of each blastocyst-
stage embryo was removed by brief exposure to acidic Tyrode’s solution (T1788;
Sigma-Aldrich), embryos were washed in the human embryo culture medium
(LGGG-020; LifeGlobal Group), or SAGE 1-Step (67010060A; LifeGlobal Group),
and transferred to in vitro culture medium (see below).
Human embryo in vitro culture from pre- to post-implantation stage. The in vitro
culture procedure is illustrated in Fig. 1a. Day 5–6 human blastocysts devoid of zona
pellucida were cultured on 8-well IbiTreat µ-plates (IB-80826; Ibidi GmbH) with
in vitro culture media at 37 ◦C, in 21% O2/5% CO2 or when indicated in 5% O2/5%
CO2. For the first 48 h the embryoswere cultured in in vitro culturemedium1 (IVC1;
see below)7. On in vitro culture day 2 (embryo day 7–8 post fertilization), 50% of the
culture medium was replaced with in vitro culture medium 2 (IVC2; see below)7.
From in vitro culture day 3 on, IVC2 medium was used and medium was refreshed
on a daily basis. The detailed composition of the media used is outlined below:
IVC1. Advanced DMEM/F12 (12634-010; Thermo Fischer Scientific)
supplemented with 20% (vol/vol) heat-inactivated FBS (produced in
house, Stem Cell Institute, the University of Cambridge or 35-015-CV;
Corning), 2mM L-glutamine (25030; Thermo Fisher Scientific), penicillin
(25 unitsml−1)/streptomycin (25 µgml−1) (15070-063; Thermo Fischer Scientific),
1X ITS-X (10mg l−1 insulin, 5.5mg l−1 transferrin, 0.0067mg l−1 sodium selenite,
2mg l−1 ethanolamine; 51500-056; Thermo Fisher Scientific), 8 nM β-oestradiol
(E8875; Sigma-Aldrich), 200 ngml−1 progesterone (P0130; Sigma-Aldrich) and
25 µM N -acetyl-L-cysteine (A7250; Sigma-Aldrich).
Defined IVC2. Advanced DMEM/F12, supplemented with 30% (vol/vol)
KnockOut Serum Replacement (10828010; Thermo Fisher Scientific),
2mM L-glutamine, penicillin (25 unitsml−1)/streptomycin (25 µgml−1), 1X ITS-X,
8 nM β-oestradiol, 200 ngml−1 progesterone, and 25 µM N -acetyl-L-cysteine. The
same catalogue numbers and suppliers apply as above.
A step-by-step protocol of the in vitro culture of human embryos through
implantation stages can be found at Nature Protocol Exchange31.
Human embryo time-lapse imaging. Time-lapse phase-contrast images were
acquired using spinning-disc confocal microscopy (3i Intelligent Imaging
Innovations) and a Zeiss 0.55 NA ×20 (EC PlnN) objective; and wide-field
microscopy (3i Intelligent Imaging Innovations) and a Zeiss Plan-Apo Chromat
0.75 NA ×20 objective. The embryos were imaged in a humidified chamber with
21% O2. A Z-range of 120 µm with 5 µm intervals was scanned every 30min. The
images were processed using Fiji (http://fiji.sc/Fiji).
Immunofluorescence of human embryos. Embryos were fixed with 4%
paraformaldehyde (PFA) for 20min at room temperature, washed with phosphate
buffered saline (PBS), and permeabilized by 0.5% Triton X-100 in PBS at room
temperature for 20min. Embryos were blocked with 10% FBS (produced in house,
Stem Cell Institute)/3% (w/vol) bovine serum albumin (A3311; Sigma-Aldrich)
in PBS, at room temperature for 4 h. The primary antibodies mouse monoclonal
anti-Oct3/4 (C-10; sc-5279; Santa Cruz Biotechnology; 1:200), rabbit polyclonal
anti-aPKC (C-20; Sc-216; Santa Cruz Biotechnology; 1:200), goat monoclonal
anti-GATA6 (clone 222228; mab1700; R&D Systems; 1:200), rabbit polyclonal
anti-PARD6B (M-64; sc-67393; Santa Cruz Biotechnology; 1:200) and mouse
monoclonal anti-cytokeratin 7 (OVTL 12-30; sc-52322; Santa Cruz Biotechnology;
1:200) were diluted in 3% (w/vol) bovine serum albumin (as above)/0.1% Tween20
(P9416; Sigma-Aldrich) in PBS and incubated at 4 ◦C overnight. Samples were
incubated with the following fluorescence-conjugated secondary antibodies:
donkey anti-mouse AlexaFluor 568, donkey anti-rabbit AlexaFluor 647, donkey
anti-goat AlexaFluor 488 from Thermo Fisher Scientific. All secondary antibodies
were diluted 1:500 in 3% (w/vol) bovine serum albumin (as above)/0.1% Tween20
(P9416; Sigma-Aldrich) in PBS. F-actin was stained with AlexaFluor 488 phalloidin
(A12379; Thermo Fisher Scientific; 1:200) and nuclei were stained with DAPI
(D3571; Thermo Fisher Scientific; 1:1,000).
Human pluripotent stem cell culture. hESC line H9 and hiPSC line FSPS
13B were kindly provided by L. Vallier (Stem Cell Institute, Anne McLaren
Laboratory, Cambridge, UK). The hiPSC line SC101A-1 (System Biosciences)32
was kindly provided by M. Lancaster (MRC Laboratory of Molecular Biology,
Cambridge, UK). These hPSCs were maintained on Geltrex (A15696-01; Thermo
Fisher Scientific)-coated culture plates in complete serum-free defined hPSC
culture media, either Essential 8 (E8; A1517001; Thermo Fisher Scientific) or
mTeSR 1 (05850; Stem Cell Technologies). Authentication of the cell lines was
performed on the basis of pluripotent gene expression. No cell lines used in this
study were found in the database of commonly misidentified cell lines that is
maintained by ICLAC and NCBI Biosample and they were not routinely tested
for mycoplasma.
3D culture of hPSCs. hPSCs were suspended as single cells using StemPro
Accutase Cell Dissociation Reagent (A11105-1; Thermo Fisher Scientific) and plated
following a 3D on-top protocol as previously described33. Briefly, IbiTreat µ-plates
(IB-80826; Ibidi GmbH) were coated with Matrigel Basement Membrane Growth
Factor Reduced (354230; Corning) and 2 × 104 cells were plated in either E8 or
mTeSR1medium.After 5min andon attachment of the cells to theMatrigel layer, the
medium was removed and either fresh E8 or mTeSR 1 medium supplemented with
5% Matrigel was added on top. When indicated, 10 µM ROCK inhibitor Y-27632
(Y0503; Sigma-Aldrich) or 10/20 µM caspase 3 inhibitor Z-DEVD-FMK (1143-5;
BioVision) was added to the medium.
A step-by-step protocol of the 3D culture of hPSCs can be found at Nature
Protocol Exchange31.
Immunofluorescence of 3D cultured hPSCs. hPSCs embedded in Matrigel were
fixed with either 4% PFA at room temperature or ice-cold methanol at −20 ◦C
for 15min. The samples were permeabilized with 0.3% Triton X-100–0.1M
glycine in PBS for 20min. The primary antibodies mouse monoclonal anti-
Oct3/4 (as above, 1:200), rabbit polyclonal anti-aPKC (as above, 1:200), rabbit
polyclonal anti-PARD6B (as above, 1:200), mouse monoclonal anti-GM130 (clone
35/GM130; 610822; BD Biosciences; 1:200), mouse monoclonal anti−γ−tubulin
(clone GTU-88; T5326; Sigma, 1:500) and mouse monoclonal anti-PODXL (clone
222328; MAB1658; R&D Systems; 1:200) were diluted in blocking buffer (1% bovine
serum albumin—A3311; Sigma-Aldrich—and 0.1% Tween) and incubated at 4 ◦C
overnight. Samples were washed three times with PBS–0.1% Tween and incubated
with AlexaFluor-conjugated secondary antibodies (as above).
Imaging. The images of the fixed samples were acquired using an inverted SP5
confocal microscope (Leica Microsystems) and Leica 1.3 NA 40× oil (HC PL
APO), Leica 1.4 NA 63× oil (HC PL APO) and Leica 1.3 NA 63× glycerol (HCX
PL APO) objectives. The images were processed using Fiji (http://fiji.sc), UCSF
Chimera (https://www.cgl.ucsf.edu/chimera) and MovIT visualization software
(BioEmergences, http://bioemergences.iscpif.fr)34.
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Statistics and reproducibility. The exact number of embryos analysed in the
different conditions, as well as the number of embryos that exhibited a polarized
epiblast, is indicated in Supplementary Table 1.
No statistical method was used to predetermine sample size. Given the
nature of the work (mostly descriptive), no statistical comparisons were done
between different embryos. Embryos that showed abnormalities (fragmented
blastomeres or developmentally arrested) were excluded from the analysis. The
investigators were not blinded to allocation during experiments and outcome
assessment.
Figure 1 involved the assessment of 5 embryos collected across 3 independent
experiments. Out of these 5 embryos 3 showed a correct development.
Figure 2 involved the assessment of 20 embryos cultured in 5% O2 and collected
across 3 independent experiment. All 20 embryos lacked the pluripotent lineage
(phenotype shown in the image). Embryos were randomly assigned to either 5% O2
or 21% O2.
Figures 3 and 4 involved the assessment of 59 embryos collected across 6
independent experiments. Briefly, 29 embryos preserved a cluster of pluripotent
cells; and out of these 29 embryos, 9 had an organized epiblast.
Figures 5 and 6 involved the assessment of a minimum of 10 hPSC cysts per
panel and condition. These were collected across a minimum of 2 independent
experiments per panel.
Qualitative data are presented in the form of a contingency table (Fig. 6h). These
data were analysed using a Fisher’s exact test.
Quantitative data are presented as mean± s.e.m. The normality of the data was
analysedwith aD’Agostino–Pearsonnormality test. Data presented in Fig. 5b showed
a normal distribution with significantly different variances. This was analysed using
an unpaired two-tailed Student’s t-test with Welch’s correction.
31. Vuoristo, S., Jedrusik, A., Shahbazi, M. N. & Zernicka-Goetz, M. Culture of human
embryos through implantation stages in vitro. Protoc. Exch. http://dx.doi.org/10.
1038/protex.2016.017 (2016).
32. Lancaster, M. A. et al. Cerebral organoids model human brain development and
microcephaly. Nature 501, 373–379 (2013).
33. Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture models
of normal and malignant breast epithelial cells. Nat. Methods 4, 359–365 (2007).
34. Faure, E. et al. A workflow to process 3D+time microscopy images of developing
organisms and reconstruct their cell lineage. Nat. Commun. 7, 8674 (2016).
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Corrigendum: Self-organization of the human embryo 
in the absence of maternal tissues
Marta N. Shahbazi, Agnieszka Jedrusik, Sanna Vuoristo, Gaelle Recher, Anna Hupalowska, Virginia Bolton, 
Norah M. E. Fogarty, Alison Campbell, Liani G. Devito, Dusko Ilic, Yakoub Khalaf, Kathy K. Niakan,  
Simon Fishel and Magdalena Zernicka-Goetz
Nature Cell Biology http://dx.doi.org/10.1038/ncb3347 (2016); published online 4 May 2016; corrected online 17 May 2016
In the version of this Technical Report originally published online, in Fig. 1d (which presents pilot in vitro culture experiments) it erroneously stated 
that 20% HCS was used in the IVC2 medium; it should have stated that 30% KSR was used. This error arose by a miscommunication between the 
postdoctoral fellow who contributed to the pilot in vitro culture experiments and prepared the media, and the postdoctoral fellow who performed 
the experiments. The composition of the media has been verified based on the laboratory notebooks that describe the media preparation. This 
error has been corrected in the labels and caption of Fig. 1d, in the description of the results in the main text, and in the Methods section, in all 
versions of the Technical Report.
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Supplementary Figure 1 3D analysis of embryonic and extra-embryonic 
lineages in human embryos cultured through implantation stages. 
Related to Figures 3 and 4. Human blastocysts developing in vitro 
until day 11 were fixed and stained at indicated time points.  a, 3D 
rendering of DAPI stain overlaid with the centre of OCT4-expressing and 
GATA6-expressing cells. Dots are projected at the back of the volume. b, 
Orthogonal views of embryos at different developmental stages stained 
for aPKC and OCT4. Note the presence of a small pro-amniotic cavity 
at day 8-9, which is enlarged as development proceeds. All scale bars, 
50 μm.
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Supplementary Figure 2 Confocal Z-sections of a day 7-8 human embryo. Related to Figure 4. Day 7-8 human embryo stained for OCT4, aPKC and F-actin. 
The different images correspond to representative confocal Z sections. Scale bar, 20 μm. Boxes indicate the magnified area (scale bar, 10 μm). 
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Supplementary Figure 3 Confocal Z-sections of a day 8-9 human embryo. Related to Figure 4. Day 8-9 human embryo stained for OCT4, aPKC and F-actin. 
The different images correspond to representative confocal Z sections. The arrow indicates the presence of a lumen. Scale bar, 20 μm. Boxes indicate the 
magnified area (scale bar, 10 μm).
© 2016 Macmillan Publishers Limited. All rights reserved
S U P P L E M E N TA RY  I N F O R M AT I O N
4  WWW.NATURE.COM/NATURECELLBIOLOGY
Supplementary Figure 4 Confocal Z-sections of a day 9-10 human embryo. 
Related to Figure 4. Day 9-10 human embryo stained for OCT4, aPKC 
and F-actin. The different images correspond to representative confocal Z 
sections. The arrow indicates the presence of a lumen surrounded by radially 
organised OCT4-expressing epiblast cells. Scale bar, 20 μm. Boxes indicate 
the magnified area (scale bar, 10 μm).
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Supplementary Figure 5 Confocal Z-sections of a day 10-11 human embryo. 
Related to Figure 4. Day 10-11 human embryo stained for OCT4, aPKC 
and F-actin. The different images correspond to representative confocal Z 
sections. The arrow indicates the presence of a small lumen surrounded by 
radially organised OCT4-expressing epiblast cells. Scale bar, 50 μm. Boxes 
indicate the magnified area (scale bar, 20 μm).
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Supplementary	  Table	  1:	  
Summary	  of	  human	  embryos	  cultured	  in	  this	  study.	  Note	  the	  lack	  of	  epiblast	  lineage	  in	  embryos	  cultured	  in	  hypoxic	  conditions
Conditions Embryos	  analysed Pluripotent	  lineage Pro-­‐amniotic	  cavity	  formation
21%	  O2	  (normoxia) 59 No	  epiblast:	  30	  (51%);	  Epiblast:	  29	  (49%) Non-­‐polarized	  epiblast:	  20	  (69%);	  Polarized	  epiblast:	  9	  (31%)
5%	  O2	  (hypoxia) 20 No	  epiblast:	  20	  (100%);	  Epiblast:	  0	  (0%) NA
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Supplementary	  Table	  2:	  
Average	  number	  of	  epiblast	  and	  hypoblast	  cells	  in	  human	  embryos	  at	  different	  stages	  of	  implantation	  development	  in	  vitro
Age	  of	  the	  embryo	  (days) Number	  of	  OCT4+	  cells Number	  of	  GATA6+	  cells
Day	  7-­‐8 17 46
Day	  8-­‐9 26 57
Day	  9-­‐10 86 61
Day	  10-­‐11 328 79
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Supplementary Video Legends
Supplementary Video 1 Development of a day 5 human blastocyst in the in vitro culture system up to day 9-10. Related to Figure 1. A day 5 human embryo 
was cultured in the in vitro culture system for approximately 100 hrs. Bright field images were taken every 30 min to record its development. Scale bar, 100 
μm.
Supplementary Video 2 Development of a day 9 human blastocyst in the in vitro culture system up to day 12. Related to Figure 1. A day 9 human embryo was 
cultured in the in vitro culture system for approximately 72 hrs. Bright field images were taken every 30 min to record its development. Scale bar, 100 μm.
Supplementary Video 3 3D reconstruction of embryonic lineages in a day 9-10 human embryo cultured in vitro. Related to Figure 3. Nuclei are shown in blue, 
OCT4 in grey and GATA6/F-actin in green. 
Supplementary Video 4 3D reconstruction of embryonic lineages in a day 10-11 human embryo cultured in vitro. Related to Figure 3. Nuclei are shown in 
blue, OCT4 in grey and GATA6/F-actin in green. 
Supplementary Video 5 3D reconstruction of the cellular and nuclear shape of representative trophectoderm cells at day 10-11. Related to Figure 3. Nuclei 
are shown in magenta and membranes in green. Note that cells in close proximity to the epiblast have a single nucleus, whereas cells in the periphery of the 
embryo are multinucleated.
Supplementary Video 6 3D reconstruction of the pro-amniotic cavity at day 9-10. Related to Figure 4. The nuclei of OCT4-expressing epiblast cells is shown 
in grey and the pro-amniotic cavity in red.
Supplementary Video 7 3D reconstruction of the cellular shape of representative OCT4-expressing epiblast cells at day 10-11. Related to Figure 4. Epiblast 
cells in close proximity to GATA6-expressing hypoblast cells are shown in green (note the columnar shape characteristic of cells within the epiblast disc). 
Epiblast cells in close proximity to cytotrophoblast cells are shown in magenta (note the squamous shape characteristic of amniotic cells). 
Supplementary Video 8 3D reconstruction of the prospective yolk sac at day 10-11. Related to Figure 4. The nuclei of OCT4-expressing epiblast cells is 
shown in grey and the prospective yolk sac in blue.
Supplementary Video 9 3D reconstruction of the hypoblast derived cells and their position with respect to the prospective yolk sac at day 10-11. Related to 
Figure 4. Nuclei of OCT4-expressing epiblast cells are shown in grey, GATA6/F-actin is shown in green and the prospective yolk sac in blue.
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Mitochondrial DNA (mtDNA) mutations cause inherited dis-
eases and are implicated in the pathogenesis of common late-
onset disorders, but how they arise is not clear1,2. Here we 
show that mtDNA mutations are present in primordial germ 
cells (PGCs) within healthy female human embryos. Isolated 
PGCs have a profound reduction in mtDNA content, with dis-
crete mitochondria containing ~5 mtDNA molecules. Single-
cell deep mtDNA sequencing of in vivo human female PGCs 
showed rare variants reaching higher heteroplasmy levels in 
late PGCs, consistent with the observed genetic bottleneck. 
We also saw the signature of selection against non-synony-
mous protein-coding, tRNA gene and D-loop variants, con-
comitant with a progressive upregulation of genes involving 
mtDNA replication and transcription, and linked to a transition 
from glycolytic to oxidative metabolism. The associated met-
abolic shift would expose deleterious mutations to selection 
during early germ cell development, preventing the relentless 
accumulation of mtDNA mutations in the human population 
predicted by Muller’s ratchet. Mutations escaping this mecha-
nism will show shifts in heteroplasmy levels within one human 
generation, explaining the extreme phenotypic variation seen 
in human pedigrees with inherited mtDNA disorders.
The 16.5-kilobase human mitochondrial genome (mtDNA) 
encodes 37 genes essential for the synthesis of 13 polypeptide sub-
units of the respiratory chain, the final common pathway of oxida-
tive metabolism1. In humans, mtDNA is inherited exclusively down 
the maternal line. Diploid cells typically contain 1–10,000 mtDNA 
molecules partitioned between a network of fusing and budding 
mitochondria. Exposed to a potent source of oxygen free radicals 
and lacking protective histone proteins, mtDNA is particularly vul-
nerable to mutation, creating a mixed population of wild-type and 
mutated mtDNA within a cell (heteroplasmy)2. MtDNA mutations 
accumulate in non-dividing (post mitotic) cells during life, with high 
levels observed in late-onset human disorders including Alzheimer’s 
disease and Parkinson’s disease. Although the overall tissue mutation 
burden is low, very high levels within single cells lead to bioener-
getic failure and ultimately cause cell death1. These findings raise the 
possibility that mtDNA mutations contribute to the pathogenesis of 
several common human diseases, and also play a part in the ageing 
process itself3, but the origin of these mutations has not been clear.
Age-associated mtDNA mutations were assumed to arise in 
somatic tissues during life, but deep sequencing of maternal rela-
tives raised the possibility that low-level mtDNA heteroplasmic 
point mutations are inherited down the maternal line4. To deter-
mine whether this is the case, we developed methods to isolate pure 
primordial germ cells (PGCs) from first trimester karyotypically 
normal human female embryos (Fig. 1). Anatomical regions con-
taining migrating PGCs were dissected from fresh 4-week embryos, 
and genital ridges were isolated from 5–8-week embryos. Single-
cell suspensions were then labelled with fluorochrome-conjugated 
antibodies against putative human germ cell surface markers, and 
sorted using fluorescence-activated cell sorting (FACS). Tissue 
non-specific alkaline phosphatase (TNAP) histochemistry5, VASA 
immunocytochemistry6 (Supplementary Fig. 1) and germ-cell-spe-
cific transcripts (Supplementary Figs. 1 and 2)7 were used to deter-
mine the proportion of PGCs after FACS sorting at appropriate 
developmental stages. Highly purified (> 97%) PGCs were isolated 
in 4-week (Carnegie stage, CS12) embryos using a combination of 
TNAP, stage-specific embryonic antigen 4 (SSEA4) and the PGC-
associated cell-surface marker CD38; and for weeks 5–8 (CS16/17–
CS20/21), we used TNAP and c-KIT antibodies (Fig. 1b).
After cell lysis, mtDNA was amplified in overlapping 2-kilobase 
fragments to minimize potential contamination from nuclear-
encoded mitochondrial insertions (NumtS), before > 5,000-fold 
depth re-sequencing. NumtS contamination was further mini-
mized by filtering-out all variants with a minor allele frequency 
(MAF) < 1%. Sequencing of a cloned mtDNA template showed no 
variants present at ≥ 1% MAF (Supplementary Fig. 3). However, 
we observed mtDNA single-nucleotide variants at > 1% hetero-
plasmy in PGCs isolated from all 12 embryos studied (Fig. 2a), 
Segregation of mitochondrial DNA heteroplasmy 
through a developmental genetic bottleneck in 
human embryos
Vasileios I. Floros1,2, Angela Pyle3, Sabine Dietmann4, Wei Wei1,2, Walfred W. C. Tang5, Naoko Irie5, 
Brendan Payne4, Antonio Capalbo6,7, Laila Noli8,9, Jonathan Coxhead4, Gavin Hudson4, Moira Crosier10, 
Henrik Strahl11, Yacoub Khalaf8,9, Mitinori Saitou12,13, Dusko Ilic8,9, M. Azim Surani5 and  
Patrick F. Chinnery! !1,2*
NATURE CELL BIOLOGY | VOL 20 | FEBRUARY 2018 | 144–151 | www.nature.com/naturecellbiology144
© 2018 Nature America Inc., part of Springer Nature. All rights reserved.
LETTERSNATURE CELL BIOLOGY
which did not map to known human NumtS8. This shows that low-
level mtDNA heteroplasmy is present within the female germ line 
in healthy humans. The variants were predominantly nucleotide 
transitions, which are less prone to in vitro sequencing error and 
less likely to be due to oxidative damage9, and are consistent with 
errors during in vivo DNA synthesis by mtDNA polymerase ϒ or 
the deamination of cytidine and adenosine10.
We also observed a change in the mutation spectrum from CS12 
to CS20/21 (Fig. 2a). For protein-coding genes, there was a decrease 
in the proportion of non-synonymous variants (non-synonymous/ 
synonymous ratio, P = 0.02) and a corresponding change in the codon 
bias (Fig. 2b,c). We also saw a decrease in the mutation rate per base 
pair for transfer RNA genes (Fig. 2d), which are hallmarks of selection 
against potentially deleterious mtDNA variants. Similar patterns have 
been seen in mice11,12, but the timing and mechanism of the selec-
tion was not known. On the basis of our observations, this occurs 
at an early stage in the developing human female germ line during 
PGC specification and migration. We were surprised to see some evi-
dence of selection against variants in the non-coding mtDNA D-loop 
(Fig. 2d), but these did not appear to be evenly distributed. CS12 
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Fig. 1 | Isolation of a pure population of human primordial germ cells (PGCs). a, Human and mouse developmental time points used in this study. Top: 
Prdm1 (Blimp1)–mVenus and Dppa3 (Stella)–eCFP (BVSC) mouse embryos (E9.5 and E10.5) and gonads (E12.5)17. The arrows show the fluorescent mouse 
PGCs subsequently isolated by fluorescent sorting. Scale bars, from left to right, 0.5!mm, 1!mm and 0.5!mm. Bottom: fresh human female embryos showing 
the lower core-body dissected area (outlined in red) for 4-week (Carnegie stage (CS)12) embryos (left), and dissected female embryonic gonads for 
5.5–6-week (CS16/17) and 8-week (CS20/21) embryos (middle and right). Scale bars, 1!mm. b, Isolation of human PGCs by fluorescent sorting: for 4-week 
(CS12) dissected embryos, using a triple-positive combination for TNAP, stage-specific embryonic antigen 4 (SSEA4) and CD38; and for weeks 5–8 
(CS16/17 to CS20/21), using gonadal tissue double-positive for TNAP and c-Kit. The boxes in the FACS plots show the sorted cell population. c, The purity 
of isolated hPGCs was validated by alkaline phosphatase (AP) activity staining showing!> !97% positive cells. Scale bars,!100!μ m. See also Fig. 4a–c and 
Supplementary Figs. 1 and 2. Observations for b and c were independently replicated three times at each developmental stage.
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Fig. 2 | Mitochondrial DNA variants in human primordial germ cells. a–e, MtDNA variants exceeding the assay detection threshold (minor allele frequency) 
of!> 1% during human primordial germ cell (PGC) development. Data were derived from n!= !80 single cells sorted from two CS12 embryos, n!= !240 cells 
sorted from four CS16/17 embryos, and n!= !360 cells sorted from six CS20/21 embryos. a, Frequency distribution of mtDNA variants at sequential stages 
of germline development. b, Codon positions affected by the coding region mutations (no codon bias for CS12, P is not significant; significant codon bias 
for CS20/21, P!=!0.005; Fisher’s exact text, two-sided). c, Proportion of non-synonymous (shaded) variants and synonymous (white) (dN/dS, P!=!0.02, 
Fisher’s exact text, two-sided). d, Evidence of selection against mtDNA variants in tRNA genes (P!= !0.03, Fisher’s exact text, two-sided) and the non-coding 
displacement (D)-loop (P!= !0.003) between CS12 and CS20/21. e, Position of the variants detected in the non-coding mtDNA D-loop region. f, MtDNA 
content of single in vivo PGCs from human (left, n!= !117) and Blimp1–mVenus and Stella–eCFP (BVSC) mouse (right, n!= !68) embryos. Each data point 
represents the mtDNA content in a single cell corresponding to the mean value from the independent qPCR measurements. Source data are available in 
Supplementary Table 6. g, MtDNA content of single human inner cell mass (ICM, n!= !20) and trophectoderm (TE, n!= !12) cells from five embryos in vivo. 
Each data point represents the mtDNA content in a single cell corresponding to the mean value from the independent qPCR measurements. Source data are 
available in Supplementary Table 6. h, MtDNA content of single human embryonic stem cells (hESCs, n!= !18), somatic cells (n!= !30) and human primordial 
germ-cell like cells (hPGCLC, n!= !48) isolated in vitro7,21. Two independent PGCLC inductions were performed for both the male (WIS2) and female (H9) 
ESC lines, with cells analysed at day 5/6. Source data are available in Supplementary Table 6. Each data point represents the mtDNA content in a single cell 
corresponding to the mean value from the independent qPCR measurements. Horizontal lines in f–h represent the mean values.
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PGCs contained variants in conserved regions not present in CS20/21 
PGCs (Fig. 2e), consistent with selection against variants in regions 
involved in mtDNA transcription and replication13.
Given that the majority of the mtDNA variants were present at 
low heteroplasmy levels (Fig. 2a), below the conventional thresh-
old required for a biochemical effect, it was not immediately 
apparent how the selection could occur. To explore the potential 
mechanism, we measured the absolute amount of mtDNA in the 
human PGCs at different stages of development in vivo, and then 
sequenced individual late-stage PGCs to look for evidence of vari-
ant segregation. First, we studied human oocytes from three healthy 
donors, which contained a mean of 1.22 × 106 mtDNA molecules 
(s.d. = 189,742, n = 3)14. This was in keeping with previous measure-
ments15 and confirmed assay reliability. The amount of mtDNA in 
human PGCs from 14 embryos in vivo was ~1,000-fold less than in 
oocytes (CS12 mtDNA copies: median 1,425, mean 1,446, s.d. = 77) 
(Fig. 2f), consistent with a human genetic bottleneck. The mtDNA 
levels in female and male PGCs were similar, as previously seen in 
mice16, and resembled new measurements made in Blimp1–mVe-
nus and Stella–eCFP [BVSC] mice17 (Fig. 2f; mouse embryonic 
day (E)9.5 corresponds to human CS12 and mouse E12.5 cor-
responds to human CS20/21). This validates previous findings in 
mice with different nuclear genetic backgrounds16,18,19, and shows a 
similar mechanism in both humans and mice. However, the lower 
amount of mtDNA we observed in human PGCs (human/mouse: 
CS12/E9.5, P < 0.0001; CS16–17/E10.5, P < 0.0001; CS20–21/E12.5, 
P < 0.0001) predicts a ‘tighter’ genetic bottleneck in humans than 
in mice, and thus the more rapid segregation of heteroplasmy. This 
is in accordance with observations in human and mouse pedigrees 
where more dramatic shifts in heteroplasmy are seen in humans 
(see Fig. 4a in ref. 20).
It is not technically possible to isolate human PGCs from earlier 
stages because the cells are collected from clinical samples. However, 
to gain further insight we also measured mtDNA levels in single 
cells from both the human inner cell mass (ICM) and trophecto-
derm cells (Fig. 2g). Although we saw a wide range of mtDNA lev-
els in ICM cells, the mean level (9,794, s.d. = 5,661) was more than 
fivefold greater than in PGCs. We then studied embryonic stem cells 
(hESCs) and human PGC-like cells (hPGCLCs)7,21 that are derived 
from the embryonic epiblast in vitro, thus allowing us to estimate 
the amount of mtDNA at an intermediate stage of human germ cell 
development (Fig. 2h). hESCs (mean = 3,264, s.d. = 378) contained 
less mtDNA than ICM cells, and hPGCLCs (mean = 896, s.d. = 368) 
contained less mtDNA than hESCs (P = 8.9 × 10−33). These find-
ings are in keeping with a post-implantation mtDNA bottleneck. 
The female hPGCLCs (mean = 533, s.d. = 203) contained signifi-
cantly less mtDNA than male hPGCLCs (mean = 991, s.d. = 342, 
P = 1.5 × 10−5), and less mtDNA than both male (mean = 1102, 
s.d. = 426, P = 2.2 × 10−16) and female (mean = 972, s.d. = 248, 
P = 2.2 × 10−16) somatic cells isolated from the same in vitro sys-
tem but not expressing germ-cell markers. These findings suggest a 
more stringent mtDNA bottleneck in the human female germ line.
Returning to the PGCs isolated in vivo, next we analysed the 
subcellular distribution of mtDNA molecules within the developing 
human female germ line. We used the dissector method to measure 
the number of mitochondria in human PGCs on adjacent-section 
electron micrographs (Fig. 3a), validating our results with super-
resolution whole-cell imaging using Nikon structured illumination 
microscopy in three dimensions (N-SIM; Supplementary Videos 1 
and 2 and Fig. 3b). The number of mitochondria did not change 
between CS12 and CS20–21, allowing us to estimate the number 
of mtDNA per mitochondrion at ~5 per organelle in human PGCs. 
The reduction in mtDNA content after fertilization of the oocyte 
(Fig. 2f), and associated intracellular compartmentalization of 
mtDNA (Fig. 3a,b), has important implications for the distribution 
of mtDNA heteroplasmy between individual organelles. Assuming 
that mutated mtDNA molecules are randomly distributed between 
mitochondria, higher levels of heteroplasmy within a cell will be 
associated with a greater proportion of mitochondria containing 
very high levels (> 80%) of a specific mutation (Fig. 3c). For exam-
ple, if the average level within a cell is 40–50% mutant, then 10–20% 
of the organelles will contain > 80% mutant mtDNA, exceeding the 
threshold required to cause a biochemical defect for pathogenic 
mutations1,2. In this context, ~10–20% of the organelles would be 
dysfunctional and potentially vulnerable to removal by mitochon-
drial quality-control mechanisms, removing mutated mtDNA 
through selection at the organellar level. To determine whether 
this is plausible, we performed deep mtDNA sequencing on indi-
vidual late-stage in vivo PGCs (Fig. 3d,e). This showed much higher 
percentage levels of mtDNA heteroplasmy within individual germ 
cells, reaching up to 47% mutant. Thus, following the bottleneck, 
high levels of mtDNA mutations are found in single PGCs, and 
are predicted to reach very high levels in individual mitochondria 
(Fig. 3c). The most likely explanation for the observed change in 
codon bias seen between CS12 and CS20–21 (Fig. 2b) is the rapid 
segregation of variants above and below the assay detection thresh-
old (1% MAF) due to the genetic bottleneck (Fig. 2a,c), rather than 
de novo mutation events per se. In this context, even a subtle bias 
against deleterious variants would tend to suppress them below the 
detection threshold, whilst allowing non-functional variants to seg-
regate freely to high levels (Fig. 3d).
To cast light on the possible mechanism of selection, we per-
formed RNA sequencing (RNA-seq) on week-4–9 human PGCs. 
Unsupervised hierarchical clustering of gene expression and prin-
cipal component analysis (PCA) of transcriptome confirmed 
strong expression of germ-cell-specific transcripts (Fig. 4a–c). 
Importantly, we also observed a distinct transcript profile for the 
nuclear-encoded mitochondrial proteins (MitoCarta2.0)22 in the 
early stages of PGC development (Fig. 4d). PCA of both the nuclear-
encoded and the mtDNA-encoded transcripts showed that the most 
dramatic changes were during the early stages of germ cell devel-
opment, with mitochondrial genes forming a cluster distinct from 
late gonadal PGC genes, such as DAZL and DDX4 (Supplementary 
Fig. 4). The mtDNA-encoded transcripts had the highest scores 
on PC1, accounting for 92% of the total variance (Fig. 4e). This 
is consistent with the developmental progression of mtDNA gene 
expression during PGC development. In contrast, genes involved 
in the canonical glycolysis pathway had opposing trends on PC1 
(Supplementary Figs. 4 and 5). Although based solely on transcript 
analysis, these findings suggest that PGCs become less dependent 
on glycolytic metabolism and more dependent on oxidative metab-
olism as they develop. As a consequence, non-synonymous mtDNA 
mutations are progressively more likely to have phenotypic conse-
quences during germ cell development. The proliferation of PGCs 
between CS12 and CS20/21 requires considerable mtDNA replica-
tion, inevitably introducing new mutations through ϒ polymerase 
errors. These new mutations are more likely to be synonymous 
(Fig. 2) and have no functional consequence. The switch from gly-
colytic to oxidative metabolism provides an explanation for these 
findings, by exposing functional variants to the selective effects dur-
ing this critical time period of PGC development.
Germline mtDNA selection at the organelle level has been pro-
posed in mammals12,23 and Drosophila24,25, but it is not known how 
this occurs. One possibility is that mitochondria depolarize when 
the proportion of mutated respiratory chain subunits is high, acti-
vating intracellular surveillance systems mediated by Pink1 and 
Parkin, and leading to the selective removal of damaged organ-
elles containing mutant mtDNA by mitophagy26,27. Alternatively, 
impaired mtDNA replication in ATP-deficient organelles28 could 
lead to the preferential turnover of mitochondria containing wild-
type genomes; or the transport of mitochondria may be compro-
mised in deficient organelles, preventing their coalescence around 
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Fig. 3 | Morphology and deep sequencing of single human primordial germ cells in vivo. a, Top: N-SIM image of a human PGC labelled with anti-TOM20 
(Supplementary Video 1) with mitochondria identified and counted by IMARIS (Supplementary Video 2). Scale bars,!2 μ m. Bottom: transmission electron 
micrographs characteristic of human PGCs40. The white arrowheads indicate the nucleoli. The white arrows indicate chromatin, electron-dense glycogen 
particles and lipid droplets; the pink arrow, pseudopodia in the migratory stage (CS12) PGCs (right image only); and the orange arrows, round discrete 
mitochondria around the nucleus. Scale bars,!2 μ m. Similar observations made from three independent experiments. b, Number of mitochondria in 
human primordial germ cells. Left (electron micrograph, n!= !24 cells): mitochondrial count per cell using the dissector method and serial-section electron 
micrographs. Right (N-SIM, n!= !12 cells): super-resolution microscopy. Each data point represents a measurement from a single PGC. Electron micrograph: 
mean!= !275.9, median!= !272, s.d. = 87.76. N-SIM: mean!= !288.8, median!= !272, s.d.!= !72.12. The horizontal bar represents the mean value. c, Probability of 
an individual mitochondrion containing mutated mtDNA molecules as a function of the overall heteroplasmy level within the cell. Binomial distributions 
assuming five molecules/mitochondrion that are randomly distributed between organelles. For cells containing 40–50% mutant mtDNA, many 
mitochondria are likely to contain four or more mutated molecules (!> !80%). If deleterious, these high levels will potentially depolarize the cell, triggering 
mitophagy, or inhibit mtDNA replication within that organelle, potentially leading to selection against mutations at the organellar level. d, Minor allele 
frequency (MAF) of mtDNA variants in 20 single human PGCs from three CS20/21 embryos detected by deep sequencing (left panel). The right panel 
shows the same data with the y axis scaled from 1–10% MAF. In both panels, the detection threshold was set at MAF!> !1%. e, Position of the variants from 
single human PGCs within the mitochondrial genome (left panel). The right panel shows the same data with the y axis scaled from 1–10% MAF. In both 
panels, the detection threshold was set at MAF!> !1%.
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the Balbiani body where intense mtDNA replication occurs18. In 
our data, specific genes that were upregulated > 2.5-fold (Fig. 4f) 
included POLRMT, C10orf2, SLC25A4 and MRPL28, which play a 
key role in mtDNA replication and gene expression (Supplementary 
Table 4), similarly seen in the PCA (Supplementary Fig. 4). 
Thus, mtDNA variants influencing mtDNA replication and expres-
sion will also be more likely to have an effect as PGCs develop, 
providing a possible explanation for the signature of selection we 
observed against tRNA and D-loop variants between CS12 and 
CS21 (Fig. 2d,e).
We also saw low levels of mtDNA somatic cells in vitro (Fig. 2h) 
and in vivo (Fig. 5a), in keeping with a somatic cell bottleneck, as 
previously observed in mice19. We also detected mtDNA variants in 
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Fig. 4 | Transcriptome analysis of human primordial germ cells. Analysis of n!= !13 transcriptomes. a, Unsupervised hierarchical clustering of RNA-seq 
expression profiles in H9 embryonic stem cells (ESCs), week 4, week 7 and week 9 female (F) human PGCs and week 5.5 male (M) hPGCs, and gonadal 
somatic cells (soma) showing clustering of gene expression consistent with the appropriate developmental stage (see also Supplementary Fig. 4). Results 
from a single analysis of the entire transcriptome data set. b, PCA of RNA-seq gene expression in hPGC samples. The dotted arrow indicates developmental 
progression along PC1. c, Heat map showing expression of key PGC-associated transcripts (early and late) and of pluripotency, mesoderm, endoderm 
and gonadal somatic markers. d, Correlation of transcription profiles of human PGCs of various stages for nuclear-encoded mitochondrial transcripts 
predicted by MitoCarta2.0 (see Methods; Pearson’s correlation, two-sided) and mtDNA-encoded transcripts. Only genes with normalized reads counts 
with (log2(normalized counts)!> !2.5) were used for analysis. Expression levels were averaged over biological replicates. The number of biological replicates 
at each developmental stage is shown in the cluster diagram shown in a generated from a total of 13 separate transcriptomes. This shows a progressive 
change in transcriptome profiles for mitochondrial genes in a sequential manner during PGC development. e, Two-dimensional PCA of RNA-seq gene 
expression (PC2 against PC1) for mitochondrial nuclear-encoded and mtDNA-encoded genes (MitoCarta2.0) at the different stages of hPGCs (left), with 
a corresponding plot of the PC scores on PC2 and PC1 (right). Gene names are colour-coded to illustrate upregulated expression in hPGCs.wk9 (purple), 
and downregulated expression in hPGs.wk9 (red) when compared with the hPGCs.wk4 sample (see also f, Supplementary Figs. 4 and 5 and Supplementary 
Table 4). The arrow line indicates potential mitochondrion-related-transcript progression for each developmental stage from migratory hPGC.w4 to gonadal 
hPGC.wk9. f, Volcano plot showing differentially expressed genes (from MitoCarta2.0 list) between week 9 (n!= !2 independent replicates) and week 4 
(this measurement was performed once) hPGCs (log2(fold change)!> !2.5, P!< !0.05, DEseq two-sided; see Methods). See also Supplementary Figs. 4 and 
5 and Supplementary Table 4. Note that the week-9 PGCs included in the RNA-seq analysis were from a slightly later developmental stage than CS20/21, 
reflecting the clinical samples that were available.
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segregation pattern appeared to be different. Some of the mtDNA 
variants were detected in both the PGCs and the somatic cells from 
the same embryo, but by the later stages (n = 15 shared variants, 
CS16–17 and CS20–21), the somatic cells contained higher hetero-
plasmy levels (P = 0.034, Fig. 5c). Although based on limited data, 
this suggests that a less stringent mtDNA bottleneck is present in 
somatic cells within human embryos, and that mtDNA variants are 
less constrained by selection in somatic tissues than in the germ line.
With rudimentary DNA repair mechanisms and negligible inter-
molecular recombination, uniparentally inherited genomes have 
limited means of removing de novo mutations. If left unchecked, 
the relentless accumulation of mtDNA mutations would eventually 
lead to ‘mutational meltdown’ through Muller’s ratchet, and extinc-
tion of the species29. The mtDNA genetic bottleneck has probably 
evolved to counteract this process, exposing potentially deleteri-
ous mutations to selective forces. On the basis of our findings, in 
humans this occurs early during germline development (Fig. 5d). 
However, if a mutation is sufficiently mild to escape germline selec-
tion, the same genetic bottleneck can have disastrous consequences. 
First observed in Holstein cows30, dramatic shifts in heteroplasmy 
levels have been observed within one generation. In humans, 
healthy mothers harbouring a low-level heteroplasmic mtDNA 
mutation can have offspring with high levels of heteroplasmy and a 












































































Fig. 5 | Mitochondrial DNA analysis of somatic cells in vivo and mechanisms of selection. a, MtDNA content of single human somatic cells in vivo at the 
same stage as the female PGCs shown in Figs. 1 and 2 (CS12 n!= !36, CS16/17 n!= !36; CS20/21 n!= !60). Each data point represents the mtDNA content in 
a single cell corresponding to the mean value from the independent qPCR measurements from 12 embryos. The horizontal bar represents the mean value. 
Source data are available in Supplementary Table 6. b, Mutation frequency for human female PGCs and corresponding somatic cells (soma) in developing 
human embryos (CS12–20/21) in vivo. The data are derived from 12 embryos. c, Segregation of the same heteroplasmic mtDNA variants detected in 
somatic cells and PGCs from the same embryo at CS16/17 and CS20/21 (n!= !15 variants) in vivo. Variants in the somatic cells had a higher heteroplasmy 
level than the PGCs (P!= !0.03, Fisher’s exact test, two-sided), which was not the case at CS12. Source data available are in Supplementary Table 6. d, In 
vivo PGCs contain ~300 discrete mitochondria that each contain 5 mtDNA molecules. In vitro data suggest that the amount of mtDNA may be even lower 
in female germ cells at an earlier stage. Some of the mtDNA molecules are mutated with either neutral (green) or deleterious (red) mutations. Between 
CS12 and CS20/21, the number of cells increases from ~3000 to ~80,000, accompanied by a massive proliferation of mtDNA molecules within the 
migrating PGCs. As the mitochondria replicate, the mutations will be copied. The random segregation of mtDNA molecules during mitochondrial fission 
will generate daughter mitochondria with either high or low levels of the original mutation. If the mutation is deleterious, then it will be selected against. 
This could be because it compromises ATP synthesis and activates surveillance systems that remove defective mitochondria, or because it compromises 
mtDNA replication, and thus prevents that particular mitochondrion from being copied. Both of these mechanisms can act in concert at both the cellular 
and mitochondrial levels.
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human mtDNA bottleneck31, but there has been no direct evidence 
in humans. Here we show that a human mtDNA genetic bottleneck 
exists, and is narrower than the bottleneck in mice16,18 (Fig. 2f). 
Reducing the amount of mtDNA during this critical time of germ 
cell development will expose variants to selection acting at the cel-
lular, organellar or mtDNA level, because this coincides with germ 
cells expressing transcripts for oxidative phorphorylation as they 
proliferate and migrate to form the gonad. Harnessing the underly-
ing cell biology could help prevent human mtDNA disease, which 
currently affects ~1 in 11,000. Moreover, given the potential role of 
mtDNA mutations in common age-related disorders32, preventing 
their transmission may have a wider impact by promoting healthy 
ageing in future generations.
Methods
Methods, including statements of data availability and any asso-
ciated accession codes and references, are available at https://doi.
org/10.1038/s41556-017-0017-8.
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Methods
Isolation of single cells. Ethically approved human embryonic tissue samples  
were provided by the Human Developmental Biology Resource (HDBR),  
Newcastle University, UK. For CS12 embryos, the lower section (see Fig. 1) was 
dissected in phosphate-buffered saline (PBS) from intact healthy embryos from 
healthy donors. For CS16 to CS21 embryos, genital ridges from individual embryos 
were dissected in PBS and the surrounding mesonephric tissue was removed.  
The dissected tissue was dissociated to a single-cell suspension with 350 μ l in the 
case of CS12 and 200 and 250 μ l in the case of CS16/7 and CS20/1, respectively, of 
5 U ml–1 Liberase DL Research Grade (Roche) at 37 °C for 20–35 min (depending 
on the stage/size of the tissue). The dissociated sample was then washed with 
750–800 μ l of cold Flow Cytometry Staining Buffer (FCSB) (R&D Systems) and the 
solution was passed through a 50 μ m cell strainer. Twenty microlitres was removed 
for the cell count using a Tali Image Cytometer (Life Technologies), before the  
cell suspension was centrifuged at 300g for 5 min at 4 °C. Cells were suspended 
in cold FCSB and incubated with 5 μ l of Brilliant Violet 421-conjugated anti-
human CD38 (Biolegend, 303526), 20 μ l of Alexa Fluor 647-conjugated SSEA-4 
(BD Pharmingen, 560796) and 5 μ l of Alexa Fluor 488-conjugated anti-alkaline 
phosphatase (BD Pharmingen, 561495) in the case of CS12 embryonic tissue, 
and 5 μ l of Brilliant Violet 421-conjugated anti-human CD117 (c-Kit) (Biolegend, 
313216) and 5 μ l of Alexa Fluor 488-conjugated anti-alkaline phosphatase  
(BD Pharmingen, 561495) in the case of CS16/7 and CS20/1 gonadal tissue for 
30 min at 4 °C. Cells were the washed with 1 ml of FCSB and centrifuged at 300g 
for 5 min at 4 °C. Cells were suspended in fresh cold FACB and sorted using a 
FACS Aria II (BD Biosciences). To determine the right antibody combination 
for isolation of pure human PGCs, different cell populations were sorted onto 
Polysine Microscope Adhesion Slides (Thermo Fisher Scientific) and left to settle 
in a humidified chamber at room temperature for 20–30 min before being fixed 
with 4% PFA for 5 min at room temperature. Purity for each sorted population was 
tested with alkaline phosphatase staining using Leukocyte Alkaline Phosphatase 
Kit (Sigma-Aldrich). Greater than 97% pure samples were used for downstream 
analysis. Initially, gender was determined by PCR as described in ref. 33 and then 
verified by karyotype analysis. Somatic cells were isolated at the same time using 
the same protocols, and inner cell mass and trophectoderm cells were manually 
dissected from in vitro-fertilized human day-6 embryos as described previously34. 
In vitro human embryonic stem cells (hESCs), human primordial germ cell-like 
cells (hPGCLCs) and somatic cells were cultured, induced and isolated as described 
previously7,21. Two independent PGCLC inductions were performed for both 
the male (WIS2) and female (H9) ESC lines. Single cells were isolated by FACS 
using the NANOS3-tdTomato knock-in reporter and the cell surface marker for 
tissue non-specific alkaline phosphatase (TNAP) in the WIS line, and TNAP/
CD38 double positivity in the h9 line. The somatic cells were isolated during the 
same FACS sort and were negative for these markers. All cell lines were regularly 
checked for mycoplasma infection.
The work with the human day-6 embryos was performed under licence from 
the UK Human Fertilisation and Embryology Authority (research license numbers: 
R0075 and R0133) and also has local ethical approval (UK National Health Service 
Research Ethics Committee Reference: 06/Q0702/90). Informed consent was 
obtained from all subjects and the experiments conformed to the principles set out 
in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial 
inducements are offered for donation. The study is compliant with all relevant 
ethical regulations regarding research involving human participants.
Measuring mtDNA content. Lysis of PGCs. PGCs collected in 96-well plates at 40 
or 80 cells per well (Life Technologies) were lysed for 16 h in 50 mM Tris-HCl, pH 
8.5, with 0.5% Tween 20 and 200 ng ml–1 proteinase K, at 55 °C, followed by heat 
inactivation at 95 °C for 10 min.
Lysis of single PGCs. PGCs collected in 96-well plates at a single cell per well (Life 
Technologies) were lysed for 30 min in 4 μ l of 50 mM Tris-HCl, pH 8.5, with 0.5% 
Tween 20 and 200 ng ml–1 proteinase K, at 37 °C, followed by heat inactivation at 
80 °C for 15 min.
Quantification of mtDNA copy number. Quantitative real-time PCR (qPCR) 
was performed on a CFX96 Touch Real-Time PCR Detection System (Bio-
Rad). Human mtDNA copy number was calculated by absolute quantification 
using a singleplex Taqman assay targeting the mitochondrial MT-ND1 gene 
(Supplementary Table 1a). Mouse mitochondrial DNA copy number was 
calculated by absolute quantification using a singleplex Taqman assay targeting 
the mitochondrial MT-ND5 gene (Supplementary Table 1b). Standard curves 
using PCR-generated templates were used for absolute quantification. Samples and 
standards were measured in triplicate.
Somatic cells, human inner cell mass, trophectoderm, human embryonic stem cells, 
human primordial germ cell-like cells, and in vitro somatic cells. MtDNA levels were 
measured using the same protocols as for the PGCs.
Immunocytochemistry. PGCs were sorted on Polysine Microscope Adhesion 
Slides (Thermo Fisher Scientific) and left to settle in a humidified chamber at 
room temperature for 20–30 min before fixation with 4% PFA for 10 min at room 
temperature, washed three times with PBS, 0.1% Tween-20, (5 min each wash) 
and incubated for 20 min with PBS, 0.3% Triton-X buffer, and washed three times 
with PBS, 0.1% Tween-20 (5 min each wash). Cells were subsequently blocked 
for 1 h with PBS, 2.5% BSA, 0.1% Tween-20 and 5% normal goat serum at room 
temperature followed by staining with DDX4 (VASA) mouse monoclonal IgG1 
antibody (Selleckchem) diluted 1:200 in the blocking solution at 4 °C overnight. 
The slides were then washed three times with PBS, 0.1% Tween-20 (5 min each 
wash) and incubated with Alexa fluorophore-conjugated secondary antibody 
(Molecular Probes) 1:500 diluted in PBS, 0.1% Tween-20 for 1 h at room 
temperature in the dark, washed three times in PBS, 0.1% Tween-20 (5 min each 
wash) and once in PBS for 5 min. Finally, the glass-bottom dishes were mounted 
in ProLong Gold Antifade Mountant with DAPI (Molecular Probes) and imaged 
using a Zeiss Axio Imager Z1/Apotome Microscope.
Electron microscopy. PGCs were collected in 1.5 ml microcentrifuge tubes 
containing 2.5% electron-microscopy-grade glutaraldehyde (TAAB Laboratories 
Equipment) in Sorenson’s phosphate buffer 0.2 M pH 7.4 (Electron Microscopy 
Sciences) and stored at 4 °C overnight. The cells were enrobed in low-melting-
point agarose (4%) to form a small block. After secondary fixation in 2% osmium 
tetroxide (Agar Scientific), the cells were dehydrated in graded acetone, embedded 
in epoxy resin (TAAB) and polymerized at 60  °C. Semi-thin sections (0.5 µ m) were 
taken from the resin block and stained with toluidine blue to identify the first cells. 
As soon as cells were found in the block, ultrathin serial sections (70 nm) were 
taken and collected on copper washer grids (Gilder Grids). Serial sections were 
taken for approximately 150 µ m to ensure that there would be at least 6 whole cells 
sectioned. The grids were stained with uranyl acetate and lead citrate (Leica UK) 
and viewed on a Philips CM100 TEM (FEI). Cells that were completely sectioned 
were imaged from each sample and mitochondria counted using the dissector 
technique35. Pairs of images 140 nm apart were taken at several levels through each 
cell. Each pair is comprised of a ‘reference’ and ‘look-up’ section. The number of 
mitochondria that are hit by the reference section but not by the look-up section 
is counted. To increase efficiency, the roles of the reference and look-up sections 
can be reversed. If the volume of the dissector is known, then the number density 
Nv can be obtained. The volume of the dissector equals the area of cell profile 
multiplied by the distance between the paired sections. Multiplying number 
density by cell volume gives mitochondrial number.
Super-resolution microscopy. PGCs were collected in 35-mm-diameter glass-
bottom dishes (glass no. 1.5, 0.170 ± 0.005 mm, high-tolerance coverslip; MatTek) 
and left to settle in a humidified chamber at room temperature for 20–30 min 
before being fixed with 4% PFA for 10 min at room temperature. Dishes were 
washed three times with TBS (pH 7.6), 0.1% Tween-20 (5 min each wash) and 
then permeabilized for 10 min using TBS, 0.1% sodium citrate, 0.2% Triton-X 
buffer, before being washed three times with TBS, 0.1% Tween-20 (5 min each 
wash). Cells were subsequently blocked for 1 h with TBS, 0.3 M glycine, 2.5% BSA, 
5% normal goat serum, 0.1% Tween-20 buffer at room temperature followed by 
staining with TOM20 mouse monoclonal IgG2a antibody (F-10), sc-17764 (Santa 
Cruz Biotechnology) diluted 1:1,000 in the blocking solution at 4 ˚ C overnight. The 
glass-bottom dishes were then washed three times with TBS, 0.1% Tween-20 (5 min 
each wash) and incubated with Alexa fluorophore-conjugated secondary antibody 
(Molecular Probes) 1:1,000 diluted in TBS, 0.1% Tween-20 for 1 h at room 
temperature in the dark, washed three times in PBS, 0.1% Tween-20 (5 min each 
wash) and once in TBS for 5 min. Finally, the glass-bottom dishes were mounted 
in ProLong Gold Antifade Mountant with DAPI (Molecular Probes) and imaged 
using a Nikon Structured Illumination Microscope.
Image segmentation analysis for measuring mitochondrion content. Three-
dimensional reconstruction of super-resolution z-stack images was rendered using 
NIS-Elements software (Nikon). Mitochondrion content count and visualization of 
PGCs were performed using Imaris software (Bitplane).
Ultradeep sequencing and variant analysis. Details of collected samples are 
given in Supplementary Table 2. PGCs and somatic cells were sorted and lysed in 
96-well plates as described above and mtDNA was amplified using PrimeSTAR 
GXL DNA polymerase (error rate = 0.00108%, Takara Bio) in nine overlapping 
fragments (Supplementary Table 1c) for grouped cells or in two overlapping 
fragments (Supplementary Table 1d) for the single cells. The specificity of 
mtDNA amplification was assessed using DNA extracted from Rho0 cell lines 
previously shown to be devoid of mtDNA4. There was no template amplification 
after > 40 PCR cycles, confirming that the primers amplified only mtDNA and 
not nuclear-mitochondrial sequences. No PCR products were generated with any 
of the primers. Amplified products were assessed by gel electrophoresis, against 
DNA-positive and DNA-negative controls. Each amplicon was individually 
purified using Agencourt AMPure XP beads (Beckman-Coulter), quantified 
using a Qubit 2.0 fluorimeter (Life Technologies) and amplicons from the same 
sample were pooled. Libraries were prepared for Next Generation Sequencing 
(NGS) using the Illumina Nextera XT DNA sample preparation kit (Illumina), and 
pooled amplicons were ‘tagmented’, amplified, cleaned, normalized and pooled 
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in equimolar concentrations for library preparation. The library was sequenced 
using MiSeq Reagent Kit v3.0 (Illumina) in paired-end, 250 bp reads. Post-run 
FASTQ files were analysed using an in-house-developed bioinformatic pipeline. 
Reads were aligned to the rCRS (NC_012920) using BWA v0.7.4 invoking –mem36. 
Aligned reads were sorted and indexed using Samtools v0.1.837 and duplicate 
reads were removed using Picard v1.85 (http://broadinstitute.github.io/picard/). 
Variant calling was performed in tandem using VarScan v2.3.138 (minimum 
depth = 1,500, supporting reads = 10, base-quality = > 30, mapping quality = > 20 
and variant threshold = 1.0%). Variants were annotated using ANNOVAR v52939. 
Heteroplasmic variants are defined as > 1% minor allele frequency. Our previous 
work using this method showed that variants present at > 1% heteroplasmy  
were highly likely to have been present in the original DNA sample, and unlikely  
to be artefacts. In-house Perl scripts were used to extract base/read quality  
data and coverage data. In addition, low-quality variants, present in low-
complexity regions, were not included in the analysis. Sequencing a cloned mtDNA 
template with the same protocol showed minimal background sequencing error 
(Supplementary Fig. 3).
RNA-seq library preparation. PGCs were sorted into 100 μ l of extraction buffer 
of PicoPure RNA Isolation Kit (Applied Biosystems) and RNA was extracted 
following the manufacturer’s protocol. The Ovation RNA-Seq System V2 (Nugen) 
was used for reverse transcription and amplification of total RNA (0.5 to 2 ng) into 
cDNA. Fragments of 250 bp were generated by sonication of amplified cDNA using 
the Covaris S220 Focused-ultrasonicators. Subsequently, using the Ovation Rapid 
DR Multiplex System (Nugen) and 500 ng of fragmented cDNA, an RNA-seq 
library was prepared. Quantification of the library was carried out by qPCR using 
the KAPA Library Quantification Kit (Kapa Biosystems) using the QuantStudio 6 
Flex Real-Time PCR System (Applied Biosystems). Libraries were sequenced by the 
HiSeq 2000/2500 sequencing system (Illumina) with single-end 50 bp read length. 
Every four indexed libraries were multiplexed to one lane of a flowcell, resulting 
in > 40 million single-end reads per sample.
RNA-seq analysis. After removal of adaptor sequence and low-quality reads, 
RNA-seq reads were mapped to the human reference genome (UCSC GRCh37/
hg19) using TopHat2 v2.0.13 (http://ccb.jhu.edu/software/tophat) guided by 
ENSEMBL gene models. The annotations of transcripts were based on Ensembl 
(Release 74) considering protein-coding, long-noncoding RNA and processed 
transcripts. Using featureCounts, the raw counts per transcripts were obtained. The 
counts for nuclear-encoded transcripts were normalized, and statistical tests for 
differential expression of transcripts were performed by using the R Bioconductor 
DESeq package (www.bioconductor.org). To account for the profound reduction 
in mtDNA content, mitochondrial transcript counts were normalized by the set of 
DESeq-scaling factors obtained for nuclear-encoded transcripts before evaluating 
their differential abundance. Further normalization of expression-normalized 
transcript counts was carried out by transcript length (per kilobase). Hierarchical 
clustering plots were generated with the R ‘hclust’ functions using Ward’s method. 
Principal components were computed by singular value decomposition with the R 
‘prcomp’ function on scaled DESeq-normalized expression values. Only the 80% 
most highly expressed transcripts were used for clustering and PCA. By selecting 
the most equivalent time points in human PGC development, mitochondrial genes 
that were significantly differentially expressed (log2(fold change) > 2.5 or < − 2.5 
and P value < 0.05) between hPGCs (week 7 or 9) and hPGCs (week 4) were 
compiled and highlighted in the plots of the principal component (PC) scores 
for each gene (Fig. 5e). Human mitochondrion-related genes were adopted from 
MitoCarta2.0 inventory.
Quantitative PCR with reverse transcription (RT–qPCR). Total RNA from 
sorted PGCs or somatic cells was extracted by the PicoPure RNA Isolation Kit 
(Applied Biosystems). cDNA was synthesized and amplified using Ovation 
RNA-Seq System V2 (Nugen). RT–qPCR reactions were set up with SYBR Green 
JumpStart Taq ReadyMix (Sigma) and 200 nM of forward and reverse primers 
(Supplementary Table 5). RT–qPCR was then performed on the QuantStudio 6 
Flex Real-Time PCR System (Applied Biosystems) at 95 °C for 10 min, 40 cycles of 
95 °C for 15 s and 60 °C for 1 min, followed by a melt curve stage. Mean threshold 
cycles were determined from 2–3 technical replicates. Relative expression levels 
were calculated using the comparative Ct method, by normalization to GAPDH 
and relative to CS12 human PGCs or soma (Supplementary Figs. 1 and 2).
Statistics and reproducibility. Statistical analyses were performed using 
parametric methods as described in the text and figure legends with exact P values 
reported. The number of biological replicates for each experiment is stated in the 
figure legend.
Life Sciences Reporting Summary. Further information on experimental design is 
available in the Life Sciences Reporting Summary.
Data availability. mtDNA-seq data that support the findings of this study are 
available in Supplementary Table 5 and are deposited in the BioSample database 
under accession codes SAMN08022267, SAMN08022310, SAMN08022311, 
SAMN08022312, SAMN08022313, SAMN08022314, SAMN08022315, 
SAMN08022316, SAMN08022317, SAMN08022318, SAMN08022319 and 
SAMN08022320. RNA-seq data generated by this study have been deposited in 
the Gene Expression Omnibus (GEO) under the accession codes GSM2060944 
(for hPGC female week 4) and GSM2060945 (for somatic cells female week 4). 
Previously published RNA-seq data that were reanalysed here are available under 
accession codes SRX857044, SRX857046, SRX901022, SRX901024, SRX901025, 
SRX901026, SRX901027, SRX901028, SRX901029, SRX901030 and SRX901031. 
Statistics source data for Figs. 2f–h and 5a,c are provided in Supplementary Table 
6. All other data supporting the findings of this study are available from the 
corresponding author on reasonable request.
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Supplementary Figure 1. Flow cytometry and RT-qPCR analysis of germ cells and somatic cells. Upper = Immuno-staining of FACS human PGCs positive for 
TNAP and c-KIT stained with anti-VASA antibody. Scale Bar = 100 μm. Lower = expression analysis of TNAP/SSEA4/CD38 triple positive (hPGCs CS12) and 
TNAP/SSEA4/CD38 triple negative (SOMA CS12) sorted cells. Relative expression levels are shown with normalization to GAPDH. Data shown represent two 
independent biological replicates with similar results.
Supplementary Figure 2.  RT-qPCR analysis for germ cell specific and soma transcripts. Left = Expression analysis of TNAP/AP double positive (hPGCs 
CS16-20) and TNAP/AP double negative (SOMA CS19-20) sorted cells. Relative expression levels are shown with normalization to GAPDH. Right = 
Comparison of expression level across all stages CS12- CS20. Relative expression levels are shown with normalization to GAPDH. Data shown represent two 
independent biological replicates with similar results.
Supplementary Figure 3. Ultra-deep sequencing quality. Amplification of a mtDNA template comparing PrimeSTAR GXL DNA polymerase (used to 
sequence mtDNA in the cell lysates) and LA, Phusion and Q5 DNA polymerases. The sequencing and bioinformatic analysis used the same protocol 
described in the Methods. (A) Sequencing depth of the cloned mtDNA fragment. (B) Variant allele frequency (VAF) distribution. No sequence variants 
present at VAF ≥1%. Variants detected at VAF>1% in the cell lysates are therefore highly likely to have been present in the original mtDNA molecules and 
are not artefacts introduced during the sequencing. MtDNA sequencing was performed once using each different polymerase.




























Supplementary Figure 4. RNAseq of human primordial germ cells (PGCs). (A) Differentially expressed genes of Wk 7 (n = 3 independent replicates) and 
Wk 4 hPGCs (the experiment was performed once). Volcano plot showing differentially expressed genes (from MitoCarta2.0 list) between week 7 and week 
4 hPGCs [log2(fold change)>2.5, p < 0.05, DEseq, two-sided]. A list of these genes is shown in Supplementary Table 4. (B) Principal component analysis 
(PCA) in hPGC samples. PCA of RNA-seq expression for MitoCarta2.0 genes in hPGC samples (n = 7 embryos). a, PC1,2 and 3 and b, PC1,2 and 4. A two-
dimensional principal components analysis (PC2 against PC1) is shown in Fig. 5e. (C) Two-dimensional principal components analyses of RNA-seq gene 
expression. (PC2 against PC1) of all transcripts for the different stages of hPGCs (inner panel a). Corresponding plots of PC scores indicates the weight of 
various genes on PC2 and PC1 (inner panels b, c and d). MitoCarta2.0 transcripts up or down regulated from 4 (n = 1 embryo) to 9 Wk (n = 2 cell embryos, 
see also Fig. 4e) are shown in inner panel b together with mtDNA-encoded transcripts and PGC-associated transcripts. Respiratory electron chain genes and 






Supplementary Figure 5. 2-D PCA of the respiratory electron transport chain complexes & gene expression correlation of hPGCs, soma and hESCs samples. 
Upper = PC2 against PC1 of all transcripts for the different complexes of the respiratory electron transport chain genes (total n = 13 transcriptomes, the 
figure shows the number of independent replicates in each group). Corresponding plots of PC scores indicates the weight of each complex on PC2 and PC1. 
Top left panel shows all five complexes together, rest of the panels show each complex individually. Lower = Gene expression correlation of hPGCs, soma 
and hESCs samples. Pearson correlation heat map (two-sided) of gene expression (log2(normalized read counts)) in various samples with unsupervised 
hierarchical clustering shown in the upper panel. The color key indicates the correlation coefficient. See also Fig. 5a&b.
Supplementary Tables Legends
Supplementary Table 1. Oligonucleotide primer sequences.
qPCR primer sequences for human mtDNA (revised Cambridge Reference Sequence (rCRS); GenBank accession number NC_012920.1).
qPCR primer sequences for mouse mtDNA (Mus musculus mitochondrion, NC_005089.1).
PCR primer sequences for human mtDNA, 9 primer pairs. (revised Cambridge Reference Sequence (rCRS); GenBank accession number NC_012920.1).
PCR primer sequences for human mtDNA, 2 primer pairs. (revised Cambridge Reference Sequence (rCRS); GenBank accession number NC_012920.1).
RT-qPCR primer sequences
Supplementary Table 2.  Number of embryos studied. The number of embryos studied, the gender, and number of cells studies from each embryo. (CS = 
Carnegie stage = CS, F = Female, sequenced = number of cells sequenced) 
Supplementary Table 3. PGC number and mtDNA molecules. The number of primordial germ cells and the corresponding number of mtDNA molecules at 
each embryonic stage in mouse and human embryos. 
Supplementary Table 4. Genes up or down regulated. log2(fold change)>2.5, p < 0.05 in wk9 and wk7 hPGCs compared to wk4 hPGCs. The genes listed for 
hPGC wk9 vs wk4 are also shown in Fig. 4F and coloured in Fig. 4E. 
Supplementary Table 5. MtDNA deep sequencing data. MtDNA variants detected in the sequenced PGCs showing the sequence read quality and variant allele 
frequency.
Supplementary Table 6. Statistics Source Data. Data values plotted in the figures
Supplementary Video Legends 
Supplementary Movie 1. Human primordial germ cell. Nikon Structured Illumination Microscope (N-SIM) image of a human PGC labelled with anti-TOM20 
isolated from a Carnegie Stage 12 embryo. 
Supplementary Movie 2. Human primordial germ cell. Nikon Structured Illumination Microscope (N-SIM) image of a human PGC labelled with anti-TOM20 
isolated from a Carnegie Stage 12 embryo. with mitochondria identified and counted by IMARIS software.
